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Abstract 
 
Overweight and obese (OWOB) women are reported to have a lower chance of 
becoming pregnant. The nutritional enrichment of the periconceptional environment 
apparent in obese women may be detrimental for embryo viability. This is the first 
study to examine the development and metabolism of embryos derived from OWOB 
women compared with those from normal weight women. 
 
Measurements of oocyte quality, embryo development and utilisation of exogenous and 
endogenous metabolites were performed. Results were compared for normal weight and 
OWOB and examined in relation to blastocyst development and pregnancy outcome. 
Patients attending the Hull IVF Unit for fertility treatment (n=176) donated 
supernumerary embryos (n=808) from day 5 to 7/9 of development. Full ethical 
approval was obtained. 
 
Oocytes from overweight or obese women were smaller than those from women of 
healthy weight, yet post-fertilization they reached the morula stage faster and, as 
blastocysts, showed reduced glucose consumption and elevated endogenous triglyceride 
levels. There were no differences in the metabolism of pyruvate or lactate. Amino acid 
metabolism was more active in embryos generated from OWOB women and significant 
differences were seen in the turnover of individual amino acids that were also predictive 
of blastocyst formation and pregnancy outcome. The significant findings were 
independent of male BMI.  
 
In vitro culture supplementation with insulin did not influence glucose consumption, but 
did appear to modulate developmental progression to the blastocyst stage as well as the 
utilisation of specific amino acids. Whereas, when the medium was supplemented with 
l-carnitine (LC), embryos consumed LC from the medium, and at 0.05mM LC addition; 
embryos showed reduced intracellular triglyceride levels and increased exogenous 
glucose consumption. However, at 0.5mM LC addition; embryo viability was 
compromised in cohorts of embryos from women with a BMI <25kg/m2.  
 
The data support the hypothesis that embryo viability is compromised in OWOB 
women. This may reduce not only the chances of conception, but have long-term 
implications for the health of the offspring in later life.  
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Chapter 1 : Introduction 
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1.1Obesity; definition, incidence and relationship with body mass index 
 
The proportion of adults who are overweight or obese (OWOB) has more than doubled 
since 1980 (World Health Organisation; WHO 2012) and currently stands at 
approximately 50% of the world’s population (Ng et al., 2014). Body mass index 
(BMI), which is the ratio of body weight in kilograms (kg) to height in metres squared 
(m2), is the most widely used assessment criterion. A BMI of <18.5kg/m2 is defined as 
underweight, 18.5-24.9 normal weight, 25-29.9 overweight and >30kg/m2 obese 
according to the WHO classification.  
 
The increased body mass associated with obesity is predominantly due to an 
accumulation of fat (Webster et al., 1984). However the relationship between BMI and 
% fat is not simple and may be described by a linear or curvilinear relationship, with a 
small, but significant age-gender interaction (Meeuwen et al., 2010; Shah & Braverman 
et al., 2012). The current cut-offs for BMI classification are based on >25% body fat for 
men and >35% for women. However, recent studies propose that using cut-offs of 
>30% body fat may be a more appropriate indicator of adiposity for women; this would 
equate to a BMI index of 25 being reclassified as obese and conversely for men the 
index should be increased to 28 to account for differences between the sexes in bone 
and muscle mass (Okorodudu et al., 2010). Such an adjustment would increase the 
sensitivity of BMI for detecting body fatness and could limit the misclassification to 
16% of women, based on the findings from 13,601 subjects (Romero-Corral et al., 
2008).  
 
Despite the shortcomings of BMI, it is a frequently used gauge of normality for a 
person’s weight. Although BMI does not account for lean body mass, nor does it 
provide any indication of the distribution of body fat it is a standardised and easily 
reproduced measurement. Furthermore, generally accepted thresholds have been 
established, originally based on the statistics of Life Insurance Companies and there is a 
wealth of data with which findings can be compared.  
 
BMI is therefore used as a proxy measure of obesity throughout this thesis, as for most 
people it correlates with their amount of body fat with sufficient accuracy (NHLBI, 
1998). Furthermore as this study primarily focuses on Caucasian women of 
reproductive age this risk of misclassification is reduced (Pedersen et al., 2011). As the 
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evidence presented above would suggest that the present cut-offs for BMI provide an 
underestimate of obesity prevalence, the data have been grouped according to normal 
(BMI <25) or overweight and obese (OWOB - BMI ≥ 25kg/m2) further reducing the 
risk of misclassification.  
 
1.2 The developmental programming of susceptibility to obesity 
 
There is substantial evidence that maternal BMI is a significant early risk factor for 
obesity in the offspring, which may first be recorded during in utero growth (Catalano 
et al., 2009), is then reflected in birth weight (McDonald et al., 2010; Kulie et al., 2011), 
during childhood (Reilly et al., 2005) and may persist into adulthood (Yu et al., 2011). 
Brisbos et al., (2012) identified 17 studies that reported a significant correlation 
between maternal BMI and both infant and adult obesity in the offspring.  
 
Leese, (2014) provided a succinct historical review of our current understanding of the 
influence that maternal, gamete, embryo, fetal and infant nutrition has on the health of 
the offspring in later life. The review highlighted the process of appreciation of 
knowledge that has lead to the current ‘Developmental Origins of Health and Disease’ 
concept (DOHaD); beginning with an understanding of how the uterine environment 
influences growth (Walton & Hammond 1938) and how fetal birth weight was 
subsequently shown to be related to the onset of adult disease (Barker 1990, 2007). The 
current emerging realisation that not only is the embryo especially sensitive to 
environmental modulation, but that this may be traced back further to the developmental 
environment of the gametes has highlighted the need for a ‘life-course approach to 
issues of human health’ (reviewed by Leese, 2014).  
 
With specific regard to how maternal over nutrition may predispose the conceptus of 
OWOB women to macrosomia; Pedersen (1967) hypothesised that fetal overgrowth and 
adiposity occur as a consequence of poor maternal glucose control, resulting in fetal 
hyperglycemia and excess fetal insulin secretion (reviewed by Catalano & Hauguel-De 
Mouzon, 2011). In support of this, is the finding that increased fat mass in utero is 
reflected in greater levels of insulin in the cord blood of these babies (Catalano et al., 
2009).  Conversely, fetal exposure to maternal under nutrition, during a critical period 
of development could result in fetal programming of metabolism and the downstream 
development of adult metabolic disorders. Such considerations underlie the initial 
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Barker Hypothesis of the fetal origins of adult disease (FOAD) (Barker 1990, 1992), a 
concept which was primarily proposed to explain the inverse relationship between 
weight at birth and predisposition to type 2 diabetes and cardiovascular disease in later 
life. Which was later extended to encompass the ‘thrifty phenotype hypothesis’, which 
suggests fetal adaptations for survival made in response to maternal under nutrition, 
predispose the offspring to rapid ‘catch-up-growth’ if subsequently exposed to a 
nutrient rich environment after birth (Hales & Barker, 1992).  Figure 1.1 aims to show 
the parallels between these described theories and the relationship between birth weight 
and later development of obesity linked through in utero adaptations to the maternal 
nutritional status.   
 
 
Figure 1.1 The intergenerational effects of obesity. 
A summation of several theories (based on text from Hales & Barker, 1992; Catalano & Hauguel-De 
Mouzon, 2011) proposed to explain the developmental programming of obesity, which may begin in 
utero in response to suboptimal nutrition.  
 
These early theories of FOAD have been modified, as it has become increasingly 
apparent that adaptations to suboptimal nutrition may begin much earlier than during 
fetal development and the period around the time of conception is viewed as a 
particularly vulnerable period of development. The preimplantation embryonic 
development phase and sensitivity to environmental modulation has become a particular 
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focus for research. Comprehensive reviews, primarily of experimental animal data have 
been compiled by Chason et al., (2011); Eckert & Fleming, (2011) and Lucas, (2013), 
although data from human embryos is currently lacking. Observations in humans have 
highlighted the possible intergenerational effects of maternal nutrition on oocyte 
development, another uniquely vulnerable period to environmental modulation 
(reviewed by Ashworth et al., 2009).   
 
With respect to maternal obesity, weight gain increases slowly between the ages of 25 
to 44, (i.e., within the fertile age range) (Bjorntorp et al., 1975). Given the fact that the 
average age of first time mothers has been gradually increasing (27.9 years in 2011 
compared to 25 in 2004) and nearly half of all live births (49%) in 2011 were to mothers 
aged 30 and over (Office for National Statistics), this may be contributing to the rising 
rates of pre-pregnancy obesity. The latest Department of Health figures indicate that 
53% of pre-gravid women were OWOB and since women who are overweight pre-
pregnancy are more vulnerable to gestational weight gain and post-partum weight 
retention (Adamo et al., 2012), this would increase the risks further in any subsequent 
maternities, potentiating the obesity cycle (as aimed to illustrate in Figure 1.2). 
However, it is also very likely that genetic and lifestyle factors will be passed on by the 
parent and will increase the probability of obesity and metabolic disorders in the 
offspring and the relative contributions of each remains a matter of controversy 
(Gluckman et al., 2005). 
 
Collectively these studies and observations serve to highlight how the wider concept of 
DOHaD may be applied to explain how obesity begets obesity and the need for focused 
studies exploring the impact of maternal BMI on the uniquely, environmentally 
sensitive periods of; oocyte and preimplantation embryo development.   
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Figure 1.2 Obesity seemingly begets obesity. 
(a) Women are increasing delaying pregnancy until their late 20 to early 30’s, a time when they are more 
vulnerable to weight gain. (b) Women who are overweight pre-pregnancy are more vulnerable to 
gestational weight gain (c) Children born to OWOB mothers are significantly more likely to be large for 
gestational age. (d) High infant birth weight is correlated with childhood obesity, obesity in adolescence 
and adulthood.   
 
1.3 Factors that lead to the development of obesity 
 
In simple terms, weight gain occurs when energy intake is greater than energy 
expenditure. The increased availability of energy dense food that are high in fat, sugar 
and salt and increasing sedentary lifestyle habits have been implicated as causal factors 
in the obesity epidemic (Leonard, 2002). Inappropriate weight gain can lead to a variety 
of health problems and metabolic disturbances. For example, a number of metabolic 
changes in obesity are associated with insulin resistance. Under normal circumstances 
insulin, secreted by pancreatic beta cells in response to the absorption of foodstuffs, 
especially glucose, stimulates the uptake of (1) glucose into target cells where it has 
numerous actions; notably, as a fuel, biosynthetic intermediate or, and, in liver and 
skeletal muscle, as a precursor of glycogen (2) lipids into adipose cells to be stored as 
triacylglycerols (3) uptake and use of amino acids. Insulin also acts on the 
hypothalamus to reduce appetite and stimulate energy expenditure. The secretion of 
leptin, which is produced by adipose tissue, is stimulated by insulin and further acts on 
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the hypothalamus to suppress appetite. In apposition to insulin are glucagon (from the 
alpha cells of the pancreas), adrenaline (from the adrenal medulla), cortisol and growth 
hormone. (The interactions of these hormones with those of the reproductive system are 
discussed in further detail in Chapter 3.)  
 
In obese individuals, both insulin and leptin secretion is increased and cells may 
become resistant to their action, leading to high blood glucose and lipid levels and lack 
of appetite regulation. Insulin resistance is thought to occur by consequence of 
increased total body fat and is associated with a central or android-type fat distribution. 
In obese individuals elevated plasma non-esterified fatty acid concentrations and a 
reduction in sensitivity to insulin leads to impaired muscle glucose utilisation and 
disruption of the glucose-fatty acid cycle, first described by Randle et al., (1963) and 
recently reviewed by Hue et al., (2009). An overview of the metabolic interactions and 
responses to high and low blood sugar is provided in Figure 1.3 and is discussed again 
in more detail in Chapter 5. In obese women, raised levels of triglycerides, glucose and 
insulin have been reported in the ovarian follicle (Robker et al., 2009) but the 
consequence this exposure has for oocyte maturation and embryo viability has not been 
investigated in any detail. 
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Figure 1.3 The glucose-fatty acid cycle. 
It was proposed by Randle et al (1963) that if muscle is able to choose between free fatty acids (FFA) and 
glucose, fatty acids will be metabolised and glucose uptake is restricted (the specific metabolic 
interactions that explain how β-oxidation of FFA prevents the oxidation of pyruvate and suppresses 
glycolysis will be discussed later).  The effects of glucose are mediated by insulin (the normal responses 
to low/ high blood glucose are described in the boxes), but when there is an abundance of glucose and 
fatty acids, insulin does not stimulate glucose uptake as normal. This cycle can contribute to insulin 
resistance, decreased utilisation of glucose and increased accumulation in the blood, failure of insulin 
function to permit activation of hormone sensitive lipase (HSL) leading to increased lipolysis of 
triacylglycerol (TAG) and increased blood fatty acid and glycerol concentrations. Insulin is also needed 
for the expression of lipoprotein lipase (LPL), which is required to clear lipids from the blood. (A more 
comprehensive description of the specific mechanisms in different cell types is provided by Frayn 1996; 
Hue et al., 2009).  
 
1.4 In vivo oocyte and embryo development and manipulations in vitro–as ‘Assisted 
Reproductive Technologies’ 
 
To provide a context for how maternal overweight and obesity impacts on the 
reproductive system a brief recap of the stages of oocyte and embryo development is 
now provided. In addition the assisted reproductive techniques (ART) used to 
manipulate and direct these events will be discussed, specifically in vitro fertilisation 
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related treatments, which are now estimated to contribute to 1-2% of all births in the 
UK (HFEA 2011). Around 1 in 7 couples experience difficulty conceiving (failure to 
become pregnant within 2 years of regular unprotected sexual intercourse; NICE 2013), 
the cause of which may be diverse and multifaceted. Male factor infertility (i.e. a low 
sperm count, motility, morphology) accounts for approximately a third of cases, with 
female factors (i.e. tubal obstruction, ovulatory disorders, endometriosis) accounting for 
a further third. In 25% of cases no cause can be identified and lifestyle factors may be a 
significant contributory, specifically the impact of maternal obesity on the time taken to 
achieve, and ability to sustain a pregnancy has received much attention in recent years.  
 
1.4.1 Oocyte development and maturation in vivo 
The ovary consists of follicles and interstitial tissue. Granulosa, theca, endothelial cells 
and supportive connective tissue form the components of the follicle in which the 
oocyte is enveloped. Follicular and oocyte development (oogenesis & folliculogenesis) 
occurs in the cortex of the ovary. 
 
Germ cells migrate from the yolk sac into the developing gonad with accompanying 
somatic cells early in fetal life, with the primordial germ cells (PGC) eventually 
becoming oocytes and the somatic cells differentiating into the follicular cells. The 
relevance of this, to the context of this thesis being that these developing cells may be 
vulnerable to environmental cues that affect their future development in the next 
generation.  
 
In oogenesis, PGC divide by mitosis and differentiate into oogonia at week 8-13 
(Gondos et al., 1986), after which they cease mitotic division before birth and enter into 
their first meiotic division, becoming primary oocytes and are arrested at the 1st meiotic 
prophase. The chromosomes, enclosed within the nucleus are referred to as the germinal 
vesicle (GV) (reviewed by Virant-Klun et al., 2015).  
 
A single layer of ovarian mesenchymal cells (granulosa cells) surround the primary 
oocytes, resulting in the formation of primordial follicle. The stroma around the follicle 
(theca) forms a capsule. Those oocytes not incorporated into follicles degenerate and the 
number of oocytes at birth is 1-2 million. Primordial follicles then remain in their 
arrested state until puberty (Eichenlaub-Ritter & Peschke, 2002), after which time, a 
few follicles are recruited regularly to form a pool of growing follicles (20-50 mature 
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each month). The primordial follicles selected increase in size, as does the primary 
oocyte. Additional layers of granulosa cells surround the oocyte, as it undergoes 
hypertrophy and proliferates in response to growth factors, including insulin like growth 
factor (IGF), epidermal growth factor (EGF) and Anti Mullerian hormone (AMH) (Fair 
2003). The growing oocyte accumulates water, lipids, RNA and protein and the number 
of mitochondria and ribosomes increases (Johnson et al., 2004). The oocyte secretes 
glycoproteins (ZP1, ZP2, ZP3 and ZP4) that form the surrounding zona pellucida (ZP). 
Granulosa-derived cumulus cells also surround the oocyte and the innermost layer 
forms the corona radiata which penetrates the ZP to form gap junctions with the oocyte 
oolemma (Anderson & Albertini, 1976). At this point the follicle is said to be at the 
primary / preantral stage. 
 
Increased granulosa cell proliferation occurs in response to endogenous and exogenous 
autocrine and paracrine effects. The outer stromal cells differentiate into the theca 
interna, which are vascularised, steroidogenic cells and the theca externa of connective 
tissue. Follicles become associated with blood vessels and Follicle Stimulating 
Hormone (FSH) from the pituitary is required for the formation of follicular fluid. The 
formation of follicular fluid marks the transition to the secondary/ antral follicle stage. 
The oocyte surrounded by a layer of cumulus cells is suspended in the fluid within the 
antral cavity and is approximately 120µm in size when the cavity is formed.  It is at this 
stage that the oocyte is capable of resuming meiosis. Figure 1.4 depicts the advancing 
stages of folliculogenesis and increasing sensitivity of preantral and antral follicles to 
gonadotrophins, the cyclic activity of which is described in Figure 1.5. These stages of 
oocyte growth and development and the dependence on appropriate cyclic activity of 
gonadotrophins are discussed further in Chapter 3, with specific reference to the ovarian 
pathophysiology associated with obesity.  
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Figure 1.4 Schematic diagram of folliculogenesis. 
The increasing follicular size (a-e) and dependence on gonadotrophins and progressive loss of growing 
follicles from the pool is depicted.  
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Figure 1.5 Overview of endocrine control of ovulatory cycle. 
The pituitary gonadotrophins (FSH & LH), under the control of gonadotrophin releasing hormone from 
the hypothalamus (GnRH), regulate the ovarian production of sex steroids. Oestradiol and Progesterone 
exert negative feedback control over FSH/LH and GnRH. Rising Oestradiol also exerts a positive 
feedback action to induce the ovulatory surge in LH, marking the end of the follicular phase (day 1-14) 
and the beginning of the luteal phase of the menstrual cycle. Progesterone production (from the corpus 
luteum) then rises, but in the absence of fertilisation the uterine endothelium (endometrium) is shed and 
the next phase begins. The impact and causes of higher free circulating estrogen in OWOB women on 
menstrual cycles is discussed in Chapter 3.  
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The majority of the group of follicles that began development will have undergone 
atresia (apoptosis and loss, though not through ovulation). The causes of this 
phenomenon are not clear, however at the preovulatory stage continued growth is 
influenced by pituitary gonadotrophin hormones; FSH and lutenizing hormone (LH) 
(Figure 1.5). These hormones bind to FSH receptors on the granulosa cells and LH 
receptors expressed on the cells of the theca interna, the synergistic action of which 
results in Oestradiol production (Figure 1.6).  Follicles compete for FSH and a 
dominant, growing follicle is selected, and increases in size from approximately 7 to 
18mm over a period of 10-15 days (de Ziegler et al., 2007). Factors which regulate the 
expression of FSH and LH receptors will no doubt influence which follicle becomes the 
dominant tertiary / Graffian follicle (Rawan et al., 2015).   
 
Figure 1.8, shows how LH binds to LH receptors on the thecal cells, causing these cells 
to synthesize androgens, which diffuse into the granulosa cells where they are 
aromatized to oestradiol under the influence of FSH. Granulosa cells also acquire LH 
receptors in the mid to late follicular phase, under the influence of FSH (Erickson et al., 
1979) and cooperate to maintain levels of oestradiol. Furthermore, oestradiol stimulates 
additional granulosa cell proliferation; these cells in turn secrete more oestradiol –in a 
system of positive feedback. At low levels, oestradiol has a negative feedback effect on 
the hypothalamus and pituitary (Figure 1.5), but at high maintained levels a threshold is 
reached and oestradiol then elicits a positive feedback effect resulting in an LH surge, 
which is the trigger for ovulation, which occurs approximately 38 hours later.  
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Figure 1.6 The two cell two gonatotrophin theory. 
Theory describes the synergistic actions of LH acting on thecal cells to produce androgens, which under 
the influence of FSH stimulate granulosa cells to produce oestradiol. Granulosa cells also acquire 
receptors for LH in the mid to late follicular phase and stimulate progesterone production (adapted from 
Hillier et al., 1994; Nunes et al., 2015). The additional contribution of adipose tissue to the peripheral 
aromatization of androgens to oestrogen and the impact of this is discussed in Chapter 3.  
 
Nuclear and cytoplasmic oocyte maturation occur in the period post LH surge and prior 
to ovulation and it is proposed that these events could be impaired in OWOB women, as 
discussed in Chapter 4. During nuclear maturation the oocyte completes the first meiotic 
division from prophase I to metaphase II, mediated by paracrine factors produced by the 
oocyte and granulosa cells acting via gap junctions, of which LH and FSH influence the 
opening and closing (Nunes et al., 2015). Hence, the actions of LH are indirect and 
there are no receptors on the oocyte (Dekel et al., 1988). Elevated levels of the 
inhibitory signal cyclic adenosine monophosphate (cAMP) within the oocyte maintain 
meiotic arrest (Norris et al., 2009). The surge of LH causes cAMP levels to drop and 
leads to activation / dephosphorylation of maturation promoting factor (MPF) and 
mitogen activated protein kinase (MAPK) leading to GV breakdown (Hashimoto et al., 
1988). MPF is a heterodimer of cyclin B and P34cdc2 and when cAMP within the oocyte 
decreases protein kinase A type I (PKA1) is inhibited which in turn, removes the 
inhibition from cdc2, allowing activation of MPF (Vaccari et al., 2009).    
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Meiotic maturation is accompanied by modification of centrosomes and microtubules 
within the spindle and the formation of metaphase spindles and homologous 
chromosomes cross over at meiosis I. The result of the first meiotic division is two 
daughter cells via asymmetrical division, a larger cell the secondary oocyte and a 
smaller cell, the polar body. The oocyte then enters a second round of meiosis, the 
chromosomes are attached to the spindle metaphase and meiosis is again halted. 
Activated MPF and cytostatic factor cMos maintain metaphase II arrest (Ya & Downs, 
2013).      
 
Cytoplasmic maturation accompanies nuclear maturation and is essential for ongoing 
oocyte competence. It is characterised by continued oocyte growth and preparation of 
reserves including; increased ribosomal production, the synthesis and storage of RNA 
and translation products (Campbell et al., 1996) and the storage of lipids, ions and 
carbohydrates. Furthermore, in preparation for fertilisation the golgi apparatus 
synthesises lysosome like cortical granules, which are translocated to the periphery, as 
are mitochondria in association with smooth endoplasmic reticulum. For this reason, 
oocyte polarity and spatial patterning of organelles is often used to define cytoplasmic 
maturation (Hegele-Hartung et al., 1999).  
 
Prior to ovulation the follicle becomes vascularised and swollen, causing increased 
tension and thinning of the follicular wall. Additionally, LH increases follicular fluid 
accumulation and the activity of collagenase, cumulus expansion enabling factor and 
the active secretion of hyaluronic acid. This culminates in the separation of the cumulus 
from the mural granulosa, facilitating the ovulation of the oocyte and embedded 
cumulus cells. Once the oocyte is expulsed from the ovary, under the influence of LH 
the theca and granulosa cells of the ruptured follicle become reorganised and shift to 
producing significant quantities of progesterone (in addition to some continued 
oestradiol production) and the collapsed follicle forms a corpus luteum (lutenization of 
the follicle) and represents the luteal phase of the menstrual cycle.  
 
The ovulated oocyte-cumulus complex (OCC) is picked up by the distended fimbriae of 
the oviduct Gordts et al., (1998).. The oocyte is then slowly transported by ciliary 
activity to the ampullary-isthmic junction- the site of fertilisation. 
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1.4.2 Oocyte development and maturation in vitro 
During ART the proliferative phase of the menstrual cycle is ‘down-regulated’, this can 
be achieved using a so-called ‘long’ or ‘short’ protocol and using a pituitary agonist or 
antagonist (Figure 1.7). Agonists initially cause an increase in oestrogen and 
testosterone, but sustained use causes their production to stop. Antagonists work by 
competing with GnRH for receptor binding sites in the pituitary.  Based on the studies 
performed so far, it is not possible to draw any a reliable conclusion about which is the 
superior protocol (Marcus & Ledger 2001) and there are several formulations of GnRH 
agonists / antagonists commercially available.  
 
 
 
Figure 1.7 Overview of stimulation regimes used in ART. 
 
Various stimulation regimes are available to achieve controlled ovarian 
hyperstimulation (COS). These include the use of highly purified FSH/ LH urinary 
preparations (i.e. human menopausal gonadotrophin- hMG) as well as FSH recombinant 
products (rFSH). Recent publications of large randomised controlled trials (RCTs) have 
shown urinary products (hMG) to be at least equivalent, if not more effective than 
recombinant FSH (Van Wely et al., 2003; Coomarasamy et al., 2008; Al-Inany et al., 
2008). The use of a FSH-only recombinant may however, have theoretical advantages 
for patients at risk of hyperstimulation (Ragni et al., 2005).  
 
Follicle development, hormone levels and endometrial thickness are carefully 
monitored to obtain a cohort of co-dominant follicles containing oocytes capable of 
responding to human chronic gonadotrophin (hCG) administration, which is 
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administered to mimic the endogenous surge of LH that would occur in a natural 
menstrual cycle to initial ovulation. 
 
Oocytes are collected approximately 36 hours post hCG injection. This injection is 
planned to release oocytes from meiotic arrest, i.e., meiosis is resumed and the oocytes 
are allowed to reach metaphase of meiosis II.  Oocyte retrieval is timed prior to 
spontaneous ovulation. Routinely >85% of oocytes recovered are graded as mature at 
the time of the procedure, when they are graded on the basis of their oocyte-cumulus 
complex morphology/ degree of expansion (Rattanachaiyanant et al., 1999). Oocyte 
grading is discussed in Chapter 2 and the relationship between oocyte quality, 
maturation and female BMI is reviewed in Chapter 4.  
 
1.4.3 Fertilisation in vivo 
Spermatozoa that have been deposited in the female tract reach the oviduct by active 
(their own motility) and passive (muscular contractions of the female tract and ciliary 
currents) transport. Suarez et al., (2006) have compiled an extensive review on how 
sperm transport differs in human to that of other mammalian species from its site of 
deposition (anterior vagina), coagulation, transport through the cervix, uterus, uterotubal 
junction and possible entrapment to endosalpingeal epithelium. It is not clear if a 
distinct sperm reservoir exists in human, as observed in other species (Williams et al., 
1993), but it is apparent that the advancement of sperm into the ampulla is somehow 
prolonged, thus ensuring only a few sperm reach the ampulla at any one time.  
 
At some point in the female tract, sperm undergo a process of hyperactivation and 
capacitation (Austin 1951). The vigorous ‘whiplash’ movement of sperm flagellum 
morphemes hyperactivation and is thought to enable sperm to penetrate viscoelastic 
solutions of the female tract and detach from the endosalphingeal epithelium and may 
also aid sperm passage through the corona radiata of the oocyte (Suarez et al., 2006). 
Only capacitated sperm are able to bind to the zona pellucida surrounding the oocyte 
(Chang et al., 1984; Lamirande et al., 1997). This essential priming step involves a 
process of changes to the sperm plasma membrane, including the loss and modification 
of proteins and cholesterol, elevation of intracellular calcium ion concentration, which 
enhances the intracellular generation of cAMP (Fraser 1989) and sperm gain the ability 
to undergo acrosome reaction. Capacitated sperm bind first, to ZP3 on zona pellucida, 
this receptor protein interaction initiates the release of proteolytic enzymes from the 
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sperm acrosome and the membrane of the acrosome, fuses with the plasma membrane 
permitting further additional binding to ZP2. Once the ZP has been fully breached the 
sperm and oocyte plasma membranes fuse resulting in the passage of the sperm and 
contents through oolema. The male pronucleus (PN) is formed, as its heterochromatin 
decondenses and protamines are quickly replaced by histones (Morgan et al., 2005). 
 
This sperm egg fusion is followed by a propagated calcium wave (Jaffe, 1980), as 
calcium is release from internal oocyte stores and additionally it this point cortical 
granules are exocytosis from their membrane-bound position at the periphery of the 
oocyte into the perivitelline space. These changes indicate that the oocyte has been 
activated and the cortical reaction results in zona hardening to prevent further sperm 
from entry. The initial rise in calcium is followed by a series of oscillating spikes which 
promotes the destruction of cyclin B, thus maturation promoting factor activity is lost 
and the oocyte is able to resume meiosis (reviewed by Whitaker, 2006). This results in 
the extrusion of the second polar body and the formation of a now true haploid nucleus 
and the formation of the female PN  
 
The male and female PN align at the periphery of the oocyte and rotate to the centre, 
approximately 16-18 hours after the initial fusion of the gametes. It is during this 
migration that chromosomes synthesize their DNA and nucleoli within the PN begin to 
condense and align. The PN membranes then disintegrate, the mitotic metaphase spindle 
forms and chromosomes are aligned and come together in syngamy, chromatids 
separate, a cleavage furrow forms and the first mitotic anaphase and telephase are 
completed. In humans syngamy of PN occurs approximately 18-24 hours after sperm-
oocyte interaction and by enlarge it results from the close alignment of PN membranes 
(Levron et al., 1995). 
 
It is important to note that during PN maturation the paternal and maternal genomes 
undergo different DNA methylation patterns; they are epigenetically asymmetrical 
(Corry et al., 2009). The paternal genomes are packaged differently to the maternal 
genomes (protasomal and nuclesomal respectively) and whilst the paternal PN 
undergoes active DNA demethylation, acquisition and modification of histones, the 
maternal PN lags behind. The maternal PN remains methylated, maintaining imprints 
post-fertilisation and into early embryo development (reviewed by Inbar-Feigenberg et 
al., 2013). Prior to this point of fertilisation, the timing of remethylation also varies 
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between the male and female germline; DNA is globally demethylated in the PGC of 
both sexes and denovo methylation occurs rapidly in spermatagonium, but is established 
gradually during the growth phase of oogenesis (this is discussed further in Chapter 4). 
DNA methylation is the process of gene silencing via methylation at CpG dinucleotides, 
and histone modifications affect chromatin accessibility to DNA replication and 
transcription, hence both processes contribute to the epigenetic regulation of gene 
expression. Much of what is known about epigenetic remodelling has been derived from 
animal studies, however the processes are believed to be largely conserved in the human 
(Lucas 2013), although the paternal demethylation may occur to a lesser extent (Santos 
et al., 2010). The process of epigenetic control and potential consequences of 
environmental disruption to this process is highly significant and relevant to this thesis.  
 
1.4.4. Fertilisation in vitro 
Men are asked to produce a semen sample, having observed 3-5 days prior abstinence 
from sexual activity, to optimize the volume and concentration (Lampe et al., 1956, 
Poland et al., 1985). The laboratory preparation of sperm is then needed to separate 
sperm from the seminal fluid – which inhibits capacitation. Semen samples are 
processed to separate motile sperm, of optimum morphology from the seminal plasma, 
either by (a) ‘swim-up’ technique – in which media is layered over seminal plasma and 
motile sperm swim up into the overlay or (b) density gradient separation –by pipetting 
semen onto a density column and centrifuging (Boomsma et al., 2007). Prepared 
samples are re-suspended in culture medium, at a concentration suitable for 
insemination (IVF) or intra cytoplasmic injection (ICSI) of the collected oocytes.   
 
Oocytes are inseminated in vitro often in 4-well plates with approximately 100,000-
150,000 sperm per ml of culture medium. Insemination concentration is optimised to 
attain successful fertilisation without overexposing oocytes to high concentrations of 
sperm and risking polyspermia, pH changes and generation of reactive oxygen species 
(Aitken et al., 1994, Ozgur et al., 1999). The timing of insemination (2 to 4 hours after 
retrieval) is performed according to the maturity of the oocyte, in order to avoid 
abnormal fertilisation, which can occur when oocytes are inseminated in an immature or 
post mature state (Trounson, 1982).  
 
When semen parameters are suboptimal (below WHO manual 2010 reference values), 
ICSI may be used to facilitate fertilisation (Cooper et al., 2009). In this procedure the 
19 
 
cumulus and corona cells, which surround the oocytes, are removed by a combination of 
enzymic and mechanical manipulations. A single sperm is then injected through the 
zona pellucida and the oolemma directly into each MII oocyte (Van Steirtingham et al., 
1999).  
 
Oocytes are inspected for pronuclear status approximately 18 hours after insemination 
(IVF) or injection (ICSI). The presence of two distinct pronuceli (PN) and two polar 
bodies (pb) is indicative of normal fertilisation. 
 
1.4.5 Embryo cleavage and blastocyst formation in vivo 
Some 20-24 hours after sperm penetration of the oocyte, the fertilised oocyte (zygote) 
completes its first cleavage division. Subsequent cell divisions (cleavage) then occur 
every 15-18 hours, as the dividing embryo moves along the fallopian tube to the uterus. 
Cleavage cell divisions occur without altering the overall size of the embryo, which is 
enclosed by the zona pellucida, hence the cytoplasm is divided between daughter cells, 
known as blastomeres, which become increasingly smaller in size and closer in 
apposition.   
 
At the 4-8 cell stage in the human (day 2-3 of development), embryonic genome 
activation  (EGA) occurs (Braude et al., 1988). At this point maternal mRNA transcripts 
are depleted and replaced by those of the zygote, hence zygotic genome expression 
increases. The transition is believed not to be absolute; as a small amount of maternal 
mRNA is needed up to the blastocyst stage and therefore environmental factors 
influencing oocyte development can still affect development post EGA (Moor et al., 
1998). Impairments of transition from maternal to embryonic control may have their 
origins in aberrant gene expression of maternal factors possibly resulting from 
incomplete oocyte cytoplasmic maturation (Schramm et al., 2003) (discussed further in 
Chapter 4). The transition to EGA is also phased, as the replacement of maternal 
transcripts occurs at different rates for different genes, for instance several sex 
determining genes are thought to be active from the pronuclear stages (Edwards & 
Beard, 1997). It is also highly probable that blastomeres develop cell automonously, 
with some cells advancing to EGA and others arresting Wong et al., (2010), possibly 
explaining why some cells fail to divide. 
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At about the 8-16 cell stage the increased contact between blastomeres, causes them to 
compact and flatten. Compaction marks the starting signal for cell differentiation, as 
intercellular junctional complexes assemble between the blastomeres and form zonal 
tight junctions composed of occludin and cingulin and gap junctions that permit the 
flow of second messengers that act to govern cellular diversification (Brison et al., 
2014; Sozen et al., 2014). Following compaction the embryo is described as a morula 
and at this point the cells on the periphery of the morula will have different contacts to 
those in the middle, which may help explain the onset of the different polarity and 
differentiation of the cells. Thus, cells on the periphery begin to differentiate into the 
trophectoderm cells (TE) and those internally form the inner cell mass (ICM). The TE 
will eventually form the placenta and extra-embryonic tissue, whereas the ICM will 
generate the embryo proper and represent a pluripotent cell population. It is likely that 
this idea of cell allocation based on positional relationships within the embryo is an 
overly simplistic view, as polarisation can occur in cells prevented from compacting 
(Cockburn et al., 2010). The opposing view is that position determines cell fate and 
gene expression determines position. This idea was initially presented by Gardner 
(2005), who has made a cogent argument for the role of pre-patterning in mammalian 
embryos, being a normal facet of development and dependent on intrinsic organisation 
of the oocyte.  
 
Coinciding with cell differentiation, de novo methylation begins in the morula and 
epigenetic differences are seen between the cells of the ICM and TE. Appropriate 
epigenetic remodelling during early embryonic development is essential and is a critical 
period of susceptibility to dysregulation, with the human trophectoderm reported to be 
highly susceptible to epigenetic misregulation (Rugg-Gunn 2012).     
 
From approximately the 32 cell onwards cavitation begins; activation of the Na+, K+, 
ATPase enzyme drives the movement of Na+ to the basolateral side of the TE creating 
an osmotic gradient which draws in water to form a fluid filled cavity known as a 
blastocoel. Tight junctions prevent the fluid from moving out (Krupinski et al., 2011).  
 
In the human the embryo forms an early blastocyst on approximately day5, fluid 
accumulation continues and the blastocyst expands on day 5-6. This causes the 
surrounding zona pellucida to thin and blastocyst hatching can be initiated usually on 
day 6-7. It is not know if this occurs as a result of hydrostatic pressure or through a 
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small rupture in the zona and given the discourse in the literature (Ebner et al., 2010; 
Miyata et al., 2010) on this topic, it is tempting to speculate that this is not only species 
specific but is also influenced by environmental factors. Figure 1.8 provides an 
illustrative summary of some of the processes as the embryo develops to the blastocyst 
stage. 
 
 
 
Figure 1.8 Embryo developmental changes from day 1 to 9. 
Development from zygote to blastocyst stage is depicted (Figure adapted from Smith & Sturmey 2013). 
 
1.4.6 Embryo cleavage, development and assessment in vivo 
Assessment of embryo development is discussed in more detail in chapter 2, however it 
is important to outline the different assessment approaches and criteria which may be 
applied. Assessments may be conducted at discreet time points throughout development 
to build up a sequential picture, alternatively in recent years attention has moved to the 
use of time-lapse imaging systems. Time-lapse imaging permits numerous observations 
to be made, with images typically being acquired every 10-20 minutes. Whilst the 
virtues of such analyses are widely extolled, randomised controlled trials demonstrating 
the efficacy of such an approach are still currently lacking (Bolton et al., 2015).   
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Traditionally, embryos are checked for development/quality at distinct time points; 
commonly at 20-24 hours post insemination (hr/pi) for early cleavage division, 46hr/pi 
(day2) and 68hr/pi (day 3) for cleavage stage assessments and 116hr/pi for blastocyst 
development (day 5). Embryos may be transferred into the uterus at the cleavage or 
blastocyst stage. In each case, embryos are checked visually immediately prior to 
transfer to ensure selection of the best quality embryos. 
 
A number of strategies have been designed for grading and selecting embryo(s) for 
transfer. These include pronucleate scoring which assesses the symmetry, position and 
localisation of nucleoli (Scott & Smith 1998), checking for the timing of the first 
cleavage division (Sakkas et al., 2001), cell scoring on day 2 and day 3 and extended 
culture which permits selection of blastocysts for transfer (details are provided in 
chapter 2).  
 
Often embryos are critiqued on their cell number and morphology on day 2/3.  The cell 
number should be appropriate for the time of assessment, with slow growing and 
unusually fast growing embryos have low implantation potential (Cummins et al., 1986, 
Puissant et al., 1987, Staessen et al., 1992, Giorgetti et al., 1995) and shown to have 
higher levels of chromosome aberrations (Van Royen et al., 1999).  Whilst gross visual 
morphology assessment criteria are imprecise (Sharpiro et al., 2000), it has been shown 
that embryos with higher fragmentation are less likely to implant and develop than 
unfragmented counterparts (Giorgetti et al., 1995). Furthermore, the presence of 
multinucleated blastomeres is associated with significantly impaired implantation 
(Pickering et al., 1995, Jackson et al., 1998, Van Royen et al., 2003), possibly through 
defective transcription of genes leading to developmental arrest. 
 
There is an established link between the surmised embryo quality score (combined cell 
number and morphology grade) and the pregnancy outcome (Giorgetti et al., 2006, 
Ziebe et al., 1997). Gerris et al., (1999), reported that patients who had embryos 
regarded as ‘top quality’ (≥7 blastomeres, <20% fragmentation, day 3) had a good 
prognosis for achieving a pregnancy, however they were significantly more likely to 
have a multiple implantation if two embryos are transferred. Multiple pregnancies carry 
a higher risk of miscarriage, maternal complications and premature delivery, therefore 
when the patient has multiple good quality embryos to select from; the pressure to 
identify the most viable embryo for transfer is increased. Extending the culture period 
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until day 5, is one way to facilitate the selection process (Cutting et al., 2008), although 
the quest to identify putative biomarkers of embryo viability is discussed throughout 
this thesis.  
 
On day 5 of development blastocysts are selected for transfer or freezing according to 
presence of cavity, visible inner cell mass, regular trophoblast cells, degree of 
expansion, and zona thinning. Analpha-numerical score is assigned for the degree of 
expansion/ hatching status and the visual appearance of the cells of the inner cell mass 
(ICM) and trophectoderm (TE). Good quality blastocysts are identified by a high 
number of cells in the ICM and tight knit epitheliem of the TE (Gardner and Schoolcraft 
et al., 1999).  
 
Studies comparing implantation and pregnancy rates following transfer of blastocyst or 
cleavage stage embryos have in the past produced conflicting results (Gardner et al., 
1998; Schoolcraft et al., 1999; Milki et al., 2000, Coskun et al., 2000; Huisman et al., 
2000).  However, Blake et al., (2007), reviewed data from 18 randomised controlled 
trials and concluded that for selected good prognosis patients blastocyst transfer offers a 
significant advantage. Furthermore, karyotype analysis has shown that whilst 68% of 8 
cell embryos were abnormal only 43 % of the cells in the blastocyst were aneuploid 
(Magli et al., 2001). Taken together, it may be argued that extended culture to the 
blastocyst allows selection of the best quality embryo for transfer and could reduce the 
likelihood of cryopreserving non viable embryos.  Despite this, safety concerns over 
blastocyst culture linger and evidence has emerged recently that suggests that prolonged 
culture in suboptimal conditions could cause long-term reprogramming in the embryo, 
thus the need for structured long-term follow up studies of children conceived by ART 
is paramount (Chronopoulou et al., 2015).  
 
The actual embryo transfer procedure requires the selected embryo(s) to be loaded into 
a transfer catheter, which is fed through the cervix, so the tip is positioned 1cm from the 
fundus and the embryo(s) expelled. Luteal support (progesterone), is necessary in IVF 
cycles (Van der Linden et al., 2001) and is continued until pregnancy testing (after 10 
days) and often up to the 9th gestational week in the case of pregnancy.  Progesterone 
prepares the endometrium for pregnancy in the luteal phase of the menstrual cycle and 
is insufficient in ART cycles, possibly due to the supra-physiological concentrations of 
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steroids secreted by a high number of corpora lutea during the early luteal phase and 
negative feedback effects (Sofuoglu et al., 2015). 
 
Surplus good quality embryos / blastocysts may be selected for cryopreservation. 
Cryopreservation coupled with frozen embryo transfer can increase cumulative 
pregnancy rates (Sharipo et al., 2011) and is also used to reduce the risk of 
hyperstimulation in vulnerable patients and as a fertility preservation strategy. There are 
two predominant methods for cryopreservation; slow freezing and vitrification and there 
is no single optimum protocol for a cryopreservation cycle, however several studies 
have shown a correlation between embryo quality and freeze tolerance (Karlstrom et al., 
1997; Check et al., 2009).  
 
1.5 Energy metabolism 
 
The sequential stages of dynamic, preimplantation development from oocyte maturation 
to blastocyst formation are obviously energy dependent. Energy metabolism can be 
described as the liberation of chemical energy from food and its conversion into 
different forms of chemical energy (as almost exclusively adenosine triphosphate- ATP 
and reducing equivalents and precursors for macromolecular synthesis) to make 
energetically unfavourable reactions possible. ATP is central to energy metabolism. The 
ratio of ATP:AMP or ATP:ADP permits cells to ‘sense’ energy availability and thus 
regulate metabolic pathways that produce or use the ATP. 
 
The principle means by which ATP may be formed are aerobic oxidation of substrates 
into carbon dioxide and water or anaerobic glycolysis of glucose to lactic acid. The 
precise metabolic requirement of oocytes, cleavage stage embryos and blastocysts are 
met via pathways specific to each cell type, utilising the oxidisable substrates; glucose, 
pyruvate, amino acids and fatty acids. The common metabolic pathway for each of these 
substrates is the tricarboxylic acid cycle (TCA), which produces reducing equivalents 
(NADH and FADH2) for use in the electron transport chain (ETC), which allows 
oxidative phosphorylation (Ox-Phos) to occur and leads to the generation of ATP. 
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The regulation of energy production is fundamental for embryo survival and 
propagation (Gardner et al., 2013) and maybe indicative of embryo viability. 
Furthermore, the rate of uptake and the metabolic fate of nutrients utilised by early 
embryos are reported to be associated with developmental outcome (Gardner et al., 
2011). This has led to a desire to identify the normal pattern of substrate utilisation, and 
how the detailed metabolic profile of an embryo may be measured using non-invasive 
biochemical assays to determine individual embryo viability. Much of the fundamental 
research, has been conducted in animals and this has facilitated our understanding of the 
dynamic changes in bioenergetic status that accompany oocyte and embryo 
development and how the loss of this control may lead to compromised viability. A 
review of studies attempting to use metabolic activity as a biomarker of individual 
embryo viability is presented in Chapter 5, but first an account of those studies that have 
led to our current understanding of normal preimplantation metabolism is provided in 
the following sections.  
 
The environment in which the oocyte / embryo develops can influence its metabolism, 
as the developing embryo is exposed to a variety of micro environments as it traverses 
the female reproductive tract from the oviduct to the uterus (Leese et al., 2008) and the 
strategies/ pathways utilised by the embryo to derive energy are reflective of this. In the 
normal course of development embryonic genes are successively turned on, as mitosis 
and biosynthesis increases after embryonic genome activation and the demand for 
energy increases (Gardner et al., 2013). The metabolic pathways and ‘machinery’ 
available to gametes and embryos are aligned with their energetic demands, substrate 
availability and crucially, oxygen and the reductive or oxidative (REDOX) state of the 
cell.  Consequently the generally accepted pattern of early embryo metabolism is; low 
activity and demand for ATP in the cleavage stages, with reliance on pyruvate and less 
so on glucose, and higher activity at the blastocyst stage with concomitant increases in 
glucose uptake, initially higher at the blastocyst stage, as energy is required to power 
the Na+/K+ ATPase and for protein synthesis since true growth only begins at this stage 
(reviewed by Leese, 2012). 
 
The embryonic cells, are the progenitor cells with the potential to express every gene 
and capacity to differentiate into every cell in the human body and therefore it is not 
known to what extent metabolic pathways available to specialised cell types (i.e. 
differences in enzymes expressed in a myocyte, adipocyte, hepatocyte) can be 
26 
 
extrapolated to the embryo. Furthermore, as the cells of the embryo become 
increasingly differentiated their metabolic properties are likely to change and maybe 
modulated by prior environmental exposure. It can be inferred that, defined and specific 
roles for different cell types (oocyte, blastomeres of a cleavage cell embryo, ICM and 
TE cells of a blastocyst) will be evident, based on their individual needs and adaptation 
to their environment. Nonetheless, an understanding of cellular metabolism and energy 
production is valued in terms of whole body health, as control of biochemical metabolic 
pathways is essential for control of obesity; the central tenant of this thesis. Figure 1.9 
highlights how the specific substrate requirements of a mammalian cell maybe met 
through these interlinked pathways. 
 
 
 
Figure 1.9 Interlinked metabolic pathways in a mammalian cell. 
ATP is generated by glycoysis and OxPhos. Glucose is metabolised by glycolysis producing ATP and 
pyruvate which is converted to lactate (anaerobic) or to acetyl CoA (aerobic) and enters the TCA cycle, 
similarly β-oxidation of fatty acids generates Acetyl CoA and amino acids can be used as substrates 
entering the TCA cycle at various points. The TCA cycle generates NADH and FADH2 for use in the 
ETC and allows OxPhos and generation of ATP. Glucose, once converted to G-6P (first step in 
glycolysis) may also be directed to the Pentose Phosphate Pathway (PPP), particularly when there is a 
need for biosynthesis during rapid phases of growth to generate NADPH and ribose moieties. (Figure 
adapted and reproduced, with the permission of P. McKeegan, 2015). 
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1.6 Oocyte metabolism 
 
The oocyte metabolises a range of substrates including pyruvate, glucose, oxygen, fatty 
acids, amino acids, purines and pyrimidines for energy production, nuclear maturation, 
production of matrices, signalling molecules and maintenance of cellular homeostasis/ 
REDOX potential (Collado-Fernandez et al., 2012). The oocyte itself has a limited 
capacity for the uptake of these substrates and is reliant on the bidirectional 
communication which occurs between it and the granulosa-derived cumulus cells (Dan-
Goor et al., 1997). The granulosa cells are metabolically coupled to the oocyte via gap 
junctions, throughout the initial growth and maturation of the oocyte (de Loos et al., 
1991). During folliculogenesis the granulosa cells proliferate, resulting in increased gap 
junctions and increased coupling due to increased surface area and attachment. The 
cumulus granulosa cells express growth factor receptors, mRNA for growth factors and 
provide angiogenic factors (involved in blood vessel formation), prostaglandins and 
metabolic precursors (amino acids and nucleotides) to the oocyte to facilitate maturation 
as well as ATP for the reactions involved in nuclear maturation and resumption of 
meiosis (reviewed by Sutton-Mcdowell et al., 2010). Thus, removing the cumulus cells 
can disrupt oocyte maturation and compromise viability (Eppig 1991). 
 
The energetic demands for GVBD and resumption of meiosis appear to be met by the 
oxidative metabolism of pyruvate (Downs et al., 1997, Sutton et al., 2003). Whilst 
glucose is the preferred metabolic substrate for cumulus cells (Leese & Barton, 1985), 
the oocyte itself has a poor capacity to utilise glucose (Biggers et al., 1967) and it is the 
cumulus cell which metabolise glucose to provide a source of pyruvate and lactate for 
uptake by the mammalian oocyte (Leese & Barton, 1985). It has been shown that 
oocytes express very few receptors for the uptake of glucose, compared to cumulus 
cells, which not only express more transporters (Dan-Goor et al., 1997), but also express 
the facilitative transporter SLC2A4, which has a high affinity for glucose and is insulin 
sensitive (Sutton-McDowall et al., 2010). Furthermore, oocytes have limited expression 
and activity of glycolytic enzymes such as phosphofructokinase (PFK) (Sutton-
McDowall et al., 2010), but their relative expression of glucose-6-phosphate 
dehydrogenase (G6PDH) is reported to be higher (Cetica et al., 2002). (The high 
G6PDH activity in developing oocytes is discussed in further detail in Chapter 4). This 
enzyme regulates the flow of substrates through the Pentose Phosphate Pathway (PPP) 
and would indicate that the PPP occurs mainly in the oocyte, which has low glycolytic 
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activity, whereas the converse expression pattern was reported for cumulus cells, which 
are thought to be primarily glycolytic. To complete maturation the oocyte does 
therefore, need to metabolise some glucose via PPP for the synthesis of the purine and 
pyrimidine precursors of DNA and RNA (Sutton et al., 2003) and NADPH for 
biosynthesis of lipids and complex molecules, which is important during growth. 
 
It is apparent that the metabolic profiles of the follicular cells and the oocyte change 
during folliculogenesis and oogenesis, as demand for energy increases. In the mouse 
oocyte growth results in increased pyruvate and oxygen consumption, whereas follicular 
growth results in increased glucose consumption and lactate production (Harris et al., 
2009). This shift from low glycolytic activity in pre-antral follicles to high glycolytic 
activity in antral follicles has also been reported in the bovine, with mature bovine 
cumulus-oocyte complexes (COC) reportedly consuming twice as much glucose, 
pyruvate and oxygen compared to immature COC (Sutton et al., 2003). The increased 
glycolytic activity of follicular cells, could be related to oxygen availability, with 
increased size compromising the supply from theca capillaries (Redding et al., 2007). 
Additionally the initiation of oestrogen synthesis in follicular cells could be creating an 
increased demand for energy (Harris et al., 2007). Consistent with this is the finding 
that FSH increases glycolytic activity (Downs et al., 1996), as glucose is required to 
support FSH-dependent cumulus expansion and oocyte maturation.   
 
During maturation the oocyte requires amino acids for protein and mRNA synthesis 
(Picton et al., 1998). Specifically, glutamine, aspartate, glycine, together with ribose-5-
phosphate from PPP are required for the de-novo synthesis of purine and pyrimidine 
nucleotides. Different amino acid transport systems have been identified in growing and 
mature oocytes. Glutamine uptake is reported to increase by 2.5 times during the first 18 
hours of maturation (Reiger & Loskutoff 1994) and during GVBD there is an increase 
in oxidative metabolism of glutamine and glycine, which can feed into the TCA cycle 
(Harris et al., 2007) to provide ATP. Aspartate uptake by the oocyte is also reported to 
increase after GVBD (Pelland et al., 2009). Additionally, amino acids maybe taken up 
by cumulus cells, as these cells poses greater activity of enzymes involved in amino 
acid metabolism than oocytes (Cetica et al., 2003).  The roles of individual amino acids 
during oocyte development are only just beginning to be understood, however the 
pattern of amino acid depletion and appearance from culture medium during in vitro 
maturation (IVM) has used to predict the developmental competence of bovine oocytes 
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(Hemmings et al., 2012), underscoring the importance of amino acid metabolism during 
acquisition of nuclear and cytoplasmic oocyte maturation. 
 
Once the oocyte has been ovulated and gap junctions coupling the oocyte to granulosa 
cells have broken down, the oocyte is surrounded by a limited number of corona cells 
and it is plausible that it will become increasingly reliant on endogenous energy stores 
of glycogen, fatty acids and protein as a source of ATP. Lipids in particular have been 
identified as good candidates for energy provision during this phase of development 
(Sturmey et al., 2009). In part, because lipid droplets have been shown to accumulate 
during initial oocyte growth and significant stores of triglycerol (TG) have been 
reported within the ova of pigs, and sheep (McEvoy et al., 2000). In addition, during 
IVM, TG levels are reported to decrease (Ferguson & Leese, 1999) and significant 
lipase activity has been reported in bovine oocytes (Cetica et al., 2002). Lipases 
hydrolyse TG and free fatty acids (FFA) can then be transported into the mitochondrial 
matrix for β-oxidation and conversion to acetyl CoA for use in the TCA cycle. This 
transport is facilitated by the ‘Carnitine-Acyl Carnitine Shuttle’ (Vaz & Wanders, 2002) 
and this is discussed in further detail in Chapter 6.   
 
The speculative role of endogenous TG stores and FFAs in supporting oocyte 
development is also born of the fact that fatty acid oxidation can generate a high number 
of ATP molecules, (given their anhydrous nature and number of carbon-carbon bonds, 
fatty acids produce more ATP per unit mass/ per mole than glucose) and the observed 
close association of lipid with mitochondria reported by ultrastructural (Sun et al., 2001) 
and FRET (Sturmey et al., 2006) analysis – leading authors to propose that these are 
acting in convoy as ‘metabolic units’. However, whilst the inhibition of β-oxidation 
during IVM results in impaired developmental competence (Dunning et al., 2010), it is 
unlikely that endogenous sources alone can supply sufficient energy, as development is 
also limited during culture without external energy substrates (Sutton-McDowall 2012). 
It is highly probable that the role of endogenous stores will be species specific akin to 
the significant differences in lipid accumulation reported for a variety of species 
(reviewed by Sturmey et al., 2009).  Similarly on the whole, species specific differences 
in substrate preference may exist, as shown by Krisher et al., (2007). 
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In summary; studies on oocyte metabolism have generally revealed that development is 
supported by low levels of oxidation of pyruvate, lactate, specific amino acids, with 
possible contribution of endogenous TG, however it is vital to note that metabolic 
activity will be influenced by the availability of substrates.  In in vitro studies, this is 
dictated by culture media, which are relatively simple in composition with a limited 
number of nutrients; in the ovarian follicle the follicular fluid is the source of energy 
substrates and the follicular environment that the growing COC is exposed to may 
affect long term developmental competence post fertilisation. Follicular fluid provides a 
source of oxygen, metabolites, growth factors, hormones and buffering molecules 
(Sutton et al., 2003). In general terms the concentration of metabolites within the 
follicular fluid is believed to be comparable to plasma levels, although individual 
follicular concentrations are positively correlated with ovarian follicular size (Nandi et 
al., 2008) and COC metabolism changes as the follicle develops (Harris et al., 2009). 
Controlled ovarian stimulation for fertility treatment results in the recruitment of a 
relatively homogenous pool of growing follicles, synchronously triggered to mature, 
and hence provides an opportunity to study the impact of maternal nutritional status on 
oocyte phenotypic features and subsequent morphokinetic development, a factor which 
is explored in detail in chapter 4 of this thesis.    
 
1.7 Embryo metabolism 
 
Embryo metabolic activity can be thought of in two phases; (1) the cleavage stage and 
(2) the blastocyst stage (Biggers et al., 1967). As previously mentioned, at the early 
stage of development the embryo’s energy demands are lower and similar to those of 
the oocyte, with ATP produced from pyruvate, lactate or amino acids, whereas at the 
later blastocyst stage energy requirements are higher primarily met by increased glucose 
consumption. Oxygen consumption believed to be low throughout embryo cleavage 
stages reaches a peak at the blastocyst stage (Sturmey et al., 2003).  The pattern appears 
to be relatively conserved across all species (human, bovine, porcine, murine) studied.   
 
Much of what we know about the different metabolic requirements of the early and later 
stage embryo have been derived from the application of inhibitory / stimulatory 
treatments- the effects differing according to whether treatment is applied pre or post-
compaction.  Inhibition of oxidative phosphorylation prior to compaction is highly 
inhibitory to development (Thompson et al., 2000), whereas suppression of glycolysis at 
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this stage improves development (Gardner & Lane 1996). The use of radiolabeled 
substrates and micro florescence analysis has provided data on the precise amount of 
substrate uptake / production, however these measurements are made under in vitro 
conditions and may not be representative of the in vivo situation. Additionally, many of 
these studies have focused on the murine embryo due to difficulties attaining research 
licensing and ethical approval to study the metabolism of human embryos.   
 
1.7.1 Embryo metabolism at the cleavage stage 
Studies in numerous species have shown that fertilisation and oocyte activation result in 
an elevation in metabolism (Dumollard et al., 2008), sperm entry causes up-regulation 
of the PPP (Urner & Sakkas, 1999) and results in an approximate 30% increase in 
pyruvate uptake (Devreker et al., 2000) and a peak in oxygen consumption has been 
observed to coincide with the time of the first cell division (Tejera et al., 2012).  
 
During the subsequent cleavage stages, the embryo displays a preference for oxidative 
(aerobic) metabolism of pyruvate, lactate and amino acids (Brinster et al., 1965). The 
energy requirements are low at this stage (Leese et al., 2001), as is the rate of oxygen 
consumption and carbon dioxide production, although the ATP:ADP ratio is high, 
indicating a degree of metabolic quiescence. At this point the energy needs of the 
embryo are relatively low, as despite the fact that DNA replication and cell division are 
occurring, there is no change in the overall embryo size (Leese et al., 2008). Pyruvate 
enters the cleavage embryo by a facilitated carrier (Gardner & Leese, 1998) and it is 
used preferentially as a substrate for generating ATP via the TCA cycle and OxPhos 
and therefore lactate production is relatively low. The conversion of some pyruvate to 
lactate is however, required to regenerate cystolic NAD+, for use in glycolyis at the later 
stages of development (Lane & Gardner, 2000), as an excess of pyruvate to lactate, can 
disrupt the ratio of NADH:NAD+ and can impair embryo development (Dumollard et 
al., 2007). Furthermore, whilst pyruvate uptake is the preferred substrate at the cleavage 
stage, it’s uptake by human embryos has been shown to continue to increase between 
successive cleavage divisions and the blastocyst stage (Hardy et al., 1989), even once 
glucose consumption rises post compaction.  
 
Prior to compaction respiration rates are low and there is a high ATP: ADP ratio, post 
compaction the reverse is true and the low ATP:ADP ratio releases PFK from inhibition 
permitting an increase in glycolytic flux. By the 8-cell stage in the mouse, glycolysis is 
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fully functional (Biggers et al., 2008) and the uptake of glucose relative to pyruvate 
increases after this stage (Leese et al., 1993). There is a shift in the REDOX state to a 
more reduced state, which may be important in accommodating an increasingly hypoxic 
environment (Harvey et al., 2002). Embryos are thought to encounter a decreasing 
oxygen concentration as they traverse down the reproductive tract towards the uterus 
(Leese, 1995). Exposure to a prolonged oxidized state is thought to be unfavorable for 
embryo development (Harvey et al., 2002), stimulating the generation of reactive 
oxygen species (ROS), primarily produced through the ETC. ROS are important 
signalling molecules, however if produced in excess they can cause cellular damage and 
compromise mitochondrial function (reviewed by Muoio 2014). 
 
The REDOX state is influenced in part by the ratio of NAD:NADH  and the ratio of 
pyruvate: lactate, which differ between the cleavage stage and blastocyst stage (Lane & 
Gardner 2000). Rather than pyruvate being utilized in the TCA cycle, as happens at the 
cleavage stage, as the embryo begins to compact, pyruvate is increasing used to 
generate of lactate and this regenerates cytosolic NAD+. A supply of NAD+ is required 
for glycolytic flux. During glycolytic metabolism of glucose the pyruvate produced may 
then be converted into lactate (usually under conditions of low oxygen); this requires 
NADH and allows the regeneration of NAD+ and prevents glycolysis from being 
stalled. This is vital for maintaining the REDOX balance and is vital for maintaining 
cellular stability (Coffman & Denegre 2007). NAD+ has also been shown to be 
regenerated indirectly by the malate-aspartate shuttle and this mitochondrial shuttle 
transports protons into the mitochondria and regenerates NAD+ in the cytosol 
(Newsholme et al., 1983). The mitochondrial structure and distribution are crucial for 
normal embryonic metabolism, the distribution appearing to be specific for embryo 
compaction (Harvey et al., 2007) and the number needing to attain a threshold to 
generate energy production to support further development and growth (Wakefield et 
al., 2011). 
 
1.7.2 Embryo metabolism at the blastocyst stage 
Prior to compaction, levels of biosynthesis of proteins, lipids and complex molecules 
are low, which increase at the post-compaction and blastocyst stages, hence the demand 
for energy rises sharply. The demand for ATP production at the blastocyst stage is 
partly due to the energy requirements of the Na+/K+ ATPase, which facilitates cavity 
formation (Houghton et al., 2003). Secondly, there is a large increase in carbon 
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incorporation into protein synthesis for growth at the blastocyst stage (Houghton & 
Leese 2004). Each of these two processes require approximately 25% of total energy 
intake (Leese at al., 1991).  
 
Protein synthesis increases at the blastocyst stage, with the onset of true growth (Leese, 
1993). In addition, amino acid consumption increases between the cleavage and 
blastocyst stage, primarily due to their role in protein synthesis. Excess amino acid/ 
protein is oxidised in preference to carbohydrate as the cell does not have the capacity 
to store it. Amino acid breakdown products can enter the TCA cycle at various points, 
as shown in Figure 1.10. In bovine and human embryos the requirements for individual 
amino acids are shown to change with development (Partridge & Leese 1996, Houghton 
et al., 2003), reflective of the distinct and varying functions of amino acids within the 
mammalian embryo. Beyond being utilised in biosynthetic pathways (protein synthesis 
and nucleotide synthesis) and as energy substrates, amino acids are precursors of signal 
transducers, they provide a defence against oxidative damage, act as pH zwitterons, 
osmolarity regulators, heavy metal chelators and donors of methyl groups (reviewed by 
Leary et al., 2012).  
 
 
Figure 1.10 Amino acids can be converted to TCA cycle intermediates. 
The TCA cycle is required for the stepwise oxidation of Acetyl CoA to produce NADH and FADH2 for 
use in the ETC. Components of the TCA cycle are also used as precursors in biosynthetic pathways, 
including the amino acids; glutamate, glutamine, proline and arginine and also in fatty acid synthesis.   
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The increase in ATP demand at the blastocyst stage is accompanied by an increase in 
glucose consumption and lactate production (Leese et al., 2001) as well as large rises in 
oxygen consumption (Houghton et al., 1996). Oxidative phosphorylation of glucose 
(mitochondrial respiration and the electron transport chain) is believed to satisfy 70-
90% of the ATP demand in most cells (Muoio 2014). However aerobic glycolytic 
activity, the conversion of glucose to lactate in the presence of oxygen, termed; 
Warburg metabolism (1956), appears to play a significant role in supporting blastocyst 
development and has been observed in the cow (Thompson et al., 1996), pig (Swain et 
al 2002) and human (Gardner et al., 2011).The possible reasons for this are described 
below and are speculated to revolve around glucose being directed through the PPP for 
biosynthesis of macromolecules (Smith & Sturmey, 2013) required for cellular growth 
and division which characterise this phase of development. 
 
The increase in glucose uptake and metabolism is believed to be as a consequence of 
increased glycolytic enzyme activity, as observed in the mouse (Houghton et al., 1996) 
and reported by Martin et al., (1993), who measured enzyme activity in single human 
embryos and found that hexokinase activity increased significantly from the 8-16 cell 
stage to the blastocyst stage. Increased glucose utilisation may also coincide with the 
expression of transporters responsible for glucose uptake at the blastocyst stage 
(reviewed by Pantaleon and Kaye 1998). Glucose uptake is regulated and facilitated by 
specific carrier proteins; the Facilitated Glucose Transporter (GLUT) or Sodium-
Dependent Glucose Transporter (SGLT) family proteins and the expression of those 
important in the embryo is reviewed in Chapter 6. Once inside the cell cytosol, glucose 
is phosphorylated to glucose-6-phosphate (G-6P) by hexokinase and this ensures that it 
is retained within the embryo. This is the first step of glycolysis and at this point the fate 
of G-6P depends on the ATP concentration in the cell and the REDOX equilibrium, it 
may (a) be metabolised by glycolysis to pyruvate, which is then converted to (i) lactate 
or (ii) acetyl CoA and used in the TCA cycle or (b) enter the pentose phosphate 
pathway (PPP).   
 
It would appear that the utilisation of glucose via the PPP is important again at the 
blastocyst stage, when cells are rapidly dividing. The PPP provides ribose moieties for 
nucleic acid synthesis and NADPH for biosynthesis of lipids and complex molecules. It 
has been proposed that the high glycolytic activity displayed by the blastocyst, whilst 
being energetically relatively inefficient, does ensure sufficient carbon substrate for 
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biosynthetic pathways, a process akin to that in cancer cells described by the Warburg 
effect (reviewed by Smith & Sturmey, 2013). High glycolysis ensures that NADP+ is 
available for PPP thus facilitating biosynthesis and the production of reduced 
glutathione, which plays an important role in the protection against oxidative stress.  
The flow of substrates through this pathway is also regulated by G6PDH and a 
deficiency in G6PDH in the embryo may reduce developmental capacity (Nicol et al., 
2000), highlighting the importance of this pathway.  
 
A further advantage of the high glycolytic flux, is that lactate production is high at the 
blastocyst stage where it may facilitate endometrial tissue breakdown, new blood vessel 
formation and induction of local immune modulation of the uterine environment 
(Gardner et al., 2015). It is speculated that the Warburg metabolism is a selective 
advantage for preparation for invasion of the endometrium –prior to the establishment 
of a vascular blood supply (Gardner et al., 2015). 
 
Once the blastocyst has completed expansion oxygen consumption is reported to fall to 
pre-compaction levels (Sturmey et al., 2003). Of note, the metabolic profile of inner cell 
mass cells is reported to differ from that of trophectoderm cells (Hewitson & Leese, 
1993; Gopichandran & Leese 2003; Houghton 2005). Trophectoderm cells reportedly 
convert approximately 50% of the glucose they consume into lactate, whereas the cells 
of the ICM were found to be almost entirely glycolytic. It has been postulated that this 
may arise due to an oxygen gradient from the outer to the centre of the embryo (Byatt-
Smith et al., 1991), resulting in the establishment of spatial relationships between 
blastomeres. This is however, controversial as it assumes O2 diffuses as it does through 
water, whereas in the embryo the O2 may diffuse more readily into lipid within the 
cytoplasm. A further factor which must be taken into consideration when attempting the 
metabolic characterization of the ICM, TE, and blastocoel fluid is, that the metabolism 
of isolated ICM and TE component cells are likely to be very different to the behaviours 
seen in an intact embryo. 
 
In summary, the pattern of preimplantation embryo metabolism has been established 
but, it is also striking that the described differences in substrate utilisation at each stage 
of development coincide with the substrate availability that has been measured in the 
female reproductive tract. It would appear that the developing embryo is exposed to a 
prominent substrate gradient as it makes its way towards the uterus. Firstly pyruvate and 
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lactate levels are significantly more abundant in the oviduct than the uterus, whereas 
glucose concentrations are significantly higher in the uterus than in the oviduct (Leese 
et al., 2008). Secondly, reduction in oxygen tension from the oviduct to the uterus has 
been reported in animal models including the primate (Fischer et al., 1993). 
 
Collectively, these reports suggest that embryos display a degree of plasticity and 
metabolic adaptation to their environment. While the metabolism of the embryo is well-
characterised under normal maternal physiological conditions- we know very little 
about how it responds to different environments for example how an embryo formed in 
response to maternal overweight/obesity may respond. The ovarian follicular 
environment is known to be enriched with metabolites in OWOB women, notably levels 
of glucose and triacylglycerol are reported to be higher (Robker et al., 2009). A steady 
influx of competing fuels can this can impair energy homeostasis (Muoio, 2014). Fatty 
acids and glucose can each be catabolised to Acetyl CoA and via the TCA cycle 
generate electron donors (NADH and FADH2). If the electron supply exceeds the 
demand for ATP (i.e. the ratio of ADP to ATP is low), the mitochondrial membrane 
potential will rise, creating increased back pressure at the pumping complexes and the 
generation of ROS, which may lead to cellular damage (Fisher-Wellman et al., 2013). 
Pyruvate dehydrogenase (PDH) complex, has a critical role regulating the flux of 
glycolitic intermediates into the TCA cycle. PDH activity is decreased when ratios of 
NADH/NAD+ and acetyl CoA/CoA are high, reducing glucose uptake. The glucose: 
fatty acid cycle is impaired in obesity resulting in reduced glucose uptake (as described 
earlier; the Randle cycle) and contributes to insulin resistance. In support of this, levels 
of insulin have been shown at an elevated concentration in the follicular fluid of obese 
women (Valckx et al., 2012) and it seems, this may compromise embryo metabolism, 
which is reviewed in further detail in Chapters 5 and 6.  
 
1.7.3 Embryo metabolism of substrates provided in vitro 
Providing the optimum culture environment for gametes and embryos is fundamental 
for viable embryo development and implantation potential. During the 1990’s there was 
a great deal of research in animal systems-biochemical studies on the metabolic 
pathways which lead to better understanding of the nutritional requirements of gametes 
and embryos. The commercialisation of culture medium has increased the production 
quality and testing procedures, compared to those performed ‘in-house’ (Chronopoulou 
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et al., 2015), but a pitfall of this has been reduced transparency, regarding the 
composition of the media, as companies seek to protect their commercial interests.  
 
Various types of commercial culture media are available, which differ in their 
complexity and their need for; (a) renewal (i.e. continuous culture to day 5 or renewal 
on day 3) and (b) their stage specificity or (c) universal use throughout development 
(i.e. single medium protocol or sequential medium protocol). A present a justification 
can be made for the use of any of these three key approaches to culture media systems, 
as the specific needs of gametes/embryos are yet to be fully elucidated, as discussed by 
Biggers & Summers (2008) in a lucid review of culture media protocols. Much of the 
debate has centred on the optimum concentration of glucose, the complement of amino 
acids and functions of glutamine and chelators, such as ethylendiaminetetraacetic acid 
(EDTA). There is plethora of literature examining the efficacy of different culture 
media formulations, the specific components and rational for inclusion/ exclusion of 
supplements based on their reported impact on oocyte and embryo development and an 
exhaustive review is beyond the scope of this thesis.  
 
The formulation of the complete culture medium aims to support the specific in vitro 
developmental needs of gametes and embryos. Culture media primarily consists of 
water and ionic salts with added carbohydrates (glucose, lactate, pyruvate), amino acids, 
antibiotics and macromolecules. Macromolecules (human serum albumin, recombinant 
albumin), play a number of roles acting as a chelator of heavy metals, functioning as a 
surfactant, increasing cryotolerance and colloidal osmotic pressure; a comprehensive 
review is provided by Pool et al., (2012). Media formulations require the correct 
balance electrolytes (to maintain water balance and avoid osmotic shock) and 
availability of substrates to support development. At the cleavage stage the balance of 
pyruvate and lactate maybe important, as early stages embryos metabolise pyruvate as 
the primary substrate (Hardy et al., 1989) and EDTA is often added to culture media 
that is targeted to support development at this stage on the basis of its ability to inhibit 
the premature stimulation of glycolysis (Lane & Gardner 2001). L-Lactate is also often 
included in the formulation, as it is shown to affect pyruvate metabolism and internal 
pH (Lane et al., 2000).  Media developed specifically for development from day 3 
onwards often contains a higher concentration of glucose, but pyruvate is also included 
as it is utilised throughout development (Hardy et al., 1989), as are amino acids, which 
act not only as an energy source but act as zwitterons to buffer pH and osmolytes to 
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control cell volume. The amino acids glycine and glutamine in particular have been 
shown to proffer a protective role (Van Winkle et al., 1990; Lawitts et al., 1992). 
 
A stable incubation environment is necessary; minor changes in both pH and 
temperature can disrupt embryo metabolism, altering enzyme function (Regula et al., 
1981; Lane et al., 1998; Phillips et al., 2002), microtubule assembly and developmental 
competence (Pickering et al., 1990; Magli et al., 2008). The pH control is accomplished 
using a bicarbonate buffered media and equilibrium with 5- 6.5% CO2, at 37oC, or an 
alternative is offered by the organic zwitterionic buffers such as a 4-(2-hydroxyethyl)-1-
piperazineethane-sulphonic acid (HEPES). 
 
A wealth of research has been conducted on the benefits of low culture at low oxygen 
(5%), which has been shown to result in higher rates of live births (difference of 10 – 
15% improvement) when compared with rates among women whose embryos were 
cultured in an atmospheric O2 environment (Meintjes et al., 2009, Dumoulin et al., 1999 
– to list but a few studies). These findings are supported by numerous studies in various 
mammalian species, in which even a brief exposure to atmospheric O2 has been 
reported to reduce blastocyst development and alter metabolism and gene expression 
(Pabon et al., 1989; Karagenc et al., 2004; Harvey et al., 2004). In vivo embryos are not 
exposed to oxygen concentrations of above 8% (Yedwab et al., 1976), significantly 
below that present atmospherically (20%). Furthermore the oxygen concentration in the 
uterus is believed to be lower than that in the oviduct (Fischer et al., 1993) and may 
explain why blastocysts are particularly sensitive to higher oxygen concentrations and 
why culture of embryos under 5% O2 not only results in a higher incidence of blastocyst 
formation, but higher mean blastocyst cell counts (Waldenström et al., 2009). The 
possible implications of oxygen concentration and different clinical embryo culture 
protocols are reviewed briefly in Chapter 7. 
 
1.8 Obesity and infertility 
 
In the UK, 20.2% of women of childbearing age are obese and a further 30% are 
overweight. The prevalence of obesity amongst women aged 24-28 has risen from 9.9% 
in 1990 and 16% in 2004 (Health Survey for England). Within the Humber and 
Yorkshire region, from where participants for the present study reside, 23.8% of 
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females are obese, making it the second highest across all regions of England 
(Scarborough & Allender 2008).  
 
 
 
Figure 1.11 Number of women treated at UK fertility clinics, per year. 
Data attained from the Human Fertilisation and Embryology Authority (HFEA) database. 
 
In parallel with the rising increase in rates of obesity the number of women seeking 
fertility treatment is rising annually (Figure 1.11). Obesity impacts on the female 
reproductive system in a number of ways and is a well-documented cause of female 
subfertility (Killick et al., 2009). Obese women are less likely to get pregnant, at 
increased risk of miscarriage and more likely to encounter health problems during 
pregnancy (Balen & Anderson 2007). Moreover, obese women are at significant risk of 
suffering gestational hypertension, pre-eclampsia, gestational diabetes later in gestation 
and have an increased caesarean section rate (Catalano & Ehrenberg 2006, Farquhar & 
Gillett 2006). Rates of fetal abnormalities including neural tube defects, spina bifida, 
cardiovascular abnormalities and cleft lip/palate are increased with maternal obesity 
(reviewed by Kulie et al., 2011). Furthermore, admission to neonatal intensive care, 
stillbirth and perinatal death are all increased in the infants of obese mothers (Farquhar 
& Gillett 2006).  
 
The impact of obesity on reproduction starts at a young age. Obese girls often 
experience the onset of puberty at a younger age than their normal weight peers (Lash et 
al., 2009). However obesity is frequently associated with disturbances of the menstrual 
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cycle, with up to 47% of OWOB women reporting menstrual irregularity (Practice 
Committee of American Society for Reproductive Medicine, 2008). The risk of 
anovulation, as a result of hyperandrogenism and granulosa cell appoptosis is 
significantly increased in obese women compared to those of normal weight (Jonard & 
Dewailly 2004). Polycystic ovarian syndrome (PCOS), a specific metabolic syndrome, 
is often associated with both annovulation and obesity. It is estimated that 
approximately 20% of overweight and obese women have PCOS, compared to 9-10% 
of women who are of normal weight (Yildiz et al., 2008). Many of the hormonal 
disturbances evident in PCOS women may be consistent with those seen in obese 
women, linkage between the two conditions has yet to be established. For this reason 
women with a diagnosis of PCOS have not been included within the scope of this study.   
In obese women, metabolic disturbances of the hypothalamic-pituitary ovarian axis may 
be caused by excessive steroid production from adipose tissue (Gambineri et al., 2002) 
and by the elevated levels of insulin, leptin (Tamer Erel & Senturk 2009) and other 
adipokines (further details in Chapter 3). Consequently, the incidence of subfertility 
(Hassan & Killick 2004, Wise et al., 2010) and menstrual and ovulatory disturbances 
are higher in these women than in women of normal weight (Clark et al., 1995). Weight 
loss has been shown to correct some of these abnormalities (Clark et al., 1995), 
however, weight loss is a long term commitment and any improvements to reproductive 
outcome as a consequence of decreasing BMI may be offset by the detrimental effects 
of advancing maternal age on oocyte quality. The impact of obesity and weight loss on 
pregnancy outcome are discussed further in chapter 3. 
 
1. 8.1 Obesity and oocyte quality. 
In assisted conception, oocyte quality plays a critical role in treatment success. For 
OWOB women, the impact of poor oocyte quality may be magnified since ovulatory 
problems are circumnavigated by the use of exogenous gonadotrphic stimulation. A 
number of studies have reported lower IVF treatment success rates in OWOB compared 
to normal weight and this evidence is reviewed in Chapter 3.  
 
There is ample evidence from animal models to suggest that oocyte quality may be 
compromised in sub-optimal maternal metabolic conditions (reviewed in Chapter 4). 
Equivalent data for the human is currently lacking, but the observation of lower oocyte 
numbers and quality in OWOB women (Maheshwari et al., 2007), combined with a lack 
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of evidence of any compromised pregnancy outcomes for OWOB donor-oocyte 
recipients (Styne-Gross et al., 2005) supports the notion that a high BMI is not 
compromising endometrial receptivity but more likely, is exerting an influence on 
oocyte development and embryo quality.  
 
Further evidence that oocyte quality may be compromised in OWOB is provided by the 
finding that the follicular fluid from obese women has been shown to have increased 
insulin, glucose, lactate, androgen levels (Robker et al., 2009), higher concentrations of 
non-esterified fatty acids (Valckx et al., 2014), decreased hCG levels (Carrell et al., 
2001) and increased leptin (Hill et al., 2007). Further study is required to assess the 
impact of this pathological environment on the developmental competence of oocytes, 
ongoing embryo development, quality and implantation potential. However, current 
methods of assessment of oocyte quality lack sensitivity and are limited to the direct 
visualisation of nuclear maturation, i.e. development to metaphase II (MII) of meiosis II 
and extruded the first polar body. The pitfalls of this assessment method and alternative 
observations that maybe used to compare the quality of oocytes from OWOB and 
normal weight women is discussed further in chapter 4.  
 
1.8.2 Obesity and embryo quality 
A number of reports have indicated that development of the embryo post fertilisation is 
sub-optimal in the obese (Metwally et al., 2007, Carrell et al., 2001), however others 
have reported no relationship (Bellver at al., 2010). Such discordance in the literature 
may well result from lack of comparable objective methods of assessment for embryo 
quality. Embryo quality assessments are traditionally based on limited observations of 
appropriate temporal patterns of cleavage division and morphological appearance of 
blastomeres on day 2/3 of development and blastocyst development on day 5, although 
advances in time-lapse imaging may strengthen the precision of assessment in the 
future. The assumption is that the observed development features are affected by 
intrinsic and environmental factors and as such are a reflection of genetic viability of an 
embryo.  
 
There is a continuing need for accurate and subjective biomarkers of embryo viability.  
One possibility is the determination of the consumption and release of metabolites from 
embryo culture medium (CORE). Compelling evidence has been amassed, 
demonstrating that the most viable cleavage stage embryos are those that exhibit 
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a‘quiet’ metabolism (Leese 2002; Leese et al., 2007; 2008). At the blastocyst stage the 
capacity to metabolise glucose increases significantly at the transition from morula to 
blastocyst (Devreker & Englert 2000). At this point embryos consuming twice the 
amount of glucose were more likely to form blastocysts than those that failed (Gardner 
et al., 2011), those embryos capable of increasing their glucose uptake, with the least 
expenditure of energy (e.g. measured by oxygen consumption) are postulated to be the 
most viable (Leese, 2012). The metabolic analysis of substrate utilisation is compared 
for embryos from women of normal and OWOB BMI in chapters 5 and 6.  
 
Metabolic events not only contribute to embryo viability, but impact on the chances of 
successful pregnancy and the health of the offspring. The extent to which maternal 
obesity-induced metabolic disturbances in women impact on embryo metabolism and 
development has not been studied in any detail but is important because the long-term 
health of children born to obese mothers is of particular concern. Obesity has been 
associated with congenital abnormalities in the offspring (Stothard et al., 2009) and the 
long term consequences of a sub-optimal maternal nutritional environment are only now 
beginning to be appreciated. The FOHaD suggest a correlation between pre and 
periconceptional maternal nutrition, embryonic, placental and fetal growth and the 
development of chronic disease in later life (O’Brien et al., 1999).  Embryo metabolism 
has therefore formed the focus of this research exploiting the unique opportunity to 
study surplus human embryos created during in vitro fertilisation (IVF) treatment cycles  
 
1.9 Working hypothesis and study aims 
 
The primary focus of the study was to elucidate the impact of obesity on reproductive 
outcome in a subfertile population seeking IVF treatment, with a focus on the 
periconceptional period. Obesity may be programmed from periconception and the 
study sought to identify early markers during the critical times of gametogenesis and 
early embryogenesis that could set a trajectory for future susceptibility to obesity and 
long-term health issues. 
 
It has been shown in this chapter that the prevalence of obesity is increasing and that 
rates of subfertility are rising in tandem, suggesting a causal link. It is proposed that this 
link between obesity and a lower chance of reproductive success (clinical pregnancy 
and live births) will be replicated in the local population. Contradictions have however, 
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been highlighted the literature, regarding the impact of obesity on oocyte developmental 
competence and embryo quality. References to embryo quality and BMI are scarce a, 
possibly owing to the subjective nature of current methods to assess embryo viability.  
 
The study of embryo metabolism has previously been linked to embryo viability and an 
overview of the acquisition of oocyte developmental competence the established normal 
pattern of metabolism has been provided. As the embryo passes through the 
developmental stages prior to implantation it undergoes very specific changes, reflected 
in differences in metabolism, hence the embryo displays plasticity and is adaptive to its 
environment. It is speculated that any inappropriate adaptations to a sub-optimal 
environment are linked to lower embryo viability. It is the central hypothesis of this 
thesis that the metabolic phenotype is sensitive to maternal body weight at the time of 
conception and oocyte and embryo metabolism will be perturbed giving rise to the 
compromised reproductive outcomes reported for OWOB women. This study will be 
the first to investigate embryo metabolism from normal and OWOB in human. Proof of 
this concept for this theory, will be sought though the simultaneous study of the 
utilisation of available key exogenous metabolites and possible endogenous energy 
sources by embryos from both normal and OWOB women.  
 
My central argument is that it is the developing oocyte, which adapts to the nutritionally 
enriched follicular environment reported for OWOB women, resulting in an altered 
utilisation of substrates for energy metabolism, growth and development. Animal 
studies have shown that exposure to a high fat diet compromises embryo development, 
however studies in humans are lacking. It is hypothesised that oocyte maturational 
events will be compromised, resulting in fewer embryos reaching the blastocyst stage of 
development and those which do may have a reduced implantation potential, 
contributing to the poorer reproductive outcomes are reported for OWOB patients. In 
the short term this results in lower pregnancy rates, increased risks in pregnancy, and 
possible longer-term adaptations relating to risks of adult onset disease, as discussed 
previously in this chapter.  
 
The specific aims of each chapter were to compare the outcomes for OWOB women to 
those of normal weight in terms of: 
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1) Clinical pregnancy outcomes from natural, IVF fresh and frozen treatment 
cycles in women of Hull and East Yorkshire. 
2) Oocyte developmental competence and morphokinetic parameters. 
3) Embryo metabolism of carbohydrates, amino acids and triglyceride content. 
4) The influence of in vitro manipulation of the developmental environment.  
 
The Hull IVF Unit sees approximately 350 patients each year, 48% of whom are 
overweight or obese. The reproductive outcomes for these women were studied in 
detail, in terms of live births, clinical pregnancy and miscarriage rates and with 
particular focus on the embryo and gamete quality.    
 
In this thesis a range of quantitative metabolic assessments were performed to look at 
the phenotype and viability of individual human embryos produced by IVF from 
women with a BMI greater than 25kg/m2 and compared with those from women, with a 
BMI in the normal range (below 25kg/m2).  Embryo metabolism provided an objective 
biomarker of human embryo health and could be measured to examine (a) the 
relationship with maternal BMI and blastocyst development and (b) whether embryo 
metabolism is characteristic of a given patient and relates to pregnancy outcome. 
 
The additional information gleaned from this study will enable us to provide 
information to patients on the effects of maternal lifestyle and how this may influence 
their prognosis. Furthermore we will be able to advise patients on what positive steps 
they can take to maximise their chances of pregnancy and ensure their offspring’s 
health.  
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Chapter 2 : Methods 
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2.1 Clinical procedures 
 
2.1.1 Clinical Investigation 
All patients underwent full clinical assessment prior to treatment to diagnose the cause 
of infertility. All blood tests (FSH, Oestradiol, LH, Prolactin, Thyroid hormones, 
Androgens, Progesterone, AMH, viral screen) and semen evaluation were performed by 
Clinical Pathology Accredited/ ISO15189 laboratories within 12 months of treatment 
starting. BMI (kg/m2) was recorded at the initial referral and at the down-regulation 
appointment prior to treatment to determining ‘weight stability’, which was defined as 
maintaining weight over a period of three months. 
 
2.1.2 Down-regulation, stimulation and follicle tracking 
Pituitary Regulation was achieved in one of two ways: 
 
(a) Down regulation with agonist Buserelin acetate. Buserelin (Suprecur®, 
supplied by Pharmasure) was commenced on approximately day 21 of the cycle 
and was given at a dose of 0.5mls once a day, and continued throughout FSH 
administration; 
(b)GnRH Antagonist; Cetrorelix acetate (Cetrotide® Merck Serono) was given 
as an additional injection during the time patients were being given stimulation 
drugs. Cetrroelix acts directly on the pituitary stopping its production of LH and 
FSH. The choice of regime was dictated by cost, cycle planning constraints and 
patients’response to previous regimes.  
 
The patient was said to be “down-regulated” when the endometrium was less than 4mm 
in width and there were no follicles on either ovary greater than 10mm diameter.  If the 
endometrium was greater than 3mm or a cystic structure was seen on the ovaries 
(polyps ≥1cm are removed), then the serum oestradiol level was checked and the 
stimulation cycle was delayed. 
 
FSH stimulation (Menopur® Ferring, Merional® Phamasure, Gonal F® Serono or 
Puregon® Organon) was started at a dose that was determined by patient age, serum 
FSH, AMH, response in previous cycles and any history of PCOS (starting dose of 
75IU, up to 100 or 150 and increments of 75IU to a possible maximum of 450IU of 
FSH). 
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All patients were scanned by ultrasound on Day 6 or 8 of FSH administration at which 
time endometrial thickness was determined and the sizes of all ovarian follicles above 
10mm were recorded. In addition, the number of follicles less than 10mm was recorded.  
Daily FSH administration was continued at the same dose, if follicular development 
was seen, and patients scanned at regular intervals. The daily dose of FSH was adjusted 
according to the total follicle number and size of the second order follicle. 
 
Patients were only accepted for egg collection when the second order follicle was at 
least 18mm in diameter on ultrasound. Thirty-six hours prior to oocyte retrieval, 
10,000IU of human menopausal gonadotrophin (hMG; Pregnyl® Ferring) was 
administered. Patients stopped Buserelin injections after the hMG was administered, 
and started taking micronized progesterone (Utrogestan® Besins), six tablets vaginally 
at night. 
 
2.1.3 Oocyte retrieval and sperm preparation 
Oocyte retrieval was performed 36 hours after Pregnyl injection under conscious 
sedation with a double channel 15-gauge needle. All follicles greater than 15mm were 
drained. Eggs were placed into commercial culture medium from Copper Surgical 
(Sage, Quinn’s Advantage QA series). Eggs were collected into tubes containing gassed 
QA Fert medium and incubated at 6% CO2/ 5%O2/Bal N2 at 370C for up to 4 hours 
prior to insemination or injection.  
 
Puresperm (Nidchem) gradients were used to prepare sperm samples. Samples were 
centrifuged at 200g for 15 minutes.  The pellet was washed and spun for a further 5 
minutes at 200g.  Samples were re-suspended in culture medium and placed into the 
incubator. Sperm parameters were assessed according to WHO manual criteria (2010) 
before and after sample work-up. Patients were scheduled for IVF or ICSI accordingly. 
 
2.1.4 Insemination, injection and fertilisation 
Where IVF was indicated, eggs were retrieved from tubes 3-4 hours after collection and 
transferred into 4-well culture dishes (up to 6 eggs per-dish).  Oocytes were then graded 
under a stereomicroscope (x15 to x40 magnification) and assigned a score of 1 to 3 
according to the extent of cumulus oocyte expansion, according to previous published 
criteria (Mikkelsen et al., 2001). Oocytes were co-incubated with 1.0-1.5 x 105 sperm 
per ml of culture media.  
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Where ICSI was indicated, oocytes were placed into 50ul droplet of cumulase (Origio) 
for 40 seconds, before being transferred to 50ul droplets of HEPES (QA). After 5 
minutes, the cumulus and corona cells were removed by mechanical manipulation. 
Approximately 3 hours after retrieval, MII oocytes were loaded in individual 4ul 
droplets of HEPES surrounding a central droplet containing PVP (Origio) and 1ul of 
sperm. Injections were performed on an Integra Ti micromanipulator (Research 
Instruments) fitted with Hoffman Modulation Contrast System. Humagen 
micromanipulation tools were used to immobilise the oocyte with the polar body at the 
‘6 o’clock’ position and injection at ‘3 o’clock’ position. Once injected, oocytes were 
cultured in QA cleavage medium in 4-well culture plates at 6% CO2/ 5%O2/Bal N2 at 
370C. 
 
2.1.5 Embryo culture and assessments 
Approximately 18 hours after insemination or injection, oocytes were assessed for 
fertilisation and moved to QA cleavage medium. Normally fertilised embryos were 
assessed on the morning of day 2 and day 3 and were transferred into QA blastocyst 
medium 112 hours post insemination. Embryos were graded according to the 
Association of Clinical Embryologists (ACE) national grading scheme, which takes 
account of cell number, evenness of cells and degree of fragmentation (Table 2.1).  
 
Table 2.1 ACE cleavage stage embryo grading scheme. 
Reproduced from Policy and practice document (Cutting et al., 2008).  
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On the basis of embryo scores patients were selected to undergo either a day 3 or day 5 
transfer. Patients with two or more good quality embryos available on day 3 (6-8 cells 
and grade 3/3 or above) were selected for blastocyst transfer. 
 
2.1.6 Blastocyst assessments 
On the morning of day 5, embryos were graded according to the ACE national grading 
scheme (Table 2.2), which necessitated the degree of expansion, integrity of ICM and 
TE to be assessed. 
 
Table 2.2 ACE blastocyst stage grading scheme. 
Reproduced from Policy and practice document (Cutting et al., 2008). 
 
 
 
2.1.7 Embryo selection transfer and cryopreservation 
One or two of the top scoring embryos were selected for transfer on the basis of female 
age, overall embryo quality score and past treatment history. Suitable good quality 
embryos were frozen on day 5 (3Bb or above). 
 
2.1.8 Determination of pregnancy/ data collection 
Positive pregnancy was determined by urinary pregnancy test.  Fetal heart beat was 
identified by ultrasound scan at 5 weeks post transfer. 
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2.2 Donation to research/ extended culture 
 
2.2.1 Consent and donation of fresh embryos 
Surplus human embryos not suitable for treatment or cryopreservation may be donated 
to research if appropriate consents are obtained, or placed into extended culture to 
permit the study of their developmental kinetics and to provide enhanced feedback at 
follow-up audit assessment. 
 
All research was carried out according to licence conditions of the Human Fertilisation 
and Embryology Authority (licence R0067), and with full ethical approval 
(09/HI304/44). Patients presenting for IVF at the Hull IVF Unit donated embryos with 
full informed consent. Nursing staff, who were not involved in the research project, 
obtained patient consent at the down-regulation appointment. Patients were given broad 
information about the research project aims, i.e. ‘The study of the biochemistry of the 
human embryo’. All patients indicating a willingness to be approached about research 
were given the opportunity to participate in the study.  
 
Two independent witnesses checked consent forms before any samples or results were 
coded and released to research. The embryos were anonymised and given a unique 
“Research Number”; a 5-digit number prefixed with “H”, starting at “H00001”.  This 
code was recorded next to the patient ID number in a research book, and on the front of 
a sealed envelope containing a copy of the consent form and on the tube in to which the 
embryos were be placed for transfer between the IVF Unit and research laboratory. 
 
Patient data were made available from routine clinical investigation and included a 
description of cause of infertility, age, BMI, smoking status, cycle number, hormonal 
profile as well as details of treatment, including stimulation, semen parameters, ovarian 
response, number and quality of eggs retrieved, rates of fertilisation and embryo 
development and quality, number replaced, number frozen and pregnancy, miscarriage 
and live birth rates. 
 
The data were retrospectively matched to that generated from the research findings (i.e. 
patient number to embryo research number) to classify data into embryos that originated 
from patients who were overweight/obese (OWOB) (BMI ≥25kg/m2) and compared to 
embryos from women of normal BMI (18.5 to 24.9kg/m2).  Women with polycystic 
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ovaries were excluded from the study as it was anticipated that these may represent an 
additional subgroup with a very specific metabolic profile linked with the condition. 
 
2.2.2 Consent and donation of frozen embryos 
Frozen embryos that had been donated to research were removed from storage at the 
monthly cryo-audits and allocated to a dedicated research tank. A detailed log of the 
storage location, patient details and witnessing procedures was maintained.  An 
anonymised version was made available for research use, detailing the embryo code, 
numbers, stage of development, freeze details and expiry dates. Embryos were 
requested for use in advance of the expiration date and were transferred to the research 
laboratory when as much identifying information as possible had been removed from 
visitubes. The embryos were thawed using commercial thaw medium appropriate to the 
stage of development (Origio cleavage stage or blastosyst stage medium) and were 
cultured and analysed as per fresh embryos donated to research. 
 
2.2.3 Research embryo culture and assessment 
Once donated to research, embryo development stage and grade were recorded and 
embryos placed individually into 4µl drops of Earle’s balanced salt solution (EBBS), 
supplemented with 0.5% (v/v) synthetic serum albumin (SSA, Sage), 1mM glucose, 
0.47mM pyruvate, 5mM Lactate and a physiological mixture of amino acids (Houghton 
et al., 2002) (details given below). Embryos were cultured under light mineral oil (Sage) 
at 37oC in 6% CO2/5% O2/Bal N2 for 24 hour periods, alongside control drops, 
maintained in identical conditions, but free of embryos. Micro-droplet culture plates 
(Falcon 0061) were prepared as displayed in Figure 2.1.  
 
 
Figure 2.1 Micro-droplet culture set up.  
Media were changed every 24hours and plates frozen at -80oC. 
 
  
    
    
Embryo 
culture 
droplet
Wash 
droplet
Control 
droplet
s
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Embryos that failed to form a blastocyst, but continued to undergo cell divisions/ 
organisation were classified as ‘slow developing’, whereas those that reached the 
blastocyst stage were classified according to their degree of expansion (unexpanded, 
expanded, hatched and graded as per clinical protocol). An embryo that failed to change 
after 48 hours culture was considered arrested.  Observations were halted on day 9 or at 
developmental arrest. After incubation, the spent culture medium was frozen 
immediately at -800C for later analysis. 
 
Culture medium was prepared from stock solutions as described in appendix A1, and 
used to prepare a working solution (Table 2.3). Media were pre-incubated at 37oC, 6% 
CO2, 5% O2 for at least 2 hours to stabilise the pH to 7.3±0.1 prior to use.  
 
Table 2.3 Final working solution of standard embryo culture medium used to culture research embryos.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3 Metabolic profiling 
 
2.3.1 Ultraflourometric methods 
Metabolic COnsumption/RElese (CORE) profiles (Guerif et al., 2013) were determined 
by measuring the depletion and appearance of key compounds from the culture medium, 
namely glucose, pyruvate, lactate and 18 amino acids, according to established 
techniques, that may be applied to individual oocytes and embryos (Sturmey et al., 
2009) and provide quantitative markers of embryo health, throughout development. 
Component 
Ml 
EBBS 1 
Sterile water 6.935 
NaHCO3 1 
Antibiotics 0.1 
Pyruvate 0.1 (0.47mM) 
Glucose 0.2 (1mM) 
Glutamine 0.2 (0.2mM) 
SSA 0.25 
D-L-Lactate 15µl (5mM) 
Amino acids 0.2 
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Triglyceride content of embryos was then determined at the end of the culture period 
from samples of embryos pooled in groups of 2-5 embryos at equivalent development 
stages for each patient.  
 
Glucose and pyruvate consumption and lactate production were measured using assays 
based on the ultramicrofluorometric methods described by Leese et al., 1984. The 
assays are based on the enzymatic phosphorylation of substrate and the subsequent 
consumption or generation of NADH or NADPH in coupled reactions. This causes an 
increase in fluorescence that is directly proportional to the concentration of substrate 
present.  Fluorescence was measured using a plate reader (Tecan Infinite M200; Tecan 
Reading, UK or BMG LabtechFLUOstar Omega Flourometric; BMG Labtech, 
Buckinghamshire, UK) (excitation 340nm, fluorescence 459nm and above). Reactions 
were carried out in 96 well assay plates with ‘V’ shaped wells. Standards were assayed 
in triplicate – in the layout given below and incubations were at 370C unless otherwise 
stated. The concentration of substrate was related to a series of standards, for each 
experiment, for sample and control droplets. All values are expressed as pmol per 
embryo per hour. 
 
2.3.2. Glucose assays 
These are based on the enzymatic phosphorylation of glucose and the subsequent 
reduction of NADP+ to NADPH. This causes an increase in fluorescence which can be 
measured. The reactions are as follows; 
 
(a) Glucose + ATP --hexokinase-! glucose-6-phosphate 
(b) Glucose-6-phosphate + NADP+ --G6PDH! Gluconate-6-phosphate +NADPH + H+ 
 
A reaction mixture was prepared, based on the following; 4-(2-Hydroxyethyl) 
piperazine-1-propanesulfonic acid (EPPS) buffer (31.25mM) and containing DL-
Dithiothreitol (0.42mM), MgSO4 (3.08mM), ATP (0.42mM), NADP+ (1.25mM), 
Hexokinase (14.17Uml)/ G6PDH (7.08U/ml) (Table 2.4) 
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Table 2.4 Components of buffer, cocktail and substrate for glucose assays 
 
Chemical Molecular weight Supplier Cat. No. 
EPPS 252.33 Sigma E9502 
Penicillin G 372.5 Sigma P4697 
Streptomycin 1457.4 Sigma S1277 
Dithiothreitol 154.2 Sigma D0632 
Magnesium sulphate 246.48 Fisons M/1050 
NADP  Roche 128 040 
ATP 551.1 Sigma A6419 
Hexokinase/G-6-P  Roche 127-825 
Glucose standard 5mM/L  Analox GMRD-010 
Sodium hydroxide 40.0 Fisher S4920/60 
 
 
EPPS buffer was prepared from 2.52g of EPPS dissolved in 150ml of distilled water 
and adjusted to pH to 8 with 1M NaOH. (4g NaOH in 100ml of distilled water) and 
made up to 200ml with distilled water.10mg Penicillin G and 10mg of Streptomycin 
were added to the buffer (Table 2.5).  
 
Table 2.5 Composition of EPPS Buffer  
-adjusted to pH8 with 1M NaOH 
Chemical Amount Final concentration 
EPPS 2.52g 50mM 
Penicillin G 10mg 50µg/l 
Streptomycin 10mg 50µg/l 
Water 200ml - 
 
 
The glucose assay cocktail was prepared using the stock solutions listed in Table 2.6.  
 
Table 2.6 Stock solutions for Glucose cocktail 
 
Chemical Weight (mg) Distilled water (ml) 
Dithiothreitol 7.715 10 
Magnesium sulphate(MgSO4) 91.2 10 
NADP 39.37 5 
ATP 30.26 5 
 
The glucose cocktail consisted of the following well mixed constituents; 15ml of EPPS 
buffer,1ml of Hexokinase glucose 6 phosphate dehydrogenase, and from table x, 2ml of 
Dithiothreitol, 2ml of Magnesium sulphate, 3ml of NADP, and 1ml of ATP. Chemicals 
were aliquoted into 1.5ml Eppendorf tubes and stored at -20°C for up to 8 weeks. 
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To prepare substrates to measure a glucose standard curve (Table 2.7), a 1mM stock of 
glucose solution was prepared (100µl of the 5mM standard glucose solution to 900µl of 
distilled water). This was diluted further as follows in Eppendorf tubes, which were 
stored on ice. 
 
Table 2.7 Glucose standards 
 
1mM stockµl Distilled water µl STD mM 
100 0 1.0 
80 20 0.8  
60 40 0.6 
40 60 0.4 
20 80 0.2 
  0 100 0.0 
 
 
The florescence of the glucose reaction mixture was measured, then the standard was 
added (to a ratio of 1:10), after ten minutes incubation at room temperature the 
fluorescence was measured again and the difference was calculated. The average value 
for each standard was calculated and plotted.  
 
A standard curve was produced for each assay in the range of 0-0.5mM with only 
standard curves with a correlation coefficient (r2) of >0.9 being accepted.  
 
The florescence was measured for sample droplets and control (non-embryo containing) 
droplets and the changes related to those given by the standards. The values were 
attained by substituting the linear regression equation.  
 
2.3.3 Lactate assays 
These are based on the reduction of NAD+ to NADPH and the conversion of lactate to 
pyruvate.  
Lactate + NAD+ --LDH! Pyruvate + NADH + H+ 
 
The equilibrium of the reaction is to the left and in order to drive it in the direction of 
Pyruvate and NADH, hydrazine sulphate is added, which combines with pyruvate to 
form hydrazine pyruvate and removes it from solution; the reaction is also carried out at 
pH 9.4 to remove the protons that are formed. 
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A reaction mixture was prepared based on glycine-hydrazine buffer (0.474mM glycine/ 
0.189mM hydrazine), ddH20, LDH (15.79U/ml) and NAD+ (4.76mM).  
 
Glycine-hydrazine buffer was prepared as listed below (Table 2.8) and used in the 
reaction cocktail mix as described in Table 2.9. 
 
Table 2.8 Composition of glycine-hydrazine Buffer  
- adjusted to pH9.4 with 1M NaOH.  
 
Chemical Amount Final concentration 
Hydrazine sulphate 5.2g 400mM 
Glycine 7.5g 322mM 
EDTA 0.2g 5.4Mm 
Water 100ml - 
 
Table 2.9 Stock solutions for lactate cocktail 
 
Chemical Amount Final concentration 
Glycine-hydrazine Buffer 9ml 0.474mM/ 0.189mM 
LDH 0.5ml 15.79U/Mm (at 250C) 
NAD+ 1.5ml 4.76mM 
ddH2O 8ml - 
 
The fluorescence was measured as per the procedure for glucose. Standards or samples 
were added to the cocktail droplet in a 1:10 dilution and the reaction time was 30 
minutes at 370C. The concentration of lactate present in the samples was compared with 
the standards and adjusted for non-specific changes in fluorescence using data from 
control droplets.  
 
2.3.4 Pyruvate assays 
This reaction is based on the oxidation of reduced NADH using LDH 
Pyruvate + NADH + H+--LDH! Lactate + NAD+ 
 
As the reaction proceeds readily to the right there is a decrease in fluorescence, as 
NADH is being oxidised to NAD+.  
 
A reaction mixture was prepared based on EPPS (47.6Mm), LDH (16.32U/ml) and 
0.1mM NADH, pH 8. 1µl sample/ standard was added to 10µl assay mixture and 
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incubated for 3 minutes at 370C. The final concentration of pyruvate in each spent 
culture sample was determined from a six point standard curve of 0-0.45mM pyruvate. 
 
2.3.5 Determination of triglyceride content 
Triglycerides were measured using a coupled colourimetric assay described by Sturmey 
and Leese (2003). In a dual reagent assay the amount of glycerol present in the sample 
was quantified by the amount of NADH oxidised to NAD+. 
 
On day 9 of development embryos were incubated with 0.1 % (w/v) pronase for 
approximately 30 seconds to remove the zona pellucida allowing the enzymes used in 
the TG assay access to the intracellular triglyceride. A 0.5 % pronase solution was 
prepared by dissolving 0.02 g pronase in 20 ml 0.9 % NaCl (0.9g NaCl + 100mls H2O). 
500 µl aliquots were stored at –20oC and pre-warmed prior to use.   
 
Individual embryos were placed into a 1.1µl droplet of freezing buffer (Table 2.10) and 
aspirated into a 5µl microcap using a syringe (Figure 2.2). The microcaps were then 
sealed with parafilm, before being coded and stored at -800C to allow blind analysis at a 
later date. 
 
 
Figure 2.2 Samples frozen in microcaps, sealed with paraffin.  
 
Table 2.10 Composition of Freezing buffer.  
*FCS of known TG content, as certified by Sigma. Freezing buffer was stored at +4oC for up to 8 weeks. 
 
 
 
 
 
 
Component 
Amount 
PBS 
BSA 
FCS* 
50 ml 
0.05 g 
0.15ml 
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The triglyceride assay (Ferguson & Leese, 1999) is based on the enzymatic hydrolysis 
of triglyceride into free fatty acids and glycerol. 
 
(a) Triglyceride --Lipase!Glycerol + Free fatty acids 
(b) Glycerol + ATP –Glycerol kinase!Glycerol-1-phosphate + ADP 
(c) ADP + Phosphenolpyruvate –Pyruvate kinase!Pyruvate + ATP 
(d) Pyruvate + NADP + H+ --Lactate dehydrogenase!Lactate +NAD+ 
 
The amount of glycerol present in the sample was quantified in terms of the amount of 
NADH oxidised to NAD+. This causes a change in the fluorescence which was 
measured using a plate reader (Tecan Infinite M200 / BMG Labtech) (excitation 340nm, 
fluorescence 459nm and above). The reagents necessary for the assay were derived 
from a triglyceride test kit (Sigma UK) which was scaled down to work at a microlitre 
level. The assay used two reaction mixtures; mixture A contained ATP, lactate 
dehydrogenase, lipase, NADH, phosphoenol pyruvate, pyruvate kinase, buffer and non-
reactive stabilisers and fillers; mixture B contained glycerol kinase and non-reactive 
stabilisers and fillers. 
 
A six point standard curve was established before each assay (r2>0.9), using triglyceride 
standards in the range of 0- 0.54 µg /ml (Table 2.11).  Standards were prepared by 
diluting certified FBS of known triglyceride concentration with ddH2O.  
     
Table 2.11 Triglyceride standards 
 
STDµg/ml Amount of ddH2O µl Amount of FCS µl 
0 100 0 
0.135 75 25 
0.27 50 50 
0.405 25 75 
0.459 15 85 
0.54 0 100 
 
 
Reactions were carried out in 96 well assay plates incubated at 370C. 10µl of reagent A 
was added to each well, the plate was then incubated for 10 minutes prior to recording 
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the fluorescence. 1µl of standard (or sample, once a suitable standard curve had been 
established) was then added to each well and the process repeated. Finally 1.1µl of 
regent B was added to each well and incubation for 7 minutes prior to reading the 
florescence.  
 
Any endogenous ADP was consumed by the pyruvate kinase and lactate dehydrogenase 
reactions, prior to the addition of cocktail B. The reactions (b), (c) and (d) could then 
proceed and any changes in fluorescence that resulted were from the conversion of 
NADH to NAD+ derived from ADP resulting from the hydrolysis of TG only. 
 
The amount of triglyceride was calculated by relating changes in fluorescence to those 
given by the standards. Blank samples containing freezing buffer but no embryos were 
also assayed and the values subtracted from the unknowns to account for dilution effects 
and any triglyceride present in the freezing buffer. 
. 
2.3.6 HPLC 
Amino acid profiles were determined in spent culture droplets by reverse-phase high 
performance liquid chromatography (HPLC), as described by Houghton et al.,(2002) 
and Leary et al.,(2012).  Briefly 2µl of sample was diluted 1:12:5 in HPLC grade water. 
The sample was then diluted into a mobile phase (83mM sodium acetate/Methanol), 
pumped under high pressure onto a C-18 ODS Hyperclone column (Phenomenex, UK) 
and the column retention time and signal amplitude was used to determine the identity 
and concentration of each amino acid. Average sums of amino acid production and 
depletion, were expressed in pmol/embryo/hour for day 5 to 9 of culture. All data were 
normalised to a non-metabolisable internal standard.  Results were recorded according 
to stage reached at the end of the period of culture. 
 
Amino acid profiles of spent culture droplets were determined using a Agilent 1100 
Series automated HPLC (Santa Clara, CA, USA) system, fitted with a 
PhenomenexHypoclone 5µm C18 octodecyl silica column 250 x 4.6mm (Phenomenex, 
Macclesfield, UK). Chromatography was performed at 250C.  
 
The reagents required are; 
1. OPA (o-phthaldialdehyde) 1ml supplemented with 2µl β-mercaptoethanol and 
aliquoted into 1.5ml glass HPLC vials and stored at -20oC. This is used as a pre-
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column derivitising reagent, as in the presence of β-mercaptoethanol (reducing 
agent) it reacts with primary amines to form flouresentthio-substituted 
isoindoles which can be separated and analysed. 
2. Solvent buffers A and B, which are based on sodium acetate (56.5g in 5 litres 
ddH2O, adjusted to pH 5.9 with glacial acetic acid) and methanol. The 
composition shown in table 2.12. Buffer A is hydrophilic and buffer B is 
hydrophobic, both are required to elute the amino acids from the column. The 
gradient of each was series automated, starting with a high concentration of A 
and adding B.   
3. Amino acid standard solution composed of 1:1 mix of (a) reference amino acid 
mixture, Sigma AA-S-18 amino acid standard solution and (b) DABA mix – a 
non-metabolisable internal standard, against which, all peak areas were 
corrected.  
 
Table 2.12 Composition of solvent buffers 
 
Chemical Amount- Buffer A Amount – Buffer B 
83mM Sodium Acetate Buffer 800ml 200ml 
Methanol 200ml 800ml 
Tetrahydrofuran 12ml - 
 
Samples were prepared for chromatography by diluting 2µl of spent and control media 
drops with 23µl of ddH2O (1:12.5). Samples were interspaced with 25µl vials of amino 
acid standard solution and loaded into the sample tray, with position 1 being occupied 
by OPA and position 100 with a vial of wash solution. During the analysis, each 25µl 
sample was mixed with 25µl OPA and after a reaction time of 2 minutes, 25µl of the 
mixture was loaded onto the column, using the autosampler device. The peaks were 
eluted with a gradient mobile phase. Using the retention time (column interaction time, 
prior to being eluted) the peaks were identified.  Quantification of amino acid 
concentration was carried out by comparing peak areas of unknowns against those given 
from the certified standard solutions (area units per pmol, corrected OPA). To calculate 
the amino acid concentration, values from peak area were then converted to actual 
number of moles in the control (from the blank culture droplet) and sample, the 
difference between these values gave the change attributed to the embryo. Values were 
corrected for sample volume and dilution and subsequently calculated in terms of 
pmoles per embryo per hour of culture. A net fall in an amino acid concentration was 
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termed ‘consumption’, a rise ‘release’ and the sum of these two was termed ‘amino acid 
turnover’. 
 
2.4 Time lapse recordings and measurements 
 
Embryos at various stages of development were placed into extended culture and 
observed using time-lapse technology (Primovision).  
 
Well-On-Well (WOWTM) 16 point dishes were prepared in advance. Each individual 
well was pre-filled with culture medium using a 135µl micropipette aimed at the side of 
each well to avoid any scratches or air bubbles. A Gilson pipette was then used to 
deliver an 80µl overlay of media, which was subsequently covered in 2-3mls oil to 
avoid osmotic changes. Prior to use, trapped air was removed by tapping the base of the 
dish firmly against the surface of the flow hood and using a pipette remove the air 
bubbles. When placed into the wells, embryos sank to the bottom. The location of each 
embryo was recorded, the dish was aligned onto the Primovision camera. The camera 
was connected and project started and assigned a project name, after which, the duration 
and frequency of imaging was set. Development was observed and data interrogated 
using the Primovision Analyser software. Recordings were made of specific 
developmental timings, blastocyst diameters and hatching patterns. Embryos were 
cultured until day 9 of development, images were acquired every 20 minutes. Further 
details are contained in chapter 4. 
 
2.5 Embryo fate; disposal, disruption and freezing & differential cell staining 
 
Embryo development was arrested of on day 9 of development (or day 7 if a weekend). 
Development was arrested by one of the following; 
• The addition of alcohol.  
• The disruption of development with pronase and freezing of embryos in 
microcaps for triglyceride analysis (details included in chapter 5). 
• Expanded blastocysts were fixed on day 7 of development using the differential 
staining technique describes by Thouas et al., 2001. Chromatin-specific dyes 
were used to determine ICM and TE counts (details included in chapter 4). 
In each scenario the removal of embryos from culture was witnessed and recorded by a 
second operator. 
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2.6 Statistical analysis 
 
The data from the metabolic profiling of spare embryos was compared between normal 
and OWOB women and retrospectively correlated to the chosen study end points of (a) 
blastocyst development and (b) clinical pregnancy outcome of the sibling embryos form 
transferred sibling embryos (which had not been analysed).  Power calculations were 
performed based on the Birket and Day method (1994), and studies were designed to 
achieve 80% power, unless otherwise stated. All analyses were performed using SPSS 
(Statistical Package for Social Sciences v11.5) and Minitab (v17). 
 
Univariate regression analysis was used to compare continuous data and paired t-test 
chosen to compare grouped two sample data. ANOVA was used to assess intra and inter 
patient variability within the embryo cohort in combination with multiple linear 
regression analysis to assess the predictive accuracy of metabolic profile on blastocyst 
development rate. To account for patient-specific effects, Generalized Estimating 
Equations (GEEs) were used to model the mean response and within cluster 
associations separately to reduce the variance and increase the power. Principal 
component analysis was used to reduce the dimensionality of the individual 18 amino 
acid measurements and adjust for multiple testing.  
 
Levens test for normality was performed and ANOVA with Tukey Kramer was utilised 
as indicated. Mann-Whitney U-test (2-groups) and Kruskal-Wallis test (2 or more 
groups) were used to compare means when homoscedasticity could not be assumed.  
 
In each scenario, the null hypothesis, that all groups are simply random samples from 
the same population i.e. female BMI has no bearing on embryo viability criteria, was 
rejected when the probability (p-value) was less than the 95% confidence threshold 
(p<0.05). The statistical design of experiments was changed in each setting to adjust 
factors and measure responses in an attempt to determine an effect, and further detail is 
included in each chapter and within the appendix. Throughout the course of this study 
(from 2010 to 2015) clinical policy and protocol changes may have introduced 
‘nuisance’ variables that need to be characterised and subsequently blocked, randomised 
or controlled for in the experimental design. The study population and details of 
extraneous variables and validation of experimental design/ modelling are described in 
full in the validation section below. 
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2.7 Method validation / refinement 
 
2.7.1 Sensitivity and specificity of assays 
A number of pilot studies were performed to validate and refine the assays. Firstly a 
monochromator florescent plate reader was used in place of conventional florescence 
microscopy. This necessitated the use of ‘v’ bottom transparent plates since 
fluorescence was read from the bottom and readings taken at 340nm excitation and 460 
emission.  The increase in fluorescence observed with increasing amounts of glucose 
was linear. The values of R2 for linear regression lines for glucose, pyruvate and lactate 
each exceeded 0.9 and replicate experiments indicated high repeatability of the method.  
 
The accuracy of the assay was determined by comparing values obtained for 
commercial culture media with those reported by the manufacturer. The average 
glucose concentration in Quinns advantage blastocyst was determined to be 2.70mM 
compared to the reported concentration of 2.78mM (Table 2.13).  
 
Table 2.13 Verification of method using media of known metabolite concentration  
(Quinn’s advantage blastocyst media) 
 
Substrate Calculated value mM Reported value mM 
Glucose 2.70 2.78 
Lactate 2.72 2.04 
Pyruvate 0.25 0.1 
 
The experiments were repeated using different dilutions; 1 in 10, 1 in 5, 1 in 2 to 
determine the most appropriate/ accurate method for determining differences due to 
embryo metabolism. A dilution factor of 1 in 10 was applied. The experiments were 
repeated using different volumes and with / without oil overlay. The lowest volume 
permitted for accurate reading is 0.5ul of sample and an oil overlay did not improve the 
sensitivity of the assay.  
 
To determine the most appropriate sample volume for embryo culture, embryos were 
cultured in 25µl, 10 µl, 5 µl and 1µl samples of QA blast media for 24 hours and 
glucose concentrations were analysed against controls. The assay was sufficiently 
sensitive to determine differences between wells of control and test media when the 
lowest volume was used, however to reduce the risk of pipetting errors reducing the 
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accuracy of the analysis- embryos were cultured in 4µl droplets of defined medium 
containing lower concentrations of substrates than those found in the commercial 
medium. A working solution of culture media was prepared, in which the concentration 
of glucose was reduced to 1mM and the concentration of pyruvate was reduced to 
0.47Mm, no lactate was added. This ensured that differences in production/ uptake 
could be readily determined.  A volume of 4ul and culture period of 24 hours was 
sufficient to ensure that substrate availability did not become a limiting factor for 
embryo development. After 24 hours the culture plate was changed the spent media was 
frozen at -800C until assay. 
 
2.7.2. Validity of using supernumerary embryos 
To determine how representative the analysis of sibling embryos metabolism is of those 
transferred, data previously collated and reported by Conaghan et al., (1993) was re-
analysed (with the Author’s permission). Inter-patient variability was compared in 
transferred embryos only and it was determined that pyruvate consumption differed 
amongst groups and could be used to predict pregnancy outcome. Figure 2.3 shows that 
implantation and pyruvate consumption on day 2 were negatively correlated (t=-2.581, 
p=0.010). The f value of 6.663 is indicative of significant variability amongst 
implantation grouping of failed implantation (0), singleton (1) and twin (2) implantation 
;p=0.010.  
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Figure 2.3 Lower pyruvate consumption on day 2 is indicative of higher implantation potential.  
When two embryos were transferred, those with the lowest pyruvate consumption were more likely to 
implant (p=0.01). 
 
When the data were analysed to assess intra-patient variability by comparing the 
pyruvate consumption of all embryos in a patient’s cohort, rather than just the two 
transferred, there was no significant variability evident amongst sibling embryos for 
each implantation category (Figure 2.4A-twin, B- singleton, C-no implantation).  
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2.4A 
2.4B
 
2.4C  
Figure 2.4 Intra patient variability; sibling embryo pyruvate consumption.  
(A) For 100% implantation group n=92 embryos transferred, 160 not transferred, from 22 patients. 
Overall no significant variability amongst sibling embryos p=0.67 (0/22 patients had any significant 
differences amongst sibling embryos). Figure (B) For the 50% implantation group p=0.148 (2/30 patients 
had variability), n=126 transferred, 193 not transferred. Figure (C) For the 0% implantation group 
p=0.422 (16/71 patients had variability), n=283 transferred, 321 not transferred. 
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The findings presented from this re-evaluation of previous collated data, serve to 
indicate that the metabolism of sibling supernumerary embryos is reflective of those 
transferred and is indicative of the probability of pregnancy, thus it is appropriate to 
relate embryo metabolism of supernumerary embryos to the pregnancy outcome of their 
transferred sibling embryos for which data is not available.   
 
2.7.3. Validity of using mean CORE profiles determined over a 24 hour period. 
To determine if 24 hour sampling and mean values provide a sufficiently accurate 
representation of metabolic CORE profile in relation to developmental progression, 
sampling was combined with time-lapse imaging. In a crude experiment, prepared 
research culture medium was dispensed into alternate wells of the WOW dish to ensure 
droplets were not in communication, the dome was not filled. Wells were individually 
selected for analysis. At 4 hour intervals the media was refreshed. Data were collated 
from 23 embryos (4 patients). Developmental stage was recorded at the start of culture –
observation point 1, after 4 hours culture (observation point 2- sample point 1) and 8 
hours (observation point 3 – sample point 2). Embryos were subsequently cultured 
under standard conditions for a further 48 hours to ascertain continued developmental 
viability or arrest. Real-time developmental activity was correlated to CORE profiles as 
shown in figure 2.5.  
 
 
 
Figure 2.5 CORE profile of embryos coupled with time-lapse observations over an 8 hour period.  
(a) Viable embryos that did not divide during the 8 hours utilised substrates at a constant rate. (b) A fall in 
CORE activity was recorded post- cell cycle arrest. (c) Division activity was associated with an initial 
increase in CORE of substrates. 
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The data indicated that if the embryo displayed no change in developmental status 
throughout the 8 hour evaluation period– but was still viable (i.e. developmental change 
observed within 48 hours) then the CORE profile did not differ significantly at sample 
point 1 and 2. Embryos that underwent further development between observation point 
1 and 2 and then subsequently arrested between point 2 and 3 and did not change after 
48 hours additional culture utilised a lower turnover of metabolites between sample 
point 1 and 2. The converse was true for those that displayed an active development 
profile – continuing to develop until culture was terminated.  
 
These findings indicate that developmental and metabolic changes are synchronised and 
whilst 24 hour sampling and static observations will carry a level of uncertainty, the 
results should be broadly representative. The findings of this crude experiment must 
however, be interpreted with caution as sampling errors will be amplified when using 
the low volumes necessitated in this analysis.    
 
2.7.4. Study population and validation of confounding variables 
This thesis has incorporated retrospective clinical data from; 
1. Antenatal clinic setting 2001 to 2007 (n=2269 women) 
2. Hull and East Yorkshire Sub-fertility clinic setting 2006 (n=345 women) 
3. Hull IVF Clinic fresh treatment cycles 2008 to 2010 (n= 709 women) 
4. Hull IVF Clinic frozen treatment cycles 2008 to 2011 (n=65 women) 
This data has been utilised to provide context for the primary research findings and 
examine the wider impact of female BMI on reproductive health, the findings are 
discussed in Chapter 3.  
 
Prospective data have been collected from those women contributing to the primary 
research project from 2010 to 2015; 
1. 29 women attained 218 oocytes and 101 embryos that were observed in studies. 
(Chapter 4) 
2. 176 women donated 808 fresh embryos (Chapter 5 and 6)  
3. 26 women donated 106 frozen embryos (Chapter 6).  
Figure 2.6 provides a summary of how these donated embryos have been utilised, 
depicting the experimental design groupings and justification. This figure will appear 
again in subsequent chapters to highlight the particular study groupings being discussed. 
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Figure 2.6 Summary of number of patients and embryos included in each study group 
 
The demographics of each study group are discussed in detail in each study chapter, 
with specific reference to the matching amongst study groups for confounding variables 
such as age, male BMI, cause of infertility. Any differences in clinical protocol applied 
throughout the duration of the study are also accounted for, including; an increase in the 
use of antagonist stimulation protocol (from August 2013), a change in culture medium 
from Sage® to Vitrolife® (from July 2014), prior culture in WOW system for a subset 
of patients (from July 2014) and use of intralipid infusion therapy for a restricted patient 
set (from August 2013). Differences in research protocol have also been accounted for – 
specifically the introduction of low oxygen culture for research from day 5-9 (from 
January 2013) – to align with the prior clinical culture conditions.  
!
!
 
Study groups
(a) Fresh
(b) Frozen – 0.5mM 
Carnitine; n= 26 patients 
106 embryos
1. Basic
n= 29 patients, 150 
embryos
2. Insulin
n= 37 patients, 149 
embryos
3. Carnitine
i. 0.005mM; n= 19 
patients, 94 
embryos
ii. 0.05mM; n= 20 
patients, 109 
embryos
iii. 0.5mM; n= 26 
patients, 99 
embryos
4. Repeats
I. Basic/ basic conditions n=6 patients, 48 embryos
II. Insulin / basic conditions n=7 patients, 56 embryos
III. Carnitine / basic conditions n=2 patients, 27 embryos
IV. Insulin / Carnitine conditions n= 4 patients, 35 embryos
V. ICSI partner sperm / IVF donor sperm n= 2 patients, 45 embryos 
0. Validation studies
I. Primo analysis  n= 
4 patients, 23 
embryos
II. Donor sperm n= 6 
patients, 25 
embryos
III. Split IVF/ ICSI n= 7 
patients , 50 
embryos
IV. Dif ferential cell 
count/ diameter 
study n= 16 
patients, 44 
embryos
V. Intralipid treatment 
n= 5, 34 embryos
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Chapter 3 : Obesity and reproductive outcome 
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3.1 Introduction 
 
3.1.1 OWOB women and rates of natural conception 
Infertility in natural cycles is almost three-times higher among obese women (Rich-
Edwards et al., 1994). OWOB women take longer to conceive even if they are young 
and have regular menstrual cycles (Robker et al., 2009). Obesity is however, commonly 
associated with menstrual disorders, primarily anovulation, implying that excess weight 
can impact on ovarian function via the endocrine system.  Obesity is coupled with 
changes in the secretion and action of insulin and other adipose hormones including 
elevated leptin, depressed adiponectin, elevated resistin and depressed ghrelin (reviewed 
by Eyster 2011).  These endocrine parameters may combine, leading to hyperinsulinism 
and hyperandrogenism (reviewed by Mitchell et al., 2005). The hormonal mechanisms 
that link nutrition and female fertility are depicted in Figure 3.1 and the metabolic and 
endocrine related disruption seen in obese women that leads to ovulatory dysfunction is 
highlighted in Figure 3.2.  
→ Stimulates, → Inhibits 
Figure 3.1 Hormonal links between nutrition and fertility. 
Insulin promotes uptake and storage of glucose, lipids, amino acids. Leptin reduces appetite and increases 
energy expenditure and lipolysis. These two hormones alter the bioavailability of oestradiol and 
testosterone and may also have direct functional actions on the ovary. 
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Figure 3.2 Representation of the link between obesity and the endocrine system. 
 
Abdominal obesity in particular is associated with increased insulin production and 
insulin resistance. Insulin resistance leads to; (1) high blood glucose levels, (2) elevated 
plasma triacylglycerol and plasma non-esterified fatty acid concentrations (3) 
suppressed hepatic sex hormone binding globulin synthesis (SHBG), resulting in 
increased functional androgen levels, (4) increased levels of bioactive insulin growth 
factor 1 (IGF1), which act on the ovary, resulting in increased androgen production. 
 
An increase in adipose tissue leads to increased oestrogen production, as the enzyme 
aromatase, found in adipose tissue (Nelson et al., 2001), converts androgens into 
oestrogens, which suppress the hypothalamic-pituitary axis. There is reduced 
availability of GnRH, which at the pituitary stimulates the synthesis and secretion of the 
gonadotrophins; follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The 
disorderly activity of these two hormones impairs follicular growth, ovulation and 
corpus luteum maintenance, leading to menstrual irregularities and anovulation 
(Mitchell et al., 2005). Similarly, Leptin influences GnRH secretion from the 
hypothalamus and pituitary secretion of LH and FSH and may also act directly to inhibit 
ovarian follicular development and steroidogenesis (Karamouti et al., 2009).  
 
Hyperandrogenism leads to granulosa cell apoptosis, increased conversion of androgen 
to oestrogen, and increased negative feedback. These alterations can affect follicle 
OBESITY  
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Increased circulatory levels of substrates 
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growth and have adverse effects on the growing oocyte, onward embryo development 
and implantation (Jungheim & Moley 2010). 
 
3.1.2 OWOB women and ART outcomes 
Studies focusing on the impact that raised BMI has on the outcome of assisted 
conception treatment cycles have yielded conflicting results. It is generally accepted that 
obese women require a longer duration and dose of ovarian stimulation and that they 
attain lower oocyte yields (ASRM practice committee report, 2008). However, not all 
studies are in agreement about the impact of obesity on pregnancy, miscarriage and live 
birth rates. For example, Ferlitsch et al., (2004) reported that, for each unit that BMI 
increased, the odds for pregnancy decreased by 0.84 in IVF and similarly, each 
reduction of BMI by one unit increased the chance of pregnancy by 1.19. Likewise 
other studies have reported that very obese women have significantly lower clinical 
pregnancy rates with ART compared to their lean counterparts (Wang et al., 2002; 
Nichols et al., 2001; Fedorcsak et al., 2004) and higher rates of early miscarriage 
(Fedorcsak et al., 2000; Wang et al., 2002). Conversely, Dokras et al., 2006 and 
Maheshwari et al.,(2007), reported no differences in pregnancy rates attributable to 
BMI. It is noteworthy that many of these studies have been retrospective, and few have 
commented on live birth rates or have been unable to adjust for key confounding factors 
such as female age. Taking account of these factors and sample sizes the majority of the 
evidence does indicate lower pregnancy rates and increased rates of miscarriage for 
obese women following IVF treatment compared to normal weight women. 
 
3.1.3 OWOB women and frozen embryo transfer outcomes 
There is even less consensus in the scientific literature about the impact that obesity has 
on the outcome of frozen embryo transfer (FET) cycles. In prospective randomized 
trials, Shapiro et al., (2011) reported that clinical pregnancy rates are improved when 
cryopreserved embryos are transferred compared to fresh transfers. It is believe that this 
is because controlled ovarian stimulation (COS) is avoided/minimized during frozen 
cycles. It is widely reported that COS is associated with impaired endometrial 
receptivity in animal models. A longer duration of COS has also been associated with 
precocious progesterone elevation and impaired endometrial receptivity in women 
(Valbuena et al., 1999). The more intense controlled ovarian stimulation (COS) required 
for OWOB women (Crosignani et al., 1994) may be detrimental for implantation. 
However links between female BMI, endometrial sensitivity to COS and embryo 
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freezing sensitivity have not previously been reported. The reproductive environment is 
likely modified in OWOB women, which may lead to adverse consequences both to the 
embryo and endometrium. This is an area meriting further investigation.  
 
3.1.4 BMI and the relationship with dizygotic twinning 
In twin pregnancies, conversely, a higher plane of nutrition may offer an advantage – 
direct evidence for this is currently lacking, but data from animal models and 
epidemiological studies suggest that maternal nutritional status is linked to twinning 
rates (Hoekstra et al., 2008). It has been proposed that reduced maternal nutrition may 
account for the decreased incidence of dizygotic twins (DZT) conceived during time of 
food scarcity (Hoekstra et al., 2008). However, since the mid-1960’s multiple birth rates 
(MBR) have increased, even after adjustments for maternal age, use of fertility 
treatment and incidence monozygotic twining (MZT) (Derom et al., 2011). One 
possibility is that the rising incidence of DZT is linked to rising female body weight. 
Women with a higher BMI may have an elevated daily food intake and may be better 
able to meet the increased nutritional demands of carrying a twin pregnancy or, 
alternatively, be more likely to ovulate more than one oocyte. DZT occurs as a result of 
multiple follicle rupture in a natural cycle or the transfer of multiple embryos in an IVF 
cycle. In each scenario the embryos must successfully implant and be sustained to term. 
It is possible to interrogate IVF data to investigate whether BMI, a proxy for nutritional 
intake, is a contributing factor in the rising incidence of DZT. 
 
3.1.5 Outcomes in repeat cycles 
Weight loss may modulate treatment cycle parameters such as ovarian responsiveness 
and chances of successful IVF cycle pregnancy outcome. It is widely believed that 
ovarian dysfunction and the follicular microenvironment may be corrected once a 
healthy weight is attained (Clark et al., 1998; Norman et al., 2004). It is not clear from 
the literature if embryo quality in successive cycles of fertility treatment is similar for 
the same couple and if it is influenced by weight change. Inconsistent embryo quality 
grading systems have prevented such analyses, it may be more informative to compare 
embryo metabolism in successive treatment cycles. This is particularly important, in 
view of the strong supporting evidence for embryo metabolic assessment as an objective 
indicator of embryo viability – as reviewed briefly in Chapter 1 and a focus of Chapter 
5.  
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If the general pattern of substrate utilization is not only inherent to the cohort of 
developing sibling embryos belonging to a couple (as demonstrated in Chapter 2 of the 
method validation), but can be demonstrated to correlate to the pattern of nutrient 
utilization in subsequent cycles of treatment in the same couples this will be a 
significant finding. Furthermore if the existence of patient specific inter-cycle 
homogeneity in embryo development and metabolism can be established this could have 
foreseeable possibilities for assessing if embryo viability might be improved by weight 
loss.  
 
Aims and objectives 
The literature on the impact that female BMI has on pregnancy outcome is inconclusive, 
and the aim of this chapter was to review treatment outcomes for consecutive patients 
attending the Hull IVF Unit, based on female BMI. 
The specific objectives were; 
a) To investigate the extent of combined obesity and fertility problems within the study 
population (i.e. women in the Humber and Yorkshire region) using data collected in a 
previous local population survey.  
b) To compare clinical pregnancy (CPR), implantation (IR) and miscarriage rates and 
live birth data from OWOB and normal weight women in both fresh and frozen transfer 
cycles (FET). 
c) To discover if a raised BMI is linked to the incidence of dizygotic-twinning (DZT), 
using data from IVF patients who had two embryos replaced, thus enabling controlled 
investigation, taking account of other known specific risk factors. 
 
d) To compare subsequent treatment cycle outcomes for patients returning for a repeat 
cycle of IVF treatment who had remained weight stable with those who had lost or 
gained weight over a 3 year period. 
 
e) To discover if embryo development and metabolism of substrates are matched in 
successive treatment cycles for a given patient. 
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3.2 Materials and methods 
 
3.2.1 Assessment of study population; natural conception rates 
A survey conducted in Hull and East Yorkshire and Sheffield, asked consecutive 
women attending the antenatal clinics between 2001 and 2007 to self-complete a 
questionnaire inquiring about their Time To Pregnancy (TTP: the interval of exposure 
to unprotected intercourse from discontinuing all birth control methods until 
conception); female height and weight were also collected. As the study of current 
pregnancies will exclude those who failed to conceive or gave up the pregnancy 
attempt, data were also collected from women attending the Subfertility Clinic at the 
Women and Children’s Hospital, Hull Royal Infirmary and used in comparison.  
Data were reviewed from 2269 consecutive women, attending the antenatal clinic. 1460 
(64.3%) conceived within 6 months rising to 1780 (78.4%) by the end of the first year, 
and 489 couples (21.6%) were sub-fecund. Patients who had fertility treatment, 
unplanned pregnancies and missing BMI results were excluded from further analysis. 
This significantly reduced the data set and complete records were available for 196 
women.  
Data were also reviewed from 345 consecutive couples referred to the Subfertility 
Clinic at the Women and Children’s Hospital, Hull Royal Infirmary.  Obese patients 
were subsequently identified from the notes of those referred to the clinic in 2006. The 
majority of patients would have subsequently been referred to the IVF clinic for further 
investigation or treatment, however women who were obese (BMI>30kg/m2) will have 
been advised to lose weight prior to IVF referral for NHS funded treatment. Full notes 
were obtained to verify this and to permit an assessment of weight loss success rates. 
The appropriateness of the advice and support was determined by whether the patient 
lost weight to such an extent that they subsequently conceived or were offered NHS 
funded fertility treatment. 
 
3.2.2 Assessment of study population; ART conception rates from fresh and frozen 
cycles 
Data were recorded from 709 consecutive IVF / ICSI patients attending the Hull IVF 
Unit between 2007 and 2011 for fresh treatment cycles. Patients receiving donated 
oocytes were excluded from the analysis; the outcome of donor and recipient cycles was 
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assessed separately (n=40). The outcomes from weight discordant (i.e. normal/OWOB) 
paired, heterosexual couples were assessed to determine any impact of male BMI on 
treatment outcome. BMI was recorded at the start of treatment and only those 
considered weight stable were included in the study.  
 
Data collected from any frozen embryo transfer (FET) cycles performed for the study 
participants, were also retrospectively interrogated. Treatment outcomes in OWOB and 
normal weight women were compared using data from first their fresh and then their 
FET cycle (n=65). The women served as their own control, meaning that any difference 
in clinical pregnancy rates (CPRs) could be attributed to endometrial receptivity and 
embryo quality rather than to inter-individual variation between treatment groups. 
 
In fresh cycles, patients underwent a standard long-protocol agonist IVF cycle. 
Embryos, selected on the basis of morphology were transferred on day 3 (prior to 2009) 
or on day 5 (post 2009). Supernumerary embryos of suitable quality were cryopreserved 
according to a slow-freeze protocol. 
 
In frozen cycles, patients were down-regulated and given oestradiol supplementation 
10–14 days before thaw to achieve a target endometrial thickness of 8 mm. 
Progesterone supplementation began on the day preceding thaw. Patients received 
similar progesterone supplements in their fresh cycle, beginning 1 day after retrieval. 
Thawed cleavage-stage embryos were cultured in vitro overnight to confirm onward 
developmental potential; thawed blastocysts were cultured for 1-2 hours. 
 
3.2.3 Assessment of maternal outcome 
In order to discover whether the prevalence of MBRs had risen over the past 30 years, 
data obtained from the UK Office for National Statistics (ONS), for all maternities in 
England and Wales between 1985 and 2008 were compared to data recorded for patients 
undergoing fertility treatment both nationally (using data from the Human Fertilisation 
and Embryology Authority- HFEA) and specifically; those attending the Hull IVF 
Clinic.   
 
Using the data from IVF patients attending the Hull IVF Clinic the impact of obesity on 
multiple pregnancies of known dizygosity- (monozygotic pregnancies were excluded) 
was compared for study participants. The incidence of DZT in women who received a 
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transfer of two embryos was 107/233 (45.9%) in normal weight women who achieved a 
positive pregnancy (PP) result compared with 74/155 (47.7%) overweight and 43/100 
(43%) obese women.  
 
3.2.4 Weight change and assessment of repeat cycle outcome 
A retrospective study was designed to compare cycle outcome in patients receiving two 
cycles of IVF / ICSI treatment between 2008 and 2011 at the Hull IVF Unit (n= 709 
cycles).  
 
Data were reviewed from first and second treatment cycles.  Clinical pregnancy 
outcomes were compared for those that had remained weight stable and those who had 
gained or lost weight between cycles.  
 
In an effort to isolate the influence of BMI on subsequent treatment outcome the BMI 
change between cycles (stable, gain or loss) was also evaluated. A total of 186 patients 
returned for a second treatment cycle in the duration of the study. The majority had 
remained weight stable between treatment cycles (n= 158), 8.6% of patients had lost 
weight between cycles (n= 16) and 6.5% had gained weight (n= 12).  
 
Regression analysis was used to control for confounding variables, such as the impact 
of increased maternal age between cycles. The likelihood of successful treatment 
outcome does not differ over 4 cycles (NICE 2007), however women returning for a 
subsequent treatment cycle within 1-2 years of their last cycle are likely to be those who 
have experienced a negative outcome. A duel regression logistic sub-model was created 
using cycle as an indicator variable to control for this.  
 
To review the impact of weight change on repeat cycle embryo development and 
substrate metabolism; data were reviewed from weight stable women, who underwent a 
first and second treatment cycle within a 12 month period. The number of fertilised 
embryos obtained in the 2nd treatment (mean 5.8) cycle did not significantly differ to the 
number obtained in the 1st cycle (mean 4) and therefore the proportion of embryos 
forming a blastocyst was compared. The quality of blastocysts (the proportion grade 
3Bb or above- assessed according to grading criteria described in chapter 2) was 
compared in each cycle for individual patients, as was the utilisation of glucose, lactate 
and pyruvate using methods described previously in chapter 2. 
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3.2.5 Statistical analysis 
Data analysis was carried out using SPSS (Statistical Package for Social Sciences 
v11.5). Outcome measures (mean TTP, PP, CP, miscarriage, LB, DZT) were calculated 
for each BMI grouping, using the non-parametric Kruskal–Wallis test, Fisher’s exact 
test or chi squared. Continuous data was assessed using ANOVA and paired t-tests. A 
general linear logistic regression model was used to examine the relationship between 
maternal BMI and the likelihood of live birth per treatment cycle and adjust for 
potential applicable confounders (e.g. age, cause of infertility, smoking and parity, 
ovarian response and embryo transfer data). An alpha of p ≤0.15 was used for adding or 
removing predictors from the model. Statistical significance was indicated by p< 0.05. 
The odds ratios (OR) and 95% confidence interval (CI) are given for each significant 
independent variable’s contribution to the model.  
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3.3 Results 
 
3.3.1 Obesity and natural conception 
The data from antenatal clinics indicates that 39% of the women who had achieved a 
pregnancy were overweight or obese (77/196). There were no significant differences in 
the proportion of women and their partners who smoked, amongst women of normal 
weight and OWOB attending the clinic. In addition OWOB women did not report a 
significantly higher incidence of menstrual infrequency (23.4% verses 16.7%), acne or 
hirsutism (1.9% verses 8.8%) compared to those of normal weight. The average age of 
onset of menarche was comparable for normal and overweight women (12.6 years and 
12.5 years respectively), however it was significantly lower for obese women (12.1 
years p<0.05). Female age at the time of first pregnancy was comparable, although time 
taken to achieve a pregnancy tended to be longer in OWOB women averaging 7.92 
months compared to 6.99 months for normal weight women, despite comparable 
reported frequency of intercourse. The adjusted regression analysis showed a negative 
relationship (β-0.015, t-1.55, p0.06) between BMI and TTP.   
The data from the subfertility clinic shows that 48.1% (166/345) of patients attending 
the clinic were be classified as overweight or obese. 15.1% of female partners were 
classified as morbidly obese (BMI > 35). 
 
Figure 3.3 Female obesity rates amongst patients attending the subfertility clinic in Hull, in 2006. 
Over half of all patients seen were overweight or obese (n = 345). 
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In total, 74% (64/82) of obese women were given advice on the effect of their body fat 
on their subfertilty and subsequent treatment. One year later 24% (16/64) of obese 
women had lost a sufficient amount of weight in order to be given NHS-funded IVF 
treatment, 12.5% continued to receive support, however the majority (62.5%) had 
stopped attending the subfertility clinic and discontinued their treatment, although they 
had not yet become pregnant.  
 
3.3.2 Obesity and assisted conception 
 
3.3.2.1 Fresh cycles 
The percentage of patients attending the Hull IVF Unit classified as overweight or obese 
was 48%; this is directly comparable to the findings reported in the previous section, for 
women who attended the subfertility clinic. Notably, non-treated were morbidly obese, 
compared to 15.2% of women who attended the subfertility clinic. 
 
The data in table 3.1 shows that clinical pregnancy outcomes did not differ significantly 
according to BMI classification, although pregnancy rates were lowest in obese patients. 
In a univariate analysis live birth rates, per cycle started were significantly lower for 
women with a BMI >25kg/m2 compared to those with a BMI <25kg/m2 (p<0.01), 
indicative of the higher rates of miscarriage in the OWOB, which included two prenatal 
losses.   
 
Table 3.1 Pregnancy and live birth outcomes for women of differing BMI (kg/m2). 
Live birth rates shown to be lowest for obese patients. Values (± SD) or (n) for percentages, * p<0.05 for 
ANOVA / Kruskal-Wallis test as appropriate. 
 
BMI kg/m2 
 
< 18.5 
n=10 
18.5-24.9 
n=361 
 25-29.9 
n=192 
30-35 
n=146 
Mean female age (SD) 29.8 (4.7) 33 (3.6) 33.6 (5.3) 33 (4.3) 
% positive pregnancy test (n) 36.4 (4) 40.4 (146) 44.3 (85) 39 (57) 
% clinical pregnancy (n) 36.4 (4) 33.5 (121) 35.4 (68) 31.5 (46) 
%  early loss <6wks 0 6.9 8.9 7.5 
%  miscarriage >6 wks 0 3.1 10.4 5.6 
% Live birth rate (n) 36.4 (4) 32.4 (117) 31.7 (61) 29.4 (43)* 
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There were no significant differences in female age (mean 33.4years ±4.6), cause or 
duration of infertility (mean 3.9years ±1.6), ethnicity  (96.4% white, British) or number 
of smokers (18.5%) among the groupings. The duration and dose of stimulation was 
significantly higher for OWOB (12.35 days, 1979.63 total FSH IU) compared to normal 
weight women (11.22 days, 1746.71 total FSH IU; p<0.05) and average oocyte numbers 
were significantly lower (9.6 compared to 10.6 p<0.01), although endometrial thickness 
on the day of oocyte retrieval was comparable (10.6 verses 10.8mm). The number of 
embryos replaced was comparable (average of 1.61 and 1.53), as were the rates of 
multiple births (16.1 for OWOB and 14.1 for normal weight group). Each exploratory 
variable was included in a stepwise logistic regression and significant predictor 
variables of the likelihood of live birth were; female age (OR 0.94, 95% CI 0.93-0.95) 
and number of oocytes (OR 1.02, 95% CI 1.01-1.02). In this adjusted model BMI 
remained a significant predictor of live birth (OR 0.36, 95% CI 0.23-0.69).  
 
The data from patients attending the IVF clinic shows that the mean female BMI was 
22.6 (±3.22 SD) whereas mean male BMI was 26.7 (±3.99 SD, full data available for 
n=88 pairings). Regression analysis showed a weak trend for assortive mating amongst 
couples, (r =0.11, p=0.3, Figure 3.4), which was more apparent when couples were 
categorized into normal (BMI 18.5-24.9) or OWOB (BMI>25) and 83% of the couples 
fell into matching categories. Male obesity was associated with significantly lower 
blastocyst development (BD), compared to all other discordant pairings of male and 
female BMI (p=0.01; Figure 3.5), however there was no significant impact on clinical 
pregnancy rates. Interestingly, this finding was independent of sperm quality. 
 
 
 
 
 
Figure 3.4 The relationship between male and female spouses in BMI (kg/m2) is not significant. 
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Figure 3.5 The relationship between male and female spouses and the impact of pairing on embryo 
development to blastocyst on day 5.  
Male OWOB appeared to contribute to higher rates of early embryo arrest (Data expressed as mean +/- 
SD * p<0.05), n=518 embryos, n=88 patients. 
 
An additional subgroup of 40 patients took part in an egg-sharing scheme and donated 
half of their retrieved oocytes to a matched recipient (n=40). Differences in fertilisation, 
embryo quality and blastocyst development, pregnancy, miscarriage and live birth rates 
were compared using a paired t-test and found to be non-significant.  
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3.6 a  
 
3.6 b  
 
 
Figure 3.6 Egg sharer (donor) and recipient treatment cycle outcomes.  
3.6a Embryo developmental competence did not significantly differ between egg donors and recipients 
despite significant differences in sperm donor BMI. 3.6b Birth weights in relation to BMI of birth mother 
show differing trends for recipients (n=16 live births) and donors (n=11 live births).  
 
The mean female BMI of matched pairs was statistically comparable, although did show 
a trend for higher BMIs in the recipient group (23.5±0.3 SEM for donors compared to 
25.6±0.6 for recipients p=0.06). Egg donors were required to have a BMI of less than 
25, although an exception was made for a known donor. The BMI of egg sharers who 
achieved clinical pregnancy and live birth was comparable to that of successful 
recipients (p=0.34). Likewise the birth weight and gestation period was analogous for 
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singleton births (all received a single embryo transfer) in the recipient and donor 
groupings. When the data were analysed according to female BMI of the birth mother a 
significant inverse relationship was apparent between increasing recipient BMI and 
birth weight of newborn (Figure 3.4b; r2 -0.57, p=0.02), whereas in donors there was no 
such relationship. When the data were stratified into BMI classifications it was 
determined via ANOVA and post-hoc Tukey-Kramer method that birth weights were 
significantly lower when eggs from a normal weight donor had been received by an 
OWOB recipient (p=0.02).  However, this study is underpowered and outlier 
observations may have influenced the test statistics.   
 
Sperm counts also showed considerable variance amongst pairings (p=0.005). When the 
data were assessed according to male BMI, the male partner of recipients had a 
significantly higher BMI than that of the partner of the paired donor (24.1 verses 25.1, 
p=0.05). 
 
3.3.2.2 Frozen cycles 
For the 65 patients included in this portion of the analysis, there were no differences in 
female age, cause of infertility, dose and duration of stimulation, day of transfer, 
proportion of elective single embryo transfer, treatment type, between the OWOB and 
normal patients. However women with normal BMI, tended to produce more eggs 
(mean 10.6) than OWOB (mean 10.1, p=0.07), although this did not result in a 
significantly different number of embryos available for cryopreservation for OWOB 
and normal weight women (3.8 verses 4.17 respectively). 
 
As reported in the previous section there were no significant differences in pregnancy or 
miscarriage rates for fresh cycles and this was also the case when the data was limited to 
those patients with embryos available for freezing (as shown in figure 3.7a). The 
clinical pregnancy rate (CPR) for normal weight women was 10% per embryo 
transferred compared to 8.6% for the OWOB. However, in frozen cycles, significantly 
lower CPRs were obtained for OWOB compared to normal weight women (CPR 20% v 
42% p=0.049). Rates of pregnancy losses in frozen cycles were also significantly higher 
for this group (13 v 6.9% p=0.049), as indicated in figure 3.7b. 
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Figure 3.7 Pregnancy outcomes from fresh and frozen treatments.  
Pregnancy outcomes for normal and OWOB women were comparable in fresh cycles (a), however 
outcomes were significantly poorer in frozen cycles (b) for OWOB compared to normal weight women. 
*p<0.05 
 
In women of normal weight, rates of pregnancy and miscarriage were significantly 
higher in their subsequent frozen cycles. Figure 3.8 shows an increase in CPRs from 
10% to 42%. In the OWOB group outcomes were improved in their frozen cycle, 
however results did not significantly differ from those of their fresh cycle (8.6% to 20% 
CPR). 
 
 
Figure 3.8 Pregnancy rates were improved in frozen cycles 
The improvement was significant in the normal weight group. *p<0.05 
 
There were no significant differences in cryosurvival or onward development/viability 
between the embryos from normal weight or OWOB (n=254 embryos), as shown in 
figure 3.9. When the evaluation was limited to blastocysts only (n=156) rates of 
cryosurvival tended to be lower for the OWOB group (44% v 59%; p=0.06).  
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Figure 3.9 Marginally poorer embryo cryosurvival is reported for OWOB compared to the normal weight 
grouping.  
There were no differences in the percentage of embryos resuming ongoing cleavage development. 
 
 
3.3.3 Obesity and birth-outcome -dizygotic twinning 
The data from the ONS shows that multiple births have risen consistently in the UK 
from 1980 to 2008 (R2=0.93, p=<0.01) (figure 3.10). MBR associated with IVF have 
remained above 25% from 1990 onwards both nationally and locally. ARTs have 
accounted for only 2% of all multiple pregnancies in 2008, suggesting other social and 
biological factors must be causal.  
 
 
 
Figure 3.10 The rising incidence of multiple pregnancies across the UK. 
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Factors previously reported to influence the incidence of multiple births are listed in 
Figure 3.11. Multiple regression was used to assess the impact of these known risk 
factors on implantation outcome (i.e. implantation of -2, -1 (miscarriage), 0 (no 
pregnancy), 1 (singleton) 2 (dizygotic twins) fetal hearts, following the transfer of two 
embryos in Hull IVF patients (n=224), using the forward enter stepwise method, a 
significant model emerged (F=3.048, p=0.02. Adjusted R square = 0.52). Female age 
and blastocyst development were independent predictors of implantation outcome. BMI 
as a continuous variable was not significant, however, the data were suggestive of a 
non-linear relationship between BMI and DZT.   
 
 
 
 
Figure 3.11 Factors influencing DZT pregnancy. 
Literature review findings and regression model evidence using Hull IVF Unit patients. Regression 
results for prediction of implantation outcome are displayed for significant predictor variables p<0.05 
 
Factors!inUluencing!DZT!Smoking!(Morales"Suarez"Varella!et!al.,!2007)!
Multivitamins!&!folate!supplementation"!although!conclusive!data!not!yet!available!
Parity!!(Hankins!&!Saade!2005)!
Seasonal!variation!–!higher!!DZT!rates!reported!for!conceptions!during!the!summer!and!autumn!seasons!!during!the!19th!century.!Speculated!to!reUlect!seasonal!changes!in!food!supply!(Erikson!&!Fellman!2000)!
BMI!!&!obesity"!5!studies!have!identiUied!a!relationship!between!increasing!maternal!weight!&!incidence!of!DZT!(Reddy!et!al.,!2005).!These!studies!have!not!been!able!to!!standardise!for!the!use!of!fertility!drugs.! Assisted!conception!
Maternal!age!(Collins!2007)!
Ethnicity!(Collins,!2007)!!
Genetic!factors!(Hoeskstra!et!al.,!2008)!
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Clinical pregnancy was confirmed for 185 of the 224 patients who achieved a positive 
pregnancy (PP); DZTs accounted for 53 of these pregnancies (28.6% MBR). The LB 
rate per cycle was 37.3% (n=183). There was no difference between normal weight and 
OW and OB women in baseline characteristics, including age (Table 3.2). There were 
no significant differences in rates of PP, CP or LB (37.9% normal weight verses 37.2% 
OWOB). The incidence of MZT was low (1.8%) and did not differ significantly 
between groups.  
 
!! Maternal!body!mass!index! !!
!! <24.99! 25829.99! >30! p"
n! 242! 153! 100! !!
Age!(years)! 33.6! 34.1! 33.3! 0.49!
Cause!of!infertility!
! ! !
0.27!
Male!factor! 73! 52! 30!
!Tubal! 41! 29! 10!
!Unexplained! 59! 47! 18!
!Ovulatory! 26! 10! 16!
!Uterine! 1! 0! 0!
!Endometriosis! 7! 1! 3!
!Multiple!factors! 35! 14! 23!
!%!Multiparous! 11.2! 10.4! 10.9! 0.94!
%!Smokers! 20! 18.8! 20! 0.13!
%!ICSI! 30.2! 35.9! 38.6! 0.25!
Endom!thickness! 10.8! 10.8! 11.3! 0.55!
Oocyte!number! 10.6! 9.6! 9.1! 0.06!
Number!fertilised! 6.7! 6.2! 5.8! 0.02!
Number!top!scoring!embryos! 3.1! 2.8! 3.2! 0.62!
Blastocyst!development,!day!5! 0.9! 1! 0.7! 0.79!
Male!age! 34.8! 36.8! 34.7! 0.08!
Male!BMI! 22! 28.1! 30.6! 0.03!
p!value!based!on!ANOVA!and!Kruskal!Wallis!tests! !! !!
 
Table 3.2 Demographic and embryological characteristics of normal, OWOB groupings. 
Each displayed no significant differences. 
 
The primary outcome measure for this study was DZT birth rate, which did not differ 
between women of differing BMI (28.1% normal weight verses 31.2% p =0.98; 0.81 
power). There were no significant differences when the data were further classified to 
normal verses overweight (22/58; 37.9% DZT) and obese (4/35; 11.4% DZT).  
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BMI and Birthweight of DZTs 
The average birth weight of the larger twin was 2401.4g and 2116.8g for the smaller 
twin. There was no significant difference in birth weights with female BMI and weight 
discordance amongst twins was comparable amongst the BMI groupings. A weight 
difference of greater than 18% between twins is considered to be clinically significant 
(Breathnach et al., 2011) and there were an equal number of incidences of this amongst 
groups (r=0.13 , p=0.4). The data indicate a very weak inverse trend between female 
BMI and average birth weight (r= -0.13, p=0.4). 
 
 
 
Figure 3.12 Female BMI and twin birth weight. 
Female BMI did not significantly correlate with twin birth weight (WT of twin 1 /2). Twin weight 
discordance (indicated by the distance between the parallel lines) was statistically comparable for women 
of differing BMI (n=48).  
 
Figure 3.13 shows the wide range in mean birth weights of twin maternities – the range 
is most evident for the OWOB grouping and data are skewed to the lower end of the 
scale. Similarly, whilst the average gestation period was 35.23 weeks for the normal 
weight group and 34.59 weeks (t=0.72, p=0.5), the data are skewed to the lower end of 
the scale for OWOB. 
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Figure 3.13 Birth weights and delivery times.  
Boxplots of the median, inter quartile and range indicate the spread and skew of data, particularly for the 
OWOB group- towards the lower values. Analysis based on n=26 normal and n=22 OWOB live birth 
events. 
 
 
When analysis was limited to include the transfer of two embryos of the same quality 
score, the data hinted at differences in birth rates of; 17% for normal weight women, 
verses 44% for overweight women and 10% for the obese group, (Figure 3.14, p=0.07). 
This association did not change upon adjustment of the regression analysis to consider 
embryo quality. 
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Figure 3.14 DZT rates presented according to female BMI and embryo quality.   
The data shows a trend for higher twin rates in the overweight grouping when two top quality embryos 
were replaced (ANOVA p=0.07). Analysis of 186 pregnancies achieved from the transfer of two embryos 
and 51 clinical pregnancies achieved from the transfer of two top quality embryos.  
 
The power calculation assumed that a quarter of all IVF pregnancies conceived from the 
transfer of two embryos would be multiple births (validated by HFEA annual figures 
2008). The study was adequately powered to make general inferences about the lack of 
differences in DZT rates amongst BMI groups. The possibility of a type II error cannot 
be excluded when the restricting the analysis to the transfer of top scoring embryos and 
further study is required to confirm or refute the reported trend. 
 
3.3.4 Repeat cycles; 
Weight change and pregnancy rates 
Clinical pregnancy rates were significantly better in patients who returned for a second 
treatment cycle (p<0.05, paired t-test), however there is no evidence to suggest that 
other confounding variables differed between cycles sufficiently to influence the 
probability of success. BMI per se was not a significant predictor of cycle outcome, nor 
did it differ significantly between cycles for the majority of patients (Table 3.3 – 
regression model). Likewise, oocyte number and embryo developmental competence, as 
assessed by morphology at the cleavage stage and the ability to form a blastocyst, did 
not significantly differ between successive cycles and could not be used to determine 
the probability of success in the first and second treatment attempts.  
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Table 3.3 Duel regression model  (cycle 1 and 2). 
Using cycle as an indicator variable to determine the influence of prognostic variables on cycle outcome. 
 
 Beta T Signif 
Female BMI- kg/m2 -.085 -.757 .451 
Number of eggs -.121 -.641 .523 
Fertilization – no. 2PN -.122 -.552 .582 
Top quality embryos day 3 .152 .924 .359 
Blastocyst development day 5 -.156 -.905 .368 
Number embryos replaced -.136 -1.036 .303 
 
CPRs in the first cycle of treatment were significantly lower than those expected (data 
not shown- based on annual audit results for clinic) however CPRs achieved in the 2nd 
cycle of treatment for those who remained weight stable were significantly improved 
(p<0.01) and were in the expected range (Table 3.4). Those who gained weight also saw 
an improvement in CPRs but this was not statistically significant, probably due to the 
sample size. Those who lost weight had CPRs on their first cycles that were closer to 
the expected values and there was no significant difference in the outcome of the second 
cycle (Figure 3.15).  
 
In the weight stable group the overall CPR for cycle 1 was 5.7% (9/158) and for cycle 2 
this was 33.5% (53/158) (p<0.01). Differences in treatment outcome between cycle 1 
and 2 were comparable amongst the BMI sub-groupings (Table 3.5 -Kruskal-Wallis 
H=0.5, p=0.9) (i.e. the proportion seeing an improvement in outcome in each BMI 
subgroup). 
 
In the group who lost weight between cycles the overall CPR for cycle 1 was 25% 
(4/16) and for cycle 2 this was 18.8% (3/16). Differences in treatment outcome between 
cycle 1 and 2 were again comparable amongst the BMI sub-groupings (Table 3.5- 
Kruskal-Wallis H=1.8, p=0.4). The average weight loss was indicated by a fall of -
0.98kg/h2 (±1.83 SD). The average BMI for cycle 1 was 28.4 and the average for cycle 
2 was 26.2. 
 
In the group who gained weight between cycles the overall CPR for cycle 1 was 8.3% 
(1/12) and for cycle 2 this was 33.3% (4/12). Differences in treatment outcome between 
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cycle 1 and 2 were again comparable amongst the BMI sub-groupings (table 3.5 -
Kruskal-Wallis H=2.0, p=0.6). The average weight gain was +2.3 BMI (± 2.3 SD). The 
average BMI for cycle 1 was 24.7 and the average for cycle 2 was 27.1 kg/m2. 
 
Similarly, there were no significant differences in rates of miscarriage, either within or 
between all groupings. 
 
 
 
Figure 3.15 Clinical pregnancy rates were compared in first and second treatment cycles according to 
weight change. 
 
Table 3.4 Breakdown according to BMI classification, cycle CPR and weight change. 
All groups showed significantly increased rates of CPR in second cycle, this was not influenced by BMI 
(kg/m2). 
 
Repeat cycles; embryo development and substrate metabolism 
The proportion of embryos capable of undergoing blastocyst formation was comparable 
amongst the cohort of zygotes generated from a patient’s first and second treatment 
cycle (paired t-test p=0.19). In addition the quality of those blastocyst was not 
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significantly different, as indicated by the proportion of blastocysts of 3bb quality or 
above (Figure 3.16)  
 
 
 
Figure 3.16 Blastocyst development in successive cycles.  
No significant differences in blastocyst development or quality in embryos generated from a first (n= 16) 
and second treatment cycle (n=21). Analysis based on paired t-test.  
 
The uptake of glucose and pyruvate and production of lactate was compared for 
embryos generated from individual patients in successive treatment cycles. As stated 
above there were no significant differences in developmental rates or quality and 
similarly substrate utilisation of those remaining at the cleavage stage and those 
reaching the blastocyst stage was comparable and intrinsic to the cohort of embryos 
produced from a patient. Figure 3.17 shows that embryo metabolism is patient specific 
and repeatable patterns of uptake and release are displayed in subsequent treatment 
cycles. In this weight stable population, the relationships observed between BMI and 
embryo development and metabolism in a first cycle of treatment were similarly 
observed in a second cycle (p> 0.05 paired t-test). 
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Figure 3.17 Inter-cycle variability in blastocyst metabolism was determined for weight stable women.  
The mean uptake/ production of substrate per embryos recorded from a first cycle (n=16) was comparable 
to that of an embryo produced in a woman’s second treatment cycle (n=21). Analysis based on paired t-
test, values depicted as mean ±SEM.   
 
Pyruvate uptake was most closely comparable for cohorts of embryos of individual 
patients in each successive cycle (p=0.64), whereas values for lactate and glucose were 
more widely dispersed (p=0.17 and 0.19 respectively).  
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3.4 Discussion 
 
3.4.1 Summary of key findings 
The data from the antenatal clinic showed that the average age of menarche was 
significantly lower for OWOB women compared to those of normal weight, suggesting 
an early origin for body weight disorders in this cohort. The subfertility clinic data 
revealed high rates of infertility among OWOB women, this was supported by the 
significantly lower live birth rates among OWOB women compared to normal weight 
women undergoing ART. Increased BMI may however increase the likelihood of a 
dizygotic pregnancy (p=0.07).  
 
In ART cycles OWOB women required a higher dose and duration of ovarian 
stimulation and produced significantly fewer oocytes. Male BMI contributed to poorer 
blastocyst developmental progression, although this was not observed in the ovum 
donation subgroup analysis. In general, the blastocyst quality data was comparable in 
subsequent treatment cycles, in terms of both morphological grade and biomarkers of 
viability, for a population of weight stable women. 
 
Reproductive outcomes were also poorer for OWOB women post FET, compared 
normal weight women (significantly lower pregnancy rates and a trend for reduced 
cryosurvival of blastocysts; p0.06).  
 
3.4.2 OWOB women and rates of natural conception 
The antenatal clinic data indicates that not all obese women have problems with their 
fertility; however it would appear that BMI does have an appreciable impact on 
fecundity. The mechanisms remain unclear and the lack of any significant difference in 
reported menstrual irregularities in this data set, suggests that the divergence in 
reproductive outcomes may not be simply due to endocrine induced ovulatory factors.  
Previous studies have reported that 30-47% of OWOB women have menstrual 
irregularities (Castillo-Martinez et al., 2003, Douchi et al., 2002). Whilst the data from 
the antenatal clinic did show a trend for increasing TTP and increasing BMI, this was 
not significant. As this new analysis focused on natural conceptions only, those with 
server ovulatory dysfunction were not included within the cohort – possibly explaining 
the lower than expected incidence of menstrual irregularities. A notable observation was 
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that obese women reported a significantly earlier age of onset of menarche. This finding 
is consistent with that widely reported in the scientific literature and was first proposed 
by Frisch and Revelle (1971) to be linked to the age at which a ‘critical body mass’ is 
achieved. Leptin, produced by adipocytes provides a signal to the hypothalamic-
pituitary with the amount produced being proportional to the size of the fat mass. 
Obesity occurring in the teenage years has been associated with a higher incidence of 
infertility in adulthood (Jokela et al., 2007). On the strength of this, one likely 
interpretation of these new data is that body weight disorders may have begun early for 
this cohort of reporting women.   
A significant number of women who are of reproductive age are overweight or obese, as 
illustrated from the antenatal, subfertility and IVF Unit findings. The proportion of 
OWOB women in the subfertility patient study group was higher than in the group 
attending the antenatal clinic, indicating a high prevalence of infertility and lower 
natural conception rates. The data also support the narrative that higher rates of 
subfertility are evident amongst overweight obese (Jenson et al., 1999, Hassan et al., 
2004) and there is an increased time to conceive for women with and without reported 
ovulatory dysfunction (Gesink et al., 2007).  The high rate of treatment drop-out for 
obese patients underlines the profound psychological consequences that may incur as a 
result of obesity stigmatisation and serves to highlight the poor-success rates associated 
with meeting weight-loss targets through dietary advice (Kulie et al., 2011). This is 
further supported by the finding of higher rates of depression amongst obese women 
attempting to conceive reported by Roberts et al., (2002).   
3.4.3 OWOB women and ART outcomes 
Over 24 studies, including more than 78,000 cycles have thus far reviewed the evidence 
of association between ART success rates and female BMI.  Of these, 14 studies have 
reported no association with CPRs, although a meta-analysis has been used to 
demonstrate lower live birth rates (Metwally et al., 2008) and a linear increase in rates 
of fetal loss with increasing BMI (Luke et al., 2011).  In the present study, there were no 
significant differences in pregnancy rates amongst women of differing BMI 
classification attending the Hull IVF Unit for IVF / ICSI treatment.  There was, 
however, a trend for increasing early pregnancy loss (biochemical and ectopic), 
miscarriage (6-22wks) and neonatal loss (>22wks) with elevated female BMI.  
Consequently, subsequent live birth rates were significantly lower for both overweight 
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and obese women. This is in contrast to earlier studies that have reported lower birth 
rates in those classified as obese but not in women who are classified as overweight 
(Lake et al., 1997, Bolumar et al., 2000).  These new data do reflect the findings of 
Wise et al., (2010), who reported a negative linear relationship with female BMI and 
birth rates.  
OWOB women attending for ART at the Hull IVF Unit received a higher dose and 
duration of stimulation. Endometrial preparation was comparable among BMI 
groupings, however, importantly, OWOB women yielded significantly fewer oocytes. 
This finding is consistent with those of Fedorcsak et al., (2004), who in a review of 
5,019 IVF cycles, noted a similar distinction in response to ovarian stimulation among 
lean and obese women. The relationship between oocyte yield and BMI has been 
reviewed in 21 prior studies, 11 of which support the finding of lower oocyte yield – 
ranging from 7-25% lower yields for OWOB (Reviewed by Chaverro & Toth 2012), 
although evidence for differences in fertilisation or embryo development is less 
convincing. Three studies have reported lower fertilisation rates (Orvieto et al., 2009, 
Matalliotakis et al., 2008, Sneed et al., 2008), whilst five refuted any association with 
BMI (Lashen et al., 1999; Fredorcsak et al 2004; Spandorfer et al., 2004; Dokras et al., 
2006; Metwally et al., 2007; Bellver et al., 2010). Embryo score was found not to 
correlate with BMI in three studies (Dechaud et al., 2006; Bellver et al., 2010; Shah et 
al., 2011) and lower embryo quality was reported for OWOB women by Carrell et al., 
(2001) and Metwally et al., (2007). 
It is possible that failing to account for the impact of male BMI may be associated with 
the lack of clear correlation with female obesity and embryo development. In the 
present study, it has been observed that body mass index is generally positively 
correlated within a couple. When the data were analysed according to both female and 
male BMI, male BMI did appear to have an effect on blastocyst formation, suggesting a 
paternal effect on early embryo development. It has previously been reported that rates 
of blastocyst formation are lower for ICSI derived embryos compared to those 
generated through IVF (Grifiths et al., 2000) and also that OWOB males have lower 
sperm counts (Jensen et al., 2004). This finding reported here, was however, 
independent of sperm count. Likewise, in the analysis of donor oocyte cycles, 
significant differences in sperm counts did not result in differences in embryo 
development or implantation. In contrast to the earlier findings, despite the higher male 
BMI in the recipient group, this did not result in lower rates of blastocyst development 
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when compared to embryos generated from males of normal BMI using eggs from the 
same female donor.   
The analysis of egg sharer (donor) / recipient studies highlights the importance of 
oocyte quality on subsequent embryo development, implantation and risk of 
miscarriage. Clinical pregnancy and miscarriage rates did not differ for discordantly 
weight matched oocyte donor and recipients, suggesting that the endometrial/ uterine 
receptivity is less influential on establishment of pregnancy than the oocyte physiology. 
This is consistent with the findings of Styne-Gross et al (2005) and would suggest that it 
is the exposure of the developing oocyte to suboptimal follicular conditions that is 
leading to poorer outcomes in OWOB.  The follicular environment has been 
demonstrated to vary according to female BMI (Robker et al., 2009).  However not all 
studies have reported similar results; in a study of 9,587 cycles using donor eggs from 
normal weight women Bellver et al., (2013) reported significantly lower success rates in 
obese recipients. Similarly, Metwally et al., (2008) reported increased rates of 
miscarriage in OWOB recipients following egg donation. The lack of clear evidence for 
higher rates of aneuploidy in 1st trimester miscarriages (using own eggs) from OWOB 
women (Landres et al., 2010; Bellver et al., 2011; Kroon et al., 2011) would also 
suggest a uterine component associated with pregnancy loss. Endometrial function, 
specifically endometrial glandular Leukemia Inhibitory Factor (LIF) concentrations are 
reported to be negatively correlated with higher BMI levels (Metwally et al., 2007), but 
the impact of differing response to COS was not accounted for in this study.  Taken 
together, the data from this chapter and the extensive published literature would suggest 
that egg quality/follicular environment is an important determining component of 
pregnancy outcme in OWOB women, although the overall likelihood of pregnancy is 
multifactorial and is affected by, amongst others, uterine factors and maternal metabolic 
physiology. 
3.4.4 OWOB women and frozen embryo transfer cycles 
The successful implantation of a transferred embryo is clearly dependent on a complex 
series of interactions with the hormonally primed endometrium.  The study of FET 
cycle outcomes permitted some inferences to be made about the BMI mediated response 
to COS which may influence endometrial receptivity. It would appear that in the 
subgroup of women studied who had embryos available to freeze, the potentially 
detrimental effects of COS may have been more acute in the normal weight women 
compared to the OWOB group. In this subgroup of patients, regression analysis of the 
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data demonstrated that COS duration and total dose was comparable for each patient, 
implying that a similar dose was adequate across the groups. However, the OWOB 
group may have had a reduced response to a fixed regimen of stimulation which may 
explain the observation that fewer oocytes were retrieved. Furthermore, these findings 
could explain the significant improvement in pregnancy outcome in frozen cycles 
compared to fresh in the normal weight group but not in the OWOB group. Replacing 
cryopreserved embryos into a minimally stimulated uterus was associated with 
improved CPR in women of normal weight, but not in OWOB women. The absence of 
ovarian stimulation may improve endometrial receptivity, but poorer initial oocyte 
quality might negate this in OWOB. 
 
An alternative hypothesis for the improvement in outcomes for FET for normal weight 
women, but not OWOB findings, centres on the observed subtle difference in 
cryosurvival rates. A modest reduction of cryosurvival of blastocysts obtained from 
OWOB women was observed. It is plausible that this occurs because oocytes from 
obese women may have increased sensitivity to cryopreservation due to altered lipid 
content resulting from development in hyperlipidemic follicular environment. 
Nagashima et al., (1996) reported in the pig that elevated levels of intracellular 
triglyceride reduces cryotolerance.  The embryo lipid content can be modified by the 
culture environment (Ferguson et al., 2006, Aardema et al., 2013) and the presence of 
triglycerides in the follicular fluid may result in a series of potentially deleterious 
events; the oocyte could be induced to absorb lipoproteins and perform neo-synthesis of 
triglycerides (Romek et al., 2010); increased lipid peroxidation could result in the 
imbalance of oxidation-reduction metabolism and increased production of free radicals 
leading to increased sensitivity to cryopreservation (Sudano et al., 2011). Conversely, 
essential and polyunsaturated fatty acids can alter the membrane lipid composition and 
fluidity (reviewed in Sampath et al., 2005). This may be especially relevant since 
physical changes in lipids during freezing are a major cause of cellular cryo-damage 
which can have significant impact of ongoing embryo viability (reviewed by Seidel, 
2006). 
 
3.4.5 BMI and relationship with DZT 
The case for compromised oocyte quality and subsequent diminished embryo 
developmental viability in OWOB women is clearly strong, however it is important to 
define the circumstances under which increased adipose may actually confer an 
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advantage in sustaining a pregnancy. Paradoxically, a nutrient-enriched uterine milieu 
that may arise in OWOB women may favour multiple implantations and an association 
between DZT and increased BMI has been highlighted in previous studies (Basso et al., 
2004, Reddy et al., 2005). In the present study, the incidence of DZT was not 
significantly influenced by maternal BMI in IVF treatment cycles although there was a 
trend for higher rates amongst the overweight group.  DZT rates in the obese group 
were lower suggesting a cut-off at which point rising BMI becomes detrimental to 
treatment outcome. Likewise, Groeneveld et al., (2010), reported that DZT was higher 
in mildly overweight women and theorised, but could not substantiate, that the adipose 
secreted angiogenic factor VEGF-A, could be increasing the microvasculature at the 
implantation site and thus helping to sustain a twin pregnancy in the overweight group.   
 
It was observed that when transferring two top quality embryos of high implantation 
potential, the trend for increased DZT in the overweight group became more 
pronounced.  One attractive explanation for this observation is that this group of women 
are better equipped to support a twin pregnancy. However the lack of any significant 
difference in rates of DZT births and incidence of miscarriages amongst women 
undergoing IVF treatment suggests that the higher probability of DZT in overweight 
women previously reported in the literature is also influenced by multiple ovulation 
rather than body reserves alone and ability to maintain the pregnancy.   
The birth weight data provide a crude measure of the mother’s nutritional status during 
pregnancy.  McDonald et al., (2010) reported that OWOB women have a decreased risk 
of having an infant of low birth weight. By contrast, numerous studies have shown that 
undernourished women are more likely to have small for gestational age infants and 
intrauterine growth restricted infants (reviewed by King et al., 2006). Interestingly, the 
data from the present study shows no significant differences in birth weights or 
gestation periods of DZT offspring born to normal and OWOB women; an observation 
that provides further support to suggest that the association between DZT and BMI is 
more complex than a simple reduced maternal constraint and increased capacity to meet 
the higher nutritional demands of a twin pregnancy.   
 
Deviations in fetal growth rates are more commonly reported among OWOB women 
compared to those of normal weight; the offspring of OWOB women are at increased 
risk of macrosomia (>4000g; Kulie et al., 2011) and large for gestational age birth 
weight, but are also at increased risk of extreme low birth weight <1000g (McDonald et 
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al., 2010).  Moreover, OWOB women are more likely to have a pre-term delivery, either 
spontaneously, or electively delivered due to increased risks of pregnancy complications 
(Guelinckx et al., 2008). Hypertension and diabetes, which are both elevated in OWOB 
women, influence gestational age at delivery (Luke et al., 2009). The box-plots show 
the observed range in fetal growth and development and indicate a trend for lower birth 
weights in OWOB in the DZT group. This difference was found to be significant in the 
singleton births among OWOB women who received donor oocytes, compared to their 
normal weight counterparts. Brooks et al (1995) reported that after ovum donation, 
small women tend to have babies with lower birth weight, even when the woman 
donating the egg is large, suggesting the in utero environment directs growth and by 
virtue of this, the association reported in the present study was unexpected.  
 
Epidemiological studies indicate that the health implications of low or high birth weight 
in childhood persist into adulthood. An inverse relationship has been reported between 
weight at birth and predisposition to type 2 diabetes and cardiovascular disease in later 
life (Barker et al., 1990, 1992), although risk may also be increased at the upper end of 
the scale too (Alfaradhi & Ozanne, 2011). Low birth weight is associated with obesity 
in childhood; an observation on which the ‘thrifty phenotype’ hypothesis of Hales and 
Barker (1992) is based; thus, it is proposed to reflect fetal programming mechanisms in 
utero which promote ‘catch-up growth’ when nutrients are in excess. Additionally, 
higher birth weight is also associated with a higher BMI mediated by increased fetal 
insulin in response to chronic maternal hyperglycemia (Hatersley& Tooke, 1999). Often 
maternal blood glucose concentrations are poorly control in OWOB (Villamor et al 
2006), although it is also possible that that OWOB women transmit a greater number of 
susceptibility genes to their offspring and that the genetic variants that reduce insulin 
sensitivity / secretion might also reduce birth weight and predispose to type 2 diabetes 
(Hatersley & Tooke 1999). It is clear that fetal growth and development is influenced by 
both genetics and the environment (Gluckman et al., 2005) and the role of each remains 
a matter unclear.  
 
3.4.6 Outcomes in repeat cycles 
Pregnancy and miscarriage outcomes were not significantly different between the first 
and second cycles in either the weight gain or loss groups. The degree of weight change 
in these women was relatively modest, and likely to be insufficient to influence the 
outcome of pregnancy.  It is unsurprising that benefits on fertility of steady gradual 
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weight loss may not be immediately apparent. For example, Chavarro et al., (2012) 
reported that an average of 3.1kg loss was required to improve oocyte quality (% MII 
cycle 1 verses 2), but this was unrelated to CPRs or LBRs.   
 
Patients whose embryos formed blastocysts in a previous cycle were more likely to 
reach blastocysts in a subsequent cycle and additionally, the pattern of substrate 
utilization was comparable in embryos of each successive cycle cohort. This extends the 
findings reported in Chapter 2, that substrate utilization was comparable amongst 
sibling embryos of the same cycle cohort. Whilst collectively this data appears to 
demonstrate that embryo substrate utilization is intrinsically characteristic to each 
patient, it is not known how changes to the environmental conditions to which the 
developing oocytes are exposed may influence this. It is speculated that oocytes from 
OWOB women will have developed in a nutritionally enriched environment and thus 
specific patterns of embryo substrate uptake and use may correlate with BMI and 
associated viability and birth outcomes. 
 
Weight loss may improve ovarian physiology, however it is a long term commitment 
and any improvements to reproductive outcome as a consequence of decreasing BMI 
may be offset by the known detrimental effects of advancing maternal age on oocyte 
quality. Furthermore the conclusions which can be drawn from this aspect of study are 
limited due to the following; it is unknown if the women who had changed weight 
between cycles were still in a state of flux and without performing dietary assessments 
it was not possible to ascertain the influence of dietary change on treatment outcome. It 
was assumed that weight changes were as a consequence of altered food consumption, 
but nothing is known about how the balance of consumption of macronutrients, such as 
carbohydrate and protein differed between cycles.  
 
3.5 Conclusion 
 
This chapter has set the context for this thesis – as it has attempted to quantify the 
impact that obesity has on the relative contributions of the oocyte, sperm, embryo and 
uterine aspects of the female reproductive system.  
There is compelling evidence from the literature and the study of the local population to 
suggest that reproductive outcomes are poorer for OWOB women, compared to those of 
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normal weight, in both natural (antenal and subfertility clinic data) and assisted 
conception cycles (including fresh and frozen cycles, Hull IVF Unit). Maternal nutrition 
in the periconceptional period appears to have an appreciable impact on ovarian 
responsiveness, resulting in significantly lower oocyte numbers in OWOB compared to 
normal weight. The chances of attaining a live birth were shown to be significantly 
lower for OWOB, compared to normal weight women. 
 
There is ample evidence in the literature to suggest that embryo metabolism is an 
objective and quantifiable measure of embryo viability. Furthermore it is reported that if 
the environmental conditions are altered the metabolism of the embryo can adapt to the 
available metabolic substrates in order to maximise its survival; i.e. Gardner et al., 
(1996) observed an up regulated glycolytic rate in in-vitro mouse embryos compared to 
in-vivo controls. There is a clear need to determine if and indeed how maternal over-
nutrition is impacting on embryo metabolism. Crucially, in this chapter it was 
demonstrated that embryo metabolism is repeatable between cycles under standardised 
conditions.  
 
It is clear that the impact of maternal BMI on oocyte and subsequent embryo 
development is an area requiring further detailed investigation; as here lower blastocyst 
development rates have been observed with raised male BMI in discordant couples, but 
male BMI appeared to exert little influence on development when oocyte donor and 
recipent cycles were compared. Cryosurvival rates tended to be lower in blastocysts 
from OWOB and maybe indicative of differences in lipid content compared to those 
from normal weight women. 
 
Obesity has a multifactoral impact on the chances of achieving and sustaining a 
pregnancy and the findings from this chapter are highlighted in the hypothetical model 
depicted in Figure 3.18. The next stage of this thesis will be to determine answers to the 
as yet undefined preconceptional factors.  
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Figure 3.18 Hypothetical impact of maternal obesity. 
 1= Increased time to pregnancy, infertility, 2 = Failed implantation, early loss (biochemical), misscarage, 
3 = Pre-eclampsia, diabetes, hypertension, alterations in fetal growth, 4 = pre-term delivery, perinatal 
deaths, macrosomia, fetal abnormalities, 5 = short and longterm adaptations to adverse conditions.  
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Chapter 4 : Markers of oocyte and embryo quality, 
metabolism and morphokinetics  
108 
 
4.1 Introduction 
 
Oocyte developmental competence is progressively acquired during follicular growth in 
the ovary. Oocyte quality maybe assessed in a number of ways. The simplest method is 
light microscopic evaluation of cumulus oocyte complex morphology. Veeck (1988), 
described a method which is commonly employed in IVF laboratories to assess cumulus 
dispersion; the homogeneity of the cytoplasm and visualisation of the polar body. 
However the accuracy of this method is low and nuclear maturation can only be truly 
assessed by the denudation of oocytes (figure 4.1), which is an invasive technique and is 
therefore only be performed in ICSI cycles. Studies suggest that higher rates of oocyte 
immaturity are associated with obese and morbidly obese women (Wittemer et al., 
2000; Dokras et al., 2006). It is reasonable to postulate from this, that oocyte 
developmental potential may be altered in these women. 
 
 
Figure 4.1 Oocytes at different stages of nuclear maturation.  
(a) Germinal vesicle stage, (b) metaphase I (c) metaphase II.  
 
The ability of the oocyte to undergo meiotic maturation is a poor marker of oocyte 
developmental capacity (Moor & Trounson, 1977) and oocyte developmental 
competence is therefore best described by the capacity of the oocyte to sustain early 
development. It is during folliculogenesis that the growing oocyte acquires the 
necessary cellular machinery to support this development (i.e. cytoplasmic maturation 
in addition to nuclear maturation at the point of ovulation (as discussed in chapter 1).  
 
Currently, our ability to predict the developmental competence of MII oocytes remains 
poor, though the diameter of a denuded oocyte has been correlated to developmental 
competence to form a blastocyst in bovine oocytes (Otoi et al., 1997). Smaller oocytes 
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may resume maturation and have the ability to support pronuclear development, 
however Otoi et al (1997), found that oocyte diameter was a critical determinant of the 
ability of a zygote to undergo cleavage. This is an interesting finding, as during in vitro 
maturation delaying nuclear maturation to permit cytoplasmic maturation to occur first, 
has been shown to improve fertilization and cleavage competence (Hegele-Hatrung et 
al., 1999). In vivo, the dominant follicle regulates the timing of key components of 
oocyte maturation. By contrast, in an IVF treatment cycle, multiple follicles are 
recruited and therefore some oocytes may be recovered from smaller follicles. Once 
extracted, these could spontaneously undergo premature nuclear maturation leading to 
lower cleavage competence rates.  
 
Few studies have examined the relationship between diameter and cleavage competence 
in humans; fewer still have sought to determine a possible link with female BMI.  Based 
on a retrospective analysis of 48 IVF cycles, Marquard et al., (2011) reported that 
oocytes from obese women had a lower diameter than those from control subjects, 
independent of PCOS. The study did not however report on embryo development. It 
could therefore be argued that the oocytes were still growing and had not reached full 
maturational state.  
 
Oocytes that have a larger diameter are known to have decreased Glucose-6-phosphate 
dehydrogenase (G6PDH) activity. G6PDH is an early enzyme in the pentose phosphate 
pathway, involved in maintenance of the level of NADPH. G6PDH activity has been 
reported to be high in developing oocytes and low in fully grown oocytes.  Such 
knowledge has been obtained by the use of the dye brilliant cresyl blue (Ericsson et al., 
1993).  The dye is reduced to become colourless through the action of G6PDH, and so 
oocytes with high G6PDH activity appear clear; low G6PDH activity is associated with 
a blue appearance. In humans it is not possible to measure this, as it may be detrimental 
to expose oocytes to such chemical dyes, however using an animal model (bovine) it 
may be possible to establish what proportion of MII oocytes are yet to complete 
cytoplasmic maturation and how this may relate to diameter and other possible physical 
differences such as density, which may provide an indication of the oocytes endogenous 
lipid content.  
 
The relationship between the ovarian and follicular environment and in vitro 
developmental competence of the oocyte is well established. It is clear that the quality / 
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nurturing capacity of the follicular environment from which the oocyte originates is a 
major determining factor that will impact on its subsequent development. There are 
extensive studies correlating follicular fluid (FF) composition with that of the serum and 
during follicular growth the follicular epithelium becomes increasingly porous in nature, 
resulting in a greater equilibrium between the two (Leroy et al., 2004).  Furthermore, it 
is becoming increasingly accepted that diet induced metabolic changes are reflected in 
the composition of follicular fluid (Robker et al., 1999).  Obese women are in a high 
plane of nutritional enrichment and it is possible that the level of metabolites could 
reach levels that impact negatively on oocyte quality. The metabolism of cumulus cells 
is adapted to control the flow of metabolites toward the oocyte, however previous 
studies have shown that elevated non-esterified fatty acid levels are detrimental to 
oocyte developmental capacity and granulosa cell function in the bovine (Leroy et al., 
2005). Lower oocyte viability could in turn lead to a diminished embryo development 
capacity. A number of reports have indicated that early embryo development is sub-
optimal in women who are OWOB (Carrell et al., 2001; Metwally et al., 2007,), 
however others have reported no relationship (Bellver at al., 2010). 
 
The growth and development of oocytes is dependent on their  energy / nutrient supply. 
This may be the exogenous energy supply (the extracellular milieu) or the endogenous. 
There are well established differences in the follicular environment of oocytes from 
obese and normal weight donors, but differences in endogenous supplies have not 
previously been studied.  Mammalian oocytes are known to contain endogenous lipid. 
Intracellular triglycerides constitute over 50% of all lipid material in mammalian 
oocytes (McEvoy et al., 2000; Kim et al., 2001). Large amounts of intracellular lipids 
can compromise embryo quality through impaired mitochondrial function (Abe et al., 
2002), as demonstrated in bovine embryos cultured using serum containing media. A 
greater content of intracellular lipids increases their sensitivity to oxidative stress. 
Increased lipid accumulation has been shown in the embryos of high yielding dairy 
cows (Leroy et al., 2005) and in the embryos of diabetic rats (Sinner et al., 2003). In 
both models energy and lipid metabolism is disturbed and oocyte quality is said to be 
reduced. 
 
It is possible to measure the triglyceride content of individual oocytes using the method 
described by Sturmey et al.,(2003) to establish if differences exist between oocytes from 
normal weight and obese patients. However the examination of lipid content is invasive 
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and renders oocytes non-viable and therefore it would only be possible record findings 
from failed to fertilise oocytes and it would not be possible to correlate any differences 
in content with any ongoing embryo developmental competence. A non-invasive 
method based on density- could facilitate this analysis, if proven to be sensitive enough. 
 
Embryo developmental competence is typically described by quality assessment at key 
stages of development. The quality of the embryo selected for transfer is obviously a 
key factor influencing the success of assisted conception. Currently such observations 
are made at static time points, however, advances in time-lapse imaging now permit the 
recording of more precise information and may strengthen these methods of assessment. 
Embryo development is a dynamic process and scoring can change markedly within a 
few hours (Montag et al., 2011). The importance of maternal and paternal weight in 
relation to embryo quality is relatively unknown and it is possible that subtle differences 
in embryo development could contribute to poorer reproductive outcomes reported for 
OWOB patients. In this chapter, this is investigated by comparing the BMI of patients at 
the time of IVF to the developmental kinetics of supernumerary embryos.  
 
Time-lapse imaging systems enable multiple observations to be made without 
disturbing the culture environment. The Primovision system (Vitrolife, Sweden) permits 
the use of a compact time-lapse microscope system, which can be placed inside a 
regular incubator. Embryos are cultured in funnel-shaped microwells, which are 350µm 
wide at the opening x 150µm deep (3x3 configuration) set in a dome shaped inset, 
meaning that the contents of each well are openly connected with the medium above 
(total volume 80µl3). The system, termed the Well of the Well (WOW) system creates a 
microenvironment for each embryo, but allows them to share in a larger common 
culture media reservoir (Swain & Smith, 2011). Higher rates of blastocyst development 
have been reported for this system in comparison to traditional microdroplet culture 
systems: using sibling human oocytes Vajta et al.,(2008) reported blastocyst rates of 
56% vs 37% respectively.  
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Figure 4.2 WOW dishes are used in combination with time-lapse technology 
 
The camera scans each of the wells in turn and acquires images of each embryo 
collected at 5-minute intervals. The analysis of data obtained has been used to generate 
an algorithm to select the embryo with the highest implantation potential (Meseguer et 
al., 2011). It is widely accepted that implantation prediction models based on time-lapse 
analysis require validation within each laboratory as a number of factors, such as the 
culture medium and incubator conditions may subtly alter the prediction parameter 
timing thresholds. It is thus apparent that morphokinetic development features are 
affected by intrinsic oocyte factors and environmental factors. The effects of the 
follicular environment on embryo development may be resolved with increased 
confidence when data are drawn from a series of multiple observations rather than 
infrequent static observation techniques which characterise conventional embryo 
assessments.  
 
Thus far implantation prediction models have been based on early embryo 
developmental activities and little attention has been focused on blastocyst 
development. Obesity may contribute to reduced rates of blastocyst formation however 
once formed, the impact of BMI on blastocyst expansion and hatching may be key to 
determining differences in viability amongst embryos generated from OWOB women 
and those of normal weight.  
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Aims and objectives 
a) To investigate the relationship between oocyte diameter and female BMI. 
b) To examine the relationship between oocyte diameter and developmental 
competence. 
c) To discover if full growth capacity is likely to have been reached prior to nuclear 
maturation, in a bovine model of in vitro maturation. 
d) To ascertain if oocytes differ in lipid content using non-invasive methods of 
analysis, in a bovine model of in vitro maturation.  
e) To compare developmental rates and timing differences amongst embryos 
generated from normal weight and OWOB women in extended culture up to day 
9 of development. 
f) To record measurements of embryo diameter at specific time points and critical 
developmental events. 
g) To ascertain if differences in blastocyst size correlate with cell counts. 
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4.2 Materials and methods 
 
4.2.1 Oocyte diameter studies; ICSI patients 
The proportion of mature oocytes retrieved after oocyte retrieval was reviewed using 
retrospective data from ICSI patients attending the Hull IVF Unit (2008-2010). 
 
To assess for differences in the quality of mature oocytes collected from normal weight 
and OWOB women, oocyte diameters were prospectively measured at x400 
magnification using an ocular micrometer. Prior to ICSI, two perpendicular 
measurements were taken of the ooplasm of 218 oocytes from 29 patients participating 
in the observational study arm of this thesis. As these measurements were taken 
prospectively, it was possible to track the onward developmental competence of the 
oocytes, based on their fertilisation, cleavage division to form embryos, development to 
form high scoring cleavage embryos (designated as having 6-8 cells on day 3 and a 
morphology score of grade 3 or above) and blastocyst formation on day 5. 
 
 
 
 
 
Figure 4.3 Measurements of oocyte dimensions. 
Two perpendicular oocyte measurements were taken and used to calculate diameter, radius and volume. 
Measurements including the zona (a) and to the edge of the ooplasm (b).  
 
The method for recording oocyte diameters was first validated by recording pilot 
measurements on bovine oocytes. There were significant correlations between all 
measurements, and increasing zona radius was correlated with a proportional increase in 
oolemma radius, although the ratio was not significant. Diameter and volume of 
oolemma were found to be the most repeatable measurements, confirmed by Shapiro-
Wilk normality test: the pass level was p=0.290. The diameter of the oolemma was 
hence measured prior to ICSI for all 29 patients participating in this study.  
 
Embryo and blastocyst diameters were recorded from outer zona to outer zona (due to 
anticipated considerable variation in zona thickness) and at the longest and widest 
cellular cross-section. The inner cell mass was assumed to be rounded. 
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4.2.2 Nuclear and cytoplasmic maturation; Bovine model 
To gauge the synchronicity of nuclear and cytoplasmic maturation in smaller oocytes a 
bovine model was used (due to the ethical constants, restricting the use of using human 
oocytes). Brilliant cresyl blue (BCB) uptake was recorded in 54 bovine oocytes to 
assess for continued Glucose-6-phosphate dehydrogenase (G6PDH) activity, an enzyme 
which is active during maturation.  
 
The method was validated to determine the most appropriate concentration and duration 
of staining. Oocytes were denuded since cumulus cells were shown to neither facilitate 
nor interfere with staining. Oocytes were incubated in a HEPES buffer without Phenol 
red (SynVitro, Origio-Denmark) containing 26 µM BCB for 90 min at 37 °C in 
humidified air atmosphere (-a concentration and duration of BCB staining, previously 
shown to be optimum- Goovaerts et al., 2010).  After staining, oocytes were washed in 
HEPES and examined under a stereomicroscope at magnification 50×. They were 
classified into different groups according to BCB coloration in the ooplasm.  
 
In order to determine if oocytes which had undergone complete maturation  differed in 
density, a continuous gradient method was used, using a 50/50 mix of PureSperm 
(Nidacon) and HEPES (Sage, Cooper Surgical), centrifuged to give a continuous 
gradient, in which oocyte descent could be measured. Differences in relative densities 
for a fixed volume were determined to assess the use of this method for future 
comparative studies of human oocyte quality. 
 
 
Figure 4.4 Recording oocyte density.  
A continues gradient was set up and used to determine relative differences in oocyte density.  
 
The method was validated to ensure that the solution was pH neutral and iso-osmotic 
(i.e. non-toxic, did not exert an osmotic influence on the oocyte resulting in shrinkage/ 
swelling). 5 minutes of centrifugation was sufficient to create a continuous gradient 
sufficient to establish a useful density range based on colour distribution/ assimilation 
After centrifugation a continuous gradient is established  
 
Low density 
 
Medium density 
 
High density 
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of the two solutions. A 6ml falcon tube, containing a continuous gradient was clamped 
in a vertical position and an oocyte which had been stained and measured for diameter 
was added. Its descent down the column was recorded using a horizontal view 
microscope. To confirm the accuracy of the recorded depth of descent, the amount of 
medium that needed to be removed from the tube prior to oocyte recovery was 
compared to the measured depth to ensure agreement.  
 
In order to determine the triglyceride (TG) content of the oocytes, the same samples 
were incubated with 0.1% (w/v) pronase for 30 seconds. Individual oocytes were placed 
in 1.1ul droplet of freezing buffer and frozen in microcaps (as described in Chapter 
2.5.6), before being coded and stored at -800C to permit blind analysis at a later date. 
 
Method development studies were conducted using two enzymatic assays kits both of 
which use a coupled colorimetric assay to measure triglycerides and relied on the 
hydrolysis of triglycerides by a lipoprotein lipase to generate glycerol, which is then 
phosphorylated by glycerol kinase forming glycerol-1-phosphate and ADP. One method 
(hereafter referred to as Method A- Reagents from Sigma UK) then measures the 
oxidation of glycerol by glycerol phosphate oxidase to produce hydrogen peroxide, 
which is in turn catalysed by peroxidase to generate quinoneimines that absorb light 
between 450 and 600nm. In the second  method (reagents from Abcam UK), ADP 
reacts with phosphophenolpyruvate to liberate pyruvate. Lactate dehydrogenase then 
catalyses the oxidation of pyruvate and NADH (measured at 340nm) to lactate and 
NAD. Method A was employed with limited success – the test is designed for 
determining triglyceride levels in blood or serum and as such measures values in the 
mg/dl range rather than the µg/ml range required. Dilution of the assay to construct a 
standard curve within the required range resulted in poor reproducibility (high intra and 
inter assay variance). It was concluded that this method lacked the sensitivity to 
determine the triglyceride content of individual oocytes. Method B resulted in more 
satisfactory standard curves and values could be determined within the desired range of 
specificity for bovine oocytes. (Further detail of this method is included in the methods 
Chapter 2.5.6) 
 
4.2.3 Time-lapse imaging; Supernumerary human ICSI embryos 
A total of 25 of the 29 patients consented to the extended culture and observation of 
their surplus embryos using time-lapse technology (Primovision technology system). 
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WOW dishes were prepared in advance; as described in Chapter 2.6. Recordings were 
made of specific developmental timings, blastocyst diameters and hatching patterns.  
 
At 68 hours post insemination a total of 101 surplus embryos at various stages of 
development were placed into extended culture. Embryos were cultured in WOW dishes 
(Primovision, supplied by Vitrolife, Sweden), in culture conditions as described in 
section 2.1.5. Embryos were cultured without media change until 116 hours post 
insemination. At this time embryos were moved into a new WOW dish in which wells 
were filled with pre-equilibrated QA Blastocyst medium (Sage, USA) supplemented 
with 10% SSA. Embryo culture was terminated on day 9. 
 
Recordings were made of specific developmental timings/events, using techniques 
described by Kirkegaard et al., 2012. The time to reach (1) morula stage was defined as 
when all cells have fused, (2) unexpanded blastocyst; the first time a blastocoel cavity 
was visible, (3) expanded blastocyst when the blastocoel expands (4) hatching; when 
the embryo escapes from the zona. The diameter of the blastocoel following collapse, 
recovery and hatching were also recorded. Collapse was defined as the time point at 
which the measured diameter is smaller than the previous time point and recovery when 
the diameter is identical to that just before collapse. The extent of collapse was noted 
from the largest diameter minus the smallest and the number of collapses was defined as 
the number per 24 hours from the appearance of blastocoel until the end of culture or 
hatching. 
 
4.2.4 Blastocyst differential staining 
Expanded blastocysts donated to research by 16 patients were fixed on day 7 of 
development using the differential staining technique based on that described by Thouas 
et al.,(2001) for mouse and bovine blastocysts. Chromatin-specific dyes were used to 
determine ICM and TE counts. 
 
Expanded blastocysts (n=44) were incubated in 500µl of solution A (Table 4.1) for 30-
45 seconds until the trophectoderm visibly changed colour and shrank slightly, as 
monitored visually using a dissecting microscope. Blastocysts were then immediately 
transferred into 500µl of solution B (Table 4.1) and stored for 5 hours at 4oC. 
Blastocysts were mounted onto a glass slide in a drop of glycerol, gently flattened with 
a coverslip and visualised for cell counting. 
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Prior validation studies were performed to empirically define the staining kinetics. 
Staining is dependent on temperature, reagent concentration, exposure times, cell 
permeability and density. Using reagents at the concentrations suggested by Thouas et 
al., (2001) 30-45 seconds was found to be the optimum time for exposure to solution 1, 
timings were adjusted according to zona and blastocyst diameters. More than 45 
seconds incubation caused non-specific cell staining. 5 hours at 4oC was found to be 
sufficient to permit staining and fixative with solution 2, this could be reduced to 1 hour 
if performed at room temperature- although longer than 1 hour resulted in signal 
degradation. 
 
Table 4.1 Composition of solutions 1 and 2 for differential staining of blastocysts. 
Component Quantity Solution A 
1% Triton X-100 0.1ml to 10ml HEPES (Synvitro, 
Orgio, Denmark) Propidium iodide (100µg/ml) 1mg  
 
 
Component Quantity Solution B 
Hoechst 33258 (25µg/ml) 50µl to 9950µl 100% ethanol 
 
Cell counting was performed directly on an inverted microscope (Vickers, UK), fitted 
with a UV lamp and excitation filters (460nm for total staining and 560nm for TE red 
only).  Propidium iodide is unable to penetrate tight gap junctions between cells and 
therefore does not reach the ICM and stains only the permeabilised TE cells. 
 
Slides were coded and stored at 4oC away from light to permit repeat cell counts to be 
performed on a separate occasion to reduce operator bias.  
 
4.2.5 The study groupings 
The patient profile of those donating to each study was compared and can be 
summarised as follows; 
a) Retrospective data from Hull IVF Clinic fresh treatment cycles 2008 to 2010 (n= 
709) 
b) Prospective data (2010-2015) from 29 women who attained 218 oocytes and 101 
embryos that were observed in studies (diameter and time-lapse; table 4.2a & b) 
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c) Data from 16 women who donated 44 embryos to research – used for differential 
cell counts (see table 4.2c).  
 
Table&4.2!Overview!of!study!groupings 
 
Table 4.2a Characteristics of patients included in the observational study (± SEM) 
 
!
 
 
 
 
Table 4.2bDetails of oocytes and embryos observed. 
 
Table 4.2c Details of embryos used in research for differential staining of blastocysts on day 7 
of development.!
!
 
 
 
 
 
 
4.2.6 Statistical Analysis 
Outcome measures (oocyte numbers, MII and endometrial thickness) were calculated 
for each BMI grouping, using ANOVA with Tukey Kramer due to unequal sample size 
groups, to reduce the risk of a type 1 error. Multiple regression was subsequently used 
Normal weight OWOB p value
Female age (years) 31.27 (1.04) 34.67 (0.96) >0.05
Male age (years) 35.25 (1.27) 39.43 (1.64) >0.05
Cycle number 1.58 (0.19) 1.71 (0.31) >0.05
Female BMI (kg/m2) 21.41 (0.59) 28.37 (0.92) <0.001
Male BMI  (kg/m2) 25.58 (0.66) 26.0 (0.36) >0.05
Av. Follicles 15.67 (1.55) 10.53 (1.02) <0.05
Av. Oocytes 12.67 (1.83) 8.82 (0.87) 0.05
Normal!BMI!n=!12! 
 
 
Supernumerary 
embryos donated 
to research n= 36 
 
 OWOB n=4 
 
Supernumerary 
embryos donated to 
research n= 8 
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to assess the interrelationship among variables predictive of oocyte numbers and 
adjusted p values are given. 
Data distributions (bovine model oocyte diameter and volume measurements) were 
checked for normality using Shapiro-Wilk test with p>0.05 being indicative of a 
normally distributed sample and confirmation of reputability of measurements. Volume 
was calculated from the equation 4/3 π (diameter/ 2)3.  Relative density was based on 
volumetric mass density (measured descent within a continuous column) and multiplied 
by measured volume to give relative total weight. The relationship between size and 
density was established based on ranks using Kruskal Wallis test and the H statistic and 
associated p value determined.  
Accuracy of test measures for triglyceride assays were assessed based on the calculated 
error to signal ratio, with relative error being determined from the coefficient of 
variance (values >10% were rejected) and absolute accuracy from the standard 
deviation.  
The measure of linear association between univariates (i.e. oocyte / embryo diameter 
measurements and female BMI) was ascertained by correlation coefficient r= -1 to 1 
and the p value associated with r ascertained according to sample size and distribution. 
Generalized Estimating Equations (GEEs) were used to account for patient-specific 
effects. Data was categorised into inter quartile ranges and groups compared using 
ANOVA or Kruskal–Wallis test as indicated.  
Embryo kinetic data recordings were validated using ImageJ software (nih.gov) to 
calculate area and pixel value statistics. To ensure impartiality and accuracy, 
PrimovisonTM videos were coded by a third party and re-run and re-annotated to 
determine the confidence of variance in measurements (values >10% were rejected). 
Continuous data was assessed using a two-sample, unpaired t-test (Welch’s t-test due to 
differences in sample size and variance). Non-parametric data (i.e. hatching pattern) was 
assessed using Fishers exact test. Multivariate regression analysis was used to determine 
the influence of explanatory variables on cell count.  
All power calculations were performed as previously described and sample sizes were 
sufficient to achieve 80% power unless otherwise stated. In all cases statistical 
significance was indicated by p< 0.05. 
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4.3 Results 
 
4.3.1 Patient assessments (ICSI patients, observational measurements)  
The number of oocytes retrieved from OWOB women was significantly lower than for 
normal weight women (9.6 verses 10.6 p<0.01), however the proportions of oocytes that 
had reached metaphase II did not differ significantly (Table 4.3). 
 
Table 4.3 Oocyte development and quality in normal weight and OWOB women. 
The retrospective comparison of data (n=709 patients) shows significantly lower oocyte numbers (**p< 
0.01), but similar rates of egg immaturity from OWOB compared to normal weight women. ANOVA 
with Tukey kramer – (standardized for female age) 
 
BMI  (kg/m2) <18.5 18.5-24.9 25-29.9 >30 
n 10 361 192 146 
Mean age (years) 29.8 33 33.6 33 
Endometrial thickness 
(mm) 12 10.6 10.8 10.8 
Number of OCC (mean) 
101 (10.1) 3809 (10.6) 1897 (9.9) 1316 (9.0)** 
% mature - MII 98 92.6 92.3 92.3 
 
The mean oocyte diameter of the 29 ICSI patients who participated in the observational 
study was 120.34±0.7µm. The mean diameter of OWOB oocytes was 118.29±1.0µm 
compared to those of a healthy BMI 121.49±1.4µm. Figure 4.5 shows a significant 
inverse relationship between maternal BMI and mean oocyte size (p<0.001).  
 
Figure 4.6 shows that as female BMI increases, there tends to be a reduced capacity for 
embryo development post-fertilisation. All oocytes generated from normal weight 
women went on to cleave and form embryos, compared to 94.3% of those from OWOB 
women (p=0.06). In addition the blastocyst development rates of 33.9% and 62.1% for 
OWOB and normal weight groups respectively (p<0.01) are of particular note.   
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Figure 4.5 Relationship between oocyte diameter and female BMI.  
Mean oocyte diameters (n=218), recorded from women of differing BMI classification (n=29), prior to 
ICSI. The R2 value (-0.45) indicates a negative relationship between diameter and increasing BMI 
(p<0.001). Error bars represent ±SEM 
 
 
Figure 4.6 Overview of oocyte development and female BMI.  
Percentage of oocytes (n=218) that fertilised normally (2PN), percentage of 2PN that cleaved to form 
embryos and the proportion of top scoring embryos (grade 3) on day 3 of development and the proportion 
of 2PN embryos forming blastocysts in extended culture. Significantly fewer embryos formed blastocysts 
in the OWOB group compared to the normal group (p<0.01). 
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Oocytes from women of higher BMI were significantly more likely to be in the lower 
quantile range for diameter; these smaller oocytes were significantly less likely to 
undergo a cleavage division, arresting at the one cell stage (Figure 4.7).  
 
 
 
Figure 4.7 Development according to oocyte diameter classification.  
The smallest oocytes, were significantly less likely to cleave and to form blastocysts ***p<0.001 and 
smaller oocytes were significantly more likely to have originated from women with a higher BMI 
***p<0.001.  
 
Embryo progression to the blastocyst stage was significantly poorer for the smaller 
oocytes and the arresting embryos were more likely to have been generated from 
OWOB women.  
***!
***!
0!10!
20!30!
40!50!
60!70!
80!90!
100!
2PN! Cleav! G3! Blast!
%!achi
eving!d
evelop
ment!s
tage!
Development!classiUied!according!to!oocyte!diameter!interquantile!ranges!
<115µm!(Q1)!115.1"122.5!µm!!>122.6µm!(Q3)!
!
Normal!
fertilisation!
(2PN)!
Zygote!
cleavage!!
(Cleav)!
Day3!
embryo!
quality!
(G3)!
!Day5!
Blastocyst!
develop.!
(Blast)!
BMI!
(kg/m2)!
Oocyte!
diameter!(µm)!!
Correlations!(r)!! 0.13! 0.23***! 0.05! 0.28***! M0.46***!
!
124 
 
4.3.2 Oocyte diameter as a marker of maturation status (in a bovine proxy model) 
Using bovine oocytes, as a mammalian model for human oocyte maturation, G6PDH 
activity was used as an indirect marker of ongoing maturation, (n=54) to determine the 
relationship between diameter and both cytoplasmic and nuclear maturation.  
 
Of the 54 bovine oocytes assessed, only 20.1% of MII oocytes retained G6PDH activity 
and these oocytes were significantly smaller (p=0.002) than those which lost G6PDH 
activity. 
 
A minimum volume of 261,000µm3was indicated as necessary for oocytes to have 
complete nuclear and cytoplamic maturation. Volumes ranged from 215,262 µm3 to 
881,712µm3. For any given oocyte volume, significant differences were observed in 
oocyte relative densities (p<0.05 Kruskal-Wallis analysis of variance ranks). The 
overall range in column descent was 0.1 to 2.8µl surface depth.  
 
 
A minimum volume of 261,000µm3 was necessary 
for completion of nuclear and cytoplasmic 
maturation. 
 
Figure 4.8 Assessment of oocyte cytoplasmic maturation.  
All immature oocytes took up BCB and appeared clear; these were significantly smaller than MII oocytes 
(p= 0.002, n =54).  At a volume of 255,300µm3- 75% completed nuclear maturation. 20.1% of MII 
retained G6PDH activity; these were significantly smaller (p=0.002) than MIIs with no G6PDH activity, a 
minimum volume of 261,000 µm3 was required to complete both nuclear and cytoplasmic maturation.  
 
Bovine oocytes of comparable dimensions/volume (calculated volume from 4/3πr3), 
displayed significant differences in density - those with a larger volume also had a 
higher density (p=0.004). The trend was however reversed when results were controlled 
for cytoplasmic and nuclear maturation – (i.e. limited to those above the identified 
critical volume -261,000µm3). Kruskal Wallis test indicates a tendency for an inverse 
relationship between size and density (p=0.07). 
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The triglyceride content of each oocyte was subsequently determined via enzymatic 
assay and plotted against the relative weight for each oocyte (volume x relative density). 
Figure 4.9 shows that relative weight is not indicative of oocytes triglyceride content  
 
 
 
Figure 4.9 Measured triglyceride content compared to measured volume/relative density. 
No significant relationship between the parameters. 
 
4.3.3 Time-lapse observations from the fertilised oocytes of the ICSI patient group   
The time-lapse developmental kinetic data recorded for 101 embryos, showed that 61 
arrested with no further development between days 5 and 7; 39 had reached the morula 
stage by 115.29±14.22 hours post insemination (hpi) and; 35 had reached the blastocyst 
stage by 128.76±12.67 hpi. An expanded blastocyst was formed at around 137.37 
±12.08 hpi in 21 embryos, 13 of which underwent hatching from the zona pellucida 
(ZP), at approximately 154.99±19.25 hpi.  
 
The time-lapse data showed significant differences in the timings of initial blastulation, 
(103.92±4.6 OWOB, 120.98±1.7 hpi ±SEM normal weight; p<0.05) and expansion in 
relation to female BMI, with embryos from OWOB women developing faster (Figure 
4.10). Intriguingly, despite higher rates of cleavage-stage arrest, embryos from oocytes 
from OWOB women that were capable of reaching the morula stage did so 17 h earlier 
than counterparts from women with a BMI < 25 (p< 0.001). The time intervals between 
stages did not significantly differ between embryos generated from normal weight and 
OWOB women.  
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The ability to form a blastocyst could be predicted by female BMI, oocyte diameter and 
embryo quality at the cleavage stage and a higher proportion of embryos failed to hatch 
from OWOB women.  
 
 
 
Figure 4.10 Mean time elapsed post insemination for each embryonic development stage to be reached in 
normal and OWOB women (values ±SEM, n= 101 embryos observed).  
 
The embryo size recorded at a static time point (116 hpi), displayed a weak correlation 
with female BMI (Figure 4.11a) and was not correlated with the initial recording of the 
oocyte diameter. Size was dependent on stage attained at the specific time point, 
however equivalent stage embryos were consistently smaller if generated from OWOB 
women (figure 4.11b).  
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Figure 4.11a Mean embryo diameters (n=101), recorded from women of differing BMI classification at 
116 hpi. The R2 value indicates a weak negative relationship between diameter and increasing BMI. 
 
 
 
Figure 4.11b Mean embryo diameters (n=101), recorded from women of differing BMI classification at 
116 hpi, according to development stage attained. 
 
Figure 4.11 Overview of relationship between female BMI, embryo diameter and development. 
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Blastocysts of obese women tended to have smaller diameters at the time of hatching 
(196µm verses 214.3µm), increased zona thickness (6.75µm verses 6.44µm) and a 
significantly altered pattern of hatching, favouring projected escape, over hydrostatic 
pressure, compared to normal weight controls (p<0.05). The findings were independent 
of age and cause of infertility. 
 
Embryos from OWOB couples had an aberrant pattern of hatching from the zona. In 
embryos generated from normal weight couples, blastocyst expansion was 
predominantly followed by alternating expansion and contraction and it appeared that 
the hydrostatic pressure exerted by the increasingly expanding blastocyst caused a break 
in the ZP and the tight junctions, as the volume alternated permitting water to move in 
and out (Fig 4.12A and B). The amplitude and frequency of contraction cycles averaged 
2.6 per hour with a mean change in volume of 73%. Hatching occurred both adjacent 
and opposite to the inner cell mass (ICM) with equal frequency.  In OWOB couples, 
blastocyst hatching was disrupted and mainly achieved via the projection of undulating 
trophectodermal extensions that pierced the ZP (Fig 4.12C). Cyclic expansion and 
contraction occurred more frequently in this group; occurring at an average frequency of 
3.2 per hour, but the amplitude of contraction was lower; a mean change in volume of 
54%. Hatching occurred adjacent to the ICM in 2 cases and opposite in 8 cases (Fig 
4.12D). 
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Figure 4.12 Hatching patterns observed. 
A shows hatching opposite ICM 
B shows an expanded blastocyst that failed to hatch, although the hatching site is visible. 
C shows multiple hatching sites 
D shows hatching adjacent to the ICM  
 
 
4.3.4 Differential cell counts from embryos donated by couples for research 
Figure 4.13 shows the differential cell counts for expanded blastocysts fixed on day 7 of 
development (n=44). Embryos from oocytes collected from OWOB women had 
significantly lower total cell counts and a proportional decline in ICM and TE cell 
counts compared to those of healthy BMI.   
 
280µm 
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Figure 4.13 Overview of blastocyst cell counts and female BMI.  
Total blastocyst cell counts, inner cell mass and trophectoderm cell counts for expanded blastocysts on 
day 7 of development from 8 embryos of OWOB women and 36 embryos from normal weight.  Mean 
values displayed. 
 
 
Total, ICM and TE counts were significantly lower for OWOB women (total counts 
104.1± 6.8 SEM verses 133.4± 2.2 for OWOB and normal weight women respectively 
p=0.01). There was no significant relationship with male BMI.  
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Figure 4.14 Overview of blastocyst cell counts and measurements.  
Total blastocyst cell counts, inner cell mass and trophectoderm cell counts for expanded blastocysts on 
day 7 of development from 8 embryos of OWOB women and 36 embryos from normal weight, according 
to measures of total blastocyst diameter (µm) and ICM diameter (µm). 
 
The relationship with expanded blastocyst diameter at the point of maximum expansion 
and ICM diameter is depicted in Figure 4.14. As shown in the previous dataset 
blastocyst diameter again shows a weak inverse relationship with female BMI. The 
resulting blastocysts from women with a BMI > 25 kg/m2 at equivalent time points, 
tended to be smaller (p= 0.07) at the point of maximum expansion, and had significantly 
lower cell counts (Fig. 4.14).  
 
In a multivariate analysis of the expanded blastocyst data, only female BMI was shown 
to be a significant predictor of cell count, independent of embryo diameter, female age, 
cause of infertility and male BMI. Furthermore, at equivalent time points, embryos from 
OWOB mothers had fewer trophectoderm cells (p=0.001). The ICM count is predicted 
by female BMI and there is a trend for increased cell count with ICM diameter 
(p=0.08). The diameter of the ICM does not correlate with total cell count or total 
blastocyst diameter. There is a weak correlation between the diameter of the ICM and 
male BMI (p=0.07).  
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4.4 Discussion 
 
4.4.1 Summary of key findings 
This chapter has shown that fewer oocytes are recovered from OWOB women 
compared to normal weight women.  Furthermore, although at first glance the 
competence of these oocytes may not appear to be compromised – with a similar 
proportion of metaphase II, fertilising and competent cleaving stage embryos, at the 
later stages of embryo development differences in competence become apparent. There 
were three key observations; firstly oocytes from overweight and obese women are 
significantly smaller than those collected from women with a BMI considered to be in 
the healthy range. Secondly these smaller oocytes from OWOB women were less likely 
to reach the blastocyst stage, but those that did so, showed accelerated preimplantation 
development, and thirdly, the subsequent blastocysts contained fewer cells, notably in 
the trophectoderm. Overall, the finding that fewer oocytes from overweight and obese 
women were competent to reach the blastocyst once fertilized may contribute to the 
lower success rates of fertility treatment reported in overweight and obese women 
(Bellver et al., 2010; Shah et al., 2011; Chavarro et al., 2012; Moragianni et al., 2012). 
 
4.4.2 Lower oocyte numbers and size 
The finding of fewer oocytes from OWOB women compared to normal weight women 
is supported by 8 other studies, although a further 9 found no difference (Tamer et al 
2009). Similar contradictory data have been obtained from animal models and clinical 
data (Purcell & Moley 2011). However, in contrast to the clinical findings of Spandorfer 
et al., (2004) and Dokras et al., (2006) found no association between obesity and the 
proportion of MII oocytes.  
 
A measurable proportion of oocyte growth has been shown to occur in the final hours of 
oocyte development as observed in human oocytes matured in vitro (Cavilla et al., 
2008). It is possible that oocytes from OWOB women are not reaching full maturation 
and growth due to a blunted response to gonadotrophins as a result of increased 
apoptosis of granulosa cells, such as been observed in a murine model of diabetes 
(Chang et al., 2005). Furthermore, decreased granulosa cell gap junction 
communication and connexion expression has been observed in diabetic mice 
(Ratchford et al., 2008). As obesity is characterised by hyperglycemia and insulin 
resistance (characteristics of diabetes), such models are highly relevant and may be 
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applicable to human oocytes of OWOB women. In this regard, the observation by 
Lucifero et al., (2004), that imprinting of certain genes in mice has been shown to occur 
in the late growth phase, is also of potential significance when considering disruption in 
the final growth stages of the oocyte. 
 
Routinely only a small percentage of oocytes fail to complete meiotic maturation after 
stimulation (estimated to be 20%, from clinic data) and therefore as a measure of oocyte 
quality the %MII oocytes may not be particularly informative. Discrepancies amongst 
published study findings may arise due to differences in sample sizes. It is therefore 
proposed that data obtained from the measurements of oocyte diameter provide a better 
measure of oocyte quality and developmental potential. This is supported by the finding 
that smaller oocytes had a significantly reduced ability to undergo embryo cleavage and 
form blastocysts. This finding was in agreement with those of Otoi et al., (1997), who 
reported lower rates of blastocyst development for bovine oocytes with a reduced 
diameter, suggesting that the diameter at which oocytes achieve meiotic competence, 
maybe below that at which they attain full developmental competence.  
 
Mean MII oocyte diameter was shown to be significantly lower for OWOB women 
compared to normal weight women. Marquard et al., (2011) reported similar findings, 
but did not track the characteristics of each oocyte after fertilisation. Likewise, previous 
observations of human oocyte dimensions have mainly focused on determining 
minimum threshold diameters at the time of collection to complete maturation (Cavilla 
et al., 2008; Durinzi et al., 1995). This is the first study to track individual oocyte size to 
embryo developmental competence and quantify the relationship with female BMI. The 
data demonstrate clearly that the physiological processes that occur within the confines 
of the ovarian follicular environment of OWOB women have measurable effects on 
oocyte size. The implications of smaller oocyte diameter may have lasting 
ramifications, especially in view of the finding that smaller oocytes in mouse were 
associated with abnormal fetal development and decreased size (Jungheim et al., 2010). 
 
It is possible that the smaller oocytes generated from OWOB had not have completed 
their full maturation, as cleavage competence is known to be acquired progressively 
during both nuclear and cytoplasmic oocyte maturation. In data obtained using the 
bovine model, approximately 20% of oocytes, displayed asynchronous nuclear and 
cytoplasmic maturation. However, the diameter of the cytoplasmically mature cohort of 
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oocytes varied significantly, an observation that may relate to differences in content of 
triglyceride and/or proteins.  
 
4.4.3 Lipid content 
The amount and composition of triglyceride in human oocytes and embryos has not 
previously been studied and current assays are invasive, rendering oocytes non-viable 
and thus halting further observations of development. Disappointingly, there was no 
correlation between TG content and relative weight calculated from the continuous 
gradient method, indicating that this method for recording density may lack the required 
sensitivity to act as a surrogate marker of TG. 
 
In domestic animals triglyceride content is accrued during oogenesis and the amount 
has been shown to be linked to female diet, (reviewed by Mckeegan & Sturmey, 2012). 
It is possible that aberrant triglyceride accumulation may occur in gametes produced in 
a high lipid environment and hinder ongoing development. Exposure to saturated fatty 
acid during development affects the balance of lipid storage in bovine oocytes and 
developmental competence (Aardema et al., 2011). Furthermore, poorer embryo 
development has been reported for bovine embryos produced in a hyperlipidaemic 
environment (Leroy et al., 2010), and excess accumulation of cytoplasmic lipid droplets 
in embryos in the presence of elevated fatty acids; notable since this affects embryo 
cryotolerance (Abe et al., 2002).  This may provide a possible explanation for the lower 
cryosurvival and success rates reported in chapter 3 for blastocysts from OWOB women 
undergoing frozen embryo transfer cycles. This is explored in later chapters of this 
thesis.  
 
Oocytes from obese mice have been shown to have higher lipid content (Wu et al., 
2010), which has been linked to impaired mitochondrial activity (Igosheva et al., 2010) 
and evidence of endoplasmic reticulum stress (Wu et al., 2010, 2011; Yang et al., 2012). 
The follicular fluid obtained from obese women contains higher levels of triglyceride 
and free fatty acids (Robker et al., 2009, Yang et al., 2012). When mouse cumulus-
oocyte complexes (COC) are cultured in this fluid, maturation is impaired (Robker et 
al., 2011) and higher rates of granulosa cell apoptosis are observed (Yang et al., 2012). 
Such evidence suggests that the obese follicular environment is lipotoxic and COC 
exposure may elicit a stress response, as lipid accumulates intracellularly and causes 
damage to organelles. In mitochondria this may manifest as abnormal morphology 
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(Luzzo et al., 2012), abnormal distribution, increased ROS production and abnormal 
metabolism (Igosheva et al., 2010).  
 
In the endoplasmic reticulum, stress pathways may be induced and in very simple terms 
this results in a cohort of genes which slow protein translation and up-regulate protein 
folding chaperones being activated. As a consequence of this the expression of 
transcription factors including ATF4, ATF6 is increased and supporting this, is the 
observation that ATF4 expression is increased in the granulosa cells of obese women 
(Wu et al., 2010). The treatment of obese mice with an ER stress inhibitor before 
ovulation has been shown to increase mitochondrial DNA and restore oocyte quality 
(Wu et al., 2015), providing further suggestive evidence of the cascade of cellular 
defects aberrant lipid exposure may initiate.  
 
An alternative explanation for the poorer oocyte and subsequent embryo development 
could be that oocytes from OWOB women are exposed to higher intrafollicular glucose 
concentrations (Robker et al.,2009) since it has been reported that oocytes from mice 
with chemically induced hyperglycemia undergo precocious resumption of meiosis 
(Kim et al., 2007), whilst a number of these oocytes fail to progress through to MII 
(Chang et al., 2005). There is also evidence that the transcription of cell cycle associated 
genes is altered in animal models of metabolic syndrome (Ma et al., 2012), leading to 
poor quality smaller MII oocytes. In addition these authors reported altered expression 
of enzymes associated with gycolysis, which, together with the data of Chi et al., (2000) 
who found decreased insulin stimulated glucose uptake and of Chang et al., (2005) who 
reported structural and functional abnormalities in the mitochondria of oocytes from 
diabetic mice, suggests these oocytes may be metabolically compromised.  
 
4.4.4 Embryo development 
Previous comparison studies of embryo quality in normal verses OWOB embryo 
cohorts have produced conflicting results (as discussed earlier) and the differences in 
developmental rates observed in this study could provide an explanation for this. The 
advanced mitotic pace of development at the cleavage stage in the OWOB embryo 
cohort could have resulted in these embryos being graded as equivalent in quality to 
those of normal weight women, if a traditional grading system based on combined cell 
number and morphology had been used.  
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Although fewer embryos from OWOB women reached the blastocyst, those that did so 
developed at a faster rate. Specifically, embryos from overweight and obese women 
reached the morula stage of development on average 17 h earlier than comparable 
embryos from women of a healthy weight. Following precocious precompaction 
blastocysts were formed earlier in overweight and obese women, although the duration 
of cavitation once the morula stage had been reached did not differ. The reasons behind 
this precocious development are unclear, particularly given the recent report by Bellver 
et al., (2013), that embryos from overweight and obese patients had similar timings in 
cell division to embryos from women of normal weight. An important distinction 
between the work reported here and that of Bellver et al., (2013) relates to the length of 
time that embryos were observed; Bellver et al.,(2013) reported findings for 72 h post-
fertilization and stopped short of looking beyond day 3 and therefore did not observe  
differences in development rates. The authors did concede that obesity may play an 
important role in the later stages of embryo development. The data presented here is the 
first to demonstrate differences in developmental timing between embryos from OWOB 
patients that only became apparent after 68 h post-insemination. 
 
Interestingly, in non-obese diabetic mice Moley et al., (1991), reported retarded embryo 
progression throughout all development stages and that  insulin was shown to correct 
this. Progression through the cell cycle is likely to be influenced by appropriate 
metabolism and cell cycle checkpoint control. Obesity has previously been associated 
with a greater prevalence of spindle anomalies and non-aligned chromosomes 
(Machtinger et al., 2012). This could lead to retarded or uncontrolled advanced 
development, it is thus likely that a viable blastocyst is one, which has shown 
development within optimum time ranges at each stage of development – neither too 
fast nor too slow. 
 
The recorded embryo diameter at a fixed time point (such as movement to extended 
culture) will likely be related to developmental pace; as blastocysts develop they 
expand. The embryo size at 116 hpi provides a measure of developmental advancement, 
which may be less subjective than morphological assessments. At this time point; more 
embryos from the OWOB cohort remained at the cleavage stage, however those capable 
of further development did so at an advanced pace, thus assessment of mean diameter 
per patient maybe misleading. When the analysis was focused to compare equivalent 
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stage embryos, the blastocysts of OWOB women showed a tendency to be smaller than 
those generated from normal weight women (trend identified p=0.07). 
 
A larger blastocyst diameter on day 5 indicates advanced blastocyst expansion, which 
has been shown to be predictive of implantation potential (Shapiro et al., 2007). 
However, since embryos of OWOB women do not reach an equivalent size of those 
from normal weight prior to hatching, full expansion is impaired in these embryos.  
 
One possible explanation for reduced expansion capability of embryos from OWOB 
women, is that impaired energy metabolism in these embryos (as proposed in rodent 
models described earlier) may result in them being unable to produce sufficient ATP to 
drive the Na+/K+ ATPase (sodium pump) and protein synthesis, resulting in lower rates 
of expansion and possibly accounting for the differences in contractile and hatching 
patterns recorded for the blastocysts from OWOB women. The frequent interruption of 
expansion due to repeated contractions, as observed in blastocysts generated from 
OWOB women may disturb the hatching process. The level of pulsatile movements that 
would be expected as part of normal development is yet to be defined, however viable 
embryos are likely to be those showing a uniform pattern of contractions (Kirkegaard et 
al., 2012).  
 
Female BMI was an independent predictor of cell count and OWOB women had 
significantly lower cell counts. Lower cell counts and increased rates of apoptosis have 
been reported for blastocysts recovered from diabetic mice (Pampfer et al., 1990; Chi et 
al., 2000) and those generated from bovine oocytes matured in a hyper-lipid 
environment (Van Hoeck et al., 2011). Given that blastocysts from OWOB women had 
fewer cells in the trophectoderm lineage, from which the cytotrophoblast and 
syncytiotrophoblast will form this might suggest that at implantation, there are fewer 
chorionicprogenitor cells.  This in turn may feasibly have an impact on the size and 
invasive properties of the trophoblast and subsequent placenta.  
 
4.5 Conclusion 
 
The data presented here provide strong evidence that oocyte developmental competence 
is compromised in OWOB women. Possible mechanisms and consequences are 
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summarised in Fig 4.15. The reduced diameters for oocytes from OWOB women are 
theorised to relate to the nutrient enriched follicular environment.  
 
 
Figure 4.15 Hypothetical impact of maternal obesity- developing picture. 
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Chapter 5 : Human embryo metabolism 
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5.1 Introduction 
 
One consequence of the high plane of nutrition of obese women could be nutritional 
enrichment of the periconceptional environments. Strong evidence of such enrichment 
in the human has been provided by Robker et al., (2009) who reported significant 
positive correlations between BMI and the ovarian follicular content of glucose, lactate, 
triglycerides, insulin and C-reactive protein.  It is hypothesised that periconceptional 
enrichment promotes an aberrant embryo metabolic phenotype which may compromise 
embryo health and lead to the reduced fertility and increased miscarriage seen in 
OWOB patients. In addition, there is concern that nutritional stress on the embryo can 
have major consequences for fetal and neonatal health (Leese et al., 1998) and long term 
health implications for the offspring.  
 
The evidence supporting the role of metabolic analysis of substrate utilisation as a 
marker of embryo health is compelling. Human embryos with a pyruvate consumption 
distributed in the mid to lower range are reported to be most likely to give rise to a 
pregnancy following embryo transfer (Turner et al., 1994), while Lopes et al., (2007) 
found that oxygen consumption in the mid range predicted the viability of cattle 
embryos post-transfer. Most notably, researchers have shown that lower depletion and 
appearance of amino acids is predictive of the capacity of human embryos to develop to 
the blastocyst stage in vitro (Houghton et al., 2002) or give rise to a pregnancy 
following transfer in clinical IVF (Brison et al., 2004). 
 
Metabolic activity has been correlated with molecular damage (Sturmey et al., 2009); 
embryos with lower levels of damage have characteristically low metabolic activity. 
This observation underpins the 'quiet embryo hypothesis' (Leese 2002; Sturmey et al 
2009) which proposed that viable embryos have less molecular and cellular damage 
than those which arrest and a reduced need to take up nutrients for repair processes.  
Leese et al., (2007) extrapolated these findings to animal models; especially domestic 
ruminants, which indicated that a high level of feeding prior to and during conception 
leads to adverse developmental outcomes; observations which have been linked to the 
metabolism of the early embryo.   
 
It is generally accepted that mammalian preimplantation embryo metabolism follows a 
set pattern, as discussed in Chapter 1. The extent to which the accepted pattern of 
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uptake and release of these substrates by the developing embryo is linked to maternal 
obesity has not been explored. Furthermore, the role of endogenous lipid as a source of 
energy during human embryo development is also unknown.  
 
Examination of the utilisation of exogenous and endogenous metabolites by OWOB and 
normal weight women may help to answer questions surrounding how the 
preimplantation embryo processes and adapts to environmental cues. Very little is 
known about the lipid changes in abundance and composition, which may occur during 
preimplantation development. Changes, which have previously been observed in animal 
models are believed to be related to the environment (Kim et al., 2001), as well as the 
diet of the animal (Wu et al., 2010). It is thus feasible that maternal diet may influence 
lipid accumulation in the oocyte and subsequent embryo metabolism and development. 
In light of this proposition it is prudent to address the role of beta-oxidation of TG in 
embryos from normal and OWOB women. Furthermore, better understanding of 
metabolic adaptation by early embryos of OWOB women might also provide an 
explanation for the lack of consensus in the literature linking obesity and embryo 
quality (Carrell et al., 2001, Metwally et al., 2007, Bellver et al., 2010, 2013). It is 
possible that phenotypic differences are subtle or do not become immediately apparent, 
rather leading to more long-term changes in the phenotype of derivative cells. Major 
findings in animal models in recent years include (1) increased blood pressure (Watkins 
et al., 2007, Sinclair et al., 2007) (2) increased anxiety related behaviour (Ecker et al., 
2004) (3) increased obesity risk (Watkins et al., 2008) (4) decreased insulin sensitivity 
(Sinclair et al., 2007) (5) altered immune function (Sinclair et al., 2007). 
 
This is the first study to investigate the metabolism of embryos derived from overweight 
and obese women and those with a BMI in the normal range. The patterns linking single 
metabolic markers with individual embryo development and viability have been 
recorded and related to the maternal environment from which they originated.  
 
Aims and objectives 
 
a) To discover if human embryo metabolism is associated with maternal obesity; 
specifically if an increased maternal BMI is related to an aberrant embryo 
metabolic profile indicative of reduced viability (i.e. reduced ability to form a 
blastocyst in vitro). 
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b) To assess if embryo metabolism provides an objective biomarker of human 
embryo health, measured using a range of quantitative, biochemical methods to 
examine the relationship with maternal BMI and IVF treatment cycle outcome.  
c) To discover if the triglyceride content of embryos generated from OWOB 
women differs from that of embryos from normal weight women. 
d) To discover if triglyceride content of cleavage stage arrested embryos differs to 
that of those capable of forming blastocysts. 
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5.2 Materials and Methods 
 
5.2.1 Patient recruitment 
IVF patients were consented and recruited to the study as described in chapter 2. A total 
of 29 consecutive patients presenting for IVF at the Hull IVF Unit donated a total of 
150 embryos with full informed consent. Female and male BMI were recorded at the 
down-regulation appointment and at the commencement of treatment. Embryos that 
originated from patients classified as OWOB (BMI > 25 kg/m2) were compared with 
embryos derived from women of normal BMI (18.5–24.9 kg/m2). The study groups 
being discussed in this chapter are highlighted below (circled in red). 
 
 
 
 
 
 
Figure 5.1Source of study group-  
from prospective data, collected from women contributing to the primary research project from 2010 to 
2015. 
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II. Insulin / basic conditions n=7 patients, 56 embryos
III. Carnitine / basic conditions n=2 patients, 27 embryos
IV. Insulin / Carnitine conditions n= 4 patients, 35 embryos
V. ICSI partner sperm / IVF donor sperm n= 2 patients, 45 embryos 
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I. Primo analysis  n= 
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patients , 50 
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IV. Dif ferential cell 
count/ diameter 
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5.2.2 Experimental methods 
The experimental methods used to generate metabolic profiles are mainly non-invasive 
and provide quantitative markers of embryo health. 
 
Surplus embryos donated to research had their development stage recorded before being 
placed individually into 4 ml drops of Earle’s balanced salt solution, supplemented with 
1mM glucose, 0.47mM pyruvate, 5mM Lactate, a physiological mixture of amino acids 
(Houghton et al., 2002; all obtained from Sigma-Aldrich Chemical, Poole, UK) and 
0.5% (v/v) QA Serum Protein Substitute. Embryos were cultured under Sage Oil at 
370Cin 6% CO2 for 24 hours, alongside embryo-free control drops. Embryos were 
subsequently moved to fresh culture droplets and developmental observations made, as 
stated in Chapter 2. All embryos donated for research were profiled and embryos 
representative of all development stages were cultured and their development 
monitored. Observations were ended on Day 9. After incubation, the spent culture 
medium was immediately frozen at -800C for later analysis. 
 
Metabolic COnsumption/RElese (CORE) profiles (Guerif et al., 2013) were determined 
by measuring the depletion and appearance of glucose, pyruvate, lactate and 18 amino 
acids, according to established techniques, that may be applied to individual oocytes 
and embryos. The exception being, triglyceride measurement which is determined by a 
coupled colorimetric assay on samples pooled in groups of 2–5 embryos at equivalent 
development stages for each patient. Full details of each method are provided in 
Chapter 2. Results were recorded according to stage reached at the end of the period of 
culture. 
 
5.2.3 Statistical Analysis 
The information from the metabolic profiling of spare embryos was compared for the 
two study groups and correlated to study endpoints: embryo cleavage development and 
blastocyst formation. ANOVA was used to assess intra and inter subject variability in 
combination with linear regression analysis to assess the predictive accuracy of 
metabolic profile on blastocyst development rate. The best embryos were transferred or 
cryopreserved as part of patient treatment but the cycle outcome of sibling embryos 
(which were not assayed) has been incorporated into the analysis.  
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Full details of the statistical analysis are included in Chapter 2. However additional 
tests/ calculations conducted included;  
• Kolmogorov-Smirnov test for normality was used in the first instance, as mean 
and variance of CORE profiles was not known and had to be estimated from the 
data 5-9 data – this allowed a judgement to be made about whether the values 
attained on each day of development could have come from a normal 
distribution.  
• The ‘glycolytic index’ of individual embryos was determined based on the 
assumption that for each molecule of glucose consumed, 2 molecules of lactate 
are produced.   
 
5.2.4 The study sub-groupings 
In the main study group a total of 37 embryos from 7 OWOB women and 113 embryos 
from 22 normal weight women were assayed for CORE profile. The end point for the 
study is blastocyst development; 18 embryos had developed to form blastocysts (48.6%) 
by day 9 in the OWOB group compared to 37 (30.3%) from the normal weight group.  
There were no differences in patient age and cycle number, but significant differences in 
follicle and oocyte numbers and male BMI have been appropriately controlled for in the 
multivariate statistical analyses. It should be noted that if male BMI is used as the 
denominator, a significantly higher proportion of cases involve ICSI in the OWOB 
group and this is explored in further detail in the supplementary sub-grouping analysis. 
The details are provided below. 
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Figure 5.2 Schematic diagram of the study group. 
Patient numbers and demographics are indicated (values are ± standard error of the mean). Shaded boxes 
indicate embryos included in the analysis. 
 
To explore the paternal influence, data from a single male sperm donor that had been 
used to fertilize oocytes from six women, all of whom had a different BMI was 
evaluated. With the male factor controlled in this way, the results of the multivariate 
analysis can be determined.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 Supplementary sub-study groupings for analysis to determine the influence of male factor 
using a single male sperm donor. 
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Given the trend for increased use of ICSI in couples in which the male BMI was raised, 
the influence of insemination method was reviewed. 17 (45.9%) of embryos in the 
OWOB group of women were fertilised by ICSI, compared to 42 (34.4%) in the normal 
weight group. The specific demographic differences are displayed below and male 
semen parameters were significantly poorer in the group receiving ICSI treatment.  
 
 
 ICSI  (n=12) IVF (n=17) p-value 
Female age years 32.91 (1.44) 34.67 (0.99) 0.31 
Female BMI kg2 23.65 (0.94) 22.89 (0.99) 0.6 
Anti-Mullerian hormone pmol/l 20.89 (3.75) 20.66 (4.32) 0.97 
Mean no. oocytes 9.91 (0.83) 9.6 (0.98) 0.82 
Male age years 38.73 (2.12) 36.33 (1.26) 0.31 
Male BMI kg2 24.42 (0.86) 26.77 (0.86) 0.07 
Sperm concentration M/ml 18.42 (5.11) 77.04 (14.93) <0.01 
Sperm motility % 40.91 (4.37) 67.0 (2.97) <0.001 
Sperm morphology % 3.73 (0.45) 7.20 (0.34) <0.001 
Mean no. fertilised oocytes 6.0 (0.38) 7.0 (0.94) 0.39 
Mean no. top grade embryos 3.0 (0.56) 3.73 (0.71) 0.73 
Mean no. blastocysts 1.64 (0.39) 1.67 (0.37) 0.96 
Clinical pregnancy rate % 27.27 66.67 0.11 
Implantation rate % 25 57.89 0.14 
 
 
Figure 5.4 Supplementary sub-study groupings for analysis to determine the influence of insemination 
method.  
Patient demographics are displayed (values are ± standard error of the mean).   
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5.3 Results 
 
5.3.1 CORE Glucose, lactate, pyruvate and embryo viability 
Embryo viability was determined in terms of its developmental stage progression or 
arrest throughout the study period. Some embryos displayed low viability; undergoing 
early arrest, conversely others progressed to the hatched blastocyst stage. Embryos 
reached blastocysts, of differing expansion status/ grade on different days in culture. 
Mean glucose consumption fluctuated from 136.3pmol/emb/hr on day 5 to 
110.9pmol/emb/hr on day 9; lactate production fell from 143.8 to 110.7pmol/emb/hr 
and pyruvate consumption remained relatively stable between 45.8 and 
34.8pmol/emb/hr during the 5 days of culture analysis. The distribution of glucose, 
lactate and pyruvate metabolism was normal for each day of development, as 
determined by a one-sample, 2-tail Kolmogorov-Smimov test p>0.05 and depicted in 
Figure 5.5. 
 
 
 
Figure 5.5 Mean embryo metabolism of substrates over 24hr time periods, during 5 days of culture.  
In total, measurements were obtained from all 150 embryos derived from 29 patients. The specific 
breakdown of measurements attained were; n=102 measurements from embryos on day 5-6, n=97 day 6-
7, n=87 measurements day 7-8, n=76 day 8 to 9. A minimum 2 sample points were obtained for each 
embryo. Bars show the glucose and pyruvate consumption and the release of lactate± 95% confidence 
interval (CI). 
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The rate of glycolysis did not significantly differ according to day of development, 
ranging from 52.8% on day 5-6, to 42% day 6-7, 36.7% day 7-8 and 49.9% day 8-9. 
The mean glucose consumption for a blastocyst which formed on day 6 was 
103.02mol/hour, whereas  an embryo reaching this stage on day 7 had a mean 
consumption of 75.89mol/hour at blastulation, this difference was not statistically 
significant (p=0.42 Figure 5.6). The majority of embryos capable of forming 
blastocysts, did so by day 6.  
 
 
 
Figure 5.6 Glucose consumption for embryos that formed a blastocyst on day 6, 7 or day 8-9.  
Individual plots and mean values depicted. Observations were recorded, at static time points i.e. when 
culture medium was refreshed, every 24 hours of culture. 
 
The consumption of glucose was found to be significantly different for embryos which 
had arrested (no change within 48 hours) compared to those continuing to divide / 
develop on each day of development (ANOVA p=0.026), shown in Figure 5.7. 
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Figure 5.7 Glucose consumption for embryos that arrested (A) and those that continued to develop (D) 
on each day of extended culture . 
Individual plots and mean values depicted. Values with the same superscript were significantly different 
(p<0.05) 
 
Initially embryos arresting between day 5 and 6 consumed significantly more glucose 
than those continuing to divide (mean consumption 201 verses 105.5 
pmoles/embryo/hour respectively). There were no significant differences between those 
developing and those arresting on days 6 to 8, however, those continuing to develop 
between days 8-9 consumed significantly more glucose than those arresting (109.8 
compared to 63.4 pmoles/embryo/hour).  
 
The results displayed a wide range, although variation was reduced when values were 
evaluated according to stage of development attained by the end of the study period. 
Table5.1 shows the mean values for glucose and pyruvate depletion and appearance of 
lactate over day 5 to 9 for embryos that arrested at each development stage. The 
distribution of glucose consumption was significantly different across the categories 
(p=0.034), although lactate production (p=0.713) and pyruvate consumption (p=0.095) 
do not significantly differ in accordance with stage of arrest.  
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Table 5.1 CORE profile and stage of development. 
The mean glucose uptake, lactate production and pyruvate uptake from embryos (n=150) cultured 
between day 5 and 9, expressed as pmol/embryo/hr. The values are shown for each stage of development 
±SEM, ANOVA was used to assess for differences based on the stage of development. Significant 
differences were recorded for glucose based on stage of development (p=0.034) Values with the same 
superscript were significantly different (p<0.05). 
 
Stage attained prior to arrest 
Mean (±SEM) consumption /production in 
pmol/embryo /hr 
Glucose 
(pmol/emb/hr) 
Lactate 
(pmol/emb/hr) 
Pyruvate 
(pmol/emb/hr) 
Cleavage cell stage (n=43) 74.96 (9.05)b 114.79 (15.42) 32.50 (4.18) 
Morula (n=48) 99.11 (11.87) 105.00 (10.97) 32.57 (3.01) 
Unexpanded blastocyst (n=11) 68.56 (8.09)a 77.16 (14.77) 19.48 (2.95) 
Expanded blastocyst (n=22) 109.61 (14.82) 109.32 (15.87) 34.53 (5.11) 
Hatched blastocyst (n=25) 116.05 (12.94)a,b 112.99 (16.07) 36.75 (3.76) 
 
Embryos that arrested at the cleavage and morula stage consumed 87.7pmol/emb/hr of 
glucose compared to 111.5pmol/emb/hr for those embryos at the equivalent stage that 
continued to develop. Notably, blastocysts that failed to expand fully had the lowest 
rates of metabolic activity. Glucose consumption in those embryos that arrested at the 
unexpanded stage was 68.56pmol/emb/hr, compared to 113.3pmol/emb/hr for 
blastocysts that continued to develop. In addition, a significantly higher proportion of 
the arresting blastocysts were generated from OWOB women (p=0.003).   
 
The development stage that an embryo had reached on day 3 (prior to donation to 
research- information from clinical notes) did not correlate with glucose consumption 
on day 5-9. Embryos which displayed a slow rate of cell progression on day 3 (<6 cells) 
or a rapid rate of progression (>8 cells) did not differ in their rate of glucose 
consumption on days 5-9 compared to those progressing at a more optimal rate of 
development (6-8 cells day 3- see Appendix A3). Cell number on day 3 was however, 
related to blastocyst development on day 5-9. The rate of blastocyst development was 
18.9% from embryos with less than 6 cells, compared to 45.1% for those with more 
than 6 cells on day 3 (7/37 and 51/113 respectively, p<0.01). Similarly, lactate and 
pyruvate metabolism on day 5-9 was comparable for embryos which had reached the 6 
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cell stage by day 3 and for those developing at a slower rate (<6 cells on day 3 – see 
Appendix A3). 
 
Glucose consumption was significantly different at different stages of blastocyst 
development expansion (early unexpanded to hatched i.e. stage 1-6, as shown in Table 
5.1). There was however, no significant relationship between blastocyst grade (aa-ec) on 
day 9 and average glucose consumption from day 5-9. Kruskal-Wallis test demonstrated 
that the distribution of glucose was the same across categories of grade (p>0.05). 
 
 
Figure 5.8 Mean glucose consumption from day 5 to 9 and blastocyst development expansion grade 
(1-6) and ICM (a-e) and TE grade (a-c).  
 
Overall the results indicate that glucose consumption differs between viable developing 
embryos and those undergoing arrest. Those undergoing early arrest displayed above 
average consumption, whereas those arresting at a later stage of development had a 
below average consumption. The relationship between CORE profile and blastocyst 
development would thus indicate an optimum mid-high range of metabolism  indicative 
of developmental viability.   
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5.3.2 The influence of female BMI on CORE Glucose, lactate, pyruvate embryo 
viability profile 
The glucose and pyruvate depletion and lactate production by embryos derived from 
OWOB women was compared to those in the normal BMI range (Figure 5.9).  Glucose 
uptake was significantly lower in embryos generated from OWOB women (p=0.001). 
The values for lactate and pyruvate did not significantly differ (p=0.259 and 0.318 
respectively).  
 
Regression analysis showed a significant negative relationship between glucose uptake 
and increasing BMI (ß-0.283, t-3.395, p0.001), a weak negative relationship with lactate 
(ß-0.097, t-1.134, p0.259) and pyruvate uptake was not significant (ß-0.082, t-1.003, 
p0.318). 
 
 
 
 
Figure 5.9 Mean embryo metabolism of substrates from day 5 to 9, according to BMI classification of 
female donor.  
37 embryos from 7 OWOB women and 113 embryos from 22 normal weight women. Error bars represent 
95% CI, ** P<0.01. 
 
** 
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The difference in glucose consumption amongst blastocysts that were able to expand 
and /or hatch was significantly different in normal (n=33) and OWOB (n=14).  Lower 
rates of glucose uptake were evident for OWOB 87.22pmol/embryo/hr, compared to 
132.16pmol/embryo/hr for embryos generated from women of normal weight (p=0.03). 
ANOVA revealed significant differences in glucose lactate and pyruvate metabolism for 
normal and OWOB women at each of the different stages of development (p<0.05).  
 
Table 5.2 CORE profile, stage of development and female BMI. 
Mean glucose uptake, lactate production and pyruvate uptake from embryos (n=150) cultured between 
day 5-9, expressed as pmol/embryo/hr, expressed as  values for each stage of development ±SD. ANOVA 
was used to assess for differences amongst embryos generated from OWOB and normal weight women at 
different stages of development arrest. 
 
 
 
Significant differences in consumption of glucose and pyruvate and release of lactate, 
were recorded between embryos from normal and OWOB women at the morula stage 
and expanded blastocyst stage (p<0.05). Embryos from OWOB women that failed to 
progress beyond the morula stage consumed significantly lower amounts of glucose and 
pyruvate and produced less lactate. Embryos from OWOB that failed to hatch also 
consumed significantly lower amounts of glucose, and pyruvate and produced less 
lactate, than those arresting at the equivalent stage from normal weight donors.  
 
Results were again analysed according to CORE profile on each day of extended 
culture, but in this instance, results were sub-classified according to female BMI. 
Distribution patterns did differ among normal and OWOB populations (Kolmogorov-
Smirnov 2-sample 2-tail test p<0.05) and were reflective of developmental activity (see 
appendix A3). Glucose consumption was significantly lower in embryos generated from 
OWOB women from day 6 to 9 (p<0.01), however, lactate production was significantly 
Mean (± SD)
consumption /
production in
pmol/emb/hr
BMI Cleavage  cell 
stage 
Morula Unexpanded Expanded Hatched
norm 78.18 (59.67) 126.58 (88.8) 80.00 (33.1) 145.79 (61.9) 117.46 (48.6)
owob 64.40 (60.4) 49.18 (31.9) *** 64.13 (25.3) 46.38 (13.0) *** 114.50 (80.9)
norm 104.94 (85.5) 135.16 (75.9) 76.33 (52.6) 142.21 (68.6) 98.69 (54.2)
owob 147.60 (141.9) 50.17 (34.7) *** 77.50 (51.2) 51.50 (43.9) *** 128.67 (101.9)
norm 31.39 (18.9) 37.65 (22.6) 23.00 (17.0) 41.71 (27.0) 34.54 (14.5)
owob 36.50 (47.1) 23.29 (13.4)** 17.86 (4.7) 22.13 (9.9) ** 39.42 (22.8)
*p<0.05,(**(<0.01(***<0.001
Glucose
Lactate
Pyruvate
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different between day 5-7 (p<0.05) and pyruvate consumption was significantly lower 
between day 6-7 only (p<0.05), compared to values from normal weight controls. 
Between day 5 and 6 approximately 8% of embryos arrested, by day 7 the number 
arrested accounted for 38% of embryos and by day 9 of culture over 75% of all embryos 
had arrested their development. A similar proportion of embryos generated from normal 
and OWOB women had hatched by day 9 (18%). Proportions are represented 
graphically in Figure 5.10. 
 
 
 
Figure 5.10 Percentage of embryos at each developmental stage at the start of culture on each day of 
extended culture. 
 
The consumption of glucose was significantly different in both BMI groups for embryos 
which had arrested compared to those continuing to divide on each day of development 
(ANOVA p=0.026). 
 
It is clear from the univariate analyses that embryos from women with a BMI in excess 
of 25 kg/m2 consumed significantly less glucose than embryos from women of a 
healthy weight at equivalent stages of development (p< 0.001), whilst there were no 
significant changes in pyruvate uptake and lactate formation (Figure 5.9). This pattern 
was consistent for each developmental stage (Table 5.3). The reduced consumption of 
glucose occurred without a compensatory increase in pyruvate uptake, or of glycolytic 
156 
 
activity as determined by lactate formation. In a multivariate analysis, developmental 
stage and female BMI were significant predictors of glucose uptake (p<0.05) and 
independent of male BMI, age, cause of infertility, embryo grade and day each stage 
was attained (see Appendix). 
The specific details of the regression analysis revealed that the relationship between 
glucose consumption on day 5-9 and female BMI (female BMI β-0.353, t-4.049, 
p<0.001) was independent of cleavage cell stage embryo developmental kinetics (day 2 
β-0.84, t-0.944, day 3 β0.116, t1.304). Average cell counts (±SEM) were 3.19±0.11 and 
3.16±0.18 on day 2 and 6.47±0.15 and 6.73±0.27 on day 3 of development for normal 
and OWOB women respectively. Male BMI was not a significant predictive variable. 
Similarly the distribution of female BMI was comparable across categories of 
blastocysts grade. 
 
Overall the results for this section show that glucose consumption is significantly lower 
in embryos generated from OWOB women compared to normal weight (p<0.001). In 
those embryos which did not undergo early stage arrest and remained viable (reached 
the next development stage within 48 hours), glucose consumption was significantly 
lower (p<0.03).  
Glucose, lactate and pyruvate did not show a correlation with pregnancy outcome of the 
sibling transferred embryo, however considerable intra-patient variability was observed. 
This variability was reduced when the analysis was limited to include only developing 
sibling embryos, however no significant correlation with pregnancy was evident. 
Despite this, a meaningful analysis of BMI, glucose, lactate and pyruvate metabolism 
and pregnancy outcome is not possible with the current sample size. However, using 
logistic regression a predictive model R20.45, was built (see Appendix). Whilst in 
general embryos generated from OWOB women had significantly lower rates of 
glucose consumption, the glucose uptake measured for sibling blastocysts from OWOB 
women who attained a pregnancy (n=10) did not differ significantly to that of normal 
weight women (n=15) who established a pregnancy (107.02 verses 
129.8pmol/embryo/hr). This suggests that uptake in the mid-range is optimal for 
viability (i.e. too high a consumption of glucose is also correlated with lower 
development / implantation potential). 
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5. 3.3 Embryo amino acid turnover and viability 
Previous studies have shown that increased overall amino acid turnover is indicative of 
poor embryo quality in terms of implantation potential (Brison et al., 2004) and DNA 
damage (Sturmey et al., 2009), based on findings from cleavage stage embryos. The 
results presented here distinguish the pattern of uptake and release of amino acids at 
later stages of development. 
 
It was observed that the net rates of depletion or appearance of amino acids varied 
between cohorts of embryos; dependent on the stage of development attained (Figure 
5.11). Embryos which arrested at the earlier stages of development had a higher 
turnover of amino acids; specifically asparagine, aspartate, glutamate and alanine 
production was greater (p<0.05), compared to those that formed blastocysts. Those 
embryos that developed beyond the unexpanded blastocyst stage produced significantly 
fewer amino acids, but consumption of methionine was significantly higher in 
developing blastocysts, as was arginine (p<0.01) and histidine production was high in 
expanded and hatched blastocysts (p<0.01). 
 
 
Figure 5.11 The net rates of depletion or appearance of amino acids and stage of development. 
Significant differences were evident between those failing to form blastocysts and those blastocysts that 
failed to expand, as analysed by ANOVA p= 0.048. Error bars represent 95% CI, values with the same 
superscript were significantly different (p<0.05). 
a, b 
a b 
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In terms of pregnancy outcome, the turnover of amino acids for all embryos from 
women achieving pregnancies was lower than in the non-pregnant group and 
approaching significance (p=0.057; Figure 5.12). When the analysis was limited to 
compare only developing blastocysts, this difference was less evident, however 
significant differences were observed in the production of asparagine (p=0.016) and 
glutamine (p=0.036), which were lower in the pregnant group; similarly the uptake of 
arginine (p=0.026) was lower.  
 
 
Figure 5.12 Amino acid turn over and pregnancy outcome.  
Average sums of amino acid production and depletion, expressed in pmoles/embryo/hour for day 5 to 9 of 
culture. Error bars represent 95% CI.  Results are recorded according pregnancy outcome of sibling 
embryos (82 embryos from 15 women who achieved a pregnancy and 68 from 29 who did not). Lower 
production and depletion of amino acids was evident for sibling embryos that gave rise to a pregnancy 
however this did not reach significance (p=0.057). Significant differences in the individual pattern of 
uptake and production of amino acids were evident. 
 
5. 3.4 Embryo amino acid turnover and female BMI 
When analysed according to BMI classification the difference in the sum of amino acids 
did not reach significance (p=0.057). However, glutamate (p=0.006), aspartate 
(p=0.001), asparagine (p=0.011) and tryptophan (p=0.047) appeared in higher 
concentrations in the medium of embryos from OWOB compared to embryos from 
those of normal weight. Furthermore, OWOB embryos depleted significantly more 
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serine (p=0.004) and glutamine (p=0.012) whereas isoleucine was less depleted by 
embryos from OWOB (p=0.031).  
 
Overall, embryos from OWOB women had a more active turnover of amino acids, 
amino acid. Figure 5.13 shows the appearance and depletion of specific amino acids 
according to BMI classification, specifically, for those embryos that developed to 
blastocyst. There were no significant differences in the sum appearance/ disappearance 
rates. Only methionine was significantly more depleted from the media by embryos 
from OWOB women (p<0.05). This was confirmed after principal component analysis.   
 
 
Figure 5.13 Overview of individual amino acid turnover.  
Amino acid depletion and appearance by blastocysts of equivalent stage for OWOB (n=20) and normal 
weight women (n=27). There are no significant differences in the sum of uptake and production, however 
significant differences are apparent for methionine (p=0.037). Error bars represent 95% CI, *p<0.05 
 
 
The data from the 18 amino acids was reduced by principal component (PC) analysis 
(the suitability of the data for this type of analysis was confirmed; standards met = 
* 
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KMO 0.77, Bartlett’s test 0.000). It is likely that differences in the consumption and 
release of individual amino acids maybe related, therefore prior to further multivariate 
testing, the variance for each of the 18 individual amino acids was used to create a 
smaller set of linear combinations. The data were transformed with 5 epigenvectors, 
accounting for 69% of the total variance. A three-component solution explains 54.9% of 
the data and is presented in Figure 5.14. Component 1 (PC1) accounted for 36% of the 
variance. 
 
 
 
Figure 5.14 PC plot of individual amino acid CORE. 
PC component plot in rotated space- rotation converged in 11 iterations (PC1; trp, glu, asp, gly, thr, 
gln,tyr, ser, asn, his, lys) 
 
 
The majority of the amino acids included in PC1 are neutral and polar and appear to 
belong to system N transporters. After the PC adjustment for covariation, a permutated-
based adjustment of p-values was undertaken – only methionine depletion significantly 
differed (p<0.05) between developing blastocysts generated from OWOB women and 
those with a BMI <24.9Kg/m2.  
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5. 3.5 Embryo triglyceride content, viability and female BMI 
Figure 5.15 shows that human embryos that arrested contained significantly more 
triglycerides than those that completed development (11.32 versus 6.7ng; p<0.001).  
 
 
 
Figure 5.15 Triglyceride content of embryos arresting prior to blastocyst formation and for those capable 
of forming blastocysts.  
 95% CI, **p<0.01 
 
In light of this finding, results were compared for the pooled samples (groups of 2 to 5 
embryos at equivalent stages for each patient) from each patient that achieved a 
pregnancy from a transferred sibling embryo and those failing to achieve a clinical 
pregnancy. The data showed a trend for lower triglyceride composition in sibling 
embryos of those that successfully implanted (p=0.079). 
 
In addition, it was observed that Day 9 blastocysts from women with a BMI ≥ 25 kg/m2 
contained significantly more triglycerides than comparable embryos from women with a 
BMI< 24.9 kg/m2 (Figure 5.16; t= 4.11, p< 0.001).   
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Figure 5.16 Triglyceride content of embryos attained from normal and OWOB women.  
95% CI, **p<0.01  
 
5.3.6 The maternal verses paternal influence on metabolic profile 
To investigate the influence of male BMI, the data have been analysed according to 
male BMI classification. When stratified in this manner 81 embryos originated from 
OWOB males and 69 from those of normal weight. 
 
The data in Table 5.3 show that there was no significant effect with male BMI and 
CORE profile. 
 
Table 5.3 CORE profile and male BMI. 
There were no significant differences in the mean glucose, lactate and pyruvate metabolism between days 
5 and 9 of culture, for embryos grouped according to the male partner BMI. 
 Male Mean (± SD) consumption / production in pmol/emb/hr p-value 
Glucose norm 101.57 (59.69) 0.279 
owob 89.50 (75.29)  
Lactate norm 107.88 (70.60) 0.987 
owob 107.66 (89.95)  
Pyruvate norm 34.94 (19.55) 0.301 
owob 31.16 (24.52)  
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A regression analysis, mixed linear model (with female BMI as a fixed effect) showed a 
weak negative relationship between glucose uptake and increasing male BMI (β-.060, t-
.678, p0.499) and weak relationship with lactate  (β.070, t.778, p0.438) and pyruvate  
(β.035, t.407, p0.685). This supports the earlier model findings using female BMI as the 
primary denominator. 
 
Obesity was more prevalent in the male partner. 45 embryos were generated from 
discordant male female weight pairings in 40 cases this was due to the pairing of an 
OWOB male with a normal weight female. ANOVA revealed significant differences in 
glucose consumption amongst the 4 pairing possibilities i.e. both partners normal 
weight (n=55 embryos), both OWOB (n=50), male OWOB and normal weight female 
(n=40), female OWOB and normal weight male (n=5) (p<0.05, Figure 5.17). 
 
 
Figure 5.17 Mean core profile day 5-9, according parental BMI classification. 
105 embryos from weight matched couples and 45 from weight discordant couples. Error bars represent 
95% CI, values with the same superscript are significantly different (p<0.05). 
 
Glucose consumption was significantly lower in embryos generated from OWOB 
pairings. Higher lactate production was linked to male BMI- each unit increase in male 
a 
a 
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BMI equates to an increase in production of 0.070 pmol/emb/hr, compared to a drop of 
0.095 pmol/emb/hr for each unit increase in female BMI. In contrast, increasing female 
BMI has less of an impact on pyruvate consumption than increasing male BMI. The 
values for lactate and pyruvate are not significant. The standard deviation is high due to 
the low sample size (n=5) in the OWOB female and normal weight male.  
 
The strongest evidence that the metabolic results attained had primarily a maternal 
origin came from the analysis of data using donor sperm. In the course of the study, 
fortuitously a single male sperm donor had been used to fertilize oocytes from six 
women, all of whom had a different BMI. With the male factor controlled in this way, it 
was possible to confirm the results of the multivariate analysis, which suggested that the 
differences in embryo glucose consumption were independent of male BMI (Figure 
5.18). 
 
 
Figure 5.18 Glucose consumption in embryos generated from a single male donor. 
The glucose consumption of blastocysts is inversely correlated to female BMI (R2-0.61; p<0.001) and 
relates to maternal BMI with little paternal influence. The oocytes in this figure were all fertilized by the 
same sperm donor, yet reduced glucose consumption was apparent in embryos from OWOB women (12 
embryos from 3 women of a normal BMI and 13embryos from 3 OWOB women; see Figure 5.3 for 
details. Data are expressed as mean ±SEM. 
 
It was noted that despite no significant differences in the proportion of ICSI or IVF 
treatments performed in the groupings based on female BMI, if male BMI is used as the 
denominator, a significantly higher proportion of cases involve ICSI in the OWOB male 
group although not significant if assessed as a continuous variable p=0.07; Figure 5.4. 
As previous studies had demonstrated, in vitro protocols may alter developmental 
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progress and change gene expression and metabolic profiles (Bell et al., 2008). It would 
be prudent to evaluate this in further detail.  
 
Table 5.4 shows that uptake of glucose and pyruvate and production of lactate did not 
differ according to the method of insemination, Values are based on average 
concentrations from day 5 to 9 (p>0.05).   
 
Table 5.4 ICSI and IVF embryos mean glucose and pyruvate uptake and lactate production 
between days 5 and 9 of culture, expressed as pmol/hr/embryo(±SEM). 
 
 
 
 
 
Data were also analysed according to amino acid turnover, Figure 5.19 shows that ICSI 
embryos produced significantly more amino acids than IVF generated embryos 
(p=0.04). The specific amino acids which were produced in higher quantities from ICSI 
embryos were; aspartate (p=0.016), asparagine (p=0.04), histidine (p=0.021), threonine 
(p=0.009). The consumption of leucine was significantly lower (p= 0.04) in ICSI 
embryos. 
 
 
Figure 5.19 Average sums of amino acid production and depletion, according to treatment type.  
Data expressed in pmoles/embryo/hour for day 5 to 9 of culture. Significant lower production and 
depletion of amino acids was evident for IVF embryos, compared to ICSI. Error bars represent 95% CI, 
*p<0.05. 
CORE pmol/emb/hr Glucose Lactate Pyruvate 
ICSI  83.11 (7.88) 107.70 (10.77) 31.17 (3.48) 
IVF   101.60 (7.84) 107.78 (8.74) 33.63 (2.1) 
* 
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To explore the possible impact the injection procedure could have on subsequent 
embryo metabolism and to ascertain if this was a patient specific effect and perhaps 
reflective of other covariate factors, data were reviewed from an additional subgroup of 
patients (identified throughout the course of the research study- see figure 5.1 for 
details), in whom semen parameters had been borderline normal. These patients 
received a split IVF / ICSI treatment cycle; i.e. half of their oocytes were fertilised by 
IVF and half by ICSI (n=50 embryos). Individual and collective differences in amino 
acids were not apparent for sibling embryos created by either technique (Figure 5.20). 
Interestingly, amino acid turnover was higher for IVF embryos patients-who had 
borderline suboptimal semen parameters compared to embryos generated via IVF 
patients, who had normal semen parameters (0.30 verses 0.83 p/mol/embryo/hr 
respectively) and conversely amino acid turnover was lower for ICSI embryos from 
those with borderline suboptimal semen evaluation compared to abnormal semen 
evaluation.   
 
 
Figure 5.20 Amino acid turn over for sibling embryos, split treatment cycles.  
Average sums of amino acid production and depletion, day5-9; comparable for sibling embryos (p=0.39). 
 
Furthermore, blastocyst development rates were comparable (p=0.11), as were rates of 
uptake and production of substrates from the culture medium. There were no significant 
difference in glucose (IVF 69.31 versus ICSI 54.45 pmol/embryo/hr p=0.47), lactate 
(p=0.75) and pyruvate (p=0.93) for IVF and ICSI embryos. Similarly there were no 
significant differences in the triglyceride content of ICSI and IVF sibling embryos.  
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5.3.7 Results overview and live birth data 
 
Numerous variables have been reviewed in the course of this chapter. The key findings 
and how they maybe pieced together will be reviewed in the discussion; however clear 
observations from this study have been as follows; 
1. Glucose consumption is significantly lower in embryos generated from OWOB 
women compared to those of normal weight.  
2. The triglyceride content of embryos from OWOB women was significantly 
higher than that of normal weight women. 
3. Glucose consumption was higher in embryos capable of forming 
developmentally viable expanded / hatched blastocysts and triglyceride levels 
were significantly lower amongst blastocysts compared to those arresting at 
earlier stages of development.   
To relate these three dimensions of data a bubble chart has been plotted (Figure 5.21). 
Blastocyst development ranged from 0-100% amongst cohorts of embryos and complete 
failure of any embryos within the cohort to reach the blastocyst stage was more 
common among OWOB patients. However, in cohorts homogenous for development; 
blastocysts of OWOB consumed less glucose and had higher triglyceride levels. Those 
from normal weight women forming blastocysts had mid-high glucose consumption and 
mid-low triglyceride levels. 
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Figure 5.21 Comparison of significant entities influenced by female BMI. 
 Comparisons plotted in terms of their relative positions with respect to each numeric axis (mean glucose 
consumption, mean triglyceride content) and size (% blastocyst formation rate) for cohorts of embryos 
from the 7 OWOB women and 22 normal weight women 
 
In chapter 4 it was established that blastocysts from OWOB women had significantly 
lower cell counts than those from normal weight women. CORE values were 
established for these embryos from day 5-7 prior to staining (see Figure 5.1 for study 
group details). This analysis was undertaken to attempt to clarify if the lower glucose 
consumption could relate to lower cell numbers. Figure 5.22 and analysis via multiple 
regression, general linear modelling (R2 0.08) shows this does not appear to be the case 
for either total cell count (F 1.053, p=0.56) or covariates; inner cell mass (t-0.85, p=0.4) 
and trophectoderm (t1.67, p=0.11). BMI remains a significant predictor of glucose 
(p=0.03) and cell counts (p=0.01); confirmation via Mann Whitney U test that 
distribution of results for both of these parameters is different in the OWOB population 
compared to that of the normal weight grouping. 
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Figure 5.22 Blastocyst cell count and glucose consumption. 
Blastocyst cell count (total, or differential) is not a predictor of glucose consumption (R2 0.08, p>0.05). 
Data reviewed from CORE profile of 44 embryos from 16 patients.  
 
The data reviewed in chapter 3 implied that clinical pregnancy rates tended to be lower 
and rates of miscarriage higher among OWOB women compared to those of normal 
BMI. This did however result in significantly lower live birth rates and data reviewed 
for live birth rates after DZT and ovum donation implied that fetal growth and 
development may be influenced by both genetics and the environment. The results from 
this chapter add to this;  
• Clinical pregnancy rates were not significantly different among groupings; 50% 
(11/22) in the normal weight group and 57% (4/7) in the OWOB group. 
• Correlations between metabolic biomarkers and establishment of clinical 
pregnancy were poor, but as a measure of viability metabolic biomarkers 
provided information about developmental potential.  
• The metabolic effects were mediated via maternal BMI as appose to male BMI 
and were not significantly influenced by in-vitro handling techniques/ 
environment. 
To determine if metabolic differences observed at the embryonic level were affecting 
clinical outcome at a later stage, such as fetal growth, live birth data for the two groups 
of women were reviewed and are displayed in Figure 5.23. Babies born to OWOB 
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women were significantly heavier (p=0.04) than those born to women of normal weight; 
mean (±SEM) of 3656.3 (173.9) compared to 3309 (75.8) grams respectively. There 
were no significant differences in number of weeks gestation (p=0.28) or proportion of 
male to female infants. The majority of babies born were however, considered 
appropriate weight for gestational age, with the exception of one large for gestational 
age baby born to an OWOB mother.   
&
 
 
 
 
Figure 5.23 Birth outcomes of infants born to normal and OWOB women. 
Babies were significantly heavier for stage from OWOB mothers.  
!
To discover potential associations between birth weights and metabolic profile of non-
transferred sibling embryos, plots of (a) birth weight and sibling glucose consumption 
(b) birth weight and sibling triglyceride content, were constructed and compared with 
those of (c) maternal BMI for those achieving a live birth and sibling embryo glucose 
consumption and (f) triglyceride content. Data is displayed in Figure 5.24. 
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Figure 5.24 Data displayed for women achieving a live birth outcome. Metabolic data for sibling 
embryos was plotted against (A) birth weight and (B) female BMI. 
 
No significant relationships were established when the patient was used as the 
denominator. The error bars depict the intra patient variability. The majority of the 
trends do follow those established as significant amongst individual embryos. The 
broad-spectrum findings were that; 
• Increasing maternal BMI was associated with lower glucose consumption at the 
pre-implantation stage and higher birth weight infants. 
• Increasing maternal BMI was associated with higher measured triglyceride 
content at the pre-implantation stage, although contrary to this and somewhat 
unexpectedly, lower sibling triglyceride levels were associated with higher birth 
weight infants.!
  
A 
B 
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5.4 Discussion 
 
5.4.1 Summary of key findings 
The data presented here provide strong evidence to support the hypothesis that embryo 
viability is compromised in OWOB women.  The most striking findings were that 
embryos from OWOB women showed significant metabolic abnormalities, with 
diminished glucose consumption, altered profile of amino acid metabolism and an 
increased endogenous triglyceride content. The data provide a link between maternal 
nutrition, the periconceptional environment, oocyte and preimplantation developmental 
competence and embryo metabolism, which could have long-term health implications 
for the offspring. 
 
5.4.2 Metabolic biomarkers, as a measure of embryo viability 
As a measure of embryo viability the metabolic biomarkers measured in the course of 
this study provided strong predictors about an embryo’s developmental potential. As 
outlined in previous studies the association between metabolic activity and viability 
appears to be independent of embryo morphology (Brison et al., 2004; Gardner et al., 
2011). Blastocyst formation, expansion and hatching were observed as key 
developmental milestones and the attainment of such status rather than the point at 
which this occurred (day 6, 7 or 8-9), that most influenced metabolic viability. Equally, 
the stage at which an embryo arrests was closely correlated with its prior metabolism. 
Early arresting embryos, still at the cleavage stage, displayed a high CORE profile and 
high triglyceride levels; those arresting at later stages displayed lower uptake of 
metabolites, as observed for those capable of forming blastocysts, but not competent to 
undergo expansion. The results for glucose, pyruvate consumption and lactate 
production from embryos on days 5-9 of development were widely distributed, though 
were suggestive of an optimum mid-range of activity, in agreement with the findings in 
embryos, 24 hours following fertilisation, reported by Turner et al., (1994).  
 
Throughout development, there appear to be specific upper and lower optimum values 
for metabolite consumption and release that define metabolic normality, and as 
indicated here; embryos displaying metabolic activity outside these ranges may have 
impaired developmental potential. A ‘mid-range’ of metabolic activity is suggestive of 
optimum viability (Gardner et al., 2011; Guerif et al., 2013). Metabolic quiescence 
seems to be responsible for developmental arrest and delayed implantation (Nilsson et 
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al., 1982). It has been postulated that too little energy production may result in reduced 
synthesis of macromolecules or on the contrary, that reduced demand for energy maybe 
as a result of decreased macromolecule synthesis (Weitlauf & Nieder, 1984). Similarly 
high metabolic activity has been associated with embryonic arrest, cellular stress and 
DNA damage, as embryos need to consume higher quantities of substrates, presumably 
in order to carry out repair processes, compared with those that continue development 
(Sturmey et al., 2009). Thus, cleavage stage embryos that exhibit a ‘quiet’ metabolism 
(Leese, 2002; Leese et al., 2007, 2008), are believed to be more viable. Later in 
preimplantation development, it has been suggested that, as the capacity to metabolise 
glucose increases significantly between the morula and blastocyst stages (Devreker et 
al.,2000), embryos that double their glucose consumption are more likely to form 
blastocysts than those where glucose consumption remains unchanged (Gardner et al., 
2011). 
 
5.4.3 Glucose consumption 
In broad terms, the data reported in this chapter on consumption of glucose by single 
human blastocysts are consistent with those previously reported (Hardy et al., 1989, 
Gardner et al., 2011). However, blastocysts from OWOB patients consumed 
significantly less glucose than equivalent embryos from women with a normal BMI. A 
diminished capacity to metabolize glucose maybe profound since a deviation from what 
appears to be an evolutionarily conserved metabolic phenotype of increased glucose 
consumption (Smith & Sturmey, 2013) during blastocyst formation, suggests some 
degree of metabolic remodelling in the blastocysts derived from oocytes collected form 
OWOB women. It is proposed that this relates back to the follicular conditions to which 
oocytes from OWOB women are exposed to prior to fertilisation. Robker et al.,(2009) 
have shown that the follicle of overweight women is enriched for glucose while Moley 
et al.,(1998) reported in a mouse model, that elevated follicular glucose leads to 
alterations in the expression of glycolytic enzymes and the appearance of functional 
defects in mitochondria. 
 
Embryos from OWOB women consumed significantly less glucose than embryos from 
women of a healthy weight at all equivalent stages of development, most notably at the 
points of compaction and expansion. The reduced consumption of glucose occurred 
without a compensatory increase in pyruvate uptake, or lactate formation and this 
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pattern appears to mirror data from animal models of nutritional enrichment (Van 
Hoeck et al., 2011). 
 
A ratio of glucose consumed to lactate produced of 1:2 implies that all the glucose may 
be accountable by lactate appearance via glycolysis. In the present study the ratio of 
lactate production was lower than expected in both groups such that glycolytic activity 
did not significantly differ for normal and OWOB groupings (mean-60.5%). This is 
supported by findings of Robker et al., 2009 and Binder et al., 2011. As the rate of 
glycolysis was unchanged, the lower utilisation of glucose by OWOB may be as a 
consequence of reduced uptake, possibly due to reduced expression of GLUT 
transporters. Differences between GLUT-1 expression and glucose uptake have been 
reported in bovine embryos and positively correlated to glucose uptake (Garcia-
Herreros et al., 2012), however this has not previously been studied in relation to 
maternal BMI. 
 
A lower oxidative utilisation of glucose, due to reduced capacity for oxidative 
phosphorylation is one possibility for the lower rates of glucose consumption among 
embryos originated from OWOB women – but glycolysis was the same in both groups 
(60%). One explanation for this might be a reliance on fatty acids to support ATP 
synthesis. Randle et al.,(1963) proposed a mechanism by which fatty acids may inhibit 
glycolysis. From the oocyte studies in chapter 4, it was suggested that the oocytes from 
OWOB, produced in a hyperlipid environment, have higher amounts of triglyceride, this 
was proven to be the case here in embryos. The fatty acid composition of high and low 
quality oocytes is reported to differ, lower quality oocytes containing more saturated 
fatty acids (Aardema et al., 2011), the metabolism of saturated fatty acids being linked 
to higher rates of developmental arrest. A consequence of the higher fatty acid 
composition could be higher levels of beta-oxidation.  According to Randle’s 
hypothesis this leads to increased levels of acetyl co A and citrate.  Accumulation of 
citrate inhibits phosphofructokinase, leading to accumulation of glucose-6-phosphate, 
decreased hexokinase activity and ultimately less glucose metabolism and in turn, 
uptake (mechanism reviewed by Hue et al., 2009). In support of this theory are the 
findings of Van Hoeck et al (2011), who reported that bovine oocytes matured in 
medium containing high concentrations of non-esterified fatty acids, had lower glucose 
consumption than those cultured under control conditions. 
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The proposition of increased fatty acid oxidation is also in-line with the reports of 
mitochondrial dysfunction in oocytes from insulin resistant rodent models (discussed in 
chapter 4; work of Igosheva et al., 2010; Wang et al., 2009). Compromised 
mitochondrial function and substrate transition are likely to impair the viability of 
embryos generated from OWOB. Figure 5.25, illustrates how these proposals may be 
linked.  
 
Figure 5.25 Possible mechanism linking lower glucose consumption and higher triglyceride content of 
embryos from OWOB women (Figure adapted from McKeegan, 2015 and Smith & Sturmey 2013).  
 
5.4.4 Utilisation of endogenous triglyceride stores 
This is the first quantitative measure of the triglyceride content in human blastocysts, 
which was significantly lower than that observed in the domestic species (Ferguson and 
Leese, 1999; Sturmey & Leese, 2003; Sturmey et al., 2009). Total endogenous 
triglyceride concentrations were lower in embryos that successfully developed to the 
blastocyst stage. Moreover blastocysts derived from oocytes of overweight and obese 
patients contained significantly elevated levels of endogenous triglyceride. It is unlikely 
that de novo synthesis of fatty acid occurs in the embryo, although this cannot be 
discounted; it is more likely that oocytes present in the lipid-rich follicles of overweight 
and obese women accumulate triglycerides from the surrounding environment as 
reported by Aardema et al. (2011) and Ferguson and Leese (1999) for domestic species. 
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Since all embryos were cultured in equivalent conditions in vitro, the apparent retention 
of triglyceride observed in embryos originating from OWOB women most likely 
originates from the period of oocyte development.  
 
Depletion of endogenous lipid stores are evident during maturation; triglyceride stores 
are reduced in bovine and porcine oocytes (Ferguson & Leese, 1999; Sturmey & Leese, 
2003) and lipase activityis increased (Cetica et al., 2002), likewise it is reported that 
beta-oxidation increases in cumulus-oocyte-complexes, (Dunning et al., 2010). Activity 
then remains constant, until the blastocyst stage, when there is a 5-fold increase in beta-
oxidation (Hillman & Flynn, 1980). When beta-oxidation is inhibited, oocyte 
developmental competence is reduced (Ferguson & Leese, 2006; Sturmey et al., 2006; 
Dunning et al., 2010), as is blastocyst development (Hewitson et al., 1996; Ferguson 
and Leese, 2006; Dunning et al., 2010). This bovine/porcine data support the theory that 
endogenous lipid stores are being utilized during development and suggests that 
triglyceride is being broken down into acetyl units by beta-oxidation and utilised as a 
source of energy. 
 
It can be implied from the animal data and from the hitherto overlooked aspect of 
human embryo metabolism of endogenous energy stores that oocyte triglyceride levels 
are reflective of the prior environmental conditions and an optimum level of 
accumulation is required for viability. Exposure to high levels of lipid in the follicle 
may result in lipotoxicity (Wu et al., 2011); studies in mice show that dietary induced 
obesity results in embryos with a higher lipid content than normal weight controls and 
evidence of endoplasmic reticulum stress, mitochondrial disfunction and apoptosis. The 
exposure of bovine oocytes to a high-fat environment during final maturation reduces 
embryo viability post fertilisation, changes the expression of key metabolic genes and 
modifies metabolic activity in the resulting blastocysts (Van Hoeck et al., 2011). 
Increased lipid accumulation has been shown in the embryos of high yielding diary 
cows (Leroy et al., 2005) and also in the embryos of diabetic rats (Sinner et al., 2003). 
In each model energy and lipid metabolism is disturbed, indicating a mechanism by 
which obesity may impact on embryo viability. 
 
5.4.5 Amino acid turnover  
The measurement of turnover of a variety of amino acids may provide information that 
can be combined to form an index that can serve as a measure of embryo viability 
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(Brison et al., 2004).  Accordingly, here it has been shown that measurements of amino 
acid metabolism have provided a more convincing association between blastocyst 
development and pregnancy outcome than those of glucose and pyruvate. Houghton et 
al., (2002) reported that blastocyst formation could be predicted by alanine, arginine, 
glutamine, methionine and asparagine turnover between days 2-3, while Brison et al 
2004 reported that pregnancy could be predicted by asparagine, glycine and leucine 
measured between days 1-2. Similar profiles of amino acid depletion/ appearance have 
been reported in the present study and shown that blastocyst development and 
pregnancy outcome could be predicted by differences in the turnover of asparagine, 
glutamate and alanine.   
 
The embryos of overweight and obese women consumed and produced a number of 
amino acids in increased quantities, compared with counterparts from women of a 
normal BMI, further pointing to a degree of alteration of metabolic regulation.  
Glutamate production was significantly higher in embryos produced from OWOB 
compared to those of normal weight, consistent with the results for poorer blastocyst 
development and lower pregnancy rates across the cohort. Increased glutamate may be 
produced under stress conditions, as shown by Picton et al., 2010. The increase may be 
an attempt to neutralise increased ammonia produced by these embryos as shown in the 
mouse (Orsi & Leese 2004). In addition aspartate production and serine and glutamine 
depletion were greater, whilst less isoleucine was depleted by embryos from OWOB 
compared to normal weight women. The increased appearance of aspartate and 
glutamate in embryos from OWOB women might be indicative of a disrupted malate-
aspartate shuttle, which is involved in regulating glucose metabolism in mouse 
blastocysts (Mitchell et al., 2009), and has a further function in regulating the REDOX 
status of the cytosol.  
 
The present study also sought to identify differences between expanding and hatching 
human blastocysts and those blastocysts that arrest at the unexpanded stage. Histidine 
production was higher in developing blastocysts and may reflect a possible role in 
signalling to the uterus to aid implantation (Zhao et al., 2000). Arginine consumption 
was high in arrested embryos, while consumption fell in those forming unexpanded 
blastocysts, before rising again in expanded blastocysts, at which point it may play an 
important role in signalling via the nitric oxide pathway and in the establishment of a 
pregnancy (Sengupta et al., 2005). Methionine consumption was significantly higher in 
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those blastocysts capable of expanding, and this difference was exaggerated in 
blastocysts from OWOB women. This is potentially significantly since methionine is 
involved in the metabolic regulation of nucleotide synthesis (Gilbody et al., 2007) and 
DNA methylation (Grillo & Colombatto, 2008); these processes are likely to be 
important up to the stage of blastocyst expansion which coincides with the end of DNA 
demethylation and loss of histone modifications and the onset of methylation (Feng et 
al., 2010). 
 
The general rise in amino acid turnover prior to arrest may be indicative of lower 
embryo viability; an elevation in metabolic activity has been correlated with molecular 
damage (Sturmey et al 2009a). At the other end of the spectrum, an inadequate 
metabolism of amino acids leads to a delay in trophectoderm development through an 
mammalian target of rapamycin (mTOR)-dependent pathway (Martin & Sutherland, 
2001). Given that a reduction in TE cells was observed in the embryos from OWOB 
patients, and altered amino acid metabolism, it is tempting to speculate that there is 
some degree of disruption to the mTOR signalling in these blastocysts.  
 
5.4.6 The influence of paternal factors on embryo metabolism 
It is assumed that the origin of the combined metabolic alterations observed in this 
study can be linked to the environment within the ovary. A caveat to this assumption is 
that the male partners of the women in the OWOB category also had a significantly 
higher BMI. There is good evidence that male obesity can indeed impact on fertility and 
embryo viability (Bakos et al., 2011). Notably, earlier in this thesis lower rates of 
blastocyst formation on day 5 of development were noted among weight-discordant 
couples attending for fertility treatment in whom only the male had a BMI>25kg/m2. 
However, the impact of male BMI on embryo metabolic markers was negligible. Thus, 
there was no significant difference in CORE values when data from embryos were 
stratified according to male BMI and secondly the results of the statistical model 
suggest that embryo metabolism was independent of male BMI. It was fortuitous that a 
cohort of six patients who received donor semen from a single donor were identified, 
allowing a significant negative correlation to be revealed between mean glucose 
consumption of blastocysts and female BMI, when the male contribution was controlled 
for.  
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The role of the paternal influence raised an additional question about the use of ICSI, 
with a disproportionate number of ICSI cases being performed in instances when the 
male partner was classified as OWOB (although not significantly different if female 
BMI is used as the denominator). ICSI adds two possible confounding variables; firstly 
reduced sperm quality is associated with increased risk of sperm DNA damage (Dupont 
et al., 2013) and secondly in vitro handling techniques may compromise embryo 
viability, resulting in epigenetic changes and/or metabolic deregulation (Thompson et 
al., 2002). Whilst, there we no differences in carbohydrate metabolism or triglyceride 
levels in embryos generated via either technique amino acid metabolism was 
significantly higher in the ICSI group compared to the IVF group. When attention was 
turned to sibling oocyte studies, no significant differences were observed in metabolic 
phenotype of embryos generated through either IVF or ICSI. Hence, the resolution to 
this quandary would appear to be that the prior observed differences related more to 
semen quality than the ICSI procedure per-se. Given then that in the current study, the 
role of micromanipulation technique has been excluded and all other embryos culture 
conditions were equivalent, it can be concluded that the origins of the altered amino 
acid metabolism in human blastocysts from overweight women can be traced back to 
conditions in the ovary.  
 
5.4.7 Embryo metabolism and pregnancy outcome 
Despite the differences in substrate utilisation between normal and OWOB women the 
relationship with pregnancy outcome was not clear.  The data comparing metabolic 
parameters to the pregnancy outcome of the sibling transferred embryos highlighted the 
differences in developmental potential apparent in a cohort of embryos; a potential 
weakness of using the woman as the ‘experimental unit’ as opposed to individual 
embryos. This assumes that the intra-follicular conditions were comparable in the 
ovaries of a given patient. However, even in follicles of comparable size, the degree of 
vascularization, oxygenation and level of nutrients vary at the time of ovum retrieval 
(reviewed by Van Blerkom, 2000). The more subtle differences in metabolic regulation 
and developmental competence of individual embryos could be attributed to these 
differences and further studies are required on the origin of intra-follicular influences. 
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5.5 Conclusion 
 
Studies on the consequences of maternal obesity have largely focused on clinical 
complications for the mother during pregnancy and on offspring health, short- and long-
term. Owing to the complexities in working with human embryos and scarcity of 
material, much research on the impact of obesity on early development has been carried 
out in experimental animals (Luzzo et al., 2012; Van Hoeck et al., 2011; Moley et al., 
1991,). Such data suggest that the early embryo is especially sensitive to nutritional and 
environmental challenges during the periconceptional period. Recent research efforts 
have begun to characterize the ‘re-programming’ that occurs at this time, and the 
consequences for future development. Deviations in fetal growth rates and incidence of 
fetal abnormalities permit some inferences to be made about the impact of early 
embryonic adaptations to metabolic adversity. Here it was reported that babies born to 
OWOB women were significantly larger for gestational age than those born to women 
of normal weight. Weak associations were evident between birth weight and level of 
metabolic deregulation, again highlighting the complexities of using the woman as the 
‘experimental unit’ rather than individual embryos. What can however be deduced is 
that maternal overweight or obesity acts via the ovary to alter the phenotype of the 
oocyte. These alterations persist in the zygote and manifest as a disrupted metabolism at 
the blastocyst stage with the potential to compromise subsequent embryonic and fetal 
growth. The consequences of such phenotypic modifications is unclear, but could 
impact on the longterm development of non-communicable diseases, including cancer 
(Walker et al., 2012) cardiovascular disease and diabetes, the aetiology of which are 
considered to have a developmental component (Hanson et al., 2011). 
 
The data generated in this chapter adds to the developing picture (Figure 5.26, below) of 
accumulating evidence of an association between obesity and poorer pregnancy 
outcomes. In chapter 3, lower oocyte recovery rates and live birth rates for OWOB 
women were demonstrated and chapter 4 described phenotypic differences in oocytes 
and resulting blastocysts. Here very clear differences in embryo metabolism are 
recorded for embryos generated from OWOB women compared to normal women. 
Even allowing for the observed differences in blastocyst formation (i.e. proportion 
arresting / rate of progression) and subsequent reduced allocation of cells to each 
lineage, these metabolic differences were evident and independently related to female 
BMI.  
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Figure 5.26 Hypothetical impact of maternal obesity- developing picture. 
 
The molecular mechanism by which intra-follicular conditions modify the oocyte and 
subsequent embryo metabolism is still unclear, but it is considered highly significant 
that bovine oocytes exposed to fatty acids at concentrations found in human ovarian 
follicles (Robker et al., 2009; Valckx et al., 2012) display reduced glucose consumption 
in the subsequent blastocysts (Van Hoeck et al., 2011) as in the present study. 
Blastocyst formation is clearly dependent on the utilisation of glucose and the 
observation of decreased utilisation of glucose at each stage of development for 
embryos from OWOB women is consistent with this. It may be possible to stimulate 
increased glucose uptake and/or metabolism, by manipulating the in vitro environment 
and this will be reviewed in the following chapter. 
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Chapter 6 : Modulating the metabolism of oocytes and 
embryos. 
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6.1 Introduction 
 
In Chapter 5 it was reported that embryos generated from OWOB women display 
significant differences in the utilisation of substrates from the culture medium compared 
to normal weight controls. In Chapter 2 it was reported that the general pattern of 
substrate utilization and viability is largely comparable among a cohort of developing 
sibling embryos belonging to a couple and it was further reported in Chapter 3 that the 
pattern of nutrient utilization is comparable in subsequent cycles of treatment in the 
same couples. Weight loss may be one way in which the nutrient enriched follicular 
environment may be modulated- however as already discussed this is a long term 
commitment and the benefits may be offset by advanced maternal age. A alternative 
approach is to investigate the possibility of driving embryo metabolic uptake / substrate 
utilization to correct the observed aberrant patterns of metabolism in embryos generated 
from OWOB women in vitro using tailored specific culture conditions to meet the 
optimal needs for development. 
 
Adding different compounds to the culture medium may lead the embryo to utilize a 
particular substrate and / or metabolic pathway. Given the observed findings for lower 
glucose consumption and higher triglyceride levels in embryos from OWOB women it 
would seem prudent to attempt to correct this pattern of metabolism; the effects of 
adding insulin and l-carnitine (LC) will be considered in further detail in this chapter.  
 
6.1.1 Glucose manipulation 
Rodent studies have shown that hyperglycemia may compromise blastocyst 
development, by causing down regulation of glucose transporters leading to abnormal 
metabolism and apoptosis (Moley et al., 1998, Chi et al., 2000).  
 
Purcell et al., (2009) provided a succinct account of glucose uptake by preimplantation 
embryos through a large family of glucose transporters, the expression of which is 
related to the glucose concentration in the environment (summarised in Table 6.1). 
Glucose can be actively taken up by sodium coupled active glucose transporters 
(SGLTs) or through facilitative glucose transporters (GLUTs). Most uptake is 
facilitative (Gardner & Leese 1988), mediated by GLUT family of transporters, of 
which there are 14 characterised members (Zhao et al., 2007).  
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Table 6.1 GLUT detected transporter expression in the preimplantation embryo.  
Transporter Expression 
GLUT1 mRNA has been detected between the oocyte and blastocyst stage in 
mouse (Hogan et al., 1991; Morita et al., 1992; Pantaleon et al., 2001), 
bovine (Lequarre et al., 1997) and human embryos (Dan Goor et al., 
1997). 
GLUT2 Located on the basolateral membrane side and present from the 8-cell 
onwards in mice (Hogan et al., 1991) 
GLUT3 Expression evident from compaction onwards in mice (Purcell et al., 
2009) 
GLUT4  Hogan et al., (1991) reported that it is not expressed at any stage in mouse 
embryos, whereas others have detected expression from the 8-cell in both 
mouse and human embryos (Dan Goor et al., 1997) and in bovine 
blastocysts (Navarete Santos et al., 2000). Under insulin stimulation 
GLUT4 is rapidly translocated from an intracellular location to the cell 
surface plasma membrane, thus rapidly increasing glucose transport 
(Gonzalez et al., 2006). 
GLUT8 This transporter has been shown to account for insulin responsive 
transport in the mouse blastocyst (Carayannopoulos et al., 2000), 
although these findings have not been reproduced in other studies 
(Tonack et al., 2009). 
 
Insulin signals through the insulin receptor (IR) and additionally through binding with 
lower affinity to the structurally similar, insulin-like growth factor-I (IGF-1) receptor. 
The IR and IGF-1 receptor have both been detected in the preimplantation embryos of 
many species, including; murine (Rappolee et al., 1992) bovine (Schultz et al., 1993) 
and human (Lighten et al., 1997). IR gene expression can be detected from 8-cell 
onwards, when the embryo begins glycoltyic metabolism (Harvey & Kayne 1991) and 
IGF-1 expression has been localised to the surface of the trophectoderm (Heyner et al., 
1989). It is thought that insulin binding to the IR regulates glucose uptake in the embryo 
via the PI3K/ Akt pathway, resulting in GLUT4 trafficking and transport activity, as is 
the case in adult cells (Figure 6.1).  
 
At the systemic/ whole body level, insulin resistance can arise due to chronic 
environmental exposure to hyperglycemia, but as it is still to be conclusively shown that 
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human preimplantation embryos express GLUT4, the action of insulin and any possible 
mode of insulin resistance in the preimplantation embryo are speculative. 
Immunohistochemical studies have shown that insulin is internalized by preimplantation 
mouse embryos (Hayner et al., 1989), although increased glucose uptake in response to 
insulin maybe acting through the IGF-1 receptor and not the IR (Pantaleon & Kaye 
1996). The IGF-1 receptor is present in granulosa cells in human oocytes (Zhou et al., 
1993), insulin and IGF-1 may act through this receptor to affect cell proliferation and 
metabolism via altered gene expression (Figure 6.1). 
 
An alternative explanation for insulin’s beneficial effects on embryo development is 
through its action as a growth factor. In support of this, insulin has been reported to 
have anabolic and proliferative effects on the early mouse embryo and its addition to the 
culture medium, increased cell numbers and morphological development (Gardner & 
Kaye, 1991). Furthermore insulin was shown to stimulate amino acid transport and 
protein synthesis (Figure 6.1), via insulin receptors present on cells of the ICM and TE 
(Harvey & Kaye, 1990). 
 
Figure 6.1Schematic of insulin signalling-  
through insulin receptor (IR) and insulin-like growth factor-I (IGF-1) receptor and its possible regulation 
of glucose homeostasis, gene expression, cellular proliferation, survival and protein synthesis. In the case 
of glucose regulation it is possible that if human pre-implantation embryos do express GLUT 4 insulin 
regulates this expression by binding to its receptor, a tyrosine kinase, which phoshorylates (P) IRSs, 
which is then able to bind PI3K, which phoshorylates PIP2 to PIP3 which can be bound to PDK-1 and 
Akt. Active Akt can initiate translocation of GLUT 4.  
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6.1.2 Lipid manipulation 
The triglyceride (TG) content of embryos was shown in the previous section, to be 
significantly higher in embryos generated from OWOB compared to normal weight 
controls. Strikingly, embryos arresting at the cleavage stages of development had a 
higher triglyceride content than those arresting at the blastocyst stage. These findings 
imply two things; firstly that endogenous stores of lipid are influenced by maternal 
environment and secondly that the embryo may use endogenous stores as an energy 
source during preimplantation development. If this is indeed the case it was thought that 
endogenous stores of lipids could be manipulated by stimulating β-oxidation during in 
vitro culture using l-carnitine (LC), which might improve embryo viability. 
 
It is thought that endogenous lipid stores accumulate during oocyte development and 
are subsequently modified during the final stages of oocyte maturation (Ferguson & 
Leese 1999). When bovine zygotes were cultured in medium lacking exogenous 
substrates, but supplemented with LC, the rates of blastocyst formation were higher 
than those of the control group (Sutton-McDowall et al., 2012). Whilst the endogenous 
lipid stores of bovine embryos are considerably higher than those reported earlier in the 
human (Chapter 5), the reduced triglyceride content that was observed in those embryos 
which formed blastocysts is suggestive of a vital role for β-oxidation of TG during 
embryo development providing a target for manipulation.  
 
Endogenous long-chain fatty acids are metabolised in the matrix of mitochondria. LC is 
essential for normal mitochondrial activity; usage affects ATP levels, which in turn 
influences an oocyte’s developmental capacity (Stojkovic et al., 2001). In the zygote, 
LC increases the transport of fatty acids into mitochondria and thus increases β-
oxidation of fatty acids into acetyl-CoA molecules, for metabolism in the TCA cycle 
and ETC to produce ATP (Van & Wanders, 2002). The initial transport of cytosolic 
fatty acids into the mitochondria, is the rate limiting step and this is catalyzed by 
carnitine palmitoyltransferase-IB (CPTIB). This enzyme transesterifes fatty acids in the 
form of fatty acyl-CoA to LC. Fatty acyl-carnitine then passes through the outer 
mitochondrial membrane, before being transported into the matrix by carnitine-
acylcarnitine translocase (CACT). Subsequently, CPTII then transesterifies the fatty 
acids to mitochondrial CoA and LC is released and recycled by CACT back to the 
cytosol. In the mitochondrial matrix, β-oxidation results in the conversion of acyl-CoA 
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to acetyl-CoA, which can then be metabolised further in the TCA cycle and oxidative 
phosphorylation to generate ATP.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2 Action of LC- 
Free fatty acids (FFA) linked to coenzyme A at the outer mitochondrial membrane are activated. Fatty 
acyl-CoA then binds to LC, catalysed by CPTBI and is translocated across the inner mitochondrial 
membrane for β-oxidation. (Figure, reproduced with permission of R. Sturmey, 2004) 
 
LC is the biologically active stereoisomer and in humans, 75% of LC is obtained from 
the diet. However, LC may also be synthesised from the amino acids lysine and 
methionine, in the kidney, liver and brain (reviewed by Flanagan et al., 2010). It is not 
clear if embryos have the capacity to synthesis carnitine, or if they must acquire it from 
the follicular / oviductal fluid. LC is present at a comparable concentration of 
approximately 29µmol/l, in serum and follicular fluid of women undergoing IVF 
treatment (Valckx et al., 2012). The presence of LC in the follicular environment 
provides justification for investigating its role in modulating embryo development. In 
this chapter, LC was adding it to culture medium at a range of concentrations from 
0.005mM to 0.5Mm to determine if human embryos take up LC from the medium and 
what effect this has on embryo viability. 
 
Despite a number of studies into the effect of LC supplementation, in murine (Pillich et 
al., 2005; Abdelrazik et al., 2009), bovine (Phongnimitr et al., 2012; Sutton-McDowall 
et al., 2012) and porcine species (Somfai et al., 2011; Wu et al., 2011), the impact of LC 
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supplementation on overall embryo metabolism has yet to be addressed, particularly in 
reference to female obesity.  
 
6.1.3 Lipid content and manipulation of frozen, thawed embryos 
Embryo cryopreservation is an integral part of ART. The post thaw survival and 
viability may differ to those of fresh embryos and few studies have sought to 
investigate, beyond comparisons of pregnancy, live birth rates and neonatal outcomes. 
 
Cryopreservation may cause cellular damage, affecting membrane permeability and 
cytoskeletal structure. In this study all donated embryos had been slow-frozen and 
therefore findings have been related to studies using this method. Slow freezing has 
been associated with altered gene expression profiles (Tachataki et al., 2003), compared 
to fresh embryos; this was speculated to relate to the level of cellular trauma. Similarly, 
the uptake of pyruvate from day 3 embryos has been shown to be lower from slow 
frozen embryos with poorer post-thaw viability (Balabon et al., 2008), as has the 
oxygen consumption (Kaidi et al., 2001), when compared to those displaying better post 
thaw morphology. In one of the few studies to examine amino acid turn-over in human 
embryos, Stokes et al (2007) conducted their analysis on embryos which had previously 
been cryopreserved and it was noted that the thawed embryos had a similar amino acid 
metabolism to those of fresh, however other investigators have reported that the 
findings may be related to the period of recovery. Fang et al., (2013), demonstrated that 
the amino acid turnover in the first half an hour post thawing was significantly lower 
than that reported in the following hour, before returning to pre-freeze levels, 
suggesting that there is a recovery period. It has been speculated that the disruption of 
the cytoplasmic microstructure may influence metabolism. The level of disruption may 
be influenced by the intracellular lipid content of the embryo and lipid composition of 
membranes.  
 
The membrane lipid composition affects a cell’s behaviour after temperature changes, 
with phospholipids being the most abundant lipids in eukaryotic cell membranes. 
Adding linoleic acid to bovine embryo culture medium has been shown to enhance 
cryosurvival of embryos (Pereira et al., 2007), whereas supplementation with palmitic 
acid has a negative effect on embryo cryosurvial (Shehab-El-Deen et al., 2009). 
Cytoplasmic lipid accumulation will also affect post thaw survival, as demonstrated in 
bovine embryos (George et al., 2008) and environmental conditions can cause changes 
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to lipid metabolism (Abe et al., 2003, Dinnyes et al., 2009, Barcelo-Fimbres et al., 2007, 
Orsi et al., 2004). Large amounts of intracellular lipids can compromise embryo quality 
through impaired mitochondrial function (Abe et al., 2002), as demonstrated in bovine 
embryos cultured using serum free or serum containing media. A greater content of 
intracellular lipids increases their sensitivity to oxidative stress and may lead to 
increased free radical generation and increased cell death.  
 
It is widely reported that lipid accumulation can aggravate cryo-injury in porcine and 
bovine- but these species have a higher embryo lipid content than the human. In chapter 
3 lower rates of cryosurvival were reported for blastocysts from OWOB women 
compared to normal women which were speculated to be due to differences in 
triglyceride content. In this chapter this concept was tested.  
 
Sufficient ATP production is required for embryo development and cryopreservation 
has been reported to damage mitochondria leading to ATP losses (Manipalviratn et al., 
2011, Zhao et al., 2011). Lipid droplets are a rich source of energy and LC is reported to 
enhance lipid metabolism and thus ATP production, with this in mind LC was added to 
the culture medium to evaluate the effects on post- thaw metabolism in embryos from 
normal and OWOB women.  
 
6.1.4 Intralipid therapy 
In the course of this study, it came to light that a small number of the participants, who 
had had a previous implantation failure received intralipid infusions (20%-100ml). 
Intralipid is generally administered between days 4 and 9 of ovarian stimulation, and 
again around the time of embryo transfer, with a 3rd dose being administered 
immediately after a positive pregnancy test result. Intravenous infusion with intralipid, 
which is a soybean oil based source of essential free fatty acids; linolenic and linoleic 
acid, purified egg phospholipids and glycerol has been promoted by a number of 
clinicians for use as an immunotherapy aimed at improving IVF pregnancy rates 
(Shreeve & Sadek, 2012; Coulam et al., 2009, Ndukwe et al., 2011). Intralipid has no 
known long-term effects and reports of adverse reactions are rare – however, substantial 
data sets are lacking and the mechanisms by which intralipid may modulate the immune 
system are unclear. It has been postulated that patients with unexpected failed 
implantation or recurrent miscarriage may have abnormal maternal Natural killer (NK) 
cell levels and functional cytotoxic activity against the embryo (Kwak-Kim & Gilman-
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Sachs, 2008; Matsubayashi et al., 2001). Intralipid reportedly has NK cell suppressive 
properties (Coulam et al., 2009) and it is hypothesized that this will reduce immune 
mediated damage to the embryo (Bansal et al., 2012).  It is not known if such 
administration alters the fatty acid profile of the follicular fluid and as such the possible 
effects on embryo metabolism have thus far been overlooked. In a number of cases 
embryo metabolic data from the patients previous failed treatment cycle were also 
available– thus permitting an informative, albeit an under-power assessment of this 
treatment intervention for both normal and OWOB women. Furthermore, as obesity is 
also a chronic inflammatory condition and intralipids reportedly also have inhibitory 
effects on pro-inflamatory factors, such as Th1 cytokines (Granato et al., 2000), the 
effects of intralipid administration have been compared in normal and OWOB women.  
 
Aims and objectives  
The aim of this chapter was to examine the effect of supplementation of the culture 
medium with insulin and LC on human embryo metabolism and development.  
 
The specific objectives were; 
a) To examine the effects of modulating the in vitro culture environment by 
studying the effect of addition of insulin on embryo development and 
metabolism.  
b) To discover if the addition of LC to the culture medium altered the embryo 
development rate of frozen thawed embryos. 
c) To discover if the addition of LC to the culture medium altered embryo 
metabolism and utilisation of triglyceride. 
d) To review data from patients receiving intralipid therapy and consider a 
potential relationship with embryo metabolism and female BMI.  
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6.2 Materials and methods 
 
6.2.1 Patient recruitment 
IVF patients were consented and recruited to the study as described in chapter 2. A total 
of 101 consecutive patients presenting for IVF at the Hull IVF Unit donated a total of 
451 embryos with full informed consent and a further 25 patients donated 105 frozen 
embryos no longer required for treatment.  Female and male BMI were recorded at the 
down-regulation appointment and at the commencement of treatment. Embryos that 
originated from patients classified as OWOB (BMI > 25 kg/m2) were compared with 
embryos derived from women of normal BMI (18.5–24.9 kg/m2). The study groups 
being discussed in this chapter are highlighted below. 
 
 
 
 
 
Figure 6.3 Source of study group- from prospective data, collected from women contributing to the 
primary research project from 2010 to 2015. 
 
 
Study groups
(a) Fresh
(b) Frozen – 0.5mM 
Carnitine; n= 26 patients 
106 embryos
1. Basic
n= 29 patients, 150 
embryos
2. Insulin
n= 37 patients, 149 
embryos
3. Carnitine
i. 0.005mM; n= 19 
patients, 94 
embryos
ii. 0.05mM; n= 20 
patients, 109 
embryos
iii. 0.5mM; n= 26 
patients, 99 
embryos
4. Repeats
I. Basic/ basic conditions n=6 patients, 48 embryos
II. Insulin / basic conditions n=7 patients, 56 embryos
III. Carnitine / basic conditions n=2 patients, 27 embryos
IV. Insulin / Carnitine conditions n= 4 patients, 35 embryos
V. ICSI partner sperm / IVF donor sperm n= 2 patients, 45 embryos 
0. Validation studies
I. Primo analysis  n= 
4 patients, 23 
embryos
II. Donor sperm n= 6 
patients, 25 
embryos
III. Split IVF/ ICSI n= 7 
patients , 50 
embryos
IV. Dif ferential cell 
count/ diameter 
study n= 16 
patients, 44 
embryos
V. Intralipid treatment 
n= 5, 34 embryos
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6.2.2 Experimental methods 
The experimental methods used to generate metabolic profiles were mainly ‘non-
invasive’ and provide quantitative markers of embryo health. 
 
As described in chapters 2 and 5 surplus embryos donated to research had their 
development stage recorded before being placed individually into 4 ml culture drops. 
The following protocol differences were implemented; 
1. Embryos were cultured under Sage Oil at 370C in 6% CO2 and 5% O2 for 24 
hours, alongside embryo-free control drops. This differs to chapter 5 and due to 
an improvement to research equipment facilities means that embryos were 
cultured in-vitro under the same low oxygen conditions, whilst in both clinical 
and research facilities. 
2. Observations were ended on day 7, rather than day 9 – to permit increased 
consistency in analysis and observations and on the basis of findings discussed 
in chapter 5. 
3. Insulin was added to the culture medium and embryos donated (n= 149) from 
each patient (n=37) in this portion of the study, were randomly assigned to ‘test’ 
and ‘standard’ media droplets. (Working solution details are provided below). 
4.  L-C was added to the culture medium at three different concentrations 
(0.005mM, 0.05mM and 0.5mM) and embryos donated (n= 302) from each 
patient (n=65) in this portion of the study, were randomly assigned to ‘test’ and 
‘standard’ media droplets (see Figure 6.3 and 6.4 for further details). (Working 
solution details are provided below). 
5. Frozen embryos that had been donated to research, were thawed using a 
commercial slow thaw protocol (Origio) and placed in to individual culture 
droplets.  LC was added to the culture medium (0.5mM) and embryos donated 
(n= 105) from each patient (n=26) in this portion of the study, were randomly 
assigned to ‘test’ and ‘standard’ media droplets. Pre-freeze development was 
recorded, as was post thaw development / survival.! !Development was recorded 
throughout the extended culture, until day 7. !
!
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Figure 6.4 Micro-droplet culture set up.  
Embryos from each individual patient were randomly divided among ‘test’ (i.e. addition of Insulin or LC, 
dependent on study protocol) and ‘standard’ research culture medium. 
 
As stated previously, culture droplets were refreshed every 24 hours and developmental 
observations made each day up to termination of culture. After incubation, the spent 
culture medium was immediately frozen at -800C for later analysis. Metabolic CORE 
profiles were determined for glucose, pyruvate, lactate and 18 amino acids, and TG 
content was measured, all as previously described. Results were recorded according to 
stage reached at the end of the period of culture. Full details of each method are 
provided in Chapter 2, however the following protocol deviations were applied; 
1. Embryos included in the insulin assessment protocol (test and standard) were 
placed into RNA later, for future research use and in view of this, no TG 
analyses have been performed on these embryos.  
2. Embryos included in the LC assessment protocol were assayed for carnitine 
consumption (details given below) and therefore amino acid CORE was not 
measured.  
 
6.2.3 Addition of Insulin to the culture medium 
A stock solution of insulin was prepared using sterile water and was serially diluted and 
added to culture medium to create a working solution of 0.5ng/ml. 
 
 
 
 
 
 
  
    
    
Embryo 
culture 
droplet
Wash 
droplets 
Control 
droplets 
‘Test’ ‘Standard’ 
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Table 6.2 Insulin supplementation protocol.  
Final concentration 0.5ng/ml 
 
 
 
 
 
 
 
 
 
 
6.2.4 Culture of embryos in the presence of L-Carnitine 
A 500m/mol stock solution of L-Carnitine (161.199g/mol, molecular weight) was 
prepared using sterile water and diluted in culture medium to create a working solution 
from 5mmol/l, from which dilutions ranging from 0.5 to 0.05m/mol were made. 
 
Table 6.3 LC supplementation protocol-to create 3 concentrations; 0.5, 0.05 and 0.005m/mol  
 
 
 
 
 
 
 
 
 
 
 
Embryos cultured in the presence and absence of LC were assayed for CORE glucose, 
pyruvate and lactate and at the end of the period of culture the triglyceride content of 
embryos cultured in LC supplemented and standard media droplets was determined as 
described in chapter 2. Additionally, spent culture medium was assayed to determine 
the consumption of LC using a scaled down version of the LC assay kit supplied by 
Abcam, UK.   
A) Stock solution  
mg / 1ml sterile water 
Insulin 5 (5mg/ml) 
B) Working solution 
µ l embryo culture medium 
5mg/ml Insulin 1000   (5µl/ml) 
5µl/ml Insulin 1000   (5ng/ml) 
5ng/ml Insulin 10       (0.5ng/ml) 
A) Stock solution (500m/mol) 
g / 10ml sterile water 
L-Carnitine  0.806 
B) Working solution 
µ l/ 1ml embryo culture medium 
500m/mol L-Carnitine  10 (5m/mol)* 
*5m/mol L-Carnitine 100 (0.5m/mol) 
*5m/mol L-Carnitine 10 (0.05m/mol) 
*5m/mol L-Carnitine 1 (0.005m/mol) 
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The assay was used to measure free LC in the culture medium. In the course of the 
assay reaction an acetyl group is transferred from CoA to carnitine to form 
acetylcarnitine.  
 
L-Carnitine + acetyl CoA –Carnitine acyltransferace→acetylcarnitine + CoA 
 
The free CoA is further processed and leads to the oxidation of the OxiRed probe to 
give fluorescence (Ex/Em 535nm 587nm) and absorbance at (570nm). 
 
A six point standard curve was established before each assay (r2>0.9), using LC 
standards in the range of 0- 1 m/mol- (0. 0.2, 0.4, 0.6, 0.8, 1.0 m/mol-1). Standards were 
prepared by diluting 1m/mol LC stock with assay buffer. Standards were prepared in 
triplicate.  
 
The reaction mix was prepared for each assay and consisted of assay buffer, carnitine 
converting enzyme, development mix and probe. Reactions were carried out in 96 well 
assay plates. 2.5µl of reaction mix was added to each well and the fluorescence was 
recorded. 2.5µl of standard (or sample, once a suitable standard curve had been 
established) was added to each well and after 30 minutes incubation the florescence was 
recorded.  
 
The amount of LC was calculated by relating changes in fluorescence to those given by 
the standards. The readings were corrected for background readings and blank culture 
droplets were also assayed to account for dilution effects during culture. 
 
6.2.5 Statistical Analysis 
The information from the metabolic profiling of spare embryos was compared for 
normal and OWOB patient groups and correlated to study endpoints: embryo cleavage 
development and blastocyst formation. ANOVA was used to assess intra and inter 
subject variability in combination with linear regression analysis to assess the predictive 
accuracy of metabolic profile on blastocyst development rate. Kruskal-Wallis one-way 
analysis of variance was used, when normal sample distributions were not evident.  Full 
details of the statistical analysis are included in Chapter 2. However additional tests/ 
calculations conducted included;  
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• The TG content of developing and early arresting embryos was compared 
using a 2 Sample t-test or Mann Whitney U test, if assumptions not met.  
• Blastocyst rates in the presence of (a) insulin or (b) LC are expressed as a 
percentage of the total number of embryos cultured and the data compared 
using a oneway ANOVA with Fisher’s or Tukey Test post-hoc.  
• Kruskal-Walis (2-sided, adjusted for tiers), with Bonferroni correction was 
used to rank patient BMI and development stage attained. It was also used to 
compare embryo development according to LC concentration in culture 
medium. 
• CORE profiles of embryos grown in the presence of (a) insulin or (b) LC 
were compared by oneway ANOVA with Fisher’s / Tukey post-hoc. General 
linear modeling was used to account for variations at different CORE levels 
in stage of development, between (a) BMI sub-groupings and (b) ‘test’ and 
‘standard’ culture medium. 
• Binominal logistic regression was used to predict blastocyst formation (1, 0), 
using the enter method coded predictor variables included; BMI (<24.9 =1 
and ≥ 25kg/m2 = 0) and culture medium (standard =1 and test =0). Cox and 
Snell R2 and Nagelkerke R2 were used to assess the goodness-of-fit and 
sensitivity / specificity. Wald test was used to determine the significance of 
independent variables and discover which variables added significantly to 
the model and predicted blastocyst formation. !
 Statistical differences at the 5% level were assumed to be significant. 
 
6.2.6 The study sub-groupings 
In the insulin study group a total of 76 embryos from 16 OWOB women and 73 
embryos from 21 normal weight women were assayed for CORE profile. The end point 
for the study was blastocyst development; of the supernumerary embryos donated to 
research 50 embryos had developed to form blastocysts (65.8%) by day 7 in the OWOB 
group compared to 26 (55.3%) from the normal weight group.  There were no 
differences in patient age and cycle number, but significant differences in male BMI 
have been appropriately controlled for in the multivariate statistical analyses. The 
details from the clinical treatment cycles are provided below, including embryo 
development of all embryos (transferred, frozen, donated to research). 
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Insulin!n=37!consecutive!IVF!&!ICSI!patients!
(±!SEM)! Normal!weight! OWOB! p!value!
Female!age!(years)! 31.86!(0.96)! 30.75!(1.04)! >0.05!
Male!age!(years)! 37.68!(1.74)! 36.64!(1.33)! >0.05!
Cycle!number! 1.43!(0.13)! 1.56!(0.18)! >0.05!
Female!BMI!(kg/m2)! 22.41!(0.40)! 27.54!(0.39)! <0.001!
Male!BMI!(kg/m2)! 24.76!(0.29)! 25.78!(0.35)! <0.05!
Av.!Oocytes! 10.38!(0.93)! 9.38!(0.94)! >0.05!
Av.!Embryos! 6.05!(0.43)! 6.25!(0.81)! >0.05!
Blastocyst!development!(%)! 32.48!(5.81)! 28.84!(7.79)! >0.05!
 
 
Figure 6.5a Schematic diagram of the study group, indicating patient numbers and demographics (values 
are±SEM). Shaded boxes indicate embryos included in the analysis. 
 
In the LC study group a total of 134 embryos from 32 OWOB women and 168 embryos 
from 33 normal weight women were assayed for CORE profile. Significant differences 
in male BMI have again been controlled for in the analysis and details below refer to the 
clinical treatment cycle data, further details of supernumerary embryo development are 
included in the results section.   
 
 
 
 
 
 
 
 
 
 
Insulin study 
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L8Carnitine!n=65!consecutive!IVF!&!ICSI!patients!
(±!SEM)! Normal!weight! OWOB! p!value!
Female!age!(years)! 33.67!(0.64)! 31.56!(0.88)! 0.06!
Male!age!(years)! 35.87!(0.96)! 35.76!(1.21)! >0.05!
Cycle!number! 1.55!(0.16)! 1.56!(0.16)! >0.05!
Female!BMI!(kg/m2)! 22.15!(0.28)! 27.68!(0.36)! <0.001!
Male!BMI!(kg/m2)! 24.64!(0.23)! 26.14!(0.26)! <0.01!
Av.!Oocytes! 11.23!(0.86)! 9.72!(0.58)! >0.05!
Av.!Embryos! 8.06!(0.68)! 6.81!(0.50)! >0.05!
Blastocyst!development!(%)! 44.64!(4.71)! 38.85!(5.29)! >0.05!
 
 
Figure 6.5b Schematic diagram of the study group, indicating patient numbers and demographics (values 
are ±SEM). Shaded boxes indicate embryos included in the analysis. 
 
In the frozen embryo study group a total of 27 embryos from 5 OWOB women and 79 
embryos from 21 normal weight women were assayed for CORE profile. Significant 
differences in male BMI have again been controlled for in the analysis and details 
below refer to the clinical treatment cycle data – from the fresh treatment cycle embryos 
originated from, further details of supernumerary embryo development are included in 
the results section.   
 
Frozen!cycles!(details!at!time!of!freeze)!n=26!consecutive!IVF!&!ICSI!patients!
(±!SEM)! Normal!weight! OWOB! p!value!
Female!age!(years)! 31.33!(1.01)! 31.60!(2.54)! >0.05!
Male!age!(years)! 35.00!(1.45)! 38.67!(1.76)! >0.05!
Cycle!number! 1.62!(0.26)! 1.20!(0.20)! >0.05!
Female!BMI!(kg/m2)! 22.50!(0.39)! 29.22!(1.55)! <0.001!
Male!BMI!(kg/m2)! 24.10!(0.36)! 26.80!(1.32)! <0.01!
Av.!Oocytes! 12.62!(1.05)! 12.40!(1.17)! >0.05!
Av.!Embryos! 9.38!(0.83)! 10.40!(1.44)! >0.05!
Blastocyst!development!(%)! 57.9!(6.67)! 45.56!(22.79)! >0.05!
 
 
L-Carnitine study 
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Figure 6.5c Schematic diagram of the study group, indicating patient numbers and demographics (values 
are ±SEM). Shaded boxes indicate embryos included in the analysis. 
 
In the course of this study it was discovered that a subset of 5 patients had been given 
intralipid therapy as part of their clinical treatment plan; two of whom were of normal 
weight and three OWOB. A total of 34 embryos (17 from each category) were donated 
to research post therapy and subject to assessment.  
 
 
 
Figure 6.5d Schematic diagram of the Intralipid sub-study group, indicating patient numbers. Shaded 
boxes indicate embryos included in the analysis. 
 
Figure 6.5 Overview of study groups (patient and embryo details)
Frozen embryos study 
Intralipid study 
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6.3 Results 
 
6.3.1The addition of insulin to the embryo culture medium 
Embryos from OWOB had a significantly lower glucose consumption 
(69.89pmol/emb/hr versus 96.70pmol/emb/hr) and no significant difference in lactate 
compared with embryos generated from normal weight women; consistent with the data 
in Chapter 5. Interestingly, significantly higher pyruvate consumption was evident for 
OWOB (38.12pmol/emb/hr) compared to embryos from normal weight women 
(30.56pmol/emb/hr) – a finding not consistent with that reported in Chapter 5. It is 
assumed that an equal number of embryos had been cultured under experimental ‘test’ 
(insulin) and ‘standard’ conditions in both BMI groupings (confirmed by one sample 
binominal test p=0.51). However, the proportion of embryos reaching the blastocyst 
stage donated by normal weight women was significantly lower at 55.3% (26/73) than 
the 65.8% (50/76) of embryos from OWOB women (p<0.01) reaching blastocyst 
formation by the end of the culture period. There was a trend for increased blastocyst 
formation when embryos were cultured in medium supplemented with insulin, 
particularly in the OWOB grouping (58.3% versus 72.3% BD for control and insulin 
experimental groups respectively). 
 
Table 6.4 CORE profiles for normal (n=21) and OWOB women (n=16) in insulin/ control groups. 
Glucose consumption was significantly lower in embryos from OWOB women (n=76) compared to those 
from normal weight women (n=73), conversely pyruvate consumption was significantly higher and there 
were no apparent differences in lactate production. 
 
Mean values  (±SEM) Normal 
weight  
OWOB F p-
value 
Glucose consumption 
(pmol/emb/hr) 
96.7 (6.4) 69.89 (3.1) 5.6 <0.01 
Lactate production 
(pmol/emb/hr) 
92.78 (4.3) 102.08 (4.6) 1.3 n/s 
Pyruvate consumption 
(pmol/emb/hr) 
30.56 (1.9) 38.12 (1.8) 2.9 <0.01 
 
There were significant differences in both glucose and pyruvate consumption at 
different stages of development. However when the data were further sub-classified to 
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include female BMI, significant differences remained apparent for glucose only 
(glucose f =2.6 p<0.01, pyruvate f=1.5 p=0.08). 
 
(a) 
(b)  
 
 
Figure 6.6 Glucose and pyruvate consumption according to stage of embryo development.  
Glucose consumption at different developmental stages was shown to be significantly altered (** p<0.01) 
when the data were stratified into normal and OWOB groupings (a); conversely differences in pyruvate 
consumption became less apparent after separation into BMI groupings (b).  
 
** 
** 
** 
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The addition of insulin (0.5ng/ml) to the culture medium resulted in no significant 
differences in glucose (p=0.71), lactate (p=0.48) or pyruvate consumption/ release 
(p=0.3), as determined by independent samples Mann-Whitney U Test and depicted in 
Figure 6.7.  
 
 
 
 
Figure 6.7 The effect of insulin supplementation on mean glucose, lactate and pyruvate metabolism by 
embryos (n=149) over days 5-7 of development. 
 
In both the normal and OWOB data sets there were no significant differences in 
glucose, lactate or pyruvate consumption/ release when embryos were cultured in 
medium supplemented with 0.5ng/ml insulin (Figure 6.8).  
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Figure 6.8 The effect of insulin supplementation on embryo metabolism in both the normal and OWOB 
groupings. 
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There was considerable variation amongst sibling embryo cohorts, with insulin addition 
resulting in both positive and negative effects in patients with differing BMIs, as 
illustrated here for both glucose and pyruvate (the two substrates found to be consumed 
in significantly different quantities in women of a BMI<24.9kg/m2 and those with a 
BMI >25kg/m2 in this dataset, as shown in Table 6.3). When the results were analysed 
as a continuous variable, rather than a categorical grouping; a weak negative 
relationship was evident for glucose and a positive trend for pyruvate metabolism and 
increasing female BMI was found. 
 
 
 
 
 
 
Figure 6.9 Intra-patient variability in substrate metabolism –according to embryo culture conditions 
(control and supplemented with insulin).  
Mean values are depicted for sibling embryos for each patient (connected line) and related to female BMI.   
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When the data were classified into stage of development, the addition of insulin was 
associated with significant differences in pyruvate consumption between those embryos 
forming hatched blastocysts and those arresting at the cleavage stage of development 
(f=0.26 p=0.045 ANOVA; Figure 6.10). The addition of insulin to the culture medium 
had no significant effect on CORE glucose (f=0.84 p=0.5) or lactate (f=0.25 p=0.9) at 
each developmental stage.  
 
 
 
 
 
 
Figure 6.10 Insulin and control culture conditions and pyruvate consumption. 
The addition of insulin to culture medium and pattern of uptake at each stage of development for embryos 
cultured from day 5-9 compared to that of sibling embryos cultured under standard conditions;  
significantly reduced pyruvate consumption was recorded for embryos arrested at both the cleavage and 
hatched blastocyst stage (* p<0.05).  
 
Further general linear modelling was conducted to test the between subject effects of 
female BMI, development stage and the addition / omission of insulin on CORE 
glucose, lactate and pyruvate metabolism. Manipulation of culture conditions did not 
result in a change in CORE glucose (p=0.63), lactate (p=0.77) or pyruvate (p=0.74) 
when other variables were accounted for (including male BMI).  
* 
* 
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The influence of insulin supplementation has on amino acid turnover was subsequently 
assessed according to general turnover and individual amino acid CORE values. Data 
were stratified to review the effects in embryos that had originated from normal and 
OWOB women   Significant differences were apparent in the amino acid turnover of 
embryos from women of normal BMI classification and those classified as OWOB 
(f=121.8 p<0.01); the cohort of embryos from normal weight women produced more 
amino acids than those attained from OWOB women, which depleted amino acids in 
higher quantities from the medium. The addition of insulin resulted in no significant 
difference in turnover (f=0.001 p=0.98). This was also the case when general linear 
modelling was used to assess the combined effects of insulin and BMI (f= 0.73 p=0.77). 
The data depicted in Figure 6.11 show the large confidence interval for embryos that 
originated from OWOB women and were cultured under control conditions, suggesting 
the precision associated with this measurement is low; this is suggestive of an 
inadequate sample size or that the data generated from CORE amino acid turnover are 
too variable to give a precise estimate.  
 
 
 
Figure 6.11 Insulin and control culture conditions and amino acid turnover. 
Average sums of amino acid production and depletion, expressed in pmoles/embryo/hour for day 5 to 7 of 
culture. Error bars represent 95% CI.  Results are recorded according culture conditions of sibling 
embryos; 39 embryos cultured in medium with insulin added and 34 in standard culture medium from 21 
women with a normal BMI. 40 embryos in insulin supplemented medium, 36 embryos in standard 
medium from 16 OWOB women. The 95% CI are indicated. 
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Differences in amino acid turnover were apparent for different developmental stages 
(f=253.0 p<0.01). The differences were not attributed to culture conditions (f=0.13 
p=0.97; Figure 6.12), rather significant differences in BMI were likely to be the 
associated contributory factor (f=231.18, p<0.01).  
 
 
 
Figure 6.12 Amino acid turnover according to stages of development/ arrest on day 7. Results grouped 
according to embryo culture conditions.  
Collectively significant differences in CORE values were evident between those arresting prior to 
blastocyst formation and developing onwards (ANOVA p= 0.01). The addition of insulin to the culture 
medium did not result in significant differences in turnover at each stage of development. Error bars 
represent 95% CI. 
 
 
Significant differences in the individual pattern of uptake and production of amino acids 
were evident, with stage and BMI (asn, arg, trp, met, val, phe, iso; p<0.05) and culture 
conditions (met and phe; p<0.05 Figure 6.13), as determined by univariate analysis.   
 
A general linear model was then used to test the significance of differences in individual 
amino acid consumption and release for embryos cultured with/ without the addition of 
insulin. Independent of stage and female BMI, significant differences were apparent in 
methionine (p=0.03), phe (p=0.03) and iso (p=0.03) 
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Figure 6.13 Amino acid depletion and appearance by embryos culture with and without the addition of 
insulin to the culture medium.  
There were significant differences (*p<0.05) in methionine depletion and phenylalanine production in the 
cohorts. Error bars represent 95% CI. 
 
Finally, to relate the findings discussed so far in this insulin study group to the 
designated study end point – blastocyst development rate, a logistic regression was 
performed (Table 6.5).  The effects of female BMI, glucose, lactate and pyruvate 
consumption/release and amino acid turnover and experimental group (control / insulin) 
were evaluated on the likelihood that embryos would reach the blastocyst stage. The 
logistic regression model explained 59.5% (Nagelkerke R2) of the variance in blastocyst 
formation/ development and correctly classified 81.9% of cases. From the results it was 
evident that female BMI (p = 0.000) and glucose consumption (p = 0.000) added 
significantly to the model/prediction, but lactate, pyruvate, amino acid turnover and 
experimental group (control/ insulin) did not add significantly to the model. 
 
Interestingly, embryos from normal weight women were 0.04 times less likely to form 
blastocysts than those from OWOB females but increasing glucose consumption was 
associated with an increased likelihood of blastocyst development. 
 
* 
* 
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Table 6.5 Binominal logistic regression; 
was used to evaluate the statistical significance for each of the independent variables to predict blastocyst 
development. Glucose and female BMI were shown to be significant. (***p<0.001) The addition of 
insulin to the culture medium did not influence the probability of blastocyst formation.  
 
 
 
 
 
 
 
 
 
Considerable intra-patient variability was observed. This variability was reduced when 
the analysis was limited to include only developing sibling embryos, however as was 
reported in the previous chapter no significant correlation with pregnancy was evident 
with the reviewed predictor variables. The clinical pregnancy rate for normal weight 
women in this study group was 66.7% (14/21) and 37.5% (6/16), the associated 
respective live birth rates were 52.4% (11/21) and 31.3% (5/16).  
 
As reported in chapter 5, babies born to OWOB women were significantly (p<0.05) 
heavier (3859.8g) compared to those born to normal weight women (3361.82g).   
 
 
6.3.2 The addition of LC (0.5, 0.05, 0.005mMol) to the embryo culture medium 
Over the course of days 5-7 in extended culture, supernumerary embryos generated 
from OWOB women consumed significantly lower quantities of glucose than those 
originating from women of normal weight  (74.07 pmol/emb/hr versus 106.51 
pmol/emb/hr p< 0.01), with no compensatory adjustments in lactate or pyruvate 
metabolism (Table 6.6). Notably the comparable rates of uptake of pyruvate are distinct 
to those reported earlier in this chapter, after insulin had been added to the medium, 
where upon pyrurate uptake was shown to be higher in embryos from OWOB women 
compared to normal weight women.  
 
Binominal Log regression Odds Ratio (95% C.I) 
 
OWOB (0), Normal (1) 0.04 (0.01-0.14)*** 
Glucose uptake  1.06 (1.03-1.08)*** 
Lactate production 0.99  (0.99-1.01) 
Pyruvate uptake 1.00 (0.97-1.03) 
Sum amino acid turnover 0.970 (0.89-1.06) 
Insulin(0) / standard (1) 0.53 (0.21-1.31) 
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Another finding analogous with data reported in Chapter 5, was that the mean 
triglyceride content per embryo was significantly higher in embryos from the OWOB 
group (8.14ng/embryo) compared to the normal weight group (4.94 ng/embryo p<0.01).  
 
Table 6.6 CORE profiles for normal (n=33) and OWOB women (n=32) in study group. 
Glucose consumption was significantly lower in embryos from OWOB women (n=168) compared to 
those from normal weight women (n134), and triglyceride content significantly higher. There were no 
apparent differences in pyruvate, LC consumption or lactate production amongst the groupings 
 
Mean values  (±SEM) Normal weight 
(n=168) 
OWOB 
(n=134) 
p-value 
Glucose consumption 
(pmol/emb/hr) 
106.51 (4.4) 69.89 (3.1) <0.01 
Lactate production 
(pmol/emb/hr) 
129.72 (5.5) 121.17 (5.7) n/s 
Pyruvate consumption 
(pmol/emb/hr) 
28.92 (1.3) 28.0.3 (1.5) n/s 
LC consumption 
(pmol/emb/hr) 
20.06 (3.6) 13.06 (2.3) n/s 
Triglyceride content 
(ng/embryo) 
4.94 (0.3) 8.13 (0.4) <0.01 
 
 
 
In this data set, overall blastocyst development rates were statistically comparable at 
46.4%(78/168) and 38.8% (52/134) for normal and OWOB categories respectively 
(p=0.24); although distribution of sample data was not evenly spread between those 
reaching the unexpanded and hatched stages of development. As such Kruskal- Wallis 
test was used to evaluate the distribution of female BMI across stage of development 
reached and significant differences were defined (independent samples Kruskal-Wallis 
Test H17.4, p=0.02). Furthermore, the distribution of glucose consumption was 
significantly different across cleavage to hatched blastocyst development stage (H81.1, 
p<0.001). 
 
At each development stage it was observed that glucose consumption increased with 
developmental progression, this differed to the pattern reported in chapter 5 but mirrors 
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that reported in the preceding subgroup analysis of embryos cultured with the addition 
of insulin. Furthermore, at each development stage consumption was lower in the 
OWOB category – this was more striking at the later development stages, as shown in 
Figure 6.14 – significant differences in pairings were determined by Bonferroni Dunn’s 
test at the hatched, expanded and cleavage stages (p<0.05).  
 
 
 
Figure 6.14 Glucose consumption at each developmental stage.  
Uptake was shown to be significantly different (* p<0.05) when data was stratified into normal and 
OWOB groupings.  
 
It was established via a general linear model analysis that in women of both normal and 
OWOB category of BMI, the addition of LC to the culture medium did not significantly 
affect the rates of blastocyst development, glucose consumption or lactate production. 
However, pyruvate consumption was shown to be significantly different amongst 
cohorts of embryos cultured with and without LC (p=0.02; univariate analysis) –
consumption was highest when embryos were cultured in medium with 0.05mMol LC 
(Figure 6.15).  
 
 
* 
* 
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Figure 6.15 The effect of LC supplementation (0.005, 0.05, 0.5mMol)-  
on mean glucose, lactate and pyruvate (*p<0.05) metabolism and the uptake of LC (**p<0.01) from 
supplemented medium by embryos over days 5-7 of development (n=302).   
 
 
LC uptake was significantly different among the cohorts of embryos cultured in LC free 
medium and supplemented medium (p<0.01) – uptake was shown to be related to the 
concentration in the medium (Figure 6.15). LC uptake per se did not significantly differ 
in embryos originating from normal and OWOB women, as shown in Table 6.5, 
however highest rates of uptake were reported in embryos cultured in 0.5mM LC that 
originated from normal weight women, as shown in Figure 6.16.  Furthermore LC 
uptake was related to stage of development (p<0.001), higher rates in hatched 
blastocysts originating from normal weight women.   
 
 
* 
** 
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Figure 6.16 The uptake of LC by embryos from normal and OWOB women-  
cultured in LC supplemented  medium at concentrations from 0 to 0.5mM (**p<0.01).   
 
LC supplementation also resulted in significant differences in the triglyceride content of 
cohorts of sibling embryos (p<0.01) – this was apparent at different concentrations of 
supplementation and differing effects were observed in cohorts of embryos originating 
from normal and OWOB weight women (p=0.002). There was no significant 
association between stage of development, female BMI and LC supplementation on the 
triglyceride content of embryos (p=0.92).  The finding that triglyceride content, 
although significantly different in embryos originating from women with a BMI above 
and below 25kg/m2(p<0.01), was not significantly lower in those forming blastocysts 
compared to those arresting prior to compaction, was not expected and is not consistent 
with any of the previous results reported in this thesis. Generally, triglyceride levels 
were lower in this study population than in earlier sections of this thesis. Increasing the 
concentration LC supplementation, was associated with reduced triglyceride levels in 
embryos from OWOB (p<0.01) and in normal weight women a similar pattern was 
observed, except at the highest concentration when triglyceride levels were shown to 
significantly higher than those reported for sibling embryos cultured in un-
supplemented medium, at equivalent development stages.  
 
 
** 
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Figure 6.17 LC supplementation and embryo triglyceride content. 
The effect of LC supplementation (0.005, 0.05, 0.5mMol) on embryo triglyceride content in normal and 
OWOB women (**p<0.01). 
 
The data were broken down further to discover the impact on CORE glucose, lactate 
and pyruvate profiles of supplementation of culture medium with LC on those embryos 
generated from both normal and OWOB women. Significant differences were apparent 
for glucose uptake (p=0.021) in embryos from normal and OWOB women. In normal 
weight women there was a general trend for reduced glucose consumption with 
increasing concentration of LC in the culture medium, the exception being at 0.5mM 
supplementation, when glucose uptake was shown to be higher and was akin to that of 
embryos cultured under control conditions (Figure 6.18 A). Conversely in OWOB 
women LC supplementation was associated with increased glucose uptake.  Differences 
in pyruvate consumption reported between cohorts of embryos cultured under control 
and 0.05mM LC were independent of female BMI, with similar uptake patterns evident 
in embryos originating from normal and OWOB women (Figure  6.18 C).  
 
 
 
 
 
** 
** 
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Figure 6.18 The effect of LC supplementation (0.005, 0.05, 0.5mMol) on CORE of (A) glucose, (B) 
lactate and (C) pyruvate in both the normal and OWOB groupings. 
 
The addition of LC to the culture medium; increased LC uptake, altered pyruvate uptake 
and decreased triglyceride levels. However, increasing BMI has been associated with 
lower glucose utilisation and higher triglyceride levels, both of which have been 
 
A 
B C 
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associated with lower rates of blastocyst formation. The addition of LC to the culture 
medium had differing effects on the pattern of substrate utilisation for embryos at 
different stages of development, the inclusion of these 3 variables (female BMI, embryo 
stage of development and LC supplementation) in a multivariate analysis was used to 
establish that significant between subject effects were apparent, only for glucose 
(p=0.008) and LC uptake (p=0.02).  Only LC uptake correlated with its concentration in 
the medium and a general dose dependent response in uptake was evident; uptake was 
lowest in control medium and highest in that supplemented with the top concentration 
of LC. This pattern was evident for women irrespective of BMI (Figure 6.19 A), this 
was not the case with glucose (Figure 6.19 B).  
 
 
 
 
Figure 6.19 Intra-patient variability in uptake of (A) LC and (B) glucose, according to embryo culture 
conditions (control and supplemented with LC at 0.005, 0.05, and 0.5mM concentration).  
Mean values are depicted for sibling embryos for each patient (connected line) and related to female BMI.   
 
Finally, to relate the findings discussed so far in this LC study group, to the designated 
study end point – blastocyst development rate a logistic regression was performed 
(Table 6.7). The effects of female BMI, glucose, lactate and pyruvate 
consumption/release and triglyceride content and experimental group (control / l-
carnitine 0.005-0.5mMol) on the likelihood that embryos would reach the blastocyst 
stage were evaluated. The logistic regression model explained 40% (Nagelkerke R2) of 
the variance in blastocyst formation/ development and correctly classified 56.8% of 
cases.  
A B 
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Unexpectedly, embryos from normal weight women were 0.3 times less likely to form 
blastocysts than those from OWOB females (a similar finding was reported from the 
insulin data model) but increasing glucose consumption was associated with an 
increased likelihood of blastocyst development. Surprisingly LC supplementation did 
not influence blastocyst formation rates but increased uptake was associated with lower 
rates of blastocyst formation and in this instance higher triglyceride content was 
associated with higher rates of blastocyst formation. This would indicate that an 
optimum mid-range of values is associated with higher rates of blastocyst formation.  
 
Table 6.7 Binominal logistic regression; 
 was used to evaluate the statistical significance for each of the independent variables to predict blastocyst 
development. Glucose and female BMI were shown to be significant (***p<0.001, **p<0.01). The 
addition of l-carnitine to the culture medium did not influence the probability of blastocyst formation.  
 
 
 
 
 
 
 
 
 
From the figures presented it was apparent that at 0.05mM LC supplementation resulted 
in more optimized values of CORE metabolites in OWOB women. At this concentration 
triglyceride levels were lowest and glucose consumption was highest. At the highest 
concentrations of culture medium supplementation, LC uptake was also highest and 
resulted in pronounced disturbances in the patterns of substrate utilisation in normal 
weight women; notably triglyceride was no longer depleted.  
 
In terms of the clinical outcomes associated with transferred sibling embryos, the 
clinical pregnancy rate for normal weight women in this sub-study group were 48.5% 
(16/33) and 15.6% (5/32), the associated respective live birth rates were 9/16 deliveries, 
plus 4 ongoing pregnancies in the normal weight group and 0 delivered, with 4 ongoing 
in the OWOB group. The clinical outcomes for this sub-study group are poorer than 
Binominal Log regression Odds Ratio (95% C.I) 
 
OWOB (0), Normal (1) 0.37 (0.19-0.69)** 
Glucose uptake 1.02 (1.01-1.02)*** 
Lactate production 1.00 (0.99-1.00) 
Pyruvate uptake 1.00 (0.99-1.01) 
triglyceride content 1.02 (1.01-1.03)** 
l-carnitine uptake 0.77 (0.69-0.84) 
l-carnitine (0), Control (1) 1.72 (0.87-3.4) 
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those reported in the previous sections, although no significant differences are evident 
in CORE viability markers between this study population and that of chapter 5. 
 
6.3.3 The addition of LC to the embryo culture medium of frozen and thawed 
embryos 
A total of 21 women of normal weight and 5 OWOB women donated their embryos that 
had been cryopreserved to research.  From these, 79 embryos from normal weight 
women and 27 embryos from OWOB were thawed and sibling embryos were divided 
between culture in standard and 0.5mM supplemented culture medium. The addition of 
LC to the culture medium did not significantly affect the rates of blastocyst 
development, akin to findings reported in the fresh embryo category. However, the 
overall rates of blastocyst development post-cryopreservation were significantly lower 
in the OWOB grouping (4/27 14.8%) compared to the normal weight group (47/79 
59.5%) p<0.001, as observed in Chapter 3. 
 
In frozen treatment cycles, the metabolism of substrates; glucose, lactate and pyruvate 
and the triglyceride content of embryos was significantly different in embryos generated 
from different BMI groupings (assuming an equal split between control and LC 
supplemented culture). 
 
Table 6.8 CORE profiles for normal (n=21) and OWOB women (n=5) in LC/ control groups. 
CORE of glucose, lactate and pyruvate were shown to be significantly lower in embryos from OWOB 
and triglyceride content was significantly higher in embryos from OWOB women (n=27) compared to 
those from normal weight women (n=79). There were no apparent differences in LC consumption. 
 
Mean values  (±SEM) Normal 
weight  
OWOB p-
value 
Glucose consumption (pmol/emb/hr) 85.12 (7.4) 28.74 (3.9) <0.01 
Lactate production (pmol/emb/hr) 100.41 (6.1) 61.52 (7.4) <0.01 
Pyruvate consumption (pmol/emb/hr) 31.17 (2.5) 14.14 (2.1) <0.01 
LC consumption (pmol/emb/hr) 16.96 (3.1) 20.54 (4.8) n/s 
Triglyceride content (ng/emb) 6.34 (0.4) 13.69 (0.6) <0.01 
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When the data are classified according to the culture conditions to which embryos were 
exposed, supplementation with LC resulted in a trend for higher lactate production (99.6 
pmol/emb/hr) than control conditions (80.9 pmol/emb/hr p=0.06). No differences were 
evident in glucose or pyruvate consumption or indeed triglyceride content of embryos; 
7.9ng and 8.9ng/embryo for the respective groupings. When the culture medium was 
supplemented with LC it was taken up in significant quantities (33.9pmol/emb/hr) 
(Figure 6.20). The CORE of substrates were lower than those of embryos originating 
from fresh embryos in the previous section, furthermore in fresh cycles the production 
of lactate tended to be lower in embryos exposed to culture medium supplemented with 
LC, compared to those cultured under standard conditions.  
 
 
 
 
Figure 6.20 The effect of LC supplementation on CORE profile of frozen thawed embryos. 
The effect of LC supplementation (0.5mMol) on mean glucose, lactate and pyruvate metabolism and the 
measured uptake of LC (**p<0.01) from supplemented medium by embryos over days 5-7 of 
development (n=106). 
 
The addition of LC did not influence substrate utilisation when the data were stratified 
into groupings according to female BMI (kg/m2). Unlike the findings reported for fresh 
embryos at 0.5mM supplementation, no significant differences were evident in 
triglyceride content of embryos from normal weight women cultured in standard 
** 
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medium (6.64ng/embryo) and those that were culture in supplemented medium 
(6.06ng/embryo).  
 
A binominal logistic regression model was constructed for normal and OWOB women 
using experimental group as the dependent variable (control -0, LC -1) and glucose, 
lactate, pyruvate, triglyceride as covariates. Embryos were no more/ less likely to have a 
higher metabolism of substrates based upon the culture medium from which they had 
originated. There was a trend for higher lactate release from embryos of normal weight 
women cultured in medium supplemented with l-carnitine (B 0.02, p =0.08), as depicted 
in Figure 6.21, this was not evident in the OWOB group.  
 
 
 
 
Figure 6.21 The effect of LC supplementation (0.5mMol) on lactate production in both the normal and 
OWOB groupings (frozen/ thawed embryos). 
The clinical pregnancy rates reported from the transfer of sibling embryos in the 
corresponding fresh treatment cycles were obtained. In the normal weight group 15/21 
(71.4%) of the cycles had resulted in a clinical pregnancy and all had resulted in a live 
birth. In the OWOB group, a clinical pregnancy had been established in 3/5 (60%) of 
the cycles and again all resulted in a live birth. The birth weights of offspring born to 
normal and OWOB women were comparable 3175.27g compared to 3175.0g. The high 
clinical pregnancy rates and comparable birth weights suggest that the embryos that had 
been transferred in these cycles in both normal and OWOB were of comparably high 
implantation potential. The sibling cryopreserved embryos from OWOB women did not 
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appear to exhibit profiles consistent with high viability – hence the influence of 
cryopreservation on metabolic biomarkers was assessed in the next section.   
 
 
6.3.4 The influence of cryopreservation per se on CORE profiles 
A comparison of two study populations was conducted; those having a fresh treatment 
cycle (n=26 patients, 99 embryos) and those having a frozen treatment cycle (n=26 
patients, 106 embryos). A covariate to this analysis was the fact was that within each 
treatment group a proportion of embryos were cultured under control conditions and a 
proportion in 0.5mMol LC. Likewise, a proportion would have been generated from 
normal weight and an assumed equivalent number from OWOB women.  Independent 
samples Mann-Whitney U Test was used to confirm these assumptions. 
 
The uptake of glucose was significantly lower in embryos that had been cryopreserved 
compared to those from fresh treatment cycles (p<0.01; Figure 6.22) and this in spite of 
the higher rates of blastocyst formation in embryos belonging to this frozen cohort.  
 
 
 
 
Figure 6.22 Comparison of CORE profile of fresh and frozen embryos.  
The effect of cryopreservation on mean glucose (**p<0.01), lactate and pyruvate metabolism and the 
measured uptake of LC from (0.5Mm LC) supplemented medium by embryos over days 5-7 of 
development.   
 
** 
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A binominal logistic regression model was constructed to identify significant 
differences among the populations of embryos that had been assayed from fresh cycles 
and frozen cycles (Table 6.9). There were no significant differences in BMI amongst the 
groups, glucose consumption was significantly different, as were pregnancy rates and 
rates of blastocyst formation.  
 
Table 6.9 Binominal logistic regression; 
 was used to evaluate the statistical differences among cohorts of embryos from fresh and frozen cycles., 
**p<0.01, ***p<0.001.  
 
Embryos from frozen cycles display different patterns of substrate utilisation to those of 
fresh cycles. 
 
 
6.3.5 The influence of Intralipid treatment 
In the course of this study it was discovered that a subset of 5 patients had been given 
intralipid therapy as part of their clinical treatment plan; two of whom were of normal 
weight and three OWOB. A total of 34 embryos (17 from each category) were donated 
to research post therapy and subject to assessment.  
 
It was determined that despite following the general reported trend in previous sections  
glucose concentrations in embryos from OWOB women (75.78 pmol/emb/hr) were not 
significantly lower than those from  normal weight women (107.15 pmol/emb/hr 
p=0.06). Pyruvate consumption was comparable, as was LC consumption, however 
there was a trend for higher LC consumption in embryos from OWOB (16.86 
pmol/emb/hr) compared to embryos from normal weight women (7.42 pmol/emb/hr; 
p=0.12). In contrast to the previous findings, blastocyst development and the 
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triglyceride content of embryos were comparable between the BMI groupings (10/17 
forming blastocysts in each category, with 3.32 and 3.25 ng/emb triglyceride for normal 
and OWOB respectively).  
 
Lactate production from embryos of normal weight women who had been given 
intralipid therapy was significantly higher (184.22 pmol/emb/hr) than that from the 
embryos of OWOB women (101.98 pmol/emb/hr) given the therapy (p<0.001; Figure 
6.23). In the normal weight grouping this is notably higher than the lactate values 
reported in the preceding subsections of this chapter, in which mean production has 
ranged from 92 to 129pmol/emb/hr for normal weight women and 61 to 121 
pmol/emb/hr for OWOB women.  
 
All 5 of the women treated had undergone at least one previous failed cycle of 
treatment, despite attaining a ‘top grade’ (≥3Bb) blastocyst for transfer. After treatment 
with intralipid 3 of the 5 women achieved a clinical pregnancy.  
 
 
 
Figure 6.23 Substrate metabolism of embryos generated from women who had received intralipid therapy 
(n=34 total). Embryos from normal weight women (n=17) display significantly higher lactate production 
than those form OWOB (n=17) (p<0.001). 
 
It was discovered that 3 of the 5 patients (1 normal weight and 2 OWOB) had 
previously donated embryos to research in their prior treatment cycles, thus permitting 
comparisons to be drawn between cycles pre and post intervention. In the repeat cycles 
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(plus intralipid) it was noted that embryos consumed significantly lower amounts of 
pyruvate and the mean triglyceride content of embryos at the end of the culture period 
was significantly lower compared to that of the embryos generated from their initial 
treatment cycle. 
 
Table 6.10 Patient control cycle (1) and intralipid treatment cycle (2) comparisons  
(n=3 women); Post intralipid therapy pyruvate consumption was significantly lower than in the previous 
cycle of treatment and the triglyceride content of embryos was significantly lower in this cohort (n=14 
embryos) compared to their counterparts in the previous control treatment cycle (n=17 embryos).  
 
Mean values  (±SEM) Cycle 1 – control, 
minus intralipid 
Cycle 2 –plus 
intralipid 
p-
value 
Blastocyst development (%) 7/17 7/14 n/s 
Glucose consumption (pmol/emb/hr) 92.88 (9.8) 78.47 (10.8) n/s 
Lactate production (pmol/emb/hr) 98.76 (14.1) 93.48 (6.1) n/s 
Pyruvate consumption (pmol/emb/hr) 39.26 (5.2) 23.21 (0.9) <0.01 
Triglyceride content (ng/emb) 9.5 (1.45) 2.6 (0.47) <0.001 
Clinical pregnancy (%) 0/3 2/3 n/s 
 
The inter-cycle differences were only significant in the cohort of embryos (n=21) 
generated from the two OWOB women (triglyceride p<0.001, pyruvate p=0.05), 
although the cohort of embryos from the normal weight woman (n=10), did mirror these 
trends.  
 
!
!
!
!
!
!
!
!
!
!
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6.4 Discussion 
 
6.4.1 Summary of the key findings 
The experiments presented in this chapter have explored the inclusion of culture media 
supplements; insulin and LC, selected as promising candidates to not only improve 
embryo development in vitro, but to improve embryo viability, as assessed by metabolic 
activity.  
 
The embryos donated to research were at different stages of development; cleavage to 
compaction or very early poor quality blastocysts not suitable for use in clinical 
treatment. This presented a window of opportunity, where the pluripotency of embryos 
previously exposed to perturbing conditions might be improved (Campbell et al., 2013).  
The findings demonstrated that embryos from women with a BMI >25kg/m2 responded 
in a different manner to those from normal weight women. Overall glucose 
consumption was not significantly altered by the addition of insulin to the culture 
medium. Insulin may however, improve blastocyst development/ cell survival, 
particularly for embryos from OWOB women. LC was taken up in significant quantities 
by embryos and triglyceride levels were significantly different as a result. An optimum 
mid-range for both LC and triglyceride was apparent.  
 
6.4.2 Insulin; blastocyst development and glucose consumption 
In this study the addition of insulin to in vitro culture did not alter glucose utilisation in 
embryos originating from normal and OWOB women.  Many of the reported adverse 
effects associated with obesity and hyperglycemia are postulated to originate in the 
ovary and impaired maternal insulin secretion pre-conception can have detrimental 
effects on embryo development that persist even after removal from the maternal 
environment.  
 
There are a number of possible explanations why the addition of insulin to the culture 
media had no effect on glucose consumption in either group this; firstly, at the 
concentration added (0.5ng/ml), it could have been too low to have an effect. This has 
been speculated as a cause of differing responses among different species (Matsui et al., 
1997). Secondly; the effect could be dependent upon the stage of development of the 
embryo prior to insulin exposure i.e. embryos introduced at the cleavage stage of 
development may not have expressed insulin sensitive GLUT transporters, the 
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expression of which remains a matter of controversy in human embryos (Purcell et al., 
2009).  
 
6.4.3 Insulin; effects in normal and OWOB women 
The addition of insulin to the culture medium resulted in; (1) a trend for increased 
blastocyst formation, (2) significantly lower pyruvate consumption at both the cleavage 
stage and the hatched blastocyst stage of development and (3) an altered pattern of 
amino acid utilisation, notably; methionine depletion and phenylalanine production. 
These findings were not independent of female BMI and considerably higher rates of 
blastocyst formation were reported from the OWOB group than expected on the basis of 
past results.  Likewise, pyruvate consumption by embryos from OWOB women was 
higher than expected and the past low rates of substrate utilisation, observed in both 
cohorts at the unexpanded stage of development were not replicated in these 
experiments.   
 
One interpretation of these novel findings is that insulin supplementation may have 
supported the development of embryos from OWOB women that would have otherwise 
undergone developmental arrest. The rates of blastocyst development were comparable 
among normal and OWOB women, and there was a trend for higher blastocyst rates 
from embryos of OWOB women cultured in supplemented medium compared to their 
siblings cultured in standard media. Insulin, possibly acting through the IGF-1 receptor 
may support development in this cohort by decreasing apoptosis and increasing cell 
proliferation. Insulin may promote cell survival by inhibiting ROS generation and has 
been shown to be antioxidative by inducing Bcl-2 and Bcl-XL via the IGF-1 receptor 
(Herrler et al., 1998).  
 
The promoted development supported by insulin, may in part explain why substrate 
utilisation by the OWOB unexpanded blastocyst was not suppressed, as reported in 
chapter 5. The variability in rate of uptake was considerably less, suggesting that those 
embryos that had reached this stage on day 7 may still have been capable of further 
development, as opposed to the majority having simply arrested due to an inability to 
meet the energy demands of blastocyst expansion. Blastocyst formation is a period of 
rapid growth requiring increased glucose uptake.  
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The caveat to this is that the stepwise progressive increase in glucose uptake was also 
observed in embryos cultured under standard conditions and glucose consumption was 
not significantly different among sibling embryos that had not been exposed to insulin. 
It is thus possible that the reduced period of extended culture from day 9 to day 7 of 
development resulted in a more synchronous development patterns. A further point to 
consider is that GLUT1 and GLUT4 transcription are reported to be influenced by other 
environmental conditions, including oxygen, which is reported to induce their 
expression (Behrooz et al., 1997) and this may explain the different pattern in glucose 
metabolism at each stage of development reported for this study population, compared 
to that in chapter 5. An upgrade to research laboratory facilities meant that embryos in 
this study had been cultured under low oxygen throughout their development (i.e. in 
both the clinical and research setting).   
 
It had been speculated in Chapter 5, that a co-regulatory cycle exists in the embryo, as 
in the whole body between glucose and fatty acids (Randle et al., 1963) and the 
inference was that the energy needs of embryos from OWOB women were met by 
enhanced β-oxidation of fatty acids. However, and in contrast to data from Chapter 5, it 
was reported here that the embryos of OWOB women cultured in standard culture 
medium may have compensated for their diminished uptake of glucose, by using 
pyruvate as a substrate for ATP generation, via complete oxidation in the TCA cycle, as 
there was no difference in lactate production.  Nevertheless, as two molecules of 
pyruvate are produced from the glycolysis of one molecule of glucose, the increased 
uptake of pyruvate may not have been sufficient to compensate completely for lower 
glucose uptake.  
 
An excess of pyruvate can impair development (Dumollard et al., 2007) and an optimal 
range of pyruvate consumption has been described in cleavage stage embryos 
correlating with blastocyst development (Guerif et al., 2013).  Pyruvate consumption 
was highest in embryos of OWOB that arrested at the cleavage stage. At the cleavage 
stages pyruvate is the preferred substrate of mouse embryos (Leese & Barton, 1984) and 
glucose uptake is low partly due to limited expression of GLUT1 (Pantaleon et al., 
1997). Insulin may increase expression of GLUT transporters, resulting in the premature 
stimulation of glycolysis glucose being favoured over pyruvate and may explain the 
significantly lower rates of pyruvate consumption in embryos arrested at this stage after 
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insulin supplementation. This supports the notion of an optimum mid-range for 
pyruvate consumption.  
 
In the whole body system, high insulin stimulates the storage of lipids, by stimulating 
phosphodiesterase-3B, which degrades cyclic AMP, preventing activation of protein 
kinase A and suppresses the activity of hormone-sensitive lipase in adipose tissue. At 
the cellular level, in vitro cultured embryos of OWOB women, surprisingly reduced 
their pyruvate uptake after the addition of insulin, assumingly preferentially utilising 
endogenous lipid to provide Acetyl-CoA for the TCA cycle. Given that this was not 
seen in sibling embryos cultured in standard medium, it would suggest that the embryos 
of OWOB women are insulin sensitive; but in both normal and OWOB insulin does not 
affect glucose transport in the same way. Insulin may act via IGF-1 receptor (Pantaleon 
& Kaye, 1996) to increase cellular proliferation and metabolic demands for increased 
growth are met by β-oxidation of fatty acids, in embryos of OWOB women. In support 
of this conjecture, a higher proportion of embryos from OWOB women cultured in 
insulin supplemented medium survived to reach the hatched blastocyst stage and 
moreover pyruvate consumption was significantly lower than those cultured in standard 
medium. 
 
The altered amino acid turnover observed after insulin supplementation, suggests that 
these too may be used as energy substrates, entering the TCA cycle at various points. 
Insulin may facilitate amino acid transport and Koo et al., (1997) demonstrated that 
insulin and amino acids act synergistically and enhance blastocoel formation in porcine 
embryos. Increased endogenous protein synthesis has been reported following short 
term exposure to insulin (Dunglison & Kaye, 1993). Amino acid turnover was shown to 
be influenced by the addition of insulin and differences were reported in methionine 
depletion and phenylalanine production, although these were not independent of female 
BMI. This disrupted methionine metabolism is consistent with the findings reported in 
Chapter 5 and is important, as such disruption could lead to altered methylation of DNA 
and expression of developmentally important genes (Ikeda et al., 2012).  
 
6.4.4 Insulin in vitro summary 
The key message of this section is that, the beneficial effects of insulin on blastocyst 
development reported for the in vitro development of bovine (Matsui et al., 1995), 
rabbit (Grundker et al., 1996), mouse (Kaye & Gardner, 1999) and here for human 
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embryos are not necessarily associated with glucose uptake. Insulin had little impact on 
glucose uptake in human embryos, which may in part suggest that reduced transport by 
GLUT transporters is unlikely to account for the lower rates of uptake among embryos 
from OWOB women compared to normal weight women. It is therefore more probable 
that the utilization of glucose is lower in embryos from OWOB women as alternative 
substrates are being used.  
 
6.4.5 LC effects on carbohydrate metabolism in normal and OWOB women 
In chapter 5 it was shown that human embryos have an endogenous store of triglyceride, 
which may be affected by maternal diet. This is also consistent with findings reported in 
the bovine (Leroy et al., 2014). In this chapter LC was used to manipulate the 
metabolism of these endogenous triglyceride by promoting fatty acid β-oxidation. The 
addition of LC to the culture medium influenced embryo development and the 
metabolism of other substrates; furthermore it was possible to resolve differences 
between embryos from normal and OWOB women. The effects observed were specific 
to the concentration of LC used to supplement the culture medium.  
 
A general finding from this study sub-population was that glucose consumption was 
significantly lower in embryos from OWOB women compared to those of normal 
weight.  Concomitantly, glucose consumption was shown to have increased with stage 
of development reached by individual embryos and this corroborates earlier findings 
from the other sub-population studied in this chapter (insulin data) and is contrary to the 
findings reported in chapter 5. This would suggest that rather than media supplements 
promoting survival and reducing the rates of arrest prior to blastocyst expansion, the 
change in study conditions to low oxygen culture and 7 days observation, rather than 9 
may have been the principle drivers for this difference (see chapter 7 for further 
analysis). 
 
Addition of LC to the culture media at concentrations ranging from 0 to 0.5mM, led to 
altered responses in the cohorts of embryos from both normal and OWOB women. LC 
supplementation influenced carbohydrate metabolism, but the stage of development that 
an embryo had reached prior to being placed into supplemented medium is likely to 
complicate any conclusions. This may be particularly important, as CPTIB expression, 
although confirmed in mouse blastocysts, was not expressed at the 8-cell stages in mice 
(Dunning et al., 2010). At a concentration of 0.05mM LC supplementation resulted in 
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significantly higher rates of uptake of pyruvate, however in a multivariate analysis 
including stage of embryo development and female BMI, glucose consumption was 
shown to be influenced by LC supplementation. A divergent pattern of utilisation was 
observed in OWOB women; glucose consumption tended to be marginally higher at 
higher concentrations of LC.  In embryos from normal weight women, glucose 
consumption was lower at higher LC concentration, with the exception of 0.5mM LC, 
when consumption was equivalent to embryos cultured in un-supplemented media.  One 
explanation for this observation is that LC may enable embryos from normal weight 
women to utilise fatty acids instead of glucose, until a threshold concentration is 
reached at which point alternative metabolic pathways must take over.  
 
Provision of LC has been shown to improved glucose tolerance in insulin resistant rat 
models (Cave et al., 2008). On the basis of this, the observed obesity-induced lower 
glucose uptake by blastocysts maybe responsive to metabolic correction if LC was used 
to deplete triglyceride stores. It would appear that at the concentrations added this was 
insufficient to elicit a significantly altered response (across all stages of development) 
or, perhaps as other studies have added LC during oocyte maturation (Sutton-McDowall 
et al 2012) it was perhaps added too late. As embryo development progresses, the 
embryo may become less responsive to modulation with LC.  
 
6.4.6 LC consumption and triglyceride levels 
A further general observation was that triglyceride levels were significantly higher in 
embryos generated from OWOB women compared to those of normal weight. 
Theoretically LC supplementation should act to facilitate increased fatty acid β-
oxidation and has been reported to improve embryo developmental competence in 
mammalian species (Downs et al., 2009, Dunning et al., 2012, Sutton-McDowall et al., 
2012). In the present study the addition of LC did not appear to influence rates of 
blastocyst development, and in a logistic regression model, LC consumption was 
actually correlated with lower rates of blastocyst development. Furthermore, in contrast 
to previous findings higher levels of triglyceride were associated with blastocyst 
formation.  
 
Interestingly the amount of LC consumed and not the amount supplemented, was the 
significant factor in the model. In general, increasing the concentration of LC in the 
culture medium resulted in uniformly higher rates of uptake by embryos of normal and 
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OWOB women, but at the highest concentration 0.5mM a sharp increase in uptake was 
observed in embryos from women of BMI <25kg/m2. A corresponding drop in 
triglyceride levels with LC uptake was demonstrated in embryos from OWOB women. 
However, in the embryos from women of normal weight, supplementation at the higher 
concentration of 0.5mMol LC led to a significant increase/ retention of triglyceride. This 
pronounced difference may be due to higher rates of cleavage stage arrest, possibly 
implying that at this concentration LC becomes toxic for embryos.  
 
The response in uptake of LC and ability to utilize it for β-oxidation of endogenous lipid 
stores is also likely to be determined by the stage of development, as during 
development positional changes in lipid droplets are known to occur. In mice oocytes an 
initial centrally located lipid droplet becomes larger and droplets are peripherally 
distributed as development progresses (Wood et al., 2008). Similarly, in porcine co-
localised mitochondria and lipid droplets tended to migrate to the periphery of the cell, 
leading the authors to suggest that lipids form functional units with organelles (Sturmey 
et al., 2006). In the oocyte, LC has been shown to reduce the amount of lipid droplets 
and change their position from the cortex to the centre (Chankitisakul et al., 
2013),whilst the movement of lipids and associated organelles away from the 
membrane, may preserve their integrity during freezing it may not be beneficial for 
immediate development. The reason lipid/mitochondrial functional organelles are 
hypothesized to move to the periphery is in response to oxygen availability for 
metabolism (Sturmey et al., 2006). 
 
6.4.7 LC consumption and frozen thawed embryos 
Embryos that had been cryopreserved displayed the hallmarks of those with low 
viability; lower pregnancy rates from sibling embryo transfers and glucose consumption 
significantly lower than that of fresh controls, and indeed, far lower than that reported in 
other study groupings in this thesis. This is however at odds with the higher rates of 
blastocyst formation from frozen embryos compared to the control group. Blastocysts 
developed from frozen embryos have a lower cell count, as prior cryo-injury and cell 
loss results in their formation from a lower number of progenitor cells and consequently 
the lower glucose consumption is reflective of the lower cell count. This may also, in 
part explain the exceptionally low glucose consumption reported for cryopreserved 
embryos from OWOB women (28.7pmol/emb/hr), as this is consistent with findings in 
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chapter 4 that blastocyst cell numbers were lower for OWOB and the report of lower 
cryosurvival in chapter 3, compared to blastocysts from normal weight women.  
 
Embryos from OWOB women were the most vulnerable post-thaw, with lactate and 
pyruvate consumption also significantly lower than that of embryos from women 
<25kg/m2.  However, LC supplementation appeared to offer little benefit. There were 
no significant differences in triglyceride levels of embryos cultured in control or LC 
supplemented conditions, furthermore post-thaw developmental potential did not appear 
to have been influenced by the supplementation. Conceivably, the burden of large 
amounts of intracellular lipids had already compromised the post-thaw embryo quality 
of OWOB women, owing to impaired mitochondrial function, increased sensitivity to 
oxidative stress leading to increased free radical generation and increased cell death 
(Abe et al., 2002). 
 
In this study sub-group LC was added at the higher concentration of 0.5mM and rather 
than appearing to have a negative influence on embryo development in women 
<25kg/m2, as observed in the fresh grouping, there appeared to have been some 
marginal benefits. This is perhaps owing to the antiapoptotic action/ antioxidant actions 
of LC on this cohort of embryos, that were not as metabolically active and therefore 
uptake of LC was considerably less than in fresh embryos exposed to this concentration.  
 
6.4.8 LC in vitro summary 
These data show, for the first time, that human embryos are capable of taking up LC in 
significant quantities from the culture medium, in an almost dose dependent manner. In 
embryos donated from fresh treatment cycles, supplementation with LC up to a 
concentration of 0.05mM it led to lower triglyceride levels, implying β-oxidation had 
been promoted. 
 
It appeared that there are optimum levels of LC consumption that correspond with 
embryo viability, particularly for cohorts of embryos from women of above and below 
25kg/m2. The impact of LC supplementation on CORE profile of metabolites and 
blastocyst development appeared to be dependent on(1) the size of the initial store of 
triglyceride (2) the stage of development attained prior to supplementation and (3) the 
level of prior oxidative stress / cellular damage.   
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From the study utilising different concentrations of LC it was apparent that at 0.05mM 
LC supplementation resulted in more optimized values of CORE metabolites in OWOB 
women. At this concentration triglyceride levels were lowest and glucose consumption 
was highest. At the highest concentrations of culture medium supplementation, LC 
uptake was also highest and resulted in pronounced disturbances in the patterns of 
substrate utilisation in normal weight women; notably triglyceride was no longer 
depleted.  
 
6.4.9 Intralipid studies 
In the course of this study, it came to light that a small number of the participants, who 
had, had a previous, unexpected implantation failure received intralipid infusions (20% 
-100ml). In a number of cases embryo metabolic data from the patient’s previous failed 
treatment cycle was also available and reviewed for both normal and OWOB women.  
 
The data presented provides some insight in to the effects of intralipid therapy on 
human embryo metabolism, which previous studies have overlooked. It is generally 
accepted that the chemical profile of the follicular fluid reflects that of the plasma 
(Rogers & Irvine-Rogers 2010), with measures of lipid components of follicular fluid 
being directly correlated to plasma concentrations (Valckx et al., 2012) and being 
notably elevated in the follicular fluid of overweight women (Robker et al., 2009). It is 
not known if the intralipid infusion that patients received during the mid-stimulation 
phase of follicular recruitment/ maturation was sufficient to alter the fatty acid profile of 
the follicular fluid and for how long the effect may have lasted. Intralipid likely contains 
additional lipids to linolenic and linoleic acid, namely palmitic acid, steric acid and 
oleic acid. In the bovine addition of palmitic or steric acid to in vitro culture during 
oocyte maturation had a negative effect on meiotic maturation, fertilization and embryo 
development (Leroy et al., 2005). Van Hoeck et al (2011) demonstrated that exposure of 
maturing bovine oocytes to elevated NEFA reduced oocyte developmental capacity, 
embryo viability and metabolism.  
 
These initial findings reported here appeared to suggest that intralipid altered embryo 
metabolism. It was observed that after exposure to intralipid embryos significantly 
increased their production of lactate; this was particularly evident in the cohort of 
embryos from the women of normal weight. This is indicative of high rates of 
glycolysis, which is favored under times of oxidative stress and may minimize the 
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production of reactive oxygen species (Kobayahi & Suda 2012), it is also advantageous 
during periods of rapid cell division (Warburg 1956). In addition increased lactate 
production may aid implantation- possibly by promoting endometrial tissue breakdown 
and providing carbon and NADPH (catabolism of glutamine into lactate) to facilitate 
biosynthesis (Gardner et al., 2015).  
 
Studies reporting on the relationship between the metabolic profile of follicular fluid 
and oocyte developmental competence have reported that lower granulosa cell lactate 
production is associated with reduced oocyte developmental competence and pregnancy 
rates (Wallace et al., 2012, Rice et al., 2005). However, it may also be speculated that 
excess lactate production is indicative of a ‘stress response’, suggestive of compromised 
mitochondrial function – pyruvate could be being shunted away from oxidation in the 
mitochondria and reduced oxidative metabolism may lead to chronic reduction in ATP 
levels, associated with implantation failure (Van Blerkom et al., 1995).  
 
A surprising finding was that intralipid resulted in comparable concentrations of 
triglyceride in embryos from OWOB women, and normal weight women. Data from 
animal models have shown that, when cultured in the presence of high fat, oocytes and 
embryos increase their intracellular triglyceride (reviewed by McKeegan & Sturmey 
2012). At first glance it may therefore be assumed that the comparable triglyceride 
content of embryos from women of differing BMI could be explained on the basis that 
oocytes developing in the follicles of OWOB women are already saturated with 
triglyceride, whereas the embryos from normal weight women are capable of 
accumulating additional lipid. This does not appear to be the case; values from normal 
weight women are comparable to those reported earlier, but values from embryos of 
OWOB women are lower than expected and are significantly lower in the same patient 
in cycle 2 (after intralipid) compared to values attained in cycle 1 (without intralipid).  
 
This pilot data would seem to suggest that an embryo’s endogenous lipid stores and 
their rate of utilization maybe inducible by transient changes in the ratio and supply of 
fatty acid in the follicular fluid bathing the maturing oocyte. If we are to assume that 
intralipid infusion increases the lipid content of follicular fluid, the reported decrease in 
triglyceride content of embryos from OWOB is contra to the findings in animal studies 
and the previously inferred results of this thesis. One possible explanation is that the 
intralipid infusions are sufficient to alter the availability of individual fatty acids (i.e. the 
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ratio of unsaturated to saturated fatty acids). Previous studies have shown that 
developing embryos have higher concentrations of linoleic acid and lower saturates 
(Haggarty et al., 2006, Matorras et al., 1998). Intralipid, which is high in linoleic acid, 
may encourage compositional changes– favoring the accumulation of the more 
abundant unsaturated fatty acids, over saturated fatty acids. As the rate of uptake has 
previously been reported to reflect the rate of cellular utilization (Haggarty et al., 2002), 
this differential uptake may in turn encourage selective channeling of unsaturated fatty 
acids towards oxidation and energy production. 
 
It is important not to read too much into these findings, as the results are based on low 
patient numbers. This does however pose a promising future area for research.  
 
6.5 Conclusion 
 
The work presented in this chapter has built upon established findings from earlier in 
this thesis and has sought to identify ways in which aberrant patterns of metabolism in 
embryos from OWOB women may be corrected. 
 
Throughout this chapter findings of lower glucose consumption and higher triglyceride 
levels have been confirmed in embryos derived from OWOB women compared to those 
of normal weight. For the most part, lower glucose has not been accounted for by a 
compensatory change in the rate of pyruvate uptake or a change in the rate of glycolysis, 
as indicated by lactate production.  Embryos have clearly been shown to utilise LC, 
implying that embryos from OWOB women may have an increased reliance upon β-
oxidation of fatty acids to derive ATP.  
 
Multiple regression models have confirmed that in each sub-study population (insulin 
treatment, LC treatment, cryopreservation group) that increased glucose consumption 
was correlated with increased likelihood of blastocyst formation.  Nonetheless, 
blastocyst rates were shown in two of the sub groups, to be higher in the OWOB cohort 
compared to the normal weight grouping. The stratified data analysis did however 
confirm that at equivalent stages of development embryos from women <25kg/m2 were 
more viable than those of OWOB women.  
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The addition of insulin to the culture medium had little effect on the utilisation of 
glucose in either population of embryos from women of above and below 25kg/m2.  
Insulin did increase rates of blastocyst formation in the OWOB group and may act as a 
growth factor to influence embryo development. The stage of development the embryo 
has attained prior to incorporation of insulin into the culture media maybe important as 
it is possible that differing effects will be observed pre and post compaction. Insulin is 
not routinely added to culture media and further research is required before considering 
this possibility, since the consumption of key amino acids was shown to be influenced 
by its addition to the culture medium.  
 
Human embryos were clearly shown to take up LC and consumption increased in 
parallel with concentration. The addition of LC did lead to changes in triglyceride 
content, carbohydrate utilisation and blastocyst development which were related to 
female BMI. These consequential differences in women of normal and OWOB BMI 
were possibly related to the size of the initial store of triglyceride. 
 
LC may influence the metabolic pattern in the embryo, with fatty acid oxidation being 
promoted at the expense of other pathways. It would appear that there are optimum 
levels of LC consumption that correspond with embryo viability, particularly for 
cohorts of embryos from women of above and below 25kg/m2. LC present in the 
follicular fluid is unlikely to be sufficient to support the increased demands of oocytes 
that have developed under conditions of raised glucose and free fatty acids. Oocytes 
recovered from OWOB women might, therefore benefit from LC supplementation but 
further work would obviously be required. 
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Chapter 7 : Overall Conclusions 
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The primary hypothesis of this thesis was that maternal nutrition in the periconceptional 
period can have a significant impact on oocyte developmental competence and embryo 
developmental viability. From the review of clinical data and primary research data 
clear evidence has been presented to suggest that the oocytes and embryos from OWOB 
women are compromised developmentally and metabolically.  
 
In this study, putative markers of embryo competence have been identified and a 
consistent pattern of uptake linked to development stage defined. Specifically, uptake of 
exogenous substrates was shown to increase with development, in particular glucose 
consumption was almost twice as high in embryos that had formed blastocysts during 
extended culture (day 5-9), compared to their slower growing counterparts and this was 
shown to be the case for embryos from normal and OWOB women. This increase in 
glucose consumption at the blastocyst stage is consistent with that described in prior 
accounts in the mouse (Lane et al., 1996) and human (Gardner et al., 2011) and is 
indicative of embryo health. The work presented here builds upon earlier work that has 
primarily focussed on cleavage stage human embryos which has sought to use embryo 
metabolism as a means of selecting embryos with the highest implantation potential 
(Conaghan et al., 1993; Turner et al., 1994; Houghton et al., 2002; Brison et al., 2004; 
Gardner et al., 2011). The data presented here are suggestive of a metabolism that is 
matched to stage and specific for embryos from normal and OWOB women.  
 
Phenotypic responses to a nutritionally enriched maternal environment were evident at; 
the intracellular biochemical level (CORE of substrates), during cellular development 
(progression to blastocyst) and ultimately at the whole body level (birth weights), with 
the potential for long-term consequences.  
 
7.1 Clinical implications of OWOB BMI on ART outcome 
 
If the data from the Hull IVF Unit is assumed to reflect that in the UK, there is 
compelling evidence that a significant proportion of women attempting to conceive are 
overweight or obese. Furthermore, the reproductive outcomes for these women are 
poorer than those of normal weight, in both natural (antenal and subfertility clinic data) 
and assisted conception cycles (including fresh and frozen cycles, Hull IVF Unit).  
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The poorer outcomes are primarily mediated through the maternal component, as 
maternal nutrition in the periconceptional period appears to have an appreciable impact 
on ovarian responsiveness, resulting in significantly fewer oocytes in OWOB compared 
to normal weight women. The chances of a live birth were significantly lower for 
OWOB, compared to normal weight women, furthermore birth weights were 
significantly higher for babies born to OWOB women compared to those of normal 
weight women (Figure 7.1). This was not surprising, as maternal supply of macro and 
micronutrients is known to affect fetal growth (Kulie et al., 2011) and it is becoming 
increasingly apparent that the developing fetus will make, adaptations, some of which 
may be irreversible, to its physiology and metabolism (de Boo et al., 2006) in order to 
survive. However, such adaptations are a source of serious concern, since according to 
the early origins programming hypothesis developed by Barker et al (1990), size at birth 
is related to the risk of developing disease later in life.  
 
Potentially more concerning still, are the data presented in this thesis indicating that 
such adaptations may begin prior to conception and during oocyte development leaving 
a lasting legacy on the growth and development of the offspring. The nutritionally 
enriched follicular environment in which oocytes, of OWOB women develop, can result 
in metabolic adaptations in the embryos, some of which may be inconsistent with 
further development (figure 7.2) and likelihood of pregnancy (7.1), with others not 
apparent until after birth. These notions of developmental plasticity and the perceived 
vulnerability of the preimplantation embryo to its environment are consistent with data 
from animal models. For example, Eckert & Fleming (2011) compiled a comprehensive 
review of studies linking maternal diet with a catalogue of conditions in the offspring 
including; increased blood pressure, obesity risk and decreased insulin sensitivity. 
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Figure 7.1 An overview of the influence of female BMI (kg/m2) on clinical outcome (PDT, CP, LBR, misc, birth weights p<0.05) and ability of 
biomarkers to predict pregnancy outcome (p>0.05). 
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7.2 Role of biomarkers to predict clinical pregnancy and blastocyst formation 
 
The levels and nature of metabolites consumed and/or produced characterise an 
embryos metabolic phenotype, and from this it is possible predict its developmental 
viability. Viability in vitro maybe assessed according to the ability to form a blastocyst 
in extended culture and the ability of transferred sibling embryos to implant and give 
rise to a viable pregnancy. Figures 7.1 and 7.2 provide a summary of all data reviewed 
as part of this thesis from all 176 women, 808 embryos and whilst (a) clinical pregnancy 
rates were significantly poorer for OWOB women, and (b) putative biomarkers 
significantly correlated with female BMI; biomarkers were not directly correlated with 
clinical pregnancy achieved by sibling embryos. Sibling embryos displayed a range of 
CORE substrate values and although the general pattern was unique to each patient (as 
evidenced in chapter 2; method validation and chapter 3; repeat cycles), substrate 
utilisation bore closer correlation to stage of development attained and ability to form a 
blastocyst (Figure 7.2).  
 
The ability to form a blastocyst could be predicted by the glucose depletion, pyruvate 
depletion, triglyceride content and amino acid turnover (figure 7.2), each of which has 
been shown to be correlated with female BMI (in chapters 5 and 6). However, as an 
independent predictor, when all other confounding variables were considered, female 
BMI did not predict blastocyst formation per se. Glucose consumption remained a 
significant predictor variable (appendix A2.3), a finding that was replicated in each 
subgroup analysis (evidenced in chapter 5 and 6).   
 
It can be concluded, that glucose consumption was generally higher in post-compaction 
embryos capable of forming developmentally viable expanded / hatched blastocysts and 
triglyceride levels were significantly lower amongst such blastocysts than those 
arresting at earlier stages of development.  When these three covariates (glucose, 
triglyceride and development) were combined it became apparent that a mid range was 
optimum for highest viability. 
 
This idea of an optimum mid range of consumption was first established in Chapter 5, 
where it was shown that those embryos which underwent early stage arrest on day 5 
(start of research culture) had consumed more substrates than those at an equivalent 
stage on day 5 that continued to develop. This indicates that at the cleavage stages, 
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consumption in the low to mid-range is more compatible with ongoing development. 
This is consistent with the data of Turner et al., (1994) and Conaghan et al., (1993), 
which was reinterpreted here to demonstrate additionally, that lower variability in 
uptake at this stage of development also implies that the cohort of embryos are dividing 
synchronously and have an increased implantation potential (established from the data 
review in chapter 2).  Conversely embryos arresting post-compaction were shown in 
chapter 5 to be consuming below average amounts of substrates, an observation which 
may reflect insufficient ATP generation to support development. Embryos consuming 
mid to higher quantities of substrates post-compaction were shown throughout this 
thesis to be significantly more likely to continued development and achieved blastocyst 
formation, expansion and hatching. These results are allied with those reported for day 4 
human embryos (Gardner et al., 2011). Conjointly, it can thus be argued from this data 
that metabolism should be appropriate for stage of development.  
 
Alignment of metabolic activity with stage of development seems to be of equivalent 
importance to temporal pattern of development, in that a blastocyst formed on day 6 
may be equally as viable as one which forms on day 7, 8 or 9 providing energy 
homeostasis is achieved. The influence of the substrate combinations (glucose: fatty 
acids) that had been utilised to meet the energetic demands has no doubt contributed to 
the differences in blastocyst expansion rates and pregnancy outcomes. 
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Figure 7.2 Biomarkers indicative of embryo viability; glucose (p<0.0001), pyruvate (p<0.05), triglyceride (p<0.0001) amino acid turnover (p<0.05).  
Multiple regression; glucose and triglyceride independent predictors of blastocyst formation (p<0.05), female BMI showed a trend but was not a significant predictor of blastocyst 
formation. In a multiple regression of factors influencing CORE profile female BMI is a significant independent predictor variable; n= 176 women, 808 embryos.
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7.3 Implications of female OWOB BMI on oocyte and embryo viability 
 
The negative impact of obesity on oocyte and embryo morphokinetics was 
demonstrated in chapter 4; obesity was shown to reduce oocyte size, overall oocyte 
developmental competence, the subsequent ability of embryos to form blastocysts and 
affect the kinetics of those capable of compacting. Blastocyst quality was impaired 
further by reduced blastocyst diameter and cell numbers in relationship to female BMI 
(summarised in Figure 7.3).  
 
These findings were proposed to relate back to the nutrient enriched environment from 
which the oocytes were generated, in particular the hyperglycemia and 
hyperinsulinaemia that were reported in the follicular fluid composition of OWOB 
women (Robker et al., 2009). The metabolic support provided by bidirectional 
communication between oocyte cells and cumulus cells is essential for oocyte 
developmental competence (Sutton-McDowall et al., 2010) and it is likely that 
suboptimal conditions during oocyte development and maturation may leave a lasting 
legacy post fertilisation, the effects of which became more apparent as development 
progressed. In support of this theory, studies in animal models have shown that oocytes 
exposed to hyperglycemia may undergo precocious maturation (Sutton-McDowall et al., 
2010), have dysfunctional AMPK activity (Ratchford et al., 2007), disrupted 
mitochondrial activity (Wang et al., 2009) and increased follicular apoptosis (Chang et 
al., 2005).  
 
In chapter 5, it was indeed shown that the embryos derived from oocytes from OWOB 
women had a higher endogenous triglyceride content, diminished glucose consumption 
and altered amino acid turnover; markers of a reduced potential to give a pregnancy 
following embryo transfer. Crucially, it was shown that these observed metabolic 
differences were independent of male BMI and other confounding variables (appendix 
A2.3 and chapter 5).  Analogous findings have again been reported in animal studies;  in 
the bovine, oocytes exposed to fatty acids at concentrations found in human ovarian 
follicles (Robker et al., 2009; Valckx et al., 2012) display reduced glucose consumption 
in the subsequent blastocysts (Van Hoeck et al., 2011) as in the present study. 
 
Blastocyst formation is clearly dependent on the utilisation of glucose and the 
observation of decreased utilisation of glucose at each stage of development for 
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embryos from OWOB women was a consistent and striking feature of this thesis. In 
each study group glucose consumption increased from the cleavage stage to the 
blastocyst stage. Differences in amino acid turnover were also apparent for different 
developmental stages. In particular embryos from overweight women consumed 
significantly more methionine, known to play an important role in the metabolic 
regulation of nucleotide synthesis and methylation (Grillo and Colombatto, 2008). 
 
The triglyceride data suggested that the amount and composition of triglyceride in the 
oocyte and embryo can be modified by the environment in which they develop. 
Embryos from OWOB women contained significantly higher quantities of triglyceride 
than those of normal weight women. One explanation for this is that triglyceride is 
accrued during the maturation of the oocyte in lipid rich follicular fluid, as evident in 
the ovaries of obese women (Robker et al., 2009). Whilst fatty acid oxidation of lipid 
stores provides a source of ATP essential for oocyte maturation and can be used to 
support cell proliferation and embryo development processes, a large accumulation of 
lipid, could impair mitochondrial function and embryo development. The role of 
lipotoxicity has been widely explored in murine models (reviewed by Wu et al., 2015; 
Grindler and Moley 2013). The premise of these studies is that lipotoxicity leads to 
endoplasmic reticulum stress, mitochondrial dysfunction and apoptosis, partly mediated 
by increased oxidative stress and generation of reactive oxygen species. 
 
The data from this thesis and from animal studies indicate that embryos from 
overweight and obese women express a different metabolic phenotype to those women 
with a desirable weight; most notably lower glucose consumption and higher 
triglyceride content (summarised in Figure 7.3 – for the full data set). This underlines 
the importance of attaining an optimum pre-pregnancy BMI for the chances of 
successful live birth.  
 
7.4 In vitro manipulation of metabolism; implications for viability 
 
Optimal lipid metabolism, combined with carbohydrate metabolism is essential for 
development and in chapter 6 ways in which aberrant patterns of metabolism in 
embryos from OWOB women may be corrected, were sought to be identified. It was 
established through the supplementation of culture medium with insulin and L-Carntine 
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(LC) that development and metabolism may be manipulated both independently and in 
concert (Figure 7.3).   
 
Insulin did not appear to influence glucose consumption, although it did modulate 
developmental progression and specific amino acid utilisation. On the other hand 
embryos were shown to utilise LC from the media to modulate their energetic reservoirs 
and use of exogenous substrates to derive energy. There were optimum levels of LC 
consumption that correspond with embryo viability, particularly for cohorts of embryos 
from women of above and below 25kg/m2. The differing responses of embryos from 
normal and OWOB women to LC supplementation were suggestive of a distinction in 
the reliance upon β-oxidation of fatty acids to derive ATP. It is possible that LC derived 
from the follicular fluid is insufficient to support the increased demands of oocytes/ 
embryos of OWOB women that have developed under conditions of raised glucose and 
free fatty acids, the addition of LC to in vitro embryo culture medium maybe highly 
beneficial in this scenario. Chronic over-nutrition is thought to cause ‘metabolic 
gridlock’, an increase in mitochondrial membrane potential, accumulation of electrons 
and intra-mitochondrial acetyl-CoA (Muoio 2014). Once placed into in vitro culture 
medium containing physiological concentrations of glucose, amino acids and serum 
substitute, the addition of LC to culture medium could act to drive oxidation of 
triglyceride stores and direct acetyl-CoA through the TCA cycle. If added at an 
appropriate concentration LC could thus realign metabolic coordination and fuel 
signalling pathways.  
 
The ability to provide in vitro conditions that foster an appropriate metabolic pattern of 
substrate CORE may improve short term embryo viability and protect against 
inappropriate adaptations at this vulnerable period of development and programming in 
the preimplantation embryo. Evidence has been presented here to suggest that it may be 
possible to manipulate the in vitro conditions to realign the embryo metabolism and 
developmental fate to favour a normal healthy development. However, the complexity 
of the obese condition means that it is difficult to determine if adaptive or pre 
conditioning factors influence on the embryo phenotype and metabolic response and 
thus when intervention steps would be most appropriately applied. Nonetheless the data 
do suggest a promising future avenue of research.  
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Figure 7.3 Overview of data showing clearly the influence of female BMI kg/m2 on oocyte and embryo phenotype; lower glucose consumption& higher tiglyceride content; 
p<0.001; n= 176 women, 808 embryos.
Summary of key findings from each chapter;  
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7.5 Caveats; words of caution and confounding variables 
 
Much of what we currently know about the interplay between environmental stimuli 
and preimplantation embryonic metabolic response has previously been derived from 
animal studies. However, as Leese (2012) points out, in a succinct review of 40 years 
research on metabolism of the preimplantation embryo, considerable caution is required 
when extrapolating such data to human embryos, since mice and other rodents are 
believed to be particularly vulnerable to dietary modification. This data from human 
embryos is therefore particularly valuable.   
 
Research using human embryos is quite rightly restricted by ethical constraints and 
therefore advancements in knowledge about human embryo physiology have not 
progressed in line with those of other mammalian species. In spite of this, the non-
invasive methods applied in this study to determine the relationship between human 
nutrition and metabolic health have highlighted many parallel findings with those 
reported in animal models such as the bovine (Leroy et al., 2010, Van Hoeck et al., 
2011) and mouse (reviewed by Grindler & Moley 2013). 
 
The scarcity of human embryos for research and the often poor quality of those that are 
donated (being unsuitable for fresh embryo transfer or cryopreservation) was a concern 
in this study. Within a cohort of embryos from the same patient there is always a spread 
of developmental accession and morphological quality, and the merits of drawing 
conclusions from the poorest embryos of the group maybe contested. Furthermore 
extrapolating data from embryos placed in extended culture from day 5-9 may be 
questioned. Clearly at this point, embryos of higher viability would have been expected 
to have reached the blastocyst stage on the morning of day 5. Be that as it may, this 
study has shown that those embryos which subsequently develop to reach the 
blastocysts, albeit at a slower rate of progression exhibit a higher rate of nutrient uptake, 
indicative of their sustained viability.  
 
A further concern is that the in vitro situation is obviously not representative of that in 
vivo and the virtue of drawing conclusions from non-transferred sibling embryos could 
be questioned. A potential dichotomy exists between the metabolic phenotype of in 
vitro compared to in vivo preimplantation embryos, as demonstrated by Gardner et al., 
(1996). A broad assumption has been made in this study that once placed into in vitro 
249 
 
culture, oocytes / embryos retain their native characteristics. This assumption is justified 
on the basis that culture conditions were identical for embryos of normal and OWOB 
women, embryos were supplied with complete medium, supplemented with synthetic 
serum substitute and there is no reason to suspect that one group would be more subject 
to culture-induced stress than the other. It was shown in chapters 5 and 6 that embryos 
appeared to be predisposed to utilise exogenous substrates in a particular manner.  
 
Questions remain about whether embryo developmental and metabolic observations are 
an artefact of the subtleties of in vitro conditions; once replaced into the uterine 
environment would such adaptations be reversed, persist, or indeed be exacerbated? For 
instance improvements to the metabolic normality of substrate utilisation by the 
addition of l-carnitine or promotion of blastocyst development by the addition of insulin 
may well be lost as soon as embryos are returned to the physiological environment. 
Alternatively it maybe that intervention at a critical ‘road-block/ misdirection’ can 
divert the embryo back on to a course of normal development and clearly further 
research is required on this topic.  
 
A further potentially contentious issue is that of the ‘experimental unit’ and if this 
should be regarded as the patient or the individual embryos. This study has been 
powered on the basis of embryo numbers rather than patient numbers. The observed 
differences may indeed be patient specific, although ANOVA and variance 
decomposition were used to assess the variance within and between patients of 
comparable BMI and cycle outcome. The data comparing metabolic parameters to the 
pregnancy outcome of the sibling transferred embryos highlights the differences in 
developmental potential apparent in a cohort of embryos; this is a potential weakness of 
using the woman as the ‘experimental unit’ as opposed to individual embryos. This 
assumes that the intra-follicular conditions were comparable in the ovaries of a patient. 
However, in a given patient, even in follicles of comparable size, the degree of 
vascularization, oxygenation and level of nutrients have been shown to vary at the time 
of ovum retrieval (reviewed by Van Blerkom, 2000). The more subtle differences in 
metabolic regulation and developmental competence of individual embryos could be 
attributed to these differences and further studies are required on the origin of intra-
follicular influences.  
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These studies were conducted over the course of 5 years and throughout that period, 
clinical necessity meant that a number of protocols were changed.  In addition, 
differences arose in the demographics of the study groups. For the most part these 
variables have been accounted for in the statistical analyses presented in each chapter 
and have not been found to be of significance. Each is briefly mentioned below to 
provide further context for the findings of this thesis and also to highlight the cautions 
and limitations that must be applied when interpreting this body of evidence.  
1. IVF and ICSI – the influence of the insemination method was reviewed in 
chapter 5 and a homogenous spread of IVF/ ICSI cases was evident in each 
study grouping. However as a predictor of blastocyst formation for transfer and 
cryopreservation, ICSI embryos did form blastocysts at a lower rate, implying 
that underlying sperm quality does influence developmental progression – as 
reported in chapter 3. Whether this is solely related to underlying sperm quality 
or is underpinned with a possible link with male BMI is not clear.  
2. Male BMI – the most cogent data for the observed embryo metabolic effects 
reported here being mediated via maternal component as appose to a paternal 
influence were provided in chapter 5, with the analysis of data from a single 
male donor and treatment of a range of women of differing BMI. Attempts have 
been made to control for the impact of male obesity, nonetheless, the detrimental 
effects of adiposity on fertility are not likely to be limited to the female (as 
evidenced in animal models; Fullston et al., 2015), even if more evident, based 
on the chosen bio-markers of viability utilised in this study. 
3. Effects of obesity rather than being overweight – Changes to health authority 
funding criteria have meant that obese women cannot access NHS funding 
(privately funded women are treated up to a BMI of 35kg/m2) and therefore the 
majority of the women in this study were overweight rather than obese. The 
limitations of female BMI as a measure of adipose tissue were discussed in the 
introduction and the amount of food consumed and composition of the diet will 
no doubt also have contributed to the variation in output from women of similar 
BMI.  
4. Female and male age –this was not found to be significantly different between 
BMI category groupings in any of the subgroups. 
5. Influence of agonists verses antagonist - Prior to August 2013 the majority of 
patients had received an agonist protocol of down regulation; post August 
2013,antagonist cycles were most frequently utilized. Antagonist cycles led to 
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significantly fewer oocytes per patient, higher rates of blastocyst formation and 
lower implantation rates in treatment cycles, despite no differences in patient 
demographics including female age, AMH levels and crucially no differences in 
female BMI. Of those embryos donated to research, blastocyst rates were 
significantly higher and accordingly the antagonist group of embryos had lower 
triglyceride content on day 7 of development (7.41ng compared to 9.96ng for 
the agonist group, p<0.01). Glucose, pyruvate and amino-acid metabolism did 
not differ among the groupings, however lactate production was significantly 
higher in the antagonist group compared to the agonist group (122.97 &100.42 
pmol/embryo/hr respectively p=0.01). The excess lactate production may be 
effective as it may allow faster incorporation of carbon into biomass, which in 
turn facilitates rapid cell division (Vander Heiden et al., 2009). This may explain 
the higher rates of blastocyst development, however it could be speculated that, 
precocious development may be detrimental for implantation, hence the lower 
pregnancy rates in fresh cycles.  
6. Influence of culture medium - Generally speaking there are three types of 
culture regimes employed in ART; (1) non-renewal single medium (2) renewal 
single medium and (3) sequential media. In the course of this study the clinical 
protocol employed for the most part was a sequential system (SageTM), however 
from June 2014 a single step non-renewal protocol was utilised (VitrolifeTM). 
Whilst all embryos are cultured in the same medium throughout the research 
phase of this study, it is well documented that the prior environment of the 
embryo can affect subsequent metabolism. Metabolic adaption by embryos in 
culture has previously been reviewed (Leese 1995). The majority of data was 
collected from embryos that had been cultured previously in sequential medium, 
however 23 patients (84 embryos) were donated after the change in clinical 
protocols. There were no significant differences in the patient groupings for 
female BMI, furthermore blastocyst development rates and CORE profiles were 
not significantly different. The exception was pyruvate consumption which was 
borderline significantly (p=0.05) different at 25.5 and 32.1pmol/embryo/hr for 
embryos cultured in Vitrolife and Sage respectively. 
7. Culture to day 7 or day 9–After the completion of the first phase of this study 
(Chapter 5), extended culture was arrested at day 7 rather than day 9. The data 
presented from chapter 5 indicated that 38% of embryos had arrested on day 7, 
whereas on day 9 the proportion was 75%. The change in profile of uptake at 
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each stage of development to a continual ‘step-up’ may reflect the increased 
proportion of embryos still actively developing at the end of culture.   
8. Influence of low oxygen culture Throughout the clinical phase of treatment 
embryos were cultured in a low oxygen environment, however once donated to 
research the embryos were cultured under atmospheric oxygen conditions for the 
first phase of this study (29 patients, 150 embryos- Chapter 5 data). From July 
2012 all culture was performed under 5% O2 (147 patients, 658 embryos- 
chapter 6 data). A lower oxygen environment is thought to be more 
physiological, associated with lower production of ROS and beneficial for 
embryo development (Wale & Gardner, 2015). Studies have shown that 
embryos cultured at 5-7% O2, were more likely to develop to the blastocyst 
stage than those generated under atmospheric O2 conditions (Thompson et al 
1990, Li & Foote 1993, Dumoulin et al 1999), however here, no significant 
differences were reported in blastocyst rates (35.5% atmospheric and 44.4% low 
O2).   
 
Incubation at reduced oxygen tension has additionally been reported to cause an 
increase in mammalian embryo oxygen uptake and pyruvate oxidation; 
metabolic activity which is suggested to correlates more closely with that of in 
vivo recovered embryos (Hooper et al., 1995). No significant differences were 
observed in the present study, in the metabolism pyruvate or other substrates 
under atmospheric and low oxygen (29.9 and 30.7pmol/embryo/hr respectively).  
ROS can affect epigenetic markers, thus culture at atmospheric O2 may have 
altered expression patterns of genes, including AQP8, CAMK1 and TGFB1 
(Rinaudo et al., 2006), genes involved in cell growth and maintenance. This may 
also have contributed to the altered pattern of substrate utilisation observed in 
chapter 5 i.e. the low metabolic activity of blastocysts that failed to expand.  
 
Importantly, women of differing BMI were equally stratified among the 
groupings, implying this would not have distorted the analysis. What is 
interesting though is that mean glucose uptake was lower in embryos of OWOB 
women cultured under atmospheric O2 than in embryos from OWOB cultured 
under low O2 (53.9 and 69.9 pmol/embryo/hr), whereas in normal weight 
women consumption was approximately the same under both sets of conditions. 
From this, it could be argued that oocytes from obese women were already 
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suffering the deleterious effects of oxidative stress and were more vulnerable to 
assault by ROS. Findings in mice support this idea; Igosheva et al., (2010), 
reported that a high fat diet could lead to mitochondrial damage and determined 
that oocytes from such mice displayed an increase in the inner mitochondrial 
membrane potential, oxidised redox state and higher ROS production than 
controls. Equally though, oocytes/ embryos from OWOB women would have 
continued to have been compromised to a greater degree than those of normal 
weight women under low O2 conditions.  This is proffered on the basis that 
under low oxygen, hypoxia-inducible factor 1α (HIF1α) forms a heterodimer 
with HIF1β and regulates the expression of genes involved in glucose 
metabolism, inducing a shift towards glycolysis (Rafalski et al., 2012). 
Conversely, on the basis of data presented in this thesis, embryos from OWOB 
women appear to have a reduced capacity for anaerobic glycolysis and are 
seemingly predisposed to favour ATP generation via oxidative mechanisms, 
including β-oxidation of fatty acids. This strategy of OWOB embryos will again 
result in increased generation of ROS and would also potentially place any 
uterine transferred embryos at a disadvantage when encountering the low 
oxygen levels reported in vivo (Fischer & Bavister 1993) at the time of 
implantation.  
 
7.6 Final remarks and future avenues for research  
 
The evidence for compromised oocyte and embryo viability in OWOB women is 
compelling.  Obesity related qualitative phenotypic changes observed in this study have 
included; significantly smaller oocytes, higher rates of developmental arrest post-
fertilisation and aberrant cell-cycle kinetics, resulting in lower ICM and TE cell counts. 
Quantitative differences in substrate uptake and production were recorded at cleavage to 
hatched blastocyst stages of development. The substrate CORE profile was established 
as an important marker of embryo health. Being OWOB significantly alters the 
metabolism of exogenous substrates, in particular glucose and amino acids and the 
storage and utilisation of endogenous lipid stores.  
 
In this thesis it has been reported for the first time that human embryos contain a 
significant store of lipid and that this store can be modified by the environment, akin to 
254 
 
findings in the bovine (Ferguson et al., 2006, Del Collado et al., 2015). Similarly, the 
amount of triglyceride was lower in embryos assessed at the blastocyst stage, compared 
to those at the cleavage stage, consistent with findings from cultured porcine embryos 
(Romek et al., 2010). This finding was suggestive of a role for lipids during embryo 
development; implying lipid was modified as a result of metabolic processes. 
Additionally, an altered lipid metabolism in embryos from OWOB women was denoted, 
with the increased supply and oxidation of fatty acids speculated to have resulted in the 
accumulation of acetyl-CoA and inhibition of glycolysis (Randle 1998), evidenced by 
the paired lower rates of glucose uptake observed in these embryos.  
 
The findings on amino acid metabolism suggested that differing rates of CORE of 
specific amino acids resulted in altered amino acid ratios between embryos of normal 
and OWOB women. Amino acids interact with the metabolism of carbohydrates in the 
TCA cycle and in the background of a high fat diet may act synergistically to promote 
insulin resistance (Newgard, 2012). Of particular note, metabolism of methionine was 
significantly altered in embryos of OWOB women and after insulin supplementation of 
the culture medium. Methionine plays a particularly important role in methylation/ 
imprinting processes and aberrant uptake, as observed in embryos from women with a 
raised BMI, during a particularly sensitive period of development coinciding with 
genome activation and establishment of epigenetic marks. 
 
Ample evidence has been presented to support the notion that appropriate development 
from oocyte maturation through to the hatched blastocyst stage relies upon the provision 
of conditions that foster a ‘fitting’ metabolism. The nutritional stress of hyperglycemia 
and lipotoxicity are two components which could lead to cellular damage including 
altered mitochondria structure, function and copy number, endoplasmic stress 
responses, inflammation and the generation of reactive oxygen species and longer term 
undesirable ‘programming events’ in embryos of OWOB women. Chason et al (2011), 
proposed that the epigenome may serve as a link between the environment and the 
genome, hence the maternal environment could thus impact upon embryo metabolism 
and development. Figure 7.4 shows a summary of some of some of the pathways that 
may be altered by over nutrition, leading to altered gene expression and metabolism. 
Studies of gene expression are a highly desirable and efforts to test the relationship 
between maternal BMI and epigenetic marks, metabolism and developmental 
competence would be an additional future research aim. 
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Figure 7.4 Summary diagram linking nutrient uptake to altered gene expression;  
Increased intracellular lipid may induce endoplasmic reticulum stress (unfolded protein response, altered 
gene expression). Oxidative stress and modulation of REDOX circuits occurs as a result of reduced 
glucose uptake (and use in glycolysis and PPP), increased β-oxidation of FFA, which requires TCA and 
ETC leading to ROS generation. mTOR is activated by amino acids and insulin and influences gene 
expression and AMPK interacts with other pathways acting as a fuel sensor. 
 
The preimplantation stage of embryo development is considered to be highly sensitive 
to environmental perturbation (Steegers-Theunissen et al., 2013) and at no other time 
point could environmental manipulation / intervention have such an impact on the long-
term health and development of an individual. An improved understanding of the 
interactions between lipid, carbohydrate and amino acid metabolism could potentially 
lead to the development of specific culture media adapted to improve the metabolic 
interplay of substrates and embryo health, particularly in embryos from women of high 
BMI.  
 
To achieve this aim, future work could be directed towards determining the metabolic 
cost of a process; determining cellular rates of CO2 production, relative to O2 
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consumption would provide a respiratory quotient (RQ), which would be an indicator of 
glucose oxidation or fat oxidation- if high or low respectively (Muoio, 2014).  The 
energetic efficiency measured alongside nutrient uptake and related to embryo 
development, would potential provide a more holistic view.  Leese (2012) theorised that 
higher quality embryos will exert reduced effort and suggested this may be determined 
by measuring oxygen uptake. One proposal would be to apply similar methodology to 
that used in bovine to measure oxygen consumption in individual embryos (Lopes et al., 
2007) and this could be expanded upon with further engineering to incorporate time-
lapse analysis.  
 
Efforts need to be made to educate and inform women about the sensitivity of the period 
prior to conception when the oocyte is maturing in the follicle and the impact that 
maternal diet and nutritional health may have on embryonic development. A very clear 
message can be derived from this and animal studies that the maternal environment 
influences embryonic development in the short term and sets a future trajectory for 
growth, with the scope to exert a lasting legacy beyond embryonic and fetal life.   
 
On the basis of these data, it is proposed that nutritional enrichment of the 
periconceptional environment, as apparent in obese women, has a significant and lasting 
impact on the embryo. Embryos produced in a periconceptionally enriched environment 
have a compromised metabolism which may reduce embryo health and lead to the 
reduced fertility; associated with increased miscarriage seen in OVOB patients. In 
addition, there is concern that nutritional stress on the embryo could have long term 
health implications for the offspring.  
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Appendix 
 
 
 
Appendix 1; Culture media preparation, supplies and metabolic profile example 
data (Chapter 2 Methods) 
 
 
A1.1 Culture media preparation (Chapter 2 Methods) 
 
Culture media was prepared using sterilised glassware and plasticware. Briefly; new 
glassware was soaked for 24 hours in 2% hydrochloric acid to remove impurities, rinsed 
three times in double distilled water (ddH2O), and dried in a drying oven at 80oC for 90 
minutes before being was wrapped in aluminium foil and sterilised at 160oC for 4 h. 
Used glassware was rinsed with tap water and placed in 2% Decon 90 detergent, diluted 
with ddH2O, for 1-14 days, before further rinsing with ddH2O, drying and sterilising, as 
described above. Plasticware; pipette tips and boxes were autoclaved prior to use and 
placed in a drying oven at 80oC to dry. Eppendorf tubes were autoclaved in glass 
beakers, covered loosely with aluminium foil. Disposable plasticware, including Pasteur 
pipettes, Falcon tubes and dishes and Nunc flasks were purchased sterile and disposed 
of after use. All purchased plasticware was suitable for in vitro culture of embryos as 
assessed bythe mouse embryo assay toxicity tested and CE marked.  
 
All media preparation was undertaken in a Class II laminar flow hood. The desired 
weights of chemicals (all chemicals from Sigma UK unless otherwise; see appendix for 
full list) were dispensed onto siliconised weighing paper/ weighing boats. The 
chemicals were then added to a sterile volumetric flask of the required volume fitted 
with a sterile glass funnel. Water For Injection (Fresenius UK) was used to prepare all 
media. Chemicals were dissolved by gentle mixing in water in flasks covered with 
Parafilm. Media stock solutions were prepared of Earle’s balanced salt solution (EBBS), 
buffer, antibiotics, carbohydrates and amino acids (Table 2.3 A1-4) and used to prepare 
a working solution (Table 2.3 B). All media and stocks were filter-sterilised through 
0.22µm Millipore syringe filters, checked for correct osmolarity and stored for 6 weeks 
at 4oC. 
 
The osmometer (Osmomat 030, Gonotech GmbH, Germany) was calibrated to 0 mOsm 
/ kg with 100µl of distilled water and to 300 mOsm / kg with 100µl of a commercial 
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standard (MOD108 Camlab, Cambridge). 100µl of medium were taken to test its 
osmolarity before adding synthetic serum substitute (SSS) (Sage) SSA. If the osmolarity 
of the medium was outside of the desired range 288±4mOsm/kg the medium re-made. 
 
 Media stock solutions 
 
(1) EBBSx 10 dilution    (2) Buffer 
 
 
 
 
 
 
 
 
 
 
(3) Antibiotics and carbohydrate (CHO) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Component 
g / 100ml 
sterile 
water 
CaCl2 (anhydrid) 0.2 
KCl 0.4 
MgSO4.7H2O 0.2 
NaCl 6.435 
NaH2PO4.H2O 0.14 
Phenol red 0.01 
Component 
g / 20ml 
sterile water 
NaHCO3 0.42 
Component 
g / 10ml sterile water 
Antibiotics 0.06 penicillin + 0.05 streptomycin 
Pyruvate 0.0517 
Glucose 0.09 
Glutamine 0.0146 
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(4) Amino acids 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A1 1.1 Media stock solutions   
Component 
g / 200ml 
sterile 
water 
Final conc in 
working media 
mMol 
Arginine.HCl 0.4214 0.20 
Cysteine HCl 0.0315 0.02 
Histidine 0.0838 0.04 
Isoleucine 0.0262 0.02 
Leucine 0.0787 0.06 
Lysine 0.1096 0.06 
Methionine 0.0298 0.02 
Phenylalanine 0.033 0.02 
Threonine 0.0596 0.05 
Tryptophan 0.0408 0.02 
Tyrosine 0.0725 0.04 
Valine 0.0351 0.03 
Alanine 0.098 0.11 
Asparagine 0.0751 0.05 
Aspartate 0.0399 0.03 
Glutamate 0.1471 0.10 
Glycine 0.03 0.04 
Proline 0.023 0.02 
Serine 0.042 0.04 
D-amino butyric acid 0.0516 0.05 
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Suppliers; 
 
Chemical  Supplier  Cat No.  
ATP Sigma-Aldrich Company Ltd  
The Old Brickyard, New Road, Gillingham, Dorset, 
SP8 4XT, UK 
A6419 
BSA  Sigma-Aldrich  A6003  
Calcium Chloride Dihydrate (CaCl2.2H2O)  Sigma-Aldrich  C7902  
Decon 90 Detergent  Scientific Laboratory Supplies Ltd (SLS)  
Wilford Industrial Estate, Ruddington Lane,Wilford, 
Nottingham NG11 7EP, UK  
CLE1020  
Di-Sodium Hydrogen Orthophosphate Dihydrate 
(Na2HPO4.2H2O)  
Sigma-Aldrich  71638  
Dithiothreitol Sigma-Aldrich S1277 
Ethanol (Mol.Bio grade)  Sigma-Aldrich  51976-
500ML-F  
EPPS Sigma-Aldrich E9502 
FBS  Sigma-Aldrich   
Glucose  Sigma-Aldrich  G6152  
Glucose standard, 5.0mmol/L, 30ml  Analox Instruments, 
Unit 22, Acton Park Estate, The Vale, London, W3 
7QE, UK 
GMRD-010  
Glycine Sigma-Aldrich  
Hydrazine sulphate Sigma-Aldrich  
Hexokinase/ G6PDH Sigma-Aldrich 127-825 
Lactate standard, 5.0mmol/L, 25ml  Analox GMRD-079  
L-Carnitine inner salt  Sigma-Aldrich  C0158  
LDH   
L-Glutamine  Sigma-Aldrich  G8540  
Magnesium Sulphate Sigma-Aldrich M/1050 
Magnesium Sulphate Heptahydrate (MgCl2.7H2O)  Sigma-Aldrich  M2643  
NADP, NADH, NAD+ free acid Roche 128 040 
PBS Tablets  Sigma-Aldrich  P4417-
100TAB  
Penicillin/Streptomycin  Sigma-Aldrich  P0781  
Phenol Red Solution  Sigma-Aldrich  P0290  
Phosphate Buffered Saline  Sigma-Aldrich  P4417-
100TAB  
Potassium Chloride (KCl)  Sigma-Aldrich  P5405  
Potassium Di-Hydrogen Orthophosphate (KH2PO4)  Sigma-Aldrich  P5655  
Pyruvate reagent kit, 30 tests, incl. std Analox GMRD-140  
Sodium Bicarbonate (NaHCO3)  Sigma-Aldrich  S4772  
Sodium Chloride (NaCl)  Sigma-Aldrich  S5886  
Sodium Di-Hydrogen Orthophosphate  Sigma-Aldrich  71500  
Sodium hydroxide Fisher Scientific UK Ltd, 
Bishop, Meadow Road, Loughborough, LE11 5RG, 
UK 
S4920/60 
Tris base Fisher Scientific  
Water for injection Fresenius Kabi 
Cestrian Court, Eastgate Way, Manor Park, Runcorn, 
Cheshire, WA7 1NT, UK 
 
 
 
Table A1 1.2 List of suppliers  
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A1.2 Example standard curve/ HPLC report – (Chapter 2 Methods) 
 
A1.2.1Glucose 
 
 
 
A1.2.2 Amino acids – Example report 
 
 
 
Figure A1 1.1 Example standard curve and amino acid report  
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Appendix 2; Statistical model example data (Chapter 5 and 6) 
 
A2.1 Chapter 5 
A2.1.1. Predictive of glucose consumption (section 5.3.2);  
 
Forwards, stepwise regression linear model;Target variable glucose. Predictor variables 
included in analysis; development stage and grade day 3, blastocyst development (i.e. 
stage day 9), day of formation, blastocyst grade, female BMI, male BMI, female age, 
male age, cause of infertility. 
 
Effects with significance <0.05 = female BMI (fbmi), blastocyst development stage by 
day 9 of research culture (bdrs) 
 
 
 
 
 
 
 
Figure A2 2.1 Forwards, stepwise regression linear model; significant predictive factors of embryo 
glucose consumption 
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A2.1.2 General linear Model – Female BMI (section 5.3.2); 
Tests of Between-Subjects Effects 
Source 
Dependent 
Variable 
Type III Sum 
of Squares df 
Mean 
Square F Sig. 
Corrected Model Glucose 170886.133a 10 17088.61 4.292 .000 
Lactate 65916.454b 10 6591.645 .959 .482 
Pyruvate 3778.887c 10 377.889 .721 .704 
Intercept Glucose 207583.559 1 207583.5 52.139 .000 
Lactate 96143.903 1 96143.90 13.981 .000 
Pyruvate 1598.955 1 1598.955 3.051 .083 
fbmi Glucose 99772.378 1 99772.37 25.060 .000 
Lactate 26740.687 1 26740.68 3.889 .051 
Pyruvate 25.188 1 25.188 .048 .827 
ivficsi Glucose 411.212 1 411.212 .103 .748 
Lactate 1985.210 1 1985.210 .289 .592 
Pyruvate 647.367 1 647.367 1.235 .268 
stage Glucose 66918.948 4 16729.73 4.202 .003 
Lactate 13531.320 4 3382.830 .492 .742 
Pyruvate 1773.455 4 443.364 .846 .498 
ivficsi * stage Glucose 38072.044 4 9518.011 2.391 .054 
Lactate 28701.890 4 7175.473 1.043 .387 
Pyruvate 941.309 4 235.327 .449 .773 
Error Glucose 545446.294 137 3981.360   
Lactate 942081.986 137 6876.511   
Pyruvate 71807.777 137 524.144   
Total Glucose 2033051.889 148    
Lactate 2718985.167 148    
Pyruvate 233501.687 148    
Corrected Total Glucose 716332.427 147    
Lactate 1007998.440 147    
Pyruvate 75586.664 147    
a. R Squared = .239 (Adjusted R Squared = .183) 
b. R Squared = .065 (Adjusted R Squared = -.003) 
c. R Squared = .050 (Adjusted R Squared = -.019) 
 
Table A2 2.1 General linear model CORE profile and female BMI.  
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A2.1.3. CORE profile and pregnancy (section 5.3.2); 
 
Logistic regression 
Model Summary 
Step -2 Log likelihood R2 
1 15.322a 0.45 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.forEXP(B) 
Lower Upper 
Step 
1a 
Female age .118 .320 .137 1 .711 1.126 .602 2.106 
Female bmi .742 .605 1.503 1 .220 2.101 .641 6.883 
Male bmi .506 .730 .480 1 .488 1.658 .397 6.936 
Cause of infert(1) -1.925 3.008 .409 1 .522 .146 .000 53.031 
Embryo gradeday3 1.895 1.446 1.717 1 .190 6.652 .391 113.222 
Male age .101 .285 .124 1 .725 1.106 .632 1.935 
Stage of dev day 5 -.152 .156 .939 1 .333 .859 .632 1.168 
Blast dev rate day 9 -.019 .044 .189 1 .664 .981 .900 1.070 
glucose -.006 .038 .027 1 .871 .994 .923 1.070 
lactate .003 .015 .035 1 .852 1.003 .974 1.032 
pyruvate -.256 .175 2.123 1 .145 .774 .549 1.092 
Constant -30.677 30.178 1.033 1 .309 .000   
a. Variable(s) entered on step 1: fage, fbmi, mbmi, tx, gradeday3, mage, bdtx, bdrs, gluc, lact, pyruv. 
 
Table A2 2.2 General linear model CORE profile and pregnancy outcome.  
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A2.1.4. Amino acid Principle component Analysis (section 5.3.4) 
 
KMO and Bartlett's Test 
Kaiser-Meyer-Olkin Measure of Sampling Adequacy. .768 
Bartlett's Test of Sphericity 
Approx. Chi-Square 1547.372 
Df 153 
Sig. .000 
 
Rotated Component Matrixa 
 Component 
1 2 3 4 5 
trp .758     
glu .721  .329   
asp .690 .570    
gly .680 .433    
thr .663 .345 .545   
gln -.604  -.439   
tyr .552  -.506   
ser -.498 -.324 -.372   
val  .880    
phe  .877    
asn .383 .675  .301  
his .379 .437   -.335 
met   .705   
iso   .687   
lys .304  .643  -.336 
ala    .842  
arg    -.733  
leu     .821 
Extraction Method: Principal Component Analysis.  
 Rotation Method: Varimax with Kaiser Normalization. 
a. Rotation converged in 11 iterations. 
Table A2 2.3 Amino acid PC analysis.  
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A2.1.5 General linear model – Male BMI (section 5.3.7) 
 
 
 
 
Table A2 2.4 General linear model CORE profile and male BMI.  
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A2.2Chapter 6 
 
A2.2.1 Insulin data – general linear model glucose, lactate, pyruvate 
 
 
Table A2 2.5 General linear model CORE profile and experimental group (control and standard).  
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Table A2 2.6 General linear model CORE profile and experimental group (control and standard) – 
individual amino acids.  
  
 
 
A2.2.1 Insulin data – general linear model amino acids (highlighted model 
utilized) 
Tests of Between-Subjects Effects 
Source Dependent Variable Type III Sum 
of Squares 
df Mean 
Square 
F Sig. 
fbmi * 
exp * 
stage 
asp .002 3 .001 .333 .801 
glu .002 3 .001 .181 .909 
asn .008 3 .003 1.134 .343 
ser .004 3 .001 .152 .928 
his .013 3 .004 .608 .612 
gln .148 3 .049 .730 .539 
gly .000 3 
7.629E-
005 
.010 .999 
thr .044 3 .015 .227 .877 
arg .063 3 .021 .305 .822 
aln .135 3 .045 1.836 .151 
tyr .002 3 .001 .022 .995 
trp .000 3 .000 .165 .919 
met .016 3 .005 3.365 .025 
val .009 3 .003 .696 .559 
phe .009 3 .003 3.310 .026 
iso .021 3 .007 3.088 .034 
leu .014 3 .005 .483 .696 
lys .005 3 .002 .483 .696 
sumaa 1.393 3 .464 1.554 .210 
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A2.2.2 Insulin data – Insulin data – Binominal Log Regression 
 
The explained variation in the dependent variable based on the model ranges from 
44.6% to 59.5%, based on the Cox & Snell R2 or NagelkerkeR2 methods, respectively. 
 
Categorical Variables Codings 
 Frequency Parameter 
coding 
(1) 
exp 
control 70 1.000 
insulin 79 .000 
fbmiclass 
n 73 1.000 
o 76 .000 
 
 
Classification Tablea 
 Observed Predicted 
 Blast Percentage 
Correct  0 1 
Step 1 
blast 
0 60 13 82.2 
1 14 62 81.6 
Overall Percentage   81.9 
a. The cut value is .500 
 
Good sensitivity and specificity 
 
  
Coding used control = 1  
Normal weight = 1 
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The Wald test ("Wald" column) is used to determine statistical significance for each of 
the independent variables. The statistical significance of the test is found in the "Sig." 
column. From these results it is evident female BMI (p = .000) and glucose (p = .000) 
added significantly to the model/prediction, but lactate, pyruvate, experimental group 
(control/ insulin) did not add significantly to the model. The probability of an event 
occurring based on a one unit change in an independent variable when all other 
independent variables are kept constant can be predicted; the odds of  blastocyst 
formation ("1" category) are0.04 times greater for normal weight as opposed to OWOB 
women.  
A logistic regression was performed to ascertain the effects of female BMI, glucose, 
lactate and pyruvate consumption/release and amino acid turnover and experimental 
group (control/insulin) on the likelihood that embryos would reach the blastocyst 
stage.The logistic regression model explained 59.5% (Nagelkerke R2) of the variance in 
blastocyst formation/development and correctly classified 81.9% of cases. Embryos 
from normal weight women were0.04 times more likely to form blastocysts than those 
from OWOB females and increasing glucose consumption was associated with an 
increased likelihood of blastocyst development. 
 
  
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% 
C.I.forEXP(B) 
Lower Upper 
Step 1a 
fbmiclass(1) -3.141 .615 26.073 1 .000 .043 .013 .144 
glucose .056 .010 30.855 1 .000 1.058 1.037 1.079 
lactate -.002 .006 .082 1 .775 .998 .987 1.010 
pyruvate .000 .015 .000 1 .991 1.000 .972 1.030 
sumaa -.031 .044 .475 1 .490 .970 .889 1.058 
exp(1) -.645 .469 1.896 1 .169 .525 .209 1.314 
Constant -2.506 .917 7.462 1 .006 .082   
a. Variable(s) entered on step 1: fbmiclass, glucose, lactate, pyruvate, sumaa, exp. 
 
 
Table A2 2.7 Binominal regression model CORE profile and experimental group (control and standard).  
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A2.2.3 Carnitine data; BMI, stage, CORE profile and LC concentration 
 
Distribution of BMI across categories of stage and distribution of glucose across stage 
of blastocyst development- significantly different. 
 
 
The distribution of pyruvate consumption and TG content of embryos is significantly 
different for different concentrations of carnitine. 
 
 
 
Figure A2 2.1 Data variance/ distribution and experimental group (control and standard).  
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Table A2 2.8 General linear model CORE profile and experimental group (control and standard).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A2.2.4 L-Carnitine data – general linear model glucose, lactate, pyruvate, 
TG (see highlighted model in red) 
Tests of Between-Subjects Effects 
Source Dependent 
Variable 
Type III Sum of 
Squares 
df Mean Square F Sig. 
fbmiclass * 
exp 
gluc 20083.146 3 6694.382 3.293 .021 
lact 9248.585 3 3082.862 .665 .574 
pyruv 1752.404 3 584.135 1.915 .128 
carn 9935.749 3 3311.916 4.156 .007 
tg 167.365 3 55.788 5.046 .002 
blast .000 3 .000 .000 1.000 
stage * exp gluc 58132.112 12 4844.343 2.383 .006 
lact 60306.988 12 5025.582 1.084 .374 
pyruv 3951.386 12 329.282 1.079 .378 
carn 32208.703 12 2684.059 3.368 .000 
tg 64.129 12 5.344 .483 .924 
blast .000 12 .000 .000 1.000 
fbmiclass * 
stage * exp 
gluc 56562.077 12 4713.506 2.319 .008 
lact 36312.340 12 3026.028 .653 .796 
pyruv 4392.868 12 366.072 1.200 .283 
carn 19382.678 12 1615.223 2.027 .022 
tg 63.977 12 5.331 .482 .924 
blast .000 12 .000 .000 1.000 
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A2.3 Chapter 7 
 
A2.3.1 Predictors of pregnancy 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 0 Constant .143 .379 .143 1 .706 1.154 
 
 
 
 
 
Table A2 2.9 General linear model- predictors of pregnancy.  
Model Summary 
Step -2 Log likelihood Cox & Snell R 
Square 
Nagelkerke R 
Square 
1 .000a .749 1.000 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 95% C.I.forEXP(B) 
Lower Upper 
Step 
1a 
age -3.340 5365.428 .000 1 1.000 .035 .000 . 
fbmi 58.193 19495.813 .000 1 .998 
187459415
944239530
00000000.0
00 
.000 . 
mbmi 27.963 2923.188 .000 1 .992 
139374934
4680.319 
.000 . 
bdtx -1.353 1335.971 .000 1 .999 .258 .000 . 
bdres -2.699 235.221 .000 1 .991 .067 .000 
1.117E+
199 
gluc 1.782 866.893 .000 1 .998 5.942 .000 . 
lact .374 617.221 .000 1 1.000 1.454 .000 . 
pyruv -8.367 722.002 .000 1 .991 .000 .000 . 
aa -9.787 3665.741 .000 1 .998 .000 .000 . 
tg -30.492 2681.677 .000 1 .991 .000 .000 . 
cycle 
119.72
9 
26211.080 .000 1 .996 9.944E+051 .000 . 
tx(1) 
-
103.06
2 
25791.241 .000 1 .997 .000 .000 . 
Constant 
-
1459.0
76 
602219.858 .000 1 .998 .000 
  
a. Variable(s) entered on step 1: age, fbmi, mbmi, bdtx, bdres, gluc, lact, pyruv, aa, tg, cycle, tx. 
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A2.3.2 Predictors of blastocyst development 
 
Forwards, stepwise regression linear model;Target variable blastocyst formation. 
Predictor variables included in analysis; female age, male age, female BMI, male BMI, 
cause of infertility, cycle number, treatment, culture media, oxygen, down regulation, 
smoking, embryo grade day 3, glucose, lactate, pyruvate, amino acid, triglyceride, l-
carnitine. 
 
 
 
 
Blastocyst formation – treatment – different predictor variable highlighted (N.B. – 
blastocysts frozen and not donated to research). 
 
Figure A2 2.2 Forwards, stepwise regression linear model; significant predictive factors of blastocyst 
development. 
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Appendix 3 Supplementary figures; 
 
A3.1 Chapter 5 
 
A3.1.1. Relationship between day 3 development and CORE profile day 5-9 
 
 
Figure A3 3.1 Mean embryo metabolism of glucose from day 5 to 9, according to developmental cell 
stage attained on day 3 
 
Day 3 development (<6 cells n=37 and ≥6 cells n=112) 
 
d3 
Mean (± SEM) consumption / production in 
pmol/ember/hour P 
Glucose ≥6 95.53 (6.45) 0.716 
< 6 90.49 (12.21)  
lactate ≥6 101.49 (7.02) 0.174 
< 6 126.68 (16.86)  
pyruvate ≥ 6 33.86 (2.33) 0.173 
< 6 29.08 (2.59)  
 
Table A3 3.1 - CORE embryo metabolism of substrates, day 5-9, according to developmental cell stage 
attained on day 3."
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A3.1.1. Relationship between BMI and CORE profile and day of development  
 
 
 
 
Figure A3 3.2 Mean embryo metabolism of substrates over 24 hour time periods, during 5 days of 
extended culture. Values with the same superscript are significantly different (p<0.05). 
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